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Sudden cardiac death (SCD), the definition of which will be given later, comprises half of all cases of 
coronary heart disease (CHD) mortality,1 which in turn account for half of all deaths globally.2 
Assessment of the risk of SCD in members of the general population is of great importance because 
about half of the cases of SCD occur in people without a previous history of cardiac disease, and 
rates of successful resuscitation remain low at about 8%).3 The electrocardiogram (ECG) is already 
being used as a tool to predict SCD,4 but it has not yet reached its full potential Further studying and 
combining currently used ECG markers and exploring the potential of new ones could aid in the 
prediction of SCD in the future. 
 
Historical background of sudden death 
In biblical times, sudden death was often viewed as divine punishment. In the Old Testament, this 
view is expressed by Elihu to Job in the book of Job. Speaking of the unrighteous, he says: 
“In a moment they die; 
at midnight the people are shaken and pass away, 
and the mighty are taken away by no human hand.” (Job 34:20, NRSV) 
In the New Testament we find the cautionary tale of Ananias and Sapphira (Acts 5:1-11) who die 
instantly as they are lying to the apostle Peter about money held back from the communal fund. 
However, where Elihu describes a natural phenomenon (sudden death at night) and gives it a 
supernatural explanation, the timing of the deaths in the story of Ananias and Sapphira seems to 
indicate a wholly supernatural or legendary phenomenon, outside the purview of medical science. 
In classical mythology, the god Apollo’s arrows strike swiftly and deadly from far. He kills the 
7 sons and 7 daughters of Niobe in quick sequence for the sole reason that she had affronted his 
mother Latona (Ovid's Metamorphoses VI:148-312). Also, in the first book of Homer's Iliad, his 
arrows wreak havoc on the Greek warriors in retaliation for the slight they had inflicted on his priest 
Chryses. Contrary to this view of sudden death as a manifestation of divine wrath, there were not a 
few who hailed it as a divine grace, mostly extended by the same [marksman] Apollo, who therewith 
spared one a perhaps miserable natural deathbed. 
 The first person to describe sudden death not as divine intervention but as a natural 
phenomenon was Hippocrates of Cos (460BC - 370 BC). In Aphorisms, one of the books ascribed to 
him, he makes the following observation: 
“Those who are subject to frequent and severe fainting attacks without obvious cause die 
suddenly” (Aphorisms II, No. 41) 
This observation not only describes sudden death, but also indicates that it might be predicted by 
signs, just like any other disease. According to some modern medical historians, it is not unlikely that 
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this observation describes congenital long-QT syndrome, currently one of the known causes of SCD.5 
In another observation in the same book, Hippocrates describes another warning sign for sudden 
death: 
“Those who are constitutionally very fat are more apt to die quickly than those who are 
thin” (Aphorisms II, No. 44) 
This observation is correct in marking obesity as a risk factor for SCD, often by way of CHD.  
 
Modern view of SCD 
Based on the circumstances during death, two types of SCD are distinguished in the modern medical 
literature. The first is that of witnessed SCD. The most common definition of witnessed SCD, which is 
endorsed by the European Society of Cardiology, is given by Myerburg: “Natural death due to cardiac 
causes, heralded by abrupt loss of consciousness within one hour from onset of acute symptoms. 
Preexisting heart disease may have been known to be present, but the time and mode of death are 
unexpected.”6,7 The second type is that of unwitnessed SCD. A case is considered unwitnessed SCD if 
the person is found dead, be it in bed or on the street, having been known to be in a stable medical 
condition in the 24 hours before discovery, and if there is no evidence of a non-cardiac cause of 
death.8 Although the distinction between unwitnessed and witnessed SCD rests on coincidence i.e. 
whether others happened to be present at the incident, the distinction is important in view of the 
difference in certainty and level of information between the circumstances of death. 
 Most cases of SCD are thought to be the result of an acute event or trigger acting in the 
context of an earlier disease substrate.4 The acute triggers include acute ischemia, environmental 
stress, and acute hemodynamic stress.4 The disease substrate can be any cardiac pathology that 
interferes with the ability of the heart to prevent fatal arrhythmias, such as ventricular tachycardia 
or ventricular fibrillation.9 There are many different disease substrates that can lead to SCD, but the 
most common in both men and women is CHD.10 Other common disease substrates are valvular 
heart disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy.4,10,11 A rarer but well-
described group of disease substrates is that of the long-QT syndromes.12,13 These are syndromes 
characterized by a long QT interval on the ECG, the occurrence of syncope, and a high risk of SCD. 
Long QT syndromes can be congenital or drug-induced. The congenital variants are caused by 
mutations in the cardiac myocyte ion channels that are responsible for the repolarization of the 
heart,12 while the drug-induced variants are caused by drugs that block these ion channels.13 
Subsidiary risk factors for SCD that are contributory to the aforementioned disease substrates are 
smoking,14,15 hypertension,16 high serum LDL/HDL cholesterol ratio,17 diabetes mellitus,18 etc. The 
aforementioned long QT interval on the ECG is a risk factor in the general population, but not the 
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only ECG-based harbinger of serious cardiac trouble.19 Many aspects of cardiac function and 
pathology associated with underlying causes of SCD can be detected by the ECG (e.g., CHD, cardiac 
hypertrophy), but accurate prediction of SCD has not yet been achieved.20 
 
The incidence and impact of SCD 
SCD is the outcome of various disease processes, the main one being CHD.11 CHD is the number one 
cause of death globally,2 and it is estimated that half of all cases of cardiac death occur suddenly and 
as the first, and last, sign of cardiac disease.1 The scope of the problem can be illustrated with the 
fact that an estimated 210,000 cases of SCD occur in the United States annually.21 Although the 
incidence of SCD seems to be decreasing somewhat in the Western world, there remains a large 
burden of mortality.22 Resuscitation techniques have improved, but the results of resuscitation 
remain poor,21 and the impact and costs of the post-cardiac arrest syndrome makes prevention and 
recognition of potential SCD cases in the general population a priority.23 CHD is a much more 
frequent cause of SCD in men than in women. A study of survivors of cardiac arrest found that in 
men, CHD accounted for 80% of the cases, while in women, this is only 45%. The same study found 
that the second common underlying cause of SCD, dilated cardiomyopathy, accounts for 19% of the 
cases in women, but for only 10% in men. The less common disease substrates, such as valvular 
heart disease and long QT syndrome also differ in frequency between men and women.11,24 
 
The electrocardiogram 
It was the British physiologist Augustus Waller who coined the term “electrocardiogram” and who 
made the first ECG in 1887. However, with the technology available at the time, it took hours to 
obtain a somewhat decent recording.25 In the 1890s, the Dutch scientist Einthoven devised the string 
galvanometer, which allowed for quicker and infinitely more accurate ECG recordings. Einthoven’s 
string galvanometer was a device based on a 3-micron thick silver-coated filament of quartz, 
suspended within the magnetic field of two poles of a large, water-cooled electromagnet. The 
filament was made by attaching the molten quartz to the tail of an arrow, which was then fired with 
a bow across the lab. As the arrow shot away, a thin filament was created.26 The device weighed 270 
kg, occupied two rooms, and required 5 people to operate.27 Einthoven introduced the standard ECG 
leads I, II, and III, together forming an equilateral triangle, and coined the terms P, Q, R, S and T 
marking the successive waves, all of which are still in use today.28 He received the Nobel Prize for his 
work on electrocardiography in 1924.29 
 The standard ECG is recorded by ten electrodes that are placed on the body.30 Figure 1 
shows the placement of these electrodes. The voltages measured between opposing electrodes are 
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called leads. Bipolar leads are voltages measured between two electrodes. Unipolar leads are the 
voltages measured between an electrode and a common connection of two or three electrodes. The 
standard ECG consists of 12 leads: three bipolar limb leads (I, II and III), three unipolar augmented 
limb leads (aVR, aVL and aVF) and six unipolar precordial leads (V1 to V6).30 The resulting ECG signal 
is characterized by a series of deflections from the baseline on the aforementioned leads. The 
general schematic shape of the ECG signal is shown in Figure 2. A positive deflection (going up) 
indicates that a current is flowing towards the electrode designated as positive, while a negative 
deflection indicates the opposite.28 The P wave is the first wave, indicating the depolarization of the 
atria. The first negative deflection, if there is one, is referred to as the Q wave. This wave indicates 
the beginning of the depolarization of the ventricles. The Q wave, R wave, and S wave together form 
the QRS complex, and reflect the depolarization of the ventricles. The T wave represents the 
repolarization of the ventricles. The QT interval spans the beginning of the Q wave to the end of the 
T wave (see Figure 1), including both depolarization and repolarization of the ventricles. The last 
wave, the small U wave, also described by Einthoven, is more prominent in the case of bradycardia, 
or in cases of hypokalemia. Its origin has not yet been fully clarified.31 
 
Heart-rate variability and QT variability 
Heart-rate variability (HRV) denotes the variability of the duration of the intervals between heart 
beats (denoted by RR intervals in Figure 1).32 The earliest studies about HRV date from the 1930s, 
and were mainly focused on psychiatric patients, an interest that remains to this day.33,34 A paper 
from 1936 noted that psychotic patients had a lower HRV than healthy controls.33 A publication from 
1949 reported that women had a higher HRV than men, and that HRV decreased over age.35  
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Figure 1. Placement of the ECG electrodes 
 
Based on FIG. 1219 from Anatomy of the Human Body. 1918. by Henry Gray (1825–1861). 
Abbreviations: LA: Left arm, LL: Left leg, RA: Right Arm, V1-V6: Precordial leads 1 to 6. 
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Figure 2. The shape of the electrocardiographic recording of two beats 
 
 
It should be noted that these old publications have serious limitations: sample sizes were very small 
(less than 100 participants), in studies that used psychiatric patients, the criteria for diagnosis were 
not reported, and most important, statistical and computational methods were very crude all 
models were univariate. Today it is thought that HRV reflects the activity of the autonomic nervous 
system: high parasympathetic nervous activity is associated with an increased HRV, while high 
sympathetic nervous activity is associated with a decrease.36-38 In a healthy heart, HRV and its 
concomitant parasympathetic activity are relatively high,38 whereas a low HRV is associated with 
high adrenergic activity and an increased risk of all-cause mortality,39-44 cardiac mortality,41,45 and 
sudden cardiac death.46,47 
While HRV in the ECG denotes the variability in RR-interval durations, QT variability denotes 
the variability in QT-interval durations. QT variability has been studied extensively in animal models 
(e.g., dogs48 and rabbits49). One study in dogs with a chronic AV-block showed that QT prolongation 
alone could not predict ventricular arrhythmias, but increased QT variability could.48 The first paper 
that studied QT variability in humans is by Berger et al. and was published in 1997.50 This study 
showed that QT variability is higher in patients with dilated cardiomyopathy than in control subjects. 
Because dilated cardiomyopathy is associated with a high incidence of malignant ventricular 
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arrhythmias and sudden death, this study suggested that QT variability is a promising marker for 
sudden cardiac death,50 which was an incentive for other studies.51,52 
 
Aim of this thesis 
Prediction and prevention of SCD remain difficult due to a number of factors: The 
ascertainment of cases is often equivocal, and information on patient characteristics shortly before 
the occurrence of SCD (e.g., heart rhythm) is not available most of the time.22 The aetiology of SCD is 
multifactorial53 and it is difficult to retrieve the underlying disease state and the triggers that led to 
the event.54 About half of the cases of SCD occur in persons without a history of cardiac disease, 
which calls for tools to estimate their risk of SCD and possibly to prevent it.55 The ECG is certainly 
one of these tools,20 and the aim of this thesis is to explore and extend the utility of the ECG in the 
risk assessment of SCD. 
General outline of the thesis 
In the first part of the thesis, we closer explore old ECG markers that have been used to predict SCD: 
heart rate, heart-rate variability, and QT interval. In chapter 1.1, we determine age- and sex 
dependent normal values for heart-rate variability. In chapter 1.2, we address the issue of whether 
depression or antidepressants are responsible for the decrease in heart-rate variability in patients 
with depression. The topic of chapter 1.3 is the method to correct the QT interval for heart rate. We 
show that Bazett’s heart-rate correction for QT duration may lead to overestimation or 
underestimation of the QTc. We end this part with chapter 1.4, a study of the genetic determinants 
of heart rate using the exome-chip data in a large meta-analysis involving more than thirty 
population-based cohorts. 
 In the second part we focus on QT variability, a relatively new marker for the risk of SCD. In 
chapter 2.1 we review the current status of the literature about short-term QT variability in humans, 
including the methods that are used to measure and quantify QT variability, and the topics that have 
been studied in relation to QT variability. In chapter 2.2 we introduce fiducial segment averaging 
(FSA), a new method to reliably determine the inflectional points in the ECG and accurately measure 
individual QT intervals. In the following chapters, we use the FSA algorithm to measure QT variability 
in standard 10-second ECGs in population-based studies. In chapter 2.3 we present normal limits for 
QT variability for both men and women, for all ages. In chapter 2.4 we study QT variability as a risk 
factor for total mortality, CHD mortality, and SCD. In chapter 2.5 we analyse QT variability as a risk 
factor for heart failure. This part of the thesis ends with chapter 2.6, where we study the association 
of QT variability and thyroid function. 
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 The third part of this thesis addresses diseases associated with sudden cardiac death. In 
chapter 3.1, a literature review of the association between SCD and chronic obstructive pulmonary 
disease (COPD) is presented, and in chapter 3.2, we study the association of thyroid function with 
SCD. These two studies point to future research of ECG markers for diseases associated with SCD. 
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Abstract 
Purpose Heart-rate variability (HRV) measured on standard 10-second electrocardiograms (ECGs) has 
been associated with increased risk of cardiac and all-cause mortality, but age- and sex-dependent 
normal values have not been established. Since heart rate strongly affects HRV, its effect should be 
taken into account. We determined a comprehensive set of normal values of heart-rate corrected 
HRV derived from 10-second ECGs for both children and adults, covering both sexes. 
 
Methods Five population studies in the Netherlands (Pediatric Normal ECG Study, Leiden University 
Einthoven Science Project, Prevention of Renal and Vascular End-stage Disease Study, Utrecht Health 
Project, Rotterdam Study) provided 10-second, 12-lead ECGs. ECGs were stored digitally and 
analyzed by well-validated analysis software. We included cardiologically healthy participants, 46% 
being women. Their ages ranged from 11 days to 91 years. After quality control, 14,004 ECGs were 
available. Heart-rate correction formulas were derived using an exponential model. Two time-
domain HRV markers were analyzed: the corrected standard deviation of normal-to-normal RR 
intervals (SDNNc) and corrected root mean square of successive RR-interval differences (RMSSDc). 
 
Results There was a considerable age effect. For both SDNNc and RMSSDc, the median and the lower 
limit of normal decreased steadily from birth until old age. The upper limit of normal decreased until 
the age of 60, but increased markedly after that age. Differences of the median were minimal 
between men and women. 
 
Conclusions We report the first comprehensive set of normal values for heart-rate corrected 10-
second HRV, which can be of value in clinical practice and in further research. 
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Introduction 
Heart-rate variability (HRV) as measured on the electrocardiogram (ECG) is the variability of intervals 
between QRS complexes generated by sinus node depolarization in one continuous recording 1. 
Many studies have indicated that reduced HRV is a strong, independent, and consistent risk factor 
for all-cause and cardiac mortality 2. HRV guidelines recommend that measurements be based on 5-
minute or 24-hour ECG recordings, but 10-second ECGs are more commonly made during routine 
medical care and are faster, cheaper, and more patient-friendly than longer ECG recordings. 
Furthermore, even though it is not possible to determine frequency-domain measurements on a 10-
second signal, it is possible to obtain valid time-domain measurements, like the standard deviation 
of the normal-to-normal RR intervals (SDNN) and the root mean square of successive RR-interval 
differences (RMSSD) 1. It has recently been demonstrated that time-domain HRV as measured in a 
given 10-second episode of a 4- to 5-minute pulse-wave recording was in substantial agreement 
(correlation coefficients varied between 0.76 and 0.93) with HRV derived from the full-length 
recording 3. In fact, time-domain HRV markers as measured on 10-second ECGs have been associated 
with heart failure 4, cardiac mortality 5, and all-cause mortality 6 in population-based studies. In one 
of these studies 5, both high HRV and low HRV were associated with adverse outcomes. Thus, 10-
second HRV seems a promising tool in both research and clinical practice. 
HRV is known to have a strong, inverse relationship with heart rate 7-11. It has been 
suggested by Monfredi et al. 9 that this relationship is exponential, and that HRV parameters should 
be exponentially corrected for heart rate. However, the above-mentioned studies either did not 
adjust for heart rate, or did a linear adjustment for heart rate. As heart-rate itself is a strong risk 
factor for cardiac morbidity and mortality 12,13, the results of the earlier studies might have been 
confounded. 
Knowledge of normal values of heart-rate corrected HRV markers from 10-second ECGs would 
allow researchers to derive well-grounded thresholds for continuous variables and enable clinicians 
to establish diagnostic criteria. A number of studies have reported normal HRV values for 5-minute 
14-16 and 24-hour 17 ECG recordings, but only one recent study reported normal values for 10-second 
ECGs 18, without investigating the age-dependency of HRV. Moreover, none of these studies applied 
heart-rate correction. Therefore, in this study we determine heart-rate corrected normal values for 
HRV as derived from 10-second ECGs across all age groups. 
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Materials and Methods 
Study populations 
In this study we combined data from five population studies conducted in the Netherlands. The 10-
second 12-lead ECGs from these studies were digitally recorded and stored at sampling rates of at 
least 500 Hz, up to 1200 Hz in the pediatric group. All data were anonymized. 
 
(1) Pediatric Normal ECG Study 19. The population of this study consists of 1,912 children, their ages 
ranging from 11 days to 16 years. The children were recruited in the year 2000 at three child health 
centers, three primary schools, and one secondary school in the city of Rotterdam. The children’s 
height and weight, measured before ECG recording, corresponded well with the Dutch growth 
standard. ECGs were recorded with a portable PC-based acquisition system (Cardio Control, Delft, 
Netherlands). 
 
(2) The Leiden University Einthoven Science Project 20. The population of this study contains 787 
medical students of Leiden University. The ages of the participants range between 17 and 29 years, 
and all attested to be in good health. The ECGs were recorded from 2005 until 2007 with Megacart 
electrocardiographs (Siemens, Erlangen, Germany). 
 
(3) The Prevention of Renal and Vascular End-stage Disease (PREVEND) Study 21. This study, which 
started 1997, has as its goal to investigate the natural course of microalbuminuria and its relation to 
renal and cardiovascular disease in the general population. The PREVEND population consists of 
8,592 participants aged 28-75 years, from the city of Groningen. Medical records, including 
medication use, were available for all participants. ECGs were recorded with CardioPerfect 
equipment (Welch Allyn Cardio Control, USA). 
 
(4) The Utrecht Health Project 22. This ongoing study started in 2000 in Leidsche Rijn, a newly 
developed residential area of Utrecht. All new inhabitants were invited by their general practitioner 
to participate. The population of this study consists of 6,542 participants. Written informed consent 
was obtained and an individual health profile was made by dedicated research nurses. Baseline 
assessment included physical examination, ECG, blood tests, and interview-assisted questionnaires. 
Pharmacy records were used to obtain medication use. ECGs were recorded with CardioPerfect 
equipment (Welch Allyn Cardio Control, USA). 
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(5) The Rotterdam Study 23. This study, which started in 1990, investigates determinants of a number 
of age-related disorders in an elderly population, prominently among them cardiovascular disease. 
The Rotterdam Study population consists of 10,994 inhabitants of Ommoord, a suburb of 
Rotterdam, aged 55 years or older. Participants were visited at home for an interview and were 
subsequently examined at the research center. Detailed information was collected on health status, 
medical history, and medication use. ECGs were recorded with an ACTA electrocardiograph (Esaote, 
Florence, Italy). 
 
From these five populations, totaling 28,827 participants, we selected a subgroup of participants 
with no indication of cardiac disease. Reasons for exclusion were a history of myocardial infarction, 
heart failure, coronary bypass surgery, coronary angioplasty, or pacemaker implantation. Other 
exclusion criteria were hypertension and diabetes mellitus. Hypertension was defined as a systolic 
blood pressure ≥160 mmHg or a diastolic blood pressure ≥100 mmHg or use of antihypertensive 
medication, including use of beta-blockers. Diabetes mellitus was defined as a non-fasting serum 
glucose ≥11 mmol/l or use of glucose-lowering drugs. After applying these criteria, 15,248 
individuals were available. We further removed ECGs with excessive noise, excessive baseline 
wander, premature ventricular beats, premature supraventricular beats, and second or third degree 
atrioventricular block. Outliers of HRV values were visually checked and discarded if related to poor 
signal quality. This resulted in 14,004 participants with a low-noise ECG containing only normal beats 
available for analysis. 
 
HRV measurement and correction 
RR intervals for all ECGs were automatically determined by the Modular ECG Analysis System 
(MEANS), an ECG computer program that has been evaluated extensively 24,25. MEANS signals 
excessive noise, baseline wander, ventricular complexes, and supraventricular complexes. We 
calculated two time-domain HRV markers: SDNN and RMSSD. As proposed by Monfredi et al. 9, we 
corrected the HRV markers for heart rate (HR) with an exponential formula, taking 60 beats per 
minute as the reference: 
 
HRVc = HRV eβ (60 – HR) 
 
To determine the correction parameter β, we fitted an exponential model: 
 
HRV = eα + β HR 
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After log-transformation, the parameters α and β were estimated using linear regression. To deal 
with possible confounding by age, regression was performed separately in predetermined age 
groups as specified in Table 1. Whereas the estimated parameters α considerably differed across age 
groups, the parameters β were largely similar. We computed an aggregate β as the weighted mean 
of the age-specific estimates, taking the inverse of the variance of the estimates as the weights 26. 
This resulted in the following correction formulas: 
 
SDNNc = SDNN e0.02294 (60 – HR)  
 
RMSSDc = RMSSD e0.03147 (60 – HR)  
 
Estimation of normal values 
Centile curves were estimated using the Box-Cox t distribution in a semi-parametric model for 
location, scale and shape 27,28. The Box-Cox t distribution allows for modeling of the distribution of 
the median, skewness, and kurtosis as functions of age. The lms function of the R-package gamlss 
was used for the creation of the centile curves. The 2nd percentile was taken as the lower limit of 
normal (LLN) and the 98th percentile as the upper limit of normal (ULN). Normal values for all age 
categories were estimated using the predict.gamlss function of the gamlss package. The normal 
values of all age categories in Tables 2 and 3 were estimated based on the modeled Box-Cox t 
distribution, taking the central age in the age group. For example, normal values for the category of 
16-20 years were based on the values of participants aged 18 years. 
 
This study was approved by the Medical Ethics Committee of the Erasmus University Medical Center. 
Since all data were anonymized and retrospectively collected, informed consent of the subjects was 
not required according to Dutch legislation. 
 
Results 
Table 1 shows the age and sex distribution of the study population. Most age groups have more than 
100 ECGs, only the age groups below six months or above 90 years consist of fewer ECGs. 
The median, LLN and ULN of the heart-rate corrected HRV markers, stratified by sex, are shown 
in Table 2 (SDNNc) and Table 3 (RMSSDc) per age group, and in Figure 1 (SDNNc) and Figure 2 
(RMSSDc) as continuous age-dependent curves. Other percentile values of SDNNc and RMSSDc are 
provided as Supplementary Material. SDNNc and RMSSDc display the same age-dependent pattern. 
The median and LLN of both markers steadily decrease from childhood to the years of middle and 
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older age. The ULN also decreases till the age of 50-60, after which both markers show a marked 
increase of their ULN, resulting in a greater range of normal values in the elderly. The difference 
between men and women appears to be small until 50 years of age, after which men attain higher 
ULN and lower LLN values than women.  
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Table 1. Age and sex distribution of the study population 
Age group No. of boys/men No. of girls/women Total 
Younger than 1 month 11 8 19 
1 to 3 months* 27 23 50 
3 to 6 months 34 38 72 
6 to 12 months 69 54 123 
1 to 3 years 51 52 103 
3 to 5 years 60 62 122 
5 to 8 years 123 104 227 
8 to 12 years 115 164 279 
12 to 16 years 141 108 249 
16 to 20 years 156 385 541 
20 to 30 years 522 844 1,366 
30 to 40 years 1,947 1,406 3,353 
40 to 50 years 1,497 584 2,081 
50 to 60 years 1,275 951 2,226 
60 to 70 years 1,180 1,070 2,250 
70 to 80 years 338 439 777 
80 to 90 years 51 110 161 
90 years and older 1 4 5 
Total 7,598 6,406 14,004 
*The term “to” specifies the upper limit in the sense of “less than”. 
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Table 2. Normal values for heart-rate corrected SDNN (in ms) per age group and for both sexes 
 Median (2nd percentile; 98th percentile) 
Age group Boys/men Girls/women 
< 1 month 99.9 (32.4; 267.6) 109.5 (35.1; 281.4) 
1 to 3 months* 99.7 (32.3; 267.2) 109.1 (34.9; 280.8) 
3 to 6 months 99.1 (32.1; 266.2) 108.5 (34.7; 279.6) 
6 to 12 months 98.3 (31.8; 264.8) 107.4 (34.3; 277.7) 
1 to 3 years 95.7 (30.6; 260.1) 104.1 (33.0; 271.6) 
3 to 5 years 91.5 (28.9; 252.6) 99.0 (31.1; 262.1) 
5 to 8 years 86.2 (26.8; 242.7) 92.8 (28.8; 250.5) 
8 to 12 years 78.7 (24.0; 227.7) 84.4 (25.8; 234.5) 
12 to 16 years 70.1 (21.0; 209.1) 75.4 (22.6; 216.6) 
16 to 20 years 62.1 (18.3; 190.6) 67.3 (19.9; 199.5) 
20 to 30 years 50.7 (14.8; 162.8) 55.5 (16.4; 172.3) 
30 to 40 years 39.8 (11.7; 135.1) 42.6 (12.9; 138.0) 
40 to 50 years 31.9 (9.5; 117.0) 32.5 (10.2; 111.4) 
50 to 60 years 25.2 (7.3; 105.2) 25.1 (8.1; 94.2) 
60 to 70 years 20.9 (5.8; 109.7) 20.5 (6.8; 90.3) 
70 to 80 years 18.0 (4.7; 136.1) 18.0 (6.0; 105.7) 
80 to 90 years 15.6 (3.9; 203.4) 16.7 (5.6; 157.8) 
*The term “to” specifies the upper limit in the sense of “less than”. 
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Table 3. Normal values for heart-rate corrected RMSSD (in ms) per age group for both sexes 
 Median (2nd percentile; 98th percentile) 
Age group Boys/men Girls/women 
< 1 month 152.5 (51.6; 443.3) 162.9 (56.9; 463.4) 
1 to 3 months* 151.8 (51.4; 441.8) 162.1 (56.5; 461.7) 
3 to 6 months 150.4 (50.8; 438.8) 160.6 (55.9; 458.3) 
6 to 12 months 148.3 (49.9; 434.2) 158.3 (55.0; 453.1) 
1 to 3 years 141.5 (47.2; 419.3) 151.0 (52.0; 436.3) 
3 to 5 years 131.1 (43.1; 396.0) 139.8 (47.5; 410.6) 
5 to 8 years 118.8 (38.3; 367.5) 126.8 (42.4; 380.2) 
8 to 12 years 102.7 (32.3; 328.2) 110.3 (36.0; 340.2) 
12 to 16 years 86.2 (26.5; 284.8) 93.8 (29.9; 298.8) 
16 to 20 years 72.3 (22.0; 245.7) 80.2 (25.1; 262.9) 
20 to 30 years 55.1 (16.8; 193.1) 62.9 (19.4; 213.8) 
30 to 40 years 41.1 (13.0; 146.4) 46.7 (14.8; 161.7) 
40 to 50 years 32.3 (10.5; 119.4) 35.0 (11.6; 124.9) 
50 to 60 years 25.3 (8.1; 106.9) 26.8 (9.3; 104.3) 
60 to 70 years 21.4 (6.4; 122.2) 22.2 (7.8; 105.6) 
70 to 80 years 19.4 (5.4; 186.5) 20.3 (7.1; 139.5) 
80 to 90 years 17.8 (4.5; 307.9) 19.6 (6.7; 209.9) 
*The term “to” specifies the upper limit in the sense of “less than”.  
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Figure 1. Median, 2nd and 98th percentiles for heart-rate corrected SDNN in men and women 
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Figure 2. Median, 2nd and 98th percentiles for heart-rate corrected RMSSD in men and women 
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Figure 3. Median, 2nd and 98th percentiles for heart-rate corrected SDNN and uncorrected SDNN 
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Discussion  
This is the first population-based study to provide heart-rate corrected normal values for SDNN and 
RMSSD as derived from 10-second ECGs across all ages and for both sexes. Our study shows that in 
both men and women, the LLN of heart-rate corrected SDNN and RMSSD decreases continuously 
from birth to old age, whereas the ULN decreases until the age of 50-60 and then starts to rise again. 
Several studies calculated uncorrected normal values for HRV from 5-minute or 24-hour ECG 
signals 14-17. Nunan et al. 14 published normal values for middle-aged and elderly people in a 
systematic review of 5-minute SDNN and RMSSD using 44 studies containing 21,438 participants. 
However, their data were not stratified by age. Seppala et al. 15 reported normal HRV values but only 
for children aged 6 to 8 years. Additionally, two studies looked at the effect of age. Kim et al. 16 
found that 5-minute SDNN and RMSSD decreased between the age of 18 and 50 in both men and 
women. Umetani et al. 17 also found that 24-hour SDNN decreases in adults, as recorded in 260 
healthy participants aged 10-99 years. The decrease of uncorrected 5-minute or 24-hour HRV in 
aging adults was similar to the decrease in uncorrected 10-second HRV found in our study, as 
illustrated in Figure 3. There is one other study that calculated normal values of uncorrected 10-
second HRV, for middle-aged and elderly participants, but this study did not take age into account 18. 
 
When HRV is not heart-rate corrected, we find a sharp increase between birth and adolescence,  
a pattern that was also observed by others 29,30. However, this increase is connected to heart rate, 
which is known to be strongly age-dependent in the young 19. After heart-rate correction, SDNNc 
and RMSSDc decrease continuously from birth to adolescence, and further into older ages. A 
continuous decrease in HRV indices was also observed in a recent study in children aged 6-13 years 
11, after correcting the indices by different powers of the heart rate. These findings underline the fact 
that meaningful comparison of HRV measurements, and their possible association with adverse 
outcomes, can only be made if the relationship between HRV and heart rate is properly taken into 
account, especially in children. Our correction formulas for SDNN and RMSSD can be applied to deal 
with this issue 
We made the observation, not previously reported in the literature, that after the age of 60 
the ULN turns upwards, in men even more than in women, while the median and LLN continue their 
downward course. This finding implies a growing instability in sinus node activity in a part of the 
aging population. This is perhaps caused by incipient dysfunction of the cardiac excitation and 
conduction tissues. 
Our study has a number of strengths. First, we are the first study to report HRV normal 
values that are corrected for heart rate. We have a total of 14,004 ECGs with wide age coverage, 
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from children of 11 days to 90-year old men and women. All ECGs from the five included study 
cohorts were analyzed automatically by a well-validated program, MEANS, which eliminates intra-
observer bias. The use of the 10-second ECG may be seen as a strength and as a limitation. 
Admittedly, the 10-second ECG contains less information than longer recordings, and may 
sometimes contain only a few RR intervals for HRV calculation. On the other hand, it was 
demonstrated in pulse wave recordings that 10-second HRV appears a valid proxy for HRV as derived 
from longer ECG recordings3. Moreover, the 10-second ECG is in universal use, cheap, and easily 
obtained without extra annoyance for the patient. Its benefits then outweigh its inadequacies. A 
further limitation of our study is the low number of ECGs in the extremes of the age distribution. For 
this reason, the normal limits of the groups younger than six months and older than ninety years 
should be used with caution. 
In conclusion, normal limits have been established for heart-rate corrected SDNN and 
RMSSD, derived from 10-second ECGs, using a consistent and automatic methodology for all ages 
and both sexes. Our coverage of the pediatric population allows age-specific comparisons of HRV of 
the pediatric ECGs, which change rapidly from birth to puberty, independent of the rapid change in 
heart rate in the same life period. Using these normal values, both researchers and clinicians have a 
tool to decide upon cut-off values of HRV, which improves the applicability of 10-second HRV in 
practice.  
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Supplementary Table 1. Percentiles of heart-rate corrected SDNN (in milliseconds) for men 
Age group 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 51.6 64.6 78.4 107.8 152.5 215.4 294.8 356.6 443.3 
1 to 3 months* 51.4 64.2 78.0 107.2 151.8 214.5 293.6 355.3 441.8 
3 to 6 months 50.8 63.5 77.2 106.2 150.4 212.7 291.3 352.6 438.8 
6 to 12 months 49.9 62.5 76.0 104.6 148.3 209.9 287.8 348.6 434.2 
1 to 3 years 47.2 59.2 72.1 99.5 141.5 201.0 276.5 335.7 419.3 
3 to 5 years 43.1 54.2 66.2 91.8 131.1 187.2 259.0 315.6 396.0 
5 to 8 years 38.3 48.4 59.3 82.7 118.8 170.8 237.8 291.1 367.5 
8 to 12 years 32.3 41.1 50.5 70.9 102.7 148.9 209.2 257.8 328.2 
12 to 16 years 26.5 33.9 41.8 59.1 86.2 125.9 178.6 221.6 284.8 
16 to 20 years 22.0 28.1 34.8 49.3 72.3 106.3 151.9 189.6 245.7 
20 to 30 years 16.8 21.5 26.6 37.6 55.1 81.3 117.1 147.2 193.1 
30 to 40 years 13.0 16.5 20.3 28.4 41.1 60.3 87.0 110.1 146.4 
40 to 50 years 10.5 13.3 16.2 22.5 32.3 47.2 68.6 87.9 119.4 
50 to 60 years 8.1 10.3 12.6 17.6 25.3 37.6 56.2 74.3 106.9 
60 to 70 years 6.4 8.3 10.3 14.6 21.4 32.8 52.3 74.2 122.2 
70 to 80 years 5.4 7.1 9.0 12.9 19.4 31.0 54.5 87.4 186.5 
80 to 90 years 4.5 6.2 7.9 11.7 17.8 29.7 58.3 107.8 307.9 
*The term “to” specifies the upper limit in the sense of “less than”. 
 
 
Supplementary Table 2. Percentiles of heart-rate corrected SDNN (in milliseconds) for women 
Age group 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 35.1 45.0 55.6 77.5 109.5 151.4 200.1 235.3 281.4 
1 to 3 months* 34.9 44.9 55.4 77.3 109.1 151.0 199.6 234.8 280.8 
3 to 6 months 34.7 44.6 55.1 76.8 108.5 150.1 198.6 233.6 279.6 
6 to 12 months 34.3 44.1 54.5 76.0 107.4 148.9 197.0 231.9 277.7 
1 to 3 years 33.0 42.5 52.6 73.5 104.1 144.6 191.9 226.4 271.6 
3 to 5 years 31.1 40.1 49.7 69.6 99.0 138.1 184.0 217.6 262.1 
5 to 8 years 28.8 37.2 46.2 65.0 92.8 130.1 174.4 207.0 250.5 
8 to 12 years 25.8 33.4 41.5 58.7 84.4 119.3 161.2 192.4 234.5 
12 to 16 years 22.6 29.4 36.7 52.1 75.4 107.4 146.6 176.2 216.6 
16 to 20 years 19.9 25.9 32.4 46.2 67.3 96.6 133.0 160.9 199.5 
20 to 30 years 16.4 21.2 26.6 37.9 55.5 80.5 112.2 137.1 172.3 
30 to 40 years 12.9 16.6 20.5 29.1 42.6 62.0 87.5 108.1 138.0 
40 to 50 years 10.2 12.9 15.9 22.3 32.5 47.7 68.3 85.5 111.4 
50 to 60 years 8.1 10.2 12.4 17.2 25.1 37.3 54.7 70.0 94.2 
60 to 70 years 6.8 8.4 10.1 14.0 20.5 31.1 47.5 63.1 90.3 
70 to 80 years 6.0 7.4 8.8 12.2 18.0 28.3 46.1 65.6 105.7 
80 to 90 years 5.6 6.8 8.1 11.2 16.7 27.3 49.0 78.1 157.8 
*The term “to” specifies the upper limit in the sense of “less than”. 
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Supplementary Table 3. Percentiles of heart-rate corrected RMSSD (in milliseconds) for men 
Age group 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 51.6 64.6 78.4 107.8 152.5 215.4 294.8 356.6 443.3 
1 to 3 months* 51.4 64.2 78.0 107.2 151.8 214.5 293.6 355.3 441.8 
3 to 6 months 50.8 63.5 77.2 106.2 150.4 212.7 291.3 352.6 438.8 
6 to 12 months 49.9 62.5 76.0 104.6 148.3 209.9 287.8 348.6 434.2 
1 to 3 years 47.2 59.2 72.1 99.5 141.5 201.0 276.5 335.7 419.3 
3 to 5 years 43.1 54.2 66.2 91.8 131.1 187.2 259.0 315.6 396.0 
5 to 8 years 38.3 48.4 59.3 82.7 118.8 170.8 237.8 291.1 367.5 
8 to 12 years 32.3 41.1 50.5 70.9 102.7 148.9 209.2 257.8 328.2 
12 to 16 years 26.5 33.9 41.8 59.1 86.2 125.9 178.6 221.6 284.8 
16 to 20 years 22.0 28.1 34.8 49.3 72.3 106.3 151.9 189.6 245.7 
20 to 30 years 16.8 21.5 26.6 37.6 55.1 81.3 117.1 147.2 193.1 
30 to 40 years 13.0 16.5 20.3 28.4 41.1 60.3 87.0 110.1 146.4 
40 to 50 years 10.5 13.3 16.2 22.5 32.3 47.2 68.6 87.9 119.4 
50 to 60 years 8.1 10.3 12.6 17.6 25.3 37.6 56.2 74.3 106.9 
60 to 70 years 6.4 8.3 10.3 14.6 21.4 32.8 52.3 74.2 122.2 
70 to 80 years 5.4 7.1 9.0 12.9 19.4 31.0 54.5 87.4 186.5 
80 to 90 years 4.5 6.2 7.9 11.7 17.8 29.7 58.3 107.8 307.9 
*The term “to” specifies the upper limit in the sense of “less than”. 
 
 
Supplementary Table 4. Percentiles of heart-rate corrected RMSSD (in milliseconds) for women 
Age group 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 35.1 45.0 55.6 77.5 109.5 151.4 200.1 235.3 281.4 
1 to 3 months* 34.9 44.9 55.4 77.3 109.1 151.0 199.6 234.8 280.8 
3 to 6 months 34.7 44.6 55.1 76.8 108.5 150.1 198.6 233.6 279.6 
6 to 12 months 34.3 44.1 54.5 76.0 107.4 148.9 197.0 231.9 277.7 
1 to 3 years 33.0 42.5 52.6 73.5 104.1 144.6 191.9 226.4 271.6 
3 to 5 years 31.1 40.1 49.7 69.6 99.0 138.1 184.0 217.6 262.1 
5 to 8 years 28.8 37.2 46.2 65.0 92.8 130.1 174.4 207.0 250.5 
8 to 12 years 25.8 33.4 41.5 58.7 84.4 119.3 161.2 192.4 234.5 
12 to 16 years 22.6 29.4 36.7 52.1 75.4 107.4 146.6 176.2 216.6 
16 to 20 years 19.9 25.9 32.4 46.2 67.3 96.6 133.0 160.9 199.5 
20 to 30 years 16.4 21.2 26.6 37.9 55.5 80.5 112.2 137.1 172.3 
30 to 40 years 12.9 16.6 20.5 29.1 42.6 62.0 87.5 108.1 138.0 
40 to 50 years 10.2 12.9 15.9 22.3 32.5 47.7 68.3 85.5 111.4 
50 to 60 years 8.1 10.2 12.4 17.2 25.1 37.3 54.7 70.0 94.2 
60 to 70 years 6.8 8.4 10.1 14.0 20.5 31.1 47.5 63.1 90.3 
70 to 80 years 6.0 7.4 8.8 12.2 18.0 28.3 46.1 65.6 105.7 
80 to 90 years 5.6 6.8 8.1 11.2 16.7 27.3 49.0 78.1 157.8 
*The term “to” specifies the upper limit in the sense of “less than”. 
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Abstract 
Background Tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may 
be associated with lower heart rate variability (HRV), a condition associated with increased mortality 
risk. We aimed to investigate the association between TCAs, SSRIs and HRV in a population-based 
study. 
 
Methods In the prospective Rotterdam Study cohort, up to five ECGs per participant were recorded 
(1991 – 2012). Two HRV variables were studied: standard deviation of normal-to-normal RR intervals 
(SDNN) and root mean square of successive RR-interval differences (RMSSD). We compared the HRV 
on ECGs recorded during use of antidepressants with the HRV on ECGs recorded during non-use of 
any antidepressant. Additionally, we analyzed the change in HRV on consecutive ECGs. Those who 
started or stopped using antidepressants before the second ECG were compared with non-users on 
two ECGs.  
 
Results We included 23,647 ECGs from 11,729 participants (59% women, mean age 64.6 years at 
baseline). Compared with ECGs recorded during non-use of antidepressants (22,971 ECGs), SDNN 
and RMSSD were lower in ECGs recorded during use of TCAs (296 ECGs) and SSRIs (380 ECGs). 
Participants who started using TCAs before the second ECG had a lower HRV, and those who 
stopped had a higher HRV than consistent non-users (p-value < 0.001) at the time of the second ECG 
recording. Starting or stopping SSRIs was not associated with HRV changes. 
 
Conclusion TCAs were associated with a lower HRV in all analyses, indicating a real drug effect. For 
SSRIs the results are mixed, indicating a weaker association, possibly due to other factors.  
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Introduction 
Heart-rate variability (HRV) refers to the beat-to-beat variability in heart rate. HRV is influenced by 
the parasympathetic and sympathetic autonomous nervous system. HRV is lowered when 
parasympathetic nerve activity is decreased or when sympathetic nerve activity is increased1-3. A 
relatively low HRV is associated with an increased risk of all-cause mortality4-9, cardiac mortality8,10, 
and sudden cardiac death 11.  
 Use of antidepressants has been associated with a lower HRV in a number of studies12-18. 
Two population-based studies on the relation between antidepressants and HRV12,16 reported that 
use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) is 
associated with a lower HRV. In both studies, the effect of the TCAs on HRV was more pronounced 
than that of SSRIs12,16. This is possibly caused by the anticholinergic effects of TCAs19. A meta-analysis 
reported that depression itself – and not antidepressant use – is associated with a lower HRV17, 
while the association between depression and HRV was found to be predominantly driven by the use 
of antidepressants in a different and larger study16. 
To date, only one population-based cohort study has addressed the association between 
TCAs, SSRIs and HRV12. However, this study neither investigated longitudinal effects of 
antidepressant use on HRV nor a possible dose-response relationship of antidepressants on HRV. 
These analyses can add to the evidence for a drug effect instead of an effect observed due to 
residual confounding. In addition, no studies to date have examined individual antidepressants with 
regard to their association with HRV, as only class effects were considered. Therefore, in order to 
address these issues, our objective was to investigate the association between TCA use, SSRI use, 
and HRV in a general middle-aged and elderly population.  
 
Methods 
Study setting 
This study is part of the Rotterdam Study, a prospective population-based cohort study. The design 
and rationale of the Rotterdam Study have been described in more detail elsewhere20,21. In short, 
from 1990 to 1993, all inhabitants aged 55 years and older from the Ommoord district in Rotterdam, 
the Netherlands, were invited to participate in the initial cohort. A total of 7,983 individuals agreed 
to participate (response rate 78%). In 2000, the cohort was extended by including all inhabitants 
from the same district who became 55 years or older, or who had moved into the district after the 
start of the initial cohort. In this extension of the cohort, 3,011 individuals agreed to participate 
(response rate 67%). The cohort was additionally extended in 2006 by inviting inhabitants of the 
same district aged 45 years and older. In total, 3,932 individuals agreed to participate (response rate 
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65%). Follow-up examinations were conducted approximately every four to five years after baseline 
examination, with a maximum of five center visits per participant. The Rotterdam Study has been 
approved by the medical ethics committee according to the Wet Bevolkingsonderzoek ERGO 
(Population Study Act Rotterdam Study), executed by the Ministry of Health, Welfare and Sport of 
the Netherlands. Written informed consent was obtained from all study participants. 
 
Study population and selection of ECGs 
ECGs of participants of the Rotterdam Study recorded between January 1st, 1991 and December 31st, 
2012 were included. ECGs recorded before January 1st, 1991 were excluded because pharmacy 
dispensing records were not available. We also excluded ECGs with less than five normal heartbeats 
and ECGs on which the following pathology was detected: left or right bundle branch block, second 
degree or third degree atrioventricular block, ventricular hypertrophy according to Sokolow-Lyon 
criteria, atrial fibrillation. ECGs recorded with a pacemaker rhythm or recorded during the use of 
monoamine-oxidase inhibitors (ATC code: N06AF/AG) and other antidepressants (ATC code: N06AX) 
were excluded, because of the low number of prescriptions and heterogeneous pharmacodynamics. 
 
Antidepressant exposure assessment 
At study entry, more than 95% of the participants had their drug prescriptions filled at one of the 
seven fully computerized regional pharmacies, which use one common computer network. 
Dispensing data was available on a day-to-day basis, which included the anatomical therapeutic 
chemical (ATC) code, the dispensing date, the total amount of tablets/capsules per dispensing, the 
prescribed daily number of tablets/capsules, and the product name of the drug. Dispensing episodes 
were calculated by dividing the total number of filled tablets/capsules by the daily prescribed 
number. If the date of an ECG recording fell within a dispensing episode of TCAs (ATC code: N06AA) 
or SSRIs (ATC code: N06AB), the participant was considered as being exposed during that ECG 
recording. We allowed a carry-over period of 7 days to define current users. For individual 
antidepressants, the complete, 7-digit ATC code was used. The dosage was defined as the ratio 
between the prescribed daily dosage by the defined daily dosage (PDD/DDD ratio), as determined by 
the World Health Organization22.  
 
Heart-rate variability  
A standard 10-second, 12-lead resting ECG was recorded with an ACTA Gnosis electrocardiograph 
(Esaote Biomedica, Florance, Italy) at a sampling frequency of 500 Hz and stored digitally. ECGs were 
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processed by the standardized modular ECG analysis system (MEANS), which has been described 
previously and has been validated and applied extensively23-27. 
HRV was calculated based on RR intervals between normal heart beats: RR intervals were 
excluded if they immediately preceded or followed premature ventricular complexes or premature 
supraventricular complexes 28. We selected two of the most commonly used HRV variables; the 
standard deviation of normal-to-normal RR intervals (SDNN) and the root mean square of successive 
RR-interval differences (RMSSD) 29,30.  
 
Depression score 
A Dutch version of the Center for Epidemiological Studies Depression (CES-D) scale was used to 
screen for depressive symptoms. The outcome of this questionnaire is a score ranging between 0 
and 60. A higher score indicates more depressed feelings 31,32. The CES-D questionnaire was taken at 
visits from 1993 onwards. Therefore, we adjusted for CES-D score in a subsample analysis, using only 
those persons and ECGs for which a CES-D score is available. 
 
Covariables 
The following covariables were considered: age, sex, smoking status, body-mass index (BMI), RR 
interval, hypertension, prevalent coronary heart disease, prevalent diabetes mellitus, heart failure, 
use of beta-blockers, use of verapamil and use of diltiazem. All covariables were determined at the 
date of ECG recording. Smoking status (current smoker or non-smoker) was determined by home 
interview. BMI was calculated by dividing weight by the squared height, with weight in kilograms 
and height in meters, which were both measured at the study center. Heart rate was taken into 
account in the form of the RR interval as recorded on the ECG (heart rate equals 60,000 / RR 
interval), because both HRV measures are also based on the RR interval. Blood pressure was 
measured twice in sitting position at the upper right arm. The average of these measurements was 
used. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher, a diastolic 
blood pressure of 90 mmHg or higher, or the use of blood pressure lowering medication for the 
indication hypertension. Coronary heart disease was defined as a prevalent myocardial infarction or 
as a history of coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention 
(PCI). Myocardial infarction was adjudicated based on a combination of symptoms, ECG 
measurements, and enzyme markers indicative for the presence of myocardial infarction 33. Diabetes 
mellitus was defined by the use of blood-glucose lowering drugs, a non-fasting glucose level of more 
than 11.0 mmol/L, or a fasting glucose level of more than 6.9 mmol/L34. The diagnosis of heart 
failure was based on typical signs and symptoms confirmed by objective cardiac dysfunction33. Use 
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of heart-rate affecting drugs (beta-blockers, verapamil, and diltiazem) at the date of ECG recording 
was based on pharmacy dispensing records. 
Statistical analyses 
 Baseline characteristics were assessed at the first eligible ECG recording for each participant. 
We log-transformed the HRV measures for all analyses, but results are presented back-transformed 
to the geometric scale. We used linear mixed models to take into account the within-person 
correlation between multiple visits. We fitted models with different covariance matrices and 
selected the model that had the lowest Akaike's information criterion (AIC). All statistical models 
were adjusted for age, sex, RR interval, and heart-rate affecting drugs (beta-blockers, verapamil, and 
diltiazem). In a second model, we included all other available covariables.  
In the first set of analyses, we compared the HRV recorded during TCA use and SSRI use with 
the HRV recorded during non-use of antidepressants. We repeated these analyses for the individual 
antidepressants if more than 10 exposed ECGs were available. For paroxetine and amitriptyline, the 
most frequently prescribed drugs in the Rotterdam Study cohort35, we additionally analyzed a 
possible dose-response relationship. In a subsample analysis, we adjusted all previously mentioned 
analyses for the CES-D score, in the subgroup for which CES-D scores were available. With this 
adjustment, we aimed to determine if the association between the antidepressants and HRV is 
mediated by depressive symptoms. In the second set of analyses, we compared the change in HRV of 
those who started or stopped using TCAs or SSRIs by the time of the second visits with the HRV of 
non-users on two consecutive visits. Because the HRV variables were log-transformed and because 
log(a) – log(b) = log(a/b), the difference between two log-transformed measurements is presented 
as the fold-change in HRV of the back-transformed measurement. We used IBM SPSS Statistics 
version 21.0 (IBM Corp., Somers, NY, USA) for all analyses. Two-sided p-values below 0.05 were 
considered statistically significant.  
 
Results 
Study characteristics  
In total, 27,833 ECGs were recorded. We excluded 3,004 ECGs (10.8%) because cardiac pathologies 
had been detected. An additional 1,072 ECGs (3.9%) were excluded because they had less than five 
normal heartbeats. 110 ECGs were excluded because they were recorded during use of 
antidepressants other than TCAs and SSRIs. In the final selection, 23,647 ECGs from 11,729 
participants were used. Baseline characteristics of the final study population are shown in Table 1. In 
short, 59 percent of the total study population was woman, and the mean age was 64.6 years with a 
standard deviation (SD) of 9.5 years.  
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Table 1. Baseline characteristics of the study population 
Characteristic Total study population 
N = 11,729 
Number of ECGs 23,647 
ECGs per participant, median (range) 2 (1 – 5) 
Time between ECG recordings in years, median (IQR) 4.1 (2.4 – 5.0) 
  
Age in years, mean (SD) 64.6 (9.5) 
Women, N (%) 6,896 (58.8) 
Body-mass index in kg/m2, mean (SD) 27.0 (4.1) 
CES-D score, median (IQR) 3 (1 – 8) 
RR interval in milliseconds (SD) 881 (141) 
Heart rate in beats per minute, mean (SD) 70 (11) 
  
Beta-blocker use, N (%) 1,470 (12.5) 
Verapamil use, N (%) 67 (0.6) 
Diltiazem use, N (%) 134 (1.1) 
  
Current smoking, N (%) 2,458 (21.0) 
Coronary heart disease, N (%) 677 (5.8) 
Heart failure, N (%) 179 (1.5) 
Hypertension, N (%) 6,060 (51.7) 
Diabetes mellitus, N (%) 845 (7.2) 
Abbreviations: CES-D, Center of Epidemiological Studies Depression Scale; ECG, electrocardiogram; 
IQR, interquartile range; SD standard deviation; RMSSD, root mean square of successive differences; 
SDNN, standard deviation of normal-to-normal RR intervals.  
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Antidepressant use and HRV 
The lowest Akaike's information criterion was achieved with the 'first-order autoregressive 
covariance structure with heterogeneous variances'. This covariance structure was therefore used in 
all analyses. Table 2 presents the geometric estimated means of SDNN and RMSSD for ECGs made 
during non-use of antidepressants and during use of TCAs and use of SSRIs. Of all 23,647 included 
ECGs, 296 were recorded during TCA use and 380 ECGs were recorded during SSRI use.  
Compared with ECGs recorded during non-use of antidepressants, ECGs recorded during TCA 
use had a significant (p-values < 0.05) lower SDNN (18.3 ms for non-use, and 15.6 ms for TCAs) and 
RMSSD (19.8 ms for non-use and 16.7 ms for TCAs). ECGs recorded during SSRI use also showed a 
significantly lower SDNN (18.3 ms for non-use and 15.4 ms for SSRI use) and a lower RMSSD (19.8 ms 
for non-use and 17.1 ms for SSRI use) than ECGs recorded during non-use. Of the individual 
antidepressants, ECGs recorded during use of clomipramine (27 ECGs), amitriptyline (185 ECGs), 
nortriptyline (13 ECGs), fluoxetine (35 ECGs) and paroxetine (237 ECGs) showed significantly lower 
HRV measures than ECGs recorded during non-use of antidepressants. A dose-response relationship 
was analyzed for amitriptyline and paroxetine, which were the most frequently prescribed 
antidepressants. A higher prescribed dosage of both amitriptyline (Figure 1A) and paroxetine (Figure 
1B) was associated with a statistically significant trend toward a lower SDNN. Results were similar for 
RMSSD (results not shown).  
Similar results were observed when adjusted for all considered covariables in this study 
(results not shown).   
 
Analyses for possible mediation by depressive symptoms 
A total of 14,693 ECGs from 9,194 participants were recorded during visit rounds when information 
of depressive symptoms was available. Of those ECGs, 180 were recorded during use of TCAs and 
318 ECGSs were recorded during use of SSRIs. In this subgroup, the associations between TCAs, SSRIs 
and the HRV measures were similar as observed in the total cohort. Additional adjustment for CES-D 
score did not materially change these results (Supplementary Tables 1 and 2).  
 
Longitudinal analysis of antidepressant use and HRV 
Table 3 shows the ECGs made on two consecutive visits, and the estimated mean fold-change in 
SDNN and RMSSD between two visits. The results show that HRV is reduced when TCA use is started, 
and that HRV is increased when TCA use is stopped. For SSRIs the same pattern is observed, but with 
a smaller effect size and no statistically significant difference with consistent non-users. 
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Table 2. Heart-rate variability recorded during non-use and use of antidepressants 
  SDNN (ms) RMSSD (ms) 
 ECGs Median  
PDD / DDD 
Meanadj in ms  
(95% CI) 
Meanadj in ms (95%CI) 
Non-use of antidepressants (ref) 22,971 NA 18.3 (17.0 – 19.7) 19.8 (18.4 – 21.4) 
     
TCA use 296 0.33   15.6 (14.0 – 17.4) ‡  16.7 (15.0 – 18.7) ‡ 
-   Imipramine 16 0.50 15.9 (11.3 – 22.5) 19.3 (13.6 – 27.4) 
-   Clomipramine 27 0.50 10.9 (8.3 – 14.4) ‡ 11.4 (8.6 – 15.0)  ‡ 
-   Amitriptyline 185 0.33 16.3 (14.4 – 18.5)  17.3 (15.2 – 19.7) * 
-   Nortriptyline 13 0.67 10.3 (6.8 – 15.5) † 11.3 (7.4 – 17.2) † 
-   Maprotiline 48 0.50 15.5 (12.5 – 19.3) 17.0 (13.6 – 21.1) 
     
SSRI use 380 1.00 15.4 (14.0 – 17.0) ‡ 17.1 (15.4 – 19.0) ‡ 
-   Fluoxetine 35 1.00 12.5 (9.8 – 15.8) † 14.1 (11.1 – 18.0) † 
-   Citalopram 28 1.00 16.8 (13.0 – 21.8) 18.0 (13.9 – 23.3) 
-   Paroxetine 237 1.00 15.2 (13.5 – 17.0) ‡ 16.9 (15.0 – 19.0) † 
-   Sertraline 37 1.00 15.8 (12.4 – 20.0) 16.8 (13.2 – 21.5) 
-   Fluvoxamine 39 1.00 17.6 (14.0 – 22.2) 19.6 (15.5 – 24.7) 
Abbreviations: ref, reference; CI, confidence interval; DDD, defined daily dosage; ECGs, number of 
electrocardiograms; Meanadj : geometric mean adjusted for covariables; ms: milliseconds; NA, not 
applicable; PDD, prescribed daily dosage; RMSSD, root mean square of successive differences; SDNN, 
standard deviation of normal-to-normal RR-interval; SSRI, selective serotonin reuptake inhibitor; 
TCA, tricyclic antidepressant. Only individual antidepressants prescribed during more than 10 ECG 
recordings were analyzed. Analyses were adjusted for age, sex, RR interval, use of beta-blockers, 
verapamil and diltiazem. * p-value <0.05; † p-value < 0.01; ‡ p-value < 0.001 compared with non-use 
of antidepressants.  
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Table 3. Antidepressant use and fold-change in heart-rate variability between two consecutive visits 
   Meanadj fold-change (95%CI) 
Use on first visit Use on second visit ECGs SDNN RMSSD  
None None 11,103 1.06 (0.96 – 1.18) 1.08 (0.97 – 1.20) 
     
None  TCA 82   0.76 (0.62 – 0.94) †   0.75 (0.61 – 0.93) † 
None  SSRI 94 0.90 (0.74 – 1.10) 0.98 (0.80 – 1.20) 
     
TCA  None 65   1.49 (1.18 – 1.87) †   1.64 (130 – 2.08) † 
SSRI  None 62 1.10 (0.87 – 1.39) 1.10 (0.87 – 1.40) 
Abbreviations: CI: confidence interval; ECGs : number of electrocardiograms; Meanadj : geometric 
mean adjusted for covariables; RMSSD, root mean square of successive differences; SDNN, standard 
deviation of normal-to-normal RR intervals; SSRI; selective serotonin reuptake inhibitor; TCA: 
tricyclic antidepressant. Analyses were adjusted for age, sex, RR interval, use of beta-blockers, 
verapamil and diltiazem. † p-value < 0.001 compared with non-use of antidepressants during both 
ECGs.  
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Figure 1. Association of amitriptyline and paroxetine dosages with heart-rate variability  
 
Abbreviations: DDD, defined daily dosage; ms, milliseconds; PDD, prescribed daily dosage; SDNN, 
standard deviation of normal-to-normal RR intervals. The bars represent the mean SDNN, the 
whiskers are the upper limit of the 95% confidence interval. P-valuetrend indicates the level of 
statistical significance across the strata. Analyses were adjusted for age, sex, RR interval, use of beta-
blockers, verapamil and diltiazem.  
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Discussion 
In this population-based study in older adults, use of TCAs and SSRIs was associated with a lower 
HRV. In addition, the individual antidepressants clomipramine, amitriptyline, nortriptyline, fluoxetine 
and paroxetine were significantly associated with a lower HRV and a dose-response relationship of 
amitriptyline and paroxetine with HRV was observed. In the longitudinal analysis, the start of TCA 
use, and not SSRI use, was associated with significant changes in HRV. Additional adjustment for CES-
D score did not materially change the results.  
 To our knowledge, only one study to date has analyzed the effect of antidepressant use on 
HRV in the general older population12. This study reported a lower HRV in users of TCAs and SSRIs, 
which is in line with the results of our study. However, we additionally investigated the effect of 
individual antidepressants on HRV: all previous studies only considered antidepressant classes. We 
observed a lower HRV for all individual TCAs, but the difference with non-use of antidepressants was 
largest for clomipramine and nortriptyline. Imipramine and maprotiline showed much smaller 
differences in HRV compared with non-use, while the prescribed daily dosages were similar. For 
amitriptyline, the smaller effect on HRV can be explained by the fact that it was prescribed at a 
lower median daily dosage than the other TCAs. This is supported by the fact that we found a 
significant trend towards a lower HRV with higher amitriptyline dosages. For individual SSRIs, the 
results were difficult to interpret. Users of fluoxetine had a notably lower HRV than users of the 
other SSRIs while the median daily dosage of all individual SSRIs was the same. Although HRV was 
somewhat lower during the use of all individual SSRIs, the difference for these individual SSRIs was 
not statistically significant, which could be due to a low number of users. Therefore, we were not 
able to exclude the possibility that HRV is dependent on the use of only certain SSRIs. Nevertheless, 
we observed a significant dose-response relationship for paroxetine, which was not statistically 
significant in the overall analysis. For this reason, these analyses should be repeated in other studies. 
Additional adjustment for depressive score did not materially change the results. This finding 
contradicts the meta-analysis17, but is in line with a different and larger cohort study16. That cohort 
study suggested that the association between depression and HRV was predominantly driven by the 
use of antidepressants.  
The previously mentioned population-based study12 had only one measurement per 
participant and could not assess longitudinal changes over time. One study did assess longitudinal 
changes in HRV with respect to starting and stopping of TCA treatment and SSRI treatment18. They 
found that starting TCA treatment or starting SSRI treatment was associated with a reduction in HRV. 
However, starting SSRI treatment was associated with less reduction in HRV than starting TCAs18. In 
our study, we observed no significant decrease in HRV after starting SSRIs, and no significant 
 Antidepressants and Heart-Rate Variability in Older Adults 
59 
 
increase after stopping SSRIs. The inconsistent results for SSRIs for the cross-sectional and 
longitudinal analyses might suggest that other, unexamined, factors than the drug itself lead to a 
lower HRV, but additional research is required to support this suggestion.  
The relatively low HRV in users of TCAs might have clinical consequences for an individual 
patient, as a relatively low HRV has been associated with an increased risk of all-cause mortality4-9, 
cardiac mortality8,10, and sudden cardiac death11. TCAs have also been associated with an increased 
risk of cardiac mortality36. Whether this increased risk is due to a low HRV should be determined in 
subsequent studies.  
 This study has a number of strengths and limitations. Major strengths were the availability 
of detailed pharmacy-dispensing data and the availability of multiple ECG recordings for most 
participants. Also, we used MEANS, which calculates the RR interval and heart-rate variability 
systematically and automatically. This enhances precision of the measurements and prevents bias in 
ECG assessment24,26. Information bias for drug use was limited as pharmacy-dispensing data was 
collected prospectively and irrespective of disease state. The analysis using the calculated within-
person changes of HRV between two consecutive visit rounds is less subjected to confounding than 
our cross-sectional analysis and the results are complementary. Finally, we added a variable for 
depressive symptoms which did not change the results. There are also some limitations to address. 
First, some of the individual antidepressants were dispensed in low numbers. Second, the median 
time interval between two ECG recordings was 4.1 years, which limits the interpretation of a change 
in HRV between visits, as other confounding factors may occur in the long time period. Finally, we 
used standard 10-second ECG recordings, while the major studies in the literature are based on 5-
minute or longer ECGs. However, in two previous studies, HRV derived from 10-second ECGs was still 
predictive for cardiovascular disease and mortality9,37, and the results of the first set of analyses in 
this paper are in line with that of previous studies12,18. Besides this, 10-second ECGs are cheaper and 
more patient friendly. 
 In conclusion, the results indicate that TCAs are associated with a lower HRV in a general 
middle-aged and elderly population, a condition associated with an increased risk of mortality. For 
SSRIs this is less clear, although we observed an association between SSRIs and HRV and a dose-
response relationship of paroxetine with HRV.  
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Abstract 
Background A prolonged heart-rate corrected QT interval (QTc) increases the risk of sudden cardiac 
death. Some methods of heart-rate correction (notably Bazett) overestimate QTc in people with high 
heart rates. Studies suggest that tricyclic antidepressants (TCAs) can prolong the QTc and increase 
heart rate. Therefore, we aimed to study whether TCA-induced QTc prolongation is a false-positive 
observation due to overestimation at high heart rates.  
 
Methods For this, we included 12,734 participants from the prospective population-based 
Rotterdam Study, with a total of 27,068 electrocardiograms (ECGs) of which 331 during TCA use. 
Associations between use of TCAs, QTc, and heart rate were studied with linear repeated 
measurement analyses. QT was corrected for heart rate according to Bazett (QTcBazett), Fridericia 
(QTcFridericia) or a correction based on regression coefficients obtained from the Rotterdam Study data 
(QTcStatistical).  
 
Results On ECGs recorded during TCA use, QTcBazett was 6.5 milliseconds (95% confidence interval: 
4.0 – 9.0) longer and heart rate was 5.8 beats per minute (95% confidence interval: 4.7 – 6.9) faster 
than during nonuse. QTcFridericia and QTcStatistical were not statistically significantly longer during TCA 
use than during non-use. Furthermore, QTcBazett was similar for ECGs recorded during TCA use and 
nonuse after statistical adjustment for heart rate. According to our results, TCA use appears not to 
be associated with QTc prolongation.  
 
Conclusion Therefore, the current advice of regulatory authorities to restrict use of these drugs and 
to do regular check-ups of the QTc may need to be revised. Other formulas, like Fridericia's, might be 
preferred. 
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Introduction 
A prolonged heart-rate corrected QT interval (denoted hereafter as QTc) on the electrocardiogram 
(ECG) is associated with an increased risk of torsade de pointes and sudden cardiac death1,2. QTc 
prolongation can be hereditary, environmentally, or drug-induced2. Drug-induced QTc prolongation 
is a frequent reason for withdrawal of a drug from the market3. In recent years, a large number of 
cardiac and non-cardiac drugs have been associated with QTc prolongation4.  
The QT interval and heart rate are highly correlated. Therefore, several formulas have been 
developed to correct the QT interval for heart rate. Both in clinical practice and in research, the 
formula by Bazett is used most frequently5-7. However, this correction is suboptimal because the 
resulting QTc is not completely independent of heart rate6,8. More specifically, Bazett's QTc is 
overestimated in individuals with a high heart rate, and underestimated in individuals with a low 
heart rate6,8. Nevertheless, QTc corrected with the formula of Fridericia is also overestimated in 
individuals with higher heart rate, but to a lesser extent than with Bazett’s8. Therefore, the American 
Food and Drug Administration recommends that studies assessing the QTc-prolonging effects of new 
drugs (thorough QT/QTc studies) should not use Bazett's formula alone7 but also other correction 
formulas, such as Fridericia's9 or correction formulas based on regression coefficients10-12.  
One of the drug groups thought to prolong the QTc are tricyclic antidepressants (TCAs)13-16. 
However, since TCAs also increase heart rate due to anticholinergic effects17, it is possible that the 
increase in QTc can be explained by a higher heart rate. The objective of our study was to reassess 
the association between use of TCAs and QTc using different heart-rate correction methods in a 
population-based cohort.  
 
Methods 
Study setting 
Our study was part of the Rotterdam Study, a prospective population-based cohort of middle-aged 
and elderly participants. The design and rationale of the Rotterdam Study is described in detail 
elsewhere18,19. In short, from 1990 to 1993, all inhabitants aged 55 years and older from the 
Ommoord district in Rotterdam, the Netherlands, were asked to participate. In total, 7983 
individuals agreed to participate (response rate 78%). The original cohort was extended in 2000. In 
this first subcohort, all inhabitants who turned 55 years of age or moved into the district (matching 
the age criterion) were asked to participate, of whom 3011 individuals agreed (response rate 67%). A 
second extension of the cohort was initiated in 2006. In this subcohort, inhabitants from the same 
district aged 45 years and older were invited to participate. In total, 3932 inhabitants agreed to 
participate (response rate 65%). Follow-up examinations were conducted every 4 to 5 years, with a 
current maximum of 5 center visits per participant. The Rotterdam Study has been approved by the 
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medical ethics committee according to the Wet Bevolkingsonderzoek ERGO (Population Study Act 
Rotterdam Study), executed by the Ministry of Health, Welfare and Sports of the Netherlands. 
Written informed consent was obtained from all study participants. 
 
Study population 
We included all participants with at least one ECG recorded in the period that drug-dispensing data 
was available (January 1, 1991 – December 31, 2011). ECGs on which atrial fibrillation or pacemaker 
rhythm was determined were excluded from the study.  
 
Assessment of TCA use  
At study entry, more than 99% of the participants had their drug prescriptions filled at one of the 
seven regional pharmacies. Drug dispensing at these pharmacies was fully computerized. Dispensing 
data included the product name, the anatomical therapeutic chemical (ATC) code, dispensing date, 
total amount of tablets/capsules per prescription and dispensed daily number of tablets/capsules. 
Dispensing episodes were calculated by dividing the total number of filled tablets/capsules by the 
daily prescribed number. If the date of a center visit during which the ECG was recorded fell within a 
dispensing episode of TCA use (ATC code: N06AA), the participant was considered as a current user.  
 
ECG measurements 
A standard 12-lead resting ECG was recorded with an ACTA Gnosis electrocardiograph (Esaote 
Biomedica, Florance, Italy) at a sampling frequency of 500 Hz and stored digitally. ECGs were 
processed by the Modular ECG Analysis System (MEANS) program, which has been described 
previously and validated and applied extensively20-24. MEANS determines common onsets and offsets 
for all 12 leads together on one representative averaged beat, with use of template matching 
techniques22. The duration of the QT interval was measured by the MEANS program from the start of 
the QRS complex to the end of the T wave, which is described more extensively elsewhere25. The 
median RR and average QT interval was computed after exclusion of RR intervals that immediately 
preceded or followed premature ventricular complexes25.  
The following methods were used to correct the QT interval for heart rate: Bazett's formula 
(QTcBazett: QT / √𝑅𝑅)
5, Fridericia's formula (QTcFridericia: QT / √𝑅𝑅
3
 )9, and one based on regression 
coefficients measured in the Rotterdam Study (QTcStatistical), which was similarly done elsewhere
11. A 
prolonged QTcBazett was defined as a QTc >450 ms for men and >470 ms for women. The method of 
the regression-based model will be discussed in the statistical analyses paragraph. Heart rate in 
beats per minute (bpm) was calculated by dividing 60,000 by the RR interval in milliseconds (ms). 
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Covariables 
The following covariables were considered additionally to age and sex: body mass index (BMI), use 
of drugs that affect the heart rate and/or QTc, heart failure, hypertension, myocardial infarction and 
diabetes mellitus. Weight and height were measured at the study center at the date of ECG 
examination. BMI was calculated with the following formula: weight (in kilograms) / height2 (in 
meters). Use of drugs associated with an altered heart rate was determined on the date of ECG 
examination, and was based on the pharmacy dispensing records. These drugs were beta-blockers 
(ATC code: C07), verapamil (ATC code: C08DA01), diltiazem (ATC code: C08DB01), and digoxin (ATC 
code: C01AA05). Of the QTc-prolonging drugs, we only considered those having probable QTc-
prolonging properties. Probable QTc-prolonging drugs are generally thought to increase the risk of 
torsade de pointes. This list contains drugs from various classes, including several antibiotics and 
antipsychotics4. TCAs on this list were not taken into account in this variable. The diagnosis of heart 
failure was based on typical signs and symptoms confirmed by objective evidence of cardiac 
dysfunction26. The presence of hypertension at the center visit was defined as a systolic blood 
pressure of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg or higher, or use of blood-
pressure lowering medication with the indication hypertension. Myocardial infarction was 
adjudicated based on a combination of symptoms, ECG measurements and enzyme markers26. The 
presence of diabetes mellitus was defined as use of glucose-lowering drugs, a non-fasting glucose 
level of more than 11.0 mmol/L, or a fasting glucose level of more than 6.9 mmol/L.  
 
Statistical analyses 
Characteristics of the study population were studied at baseline, which was defined as the first 
eligible ECG recording of a participant included in the study irrespective of the TCA-use status. As 
most participants had multiple ECG recordings, analyses were conducted with linear mixed models 
to correct for within-person correlations between visits. We tested covariance structures and 
selected the one with the lowest Akaike's information criterion. We based QTcStatistical on the 
regression coefficients of the independent variables heart rate and heart rate squared as computed 
in the Rotterdam Study. Heart rate squared was included in the regression model to take into 
account the nonlinear relationship between heart rate and QT interval. QTcStatistical was calculated 
with the following formula: QT – 3.984323*(60 – heart rate) + 0.014126*(3600 – heart rate 
squared).  
We analyzed the data in two ways: cross-sectional and longitudinal. In the cross-sectional 
analysis all ECGs made during TCA use were compared with ECGs made during nonuse, with respect 
to QTcBazett, QTcFridericia, QTcStatistical and heart rate. After assessing the effects of TCAs as a class, we 
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analyzed the effect of individual drugs. We also stratified the analysis based on tertiles of heart rate. 
For the longitudinal analysis, we studied the within-person changes in QTcBazett, QTcFridericia, QTcStatistical 
and heart rate in between two consecutive visits (an ECG pair). The within-person changes were 
calculated by subtracting the first measurement from the second measurement. We classified the 
following exposure classes in an ECG pair: no TCA use at both visits (none-none), use of TCAs only at 
the second visit (none-TCA), use of TCAs only at the first visit (TCA-none), and use of TCAs at both 
consecutive visits (TCA-TCA). For the analyses, we compared the within-person changes between 
exposure classes using none-none as the reference. All analyses were adjusted for age and sex. 
Other covariables were included if they changed the effect size by a minimum of 10%.  
In the sensitivity analysis we excluded all ECGs in which left bundle branch block, right 
bundle branch block, second and third degree atrioventricular block, left ventricular hypertrophy 
(according to Sokolow-Lyon criteria) or QRS duration > 120 milliseconds, were detected as well as 
ECGs recorded during use of beta-blocking agents, verapamil, diltiazem and digoxin. For every 
analysis, we used SPSS (version 21.0, IBM Corp., Somers, NY, USA). Two-sided p-values below 0.05 
were considered statistically significant.  
 
Results 
Baseline characteristics 
Baseline characteristics of the study population are presented in Table 1. We included 
12,734 participants with a total of 27,048 ECGs. At baseline, the mean age of the study population 
was 65.1 years (standard deviation (SD) = 9.8), and 58.1% of the participants were women. Mean 
QTcBazett was 430 ms (SD = 25), QTcFridericia 421 ms (SD = 22), QTcStatistical 422 ms (SD = 21) and mean 
heart rate was 69 bpm (SD = 11).  
 
Association between TCAs, QTc and heart rate 
Of the tested covariance matrices, the first-order autoregressive covariance structure with 
homogenous variances had the lowest Akaike's information criterion, which we therefore used in 
the rest of the study for all analyses. The results of the cross-sectional analyses are presented in 
Table 2. Compared to ECGs made during nonuse, QTcBazett was 6.5 ms (95% confidence interval (CI): 
4.0 – 9.0 longer in ECGs made during TCA use. However, when heart rate was added to the statistical 
model, the difference was no longer statistically significant. Furthermore, neither QTcFridericia nor 
QTcStatistical were significantly different when comparing ECGs made during TCA use with ECGs made 
during nonuse. These results remained similar when we added heart rate to the statistical model.  
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Table 1. Baseline characteristics of the study population 
Characteristics                                                                    Total population 
N=12,734 
Number of ECGs 27,068 
ECGs per participant, median (range) 2 (1 – 5) 
Age in years 65.1±9.8 
Females 7,402 (58.1) 
Body mass index in kg/m2 26.9±4.2 
QTcBazett in milliseconds
 430±25 
   Prolonged QTcBazett in men(>450 ms) 714 (13.4) 
   Prolonged QTcBazett in women (>470 ms)  445 (6.0) 
QTcFridericia in milliseconds
 421±22 
QTcStatistical in milliseconds 422±21 
QRS in milliseconds 101±18 
QRS in milliseconds 101±18 
Diabetes mellitus 967 (7.6) 
Hypertension 6,761 (53.1) 
History of myocardial infarction 952 (7.4) 
History of heart failure 261 (2.0) 
Left ventricular hypertrophy 391 (3.1) 
Left bundle branch block 193 (1.5) 
Right bundle branch block 315 (2.5) 
2nd or 3rd degree atrioventricular block 12 (0.1) 
Beta blockers 1,666 (13.1) 
Verapamil 83 (0.7) 
Diltiazem 156 (1.2) 
Digoxin 157 (1.2) 
Probable QTc-prolonging drugs* 271 (2.1) 
Abbreviations: ECG: electrocardiogram; QTcBazett: heart-rate corrected QT interval according to 
Bazett’s formula; QTcFridericia: heart-rate corrected QT interval according to Fridericia’s formula; 
QTcStatistical: heart-rate corrected QT interval using linear regression coefficients observed in the 
Rotterdam Study. Presented data refer to the first eligible center visit with an ECG measurement of a 
participant. Data presented as mean±standard deviation or number of participants (percentage), or 
as indicated otherwise. 
* Tricyclic antidepressants defined as probable QT prolonging drugs were excluded. 
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Table 2. Cross-sectional association between use of tricyclic antidepressants and QT interval using different heart-rate correction methods and heart 
rate 
  QTcBazett  QTcFridericia  QTcStatistical  Heart rate 
 N β in ms 95%CI  β in ms 95%CI  β in ms 95%CI  β in bpm (95%CI) 
No TCA use 26,737 ref   ref   ref   Ref  
             
Any TCA 331 6.5  4.0 – 9.0†  0.6  -1.5 – 2.8  0.9  -1.2 – 3.0  5.8  4.7 – 6.9† 
  Amitriptyline 200 5.5  2.3 – 8.8†  -0.5  -3.3 – 2.3  -0.2  -3.0 – 2.5  5.8  4.4 – 7.3† 
  Maprotiline 56 10.8  4.9 – 16.7†  5.1  0.0 – 10.2*  5.0  0.1 – 9.9*  5.7  3.0 – 8.4† 
  Clomipramine 31 3.6 -4.0 – 11.1  0.5  -0.6 – 7.0  0.6  -5.7 – 6.9  3.0  -0.3 – 6.4 
  Imipramine 17 11.3  0.7 – 21.9*  0.5  -8.7 – 9.7  0.7  -8.1 – 9.6  10.9  6.0 – 15.7† 
  Nortriptyline 16 13.0  1.8 – 24.2*  1.9  -8.1 – 11.9  2.4  -7.3 – 12.1  11.5  6.7 – 16.3† 
  Doxepin 7 -7.8 -24.3 – 22.8  -3.4  -17.6 – 10.8  -3.2  -16.7 – 10.4  -5.0  -12.8 – 2.7 
  Dosulepin 4 -2.2 -27.2 – 22.7  -2.2  -24.2 – 19.6  -1.8  -22.9 – 19.3  -0.7  -12.1 – 10.7 
Abbreviations: bpm: beats per minute; CI: confidence interval; ECG: electrocardiogram; ms: milliseconds; N: number of ECGs; QTcBazett: heart-rate corrected 
QT interval according to Bazett’s formula; QTcFridericia: heart-rate corrected QT interval according to Fridericia’s formula; QTcStatistical: heart-rate corrected QT 
interval using linear regression coefficients observed in the Rotterdam Study; TCA: tricyclic antidepressant. Data presented as the mean adjusted difference 
in milliseconds of the QTc or beats per minute of heart rate between TCA users and nonusers. Analyses are adjusted for age and sex. * P-value < 0.05; † P-
value <0.001. 
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Figure 1. Changes in intervals between repeated center visits 
 
 
None-none: no use of tricyclic antidepressants (TCAs) at both consecutive visits; None-TCA: used a 
TCA at the second of two consecutive visits; TCA-none: used a TCA at the first of two consecutive 
visits: TCA-TCA, used TCAs at both consecutive visits. A) Change in QTcBazett. B) Change in QTcFridericia. 
C) Change in QTcStatistical. D) Change in heart rate. Data presented as the mean change in milliseconds 
with 95% confidence interval between consecutive center visits. Analyses were adjusted for age and 
sex.  
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When we stratified on tertiles based on heart rate, QTcBazett was 4.4 ms (95%CI: 1.0 – 7.7) longer in 
ECGs made during use than in ECGs made during nonuse, but only in the highest tertile (heart rate > 
73 bpm). In all tertiles, there was no association between TCA use during ECG recording and 
QTcFridericia and QTcStatistical. When stratified on individual TCAs, QTcBazett was statistically longer than 
nonuse during use of the following TCAs: imipramine, amitryptiline, nortriptyline and maprotiline. 
However, only maprotiline use of showed a significantly longer QTcFridericia or QTcStatistical than nonuse. 
Heart rate was 5.8 bpm (95%CI: 4.7 – 6.9) faster on ECGs recorded during TCA use than on ECGs 
recorded during nonuse. Of the individual TCAs, heart rate was significantly faster on ECGs recorded 
during use of imipramine, amitriptyline, nortriptyline and maprotiline.  
Results did not materially change when ECGs were excluded that were made in participants 
with cardiac pathology and that were made during use of heart-rate affecting drugs. 
 
Longitudinal analyses: changes in QTc and heart rate  
A total of 13,885 ECG pairs were available with a median time interval between two consecutive 
visits of 4.3 years (interquartile range: 2.4 – 5.0). In the TCA exposure class none-TCA, QTcBazett was 
4.7 ms (95%CI: 0.5 – 9.0) higher at the second ECG (Figure 1A) than the none-none class. Conversely, 
in the TCA exposure class TCA-none, QTcBazett was lower at the second ECG (-7.1 ms, 95%CI: -11.8 – 
2.3) than at the first ECG. These associations were neither observed for QTcFridericia (Figure 1B) nor for 
QTcStatistical (Figure 1C). In the same TCA exposure classes, heart rate was higher at the second ECG 
than at the first ECG when TCAs were used during the second ECG, and heart rate was lower at the 
second ECG than at the first ECG when TCAs were used during the first ECG. 
Results did not materially change when we excluded ECGs made in participants with cardiac 
pathology and ECGs made during use of drugs affecting the heart rate.  
 
Discussion 
In the present study, use of TCAs was associated with a prolonged QTc according to Bazett's formula, 
but not with a significant increase in QTc when using Fridericia's formula or when QT was corrected 
for heart rate using regression coefficients obtained from the included ECGs of the present study. 
Furthermore, TCA use was not associated with prolongation of QTcBazett when we additionally 
adjusted for heart rate. Of the individual TCAs, only use of maprotiline showed a significantly higher 
QTc with the correction methods other than Bazett’s, although the effect size with these methods 
was lower than with Bazett. QTcBazett was only higher in ECGs made during TCA use than in ECGs 
made during nonuse in the tertile with the highest heart rates. Results were similar in the 
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longitudinal analyses of QTc interval and heart rate. In addition, use of TCAs was associated with a 
faster heart rate of 5.8 bpm.  
Because the association between TCAs and QTcBazett was no longer significant when 
additionally adjusted for heart rate, the higher heart rate is likely the cause of the overestimation of 
the TCA-induced QTc prolongation. Therefore, the results of our study indicate that the previously 
described TCA-induced prolongation of QTcBazett is possibly observed because of overestimation 
instead of a real drug effect. This is supported by our finding that TCA-induced prolongation of 
QTcBazett was only observed in participants with the highest heart rates (i.e. upper tertile). 
Furthermore, of the individual TCAs, we observed the largest difference between QTcBazett and 
other correction methods for those TCAs with the largest effect on heart rate.  
The association between TCA use and QTcBazett prolongation has been consistently observed 
in cohort studies13-15. In addition, a number of case reports on TCA-induced QTc prolongation have 
been published16. Although these case reports did not support our findings directly, it should be 
noted that these case studies reported TCA-induced QTc prolongation in patients with severe cardiac 
pathologies or in patients with a TCA overdose16. As further support of our findings, no association 
was observed in population-based studies between use of TCAs and sudden cardiac death, which is 
one of the hard endpoints associated with QTc prolongation27,28. However, this does not imply that 
use of TCAs is without risk with respect to cardiovascular end points. A higher heart rate has 
previously been associated with an increased risk of cardiac conditions like heart failure and overall 
cardiovascular mortality29-31. As use of TCAs is associated with an increased risk of cardiovascular 
mortality32, detrimental cardiovascular effects of TCAs can be caused by an increase in heart rate 
rather than a prolonged QT interval. TCAs have also been associated with an increased risk of 
torsade de pointes16. Because the correlation between QTc prolongation and torsade de pointes is 
modest at best, this may still be in line with our findings33. 
Bazett’s formula is the most often used method to correct the QT interval for heart rate in 
both clinical practice and in research6,7. The two other studied correction formulas are less 
dependent on heart rate after correction, as point estimates did not materially differ when 
additionally adjusted for heart rate in the statistical model. This indicates that these formulas are 
less prone to overestimation of QTc in persons with high heart rates. To study the safety of TCAs 
with respect to QTc prolongation, these formulas might be more appropriate. The correction 
formula based on regression coefficients would be the best, as the coefficients were obtained from 
the same population as the one we used for the analyses, and therefore this formula would correct 
for heart rate optimally. However, such a model is specific for a study population, and thus the 
clinical use is limited8. Heart-rate correction with Fridericia’s formula might be preferred in patients 
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taking heart-rate increasing drugs, as it is also easily calculated and results were similar with respect 
to the model based on regression coefficients.  
A strength of our study is the analysis of longitudinal changes in QTc and heart rate. The 
cross-sectional analysis is more prone to be confounded by a contraindication, as participants with a 
longer QTc interval are less likely to be prescribed TCAs. Also, the cross-sectional analysis cannot 
infer causality between TCAs and QTc prolongation. Although the longitudinal analysis is still 
observational, it can provide additional arguments in favor of a causal relationship. As similar results 
were obtained with cross-sectional and longitudinal analyses, our findings are more likely due to the 
drug rather than due to other unmeasured factors. Another strength of our study is the MEANS 
algorithm to calculate QT interval and heart rate. This algorithm works systematically and 
automatically and has been evaluated extensively21-23. Finally, information bias was limited as 
pharmacy-dispensing data was recorded irrespective of disease state. Our study also has some 
limitations. In our study, only a limited number of participants were using TCAs. Second, the median 
time interval between two examination rounds is 4.3 years, which might be too lengthy for the 
calculation of changes in QTc intervals. Therefore, it is still possible that there is an acute QTc-
prolonging effect of TCA use, which is visible with all heart-rate correction models. However, our 
results indicate that long-term treatment with TCAs is not accompanied by QTc prolongation. And 
last, being an observational study, our study is subjected to confounding. However, none of the 
considered covariables changed the effect sizes substantially.  
In conclusion, the results of our study suggested that TCA-induced prolongation of QTcBazett 
might be the result of overestimation that occurs in persons with high resting heart rates. TCA 
prescribing should nonetheless still be done with caution due to the associated increase in resting 
heart rate. When the QT interval was corrected for heart rate with Fridericia's formula or with a 
model based on regression coefficients, no increase in QTc was observed. Reported effects on the 
QTc interval should be reconsidered for heart-rate increasing drugs. For such drugs Fridericia’s 
correction might be preferred. The advice of regulatory authorities to restrict use of these drugs and 
to do regular check-ups of the QTc, may need to be revised.  
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Abstract 
Background Resting heart rate is a heritable trait, and an increase in heart rate is associated with 
increased mortality risk. GWAS analyses have found loci associated with resting heart rate, at the 
time of our study these loci explained 0.9% of the variation. 
 
Aim To discover new genetic loci associated with heart rate from Exome Chip meta-analyses. 
 
Methods Heart rate was measured from either elecrtrocardiograms or pulse recordings. We meta-
analysed heart rate association results from 104,452 European-ancestry individuals from 30 cohorts, 
genotyped using the Exome Chip. Twenty-four variants were selected for follow-up in an 
independent dataset (UK Biobank, N = 134,251). Conditional and gene-based testing was 
undertaken, and variants were investigated with bioinformatics methods.  
Results We discovered five novel heart rate loci, and one new independent low-frequency non-
synonymous variant in an established heart rate locus (KIAA1755). Lead variants in four of the novel 
loci are non-synonymous variants in the genes C10orf71, DALDR3, TESK2, SEC31B. The variant at 
SEC31B is significantly associated with SEC31B expression in heart and tibial nerve tissue. Further 
candidate genes were detected from long range regulatory chromatin interactions in heart tissue 
(SCD, SLF2, MAPK8). We observed significant enrichment in DNase I hypersensitive sites in fetal 
heart and lung. Moreover, enrichment was seen for the first time in human neuronal progenitor cells 
(derived from embryonic stem cells) and fetal muscle samples by including our novel variants. 
 
Conclusion Our findings advance the knowledge of the genetic architecture of heart rate, and 
indicate new candidate genes for follow-up functional studies. 
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Introduction 
Increased resting heart rate (HR) is a known risk factor for cardiovascular morbidity and mortality 1-3, 
including stroke 4 and sudden cardiac death 5,6. A HR increased by 20 beats per minute (bpm) is 
associated with 30-50% higher mortality that appears independent of confounding factors 7. High HR 
increases myocardial oxygen consumption yet lessens oxygen delivery to myocardial tissue. It also 
increases arterial stiffness and risk of plaque rupture 8 .  Although HR can be influenced by many non-
genetic factors (e.g., exercise, smoking and cardiovascular drugs), the heritability of resting HR is 
estimated to be 26–32% from family studies 9,10, and 55–63% from twin studies 11.  
Several meta-analyses of genome-wide association studies (GWAS) studies have been 
undertaken to detect genetic determinants of HR 12-16. There were 21 HR loci previously reported at 
the time of our study by den Hoed et al. 12 in a GWAS analysis of 180,000 individuals, predominantly 
of European ancestry. The study implicated 20 candidate genes from follow-up functional studies in 
Danio rerio and Drosophila melanogaster models. Smaller GWAS analyses have also been performed 
in Icelandic and Norwegian populations 15, African Americans 13, and genetically isolated European 
populations 16. The variants discovered by GWAS are common, and are mostly in introns or 
intergenic regions. Together the previous loci from GWAS at the time of our study only explain a 
small percentage (0.9% of the variability in heart rate 12,17.  
To increase our knowledge of genetic determinants influencing HR and discover novel loci, 
especially rare or low frequency coding variants with larger effects, we meta-analysed data from 
104,452 individuals of European-ancestry using the Exome Chip, from cohorts that participated in 
the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE) EKG consortium. The 
Exome Chip permits a cost-efficient analysis of coding variants derived from sequencing of >12,000 
individuals and includes many rare and low frequency variants . We performed a validation 
experiment using independent replication samples from UK Biobank data, and bioinformatics 
investigations to gain an understanding of the new HR loci.  
 
Results 
Single nucleotide variant analysis in individuals of European-ancestry 
In the discovery phase, association results of 235,677 single nucleotide variants (SNVs) from 104,452 
individuals were meta-analysed using a fixed-effects model (Supplementary Figure 1). Two analyses 
were performed. The first used RR intervals (RR in milliseconds= 60,000/HR, in beats per minute, 
according to the inverse relationship between HR and RR). The second used the inverse-normalized 
residuals of the linear regression RR interval adjusted for age + sex + BMI as covariates (denoted as 
RR-INVN). An overview of the study design is provided in Figure 1. 
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Figure 1. Schematic flow diagram of the study design 
 
 
N: sample size; SKAT: SNV-set Kernel Association Test; P: P-value; LD: linkage disequilibrium; SNV: 
single nucleotide variant; GCTA: Genome-wide Complex Traits Analysis software; 1958BC: 1958 Birth 
Cohort. UKB = UK Biobank. 
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We observed a high correlation of effect sizes and P-values between the RR-interval and RR-
INVN meta-analyses (r2 = 0.99 and 0.98, respectively; Supplementary Figure 2). Furthermore, the RR 
interval was near-normally distributed, so inverse normalization was deemed unnecessary 
(Supplementary Figure 3).  
Beta-blockers are clinically known to lower HR, therefore the phenotype measurements of 
beta-blocker users may be under-estimated, and hence the inclusion of beta-blocker users in our 
analysis may potentially bias our analysis results. We therefore performed a sensitivity analysis by 
also meta-analysing a subgroup of cohorts that provided beta-blocker data (N = 48,347; 17 cohorts). 
Results including or excluding beta-blocker users were highly correlated (r2 of the betas = 0.97; r2 of 
the P values = 0.74; Supplementary Figure 4), suggesting there is little or no bias from including beta-
blocker users in the analysis. Therefore we report the meta-analysis results from the full dataset for 
the RR-interval, to maximize sample size and power.  
 
Replication and meta-analysis with the UK Biobank dataset 
To identify novel associated loci, we selected 12 variants with P < 1 × 10-5 that mapped outside the 
21 HR loci reported in the previous GWAS 12 for follow-up in an independent dataset. Within each 
unknown locus, there were no potential secondary SNVs not in LD with the lead SNV (r2 < 0.2) and 
meeting our look-up significance threshold P < 1 × 10-5). Hence only 12 new lead SNVs were carried 
forward. We also followed-up 12 potential secondary signals at nine of the 21 previously reported 
HR loci (further details on selection criteria are provided in the Methods).12 None of the selected 
variants were in LD (r2 < 0.2) with each other, or with the published SNVs. Thus a total of 24 variants 
were taken forward into replication. The UK Biobank dataset provided results for the selected 
genetic variants (N = 134,251 individuals).  
Nine of the 12 previously unknown variants were validated based on exome-wide 
significance (P ≤ 2.12 × 10-7) in the combined meta-analysis of CHARGE and UK Biobank data, and on 
Bonferroni-adjusted significance (P ≤ 0.0042 for 12 tests) in the replication dataset alone, with 
concordant directions of effects taking into account the inverse relationship between the RR-interval 
from the discovery data and HR from the replication data (Table 1; Figure 2). Indeed all nine SNV 
associations were genome-wide significant in the combined meta-analysis (P < 5.0 × 10-8). Four of 
our nine validated novel loci were reported in a UK Biobank study 17, that was published after 
completion of our study (Table 1B). Hence, we present results here for five unreported novel loci 
(Table 1A; Supplementary Figures 5 and 6).  
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Table 1. Heart rate associated loci identified from Exome Chip analysis 
Abbreviations: SNV: single-nucleotide variant, Chr:Pos: Chromosome:Position based on HG build 19, EA: Effect allele, EAF: Effect allele frequency from the 
discovery data, BETA-RR: Beta effect estimate of RR Interval (milliseconds) taken from the ExomeRR discovery data, SE: Standard error of the effect 
estimate, N: sample size analyzed per variant (provided for genotyped discovery data only, as replication data was imputed so N=maximum N for all 
variants), BETA-HR: Beta effect for heart rate (in beats per minute) taken from the UK Biobank replication data, P: P-value from either the discovery meta-
analysis, the replication data, or the combined meta-analysis of discovery and replication data. Locus name indicates the nearest gene to the HR-associated 
SNV. * indicates that the lead or a proxy SNV (r2>0.8) is a non-synonymous SNV. ‡ indicates if the lead SNV is predicted to be damaging. A novel locus is a 
genomic region with no SNVs in LD (r2 < 0.2) with HR-associated SNVs and (ii) mapping to more than 500 kb from either side of a previously reported HR-
associated SNV. Note: due to the inverse relationship between RR-interval and HR that opposite beta directions do relate to concordant directions of effect 
between discovery and replication.
SNV  Locus Chr:Pos EA EAF NDISCOVERY BETA-RR (SE) PDISCOVERY BETA-HR (SE) PREPLICATION PCOMBINED 
(A) Five unreported novel loci 
rs17853159* TESK2 1:45810865 A 0.07 104,452 -6.03 (1.20) 5.02×10-7 0.31 (0.08) 9.55×10-5 4.09×10-10 
rs3087866* DALRD3 3: 49054692 T 0.25 104,452 3.29 (0.72) 4.92×10-6 -0.31 (0.05) 7.06×10-10 2.09×10-14 
rs1635852 JAZF1 7: 28189411 C 0.50 104,452 2.96 (0.62) 2.04×10-6 -0.15 (0.04) 4.10×10-4 6.97×10-9 
rs10857472* C10orf71 10: 50534599 A 0.45 104,452 -2.97 (0.63) 2.11×10-6 0.16 (0.04) 1.49×10-4 2.21×10-9 
rs3793706*‡ SEC31B 10: 102269085 A 0.22 104,452 3.52 (0.75) 2.54×10-6 -0.19 (0.05) 2.06×10-4 3.72×10-9 
(B) Four loci validated in our study and also recently published in the UK Biobank study 
rs709209* RNF207 1:6278414 G 0.35 104,452 -3.30 (0.66) 4.94×10-7 0.27 (0.04) 2.14×10-9 5.44×10-15 
rs6795970* SCN10A 3: 38766675 A 0.40 104,452 2.97 (0.64) 3.10×10-6 -0.24 (0.04) 1.81×10-8 2.73×10-13 
rs4282331 5p13.3 5: 30881510 G 0.42 104,452 -3.56 (0.63) 2.03×10-8 0.26 (0.04) 2.97×10-9 3.34×10-16 
rs12004* KDELR3 22: 38877461 G 0.30 104,452 3.30 (0.68) 1.24×10-6 -0.31 (0.05) 4.92×10-11 4.04×10-16 
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Figure 2. Manhattan plot for the RR-interval discovery meta-analysis in European individuals 
 
The Manhattan plot displays the results from the discovery meta-analysis of RR-intervals from N = 104,452 individuals of European ancestry (from 30 
cohorts). On the X axis, P-values are expressed as -log10(P) are plotted according to physical genomic locations by chromosome. The Y-axis is truncated to -
log10(P)  = 20 with any variants with P < 1x10
-20 displayed on the -log10(P)  = 20 line. The nine novel variants validated from the combined meta-analysis with 
UK Biobank data are shown as squares. Variants in linkage disequilibrium (LD; r2 > 0.8) with published GWAS variants are shown as circles12. New secondary 
variants validated in our analysis are shown as triangles. Locus names of the novel loci correspond to the nearest annotated gene, with 5p13.3 denoting an 
intergenic variant. The dashed line indicates a P-value threshold of 1x10-5, corresponding to the lookup significance threshold and the continuous line 
indicates a P-value threshold of 2x10-7, corresponding to exome-wide significance. 
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Twelve of the 21 HR-associated SNVs from the previously reported GWAS 12 were covered 
on the Exome Chip, either directly or by a proxy SNV in high linkage disequilibrium (LD; r2 > 0.8). Our 
discovery meta-analysis showed strong support for the previous findings, with 11 of the 12 SNVs 
validated at Bonferroni-adjusted significance (P ≤ 0.0042 for 12 tests), of which 9 were validated at 
exome-wide significance (P < 2 × 10-7; Figure 2). Only rs4140885 at the TFPI locus was not supported 
in our data (P = 0.10; Supplementary Table 1).  
 
Independent secondary signals at known loci 
All 12 potential secondary signals at loci previously reported by Den Hoed et al.12 were genome-wide 
significant in the combined meta-analysis (Supplementary Table 2) and are independent to the 
known SNPs according to LD (r2 < 0.2). We performed a conditional analysis using GCTA to formally 
identify secondary signals of association. Five of the 12 validated potential secondary SNVs (within 
CD46, CCDC141, SLC35F1, ACHE and KIAA1755 loci) were selected within the final GCTA model 
(Supplementary Table 3). At four of the previously reported HR regions the secondary signals that 
we identified were confirmed to be statistically independent signals of association: CD46 
(rs2745967), CCDC141 (rs10497529), SLC35F1 (rs12210810) and KIAA1755 (rs41282820) in addition 
to the known SNV, as both the published SNV and the new secondary SNV were present in the final 
GCTA model of jointly independent associated variants. Hence we identified two distinct signals of 
association at each of these four known HR loci. However, the published SNV at the ACHE locus 
(rs13245899) is not covered on the Exome-chip, or by any proxies (Supplementary Table 1), so the 
GCTA analysis does not include the known variant. As we are not able to condition on the 
unavailable published SNV and formally test association jointly with the known SNV, we are unable 
to statistically confirm the total number of independent signals at the ACHE locus.  
The secondary SNVs at CCDC141, ACHE and KIAA1755 are non-synonymous variants. 
Furthermore, the SNVs at CCDC141 and KIAA1755 are low-frequency with minor allele frequencies 
(MAFs) of 3.6% and 1.7%, respectively. Secondary signals have also recently been observed at four of 
the five loci (CD46, CCDC141, SLC35F1 and ACHE) in UK Biobank data 17, since completion of our 
meta-analysis. At CD46, our secondary SNV (rs2745967) is in high LD (r2 = 0.78) with the secondary 
SNV (rs2745959) reported in UK Biobank, so likely to be the same signal. At CCDC141 our secondary 
variant is exactly the same SNV as from UK Biobank (rs10497529). Similarly, at SLC35F1, our 
secondary SNV (rs12210810) is in very high LD (r2 = 0.98), so is likely to be the same signal. Hence at 
these three known loci (CD46, CCDC141, SLC35F1), all existing data suggests there are two 
independent signals of association. At the ACHE locus, our secondary SNV (rs542137; ~38kb and r2 < 
0.2 from the published SNV) is not in LD (r2 < 0.2) with the secondary SNV from UK Biobank 
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(rs140367586; ~659kb and r2 < 0.2 from the published SNV). We are unable to clearly determine the 
number of distinct signals at the ACHE locus from our Exome-chip RR-interval discovery meta-
analysis data, without the published SNV being covered on the Exome-chip. The low-frequency non-
synonymous variant (rs41282820) at the known KIAA1755 locus is a new, secondary variant, with 
strong evidence of independent association, it does not overlap with other published findings. 
 
Variance explained 
Twelve of the 21 previously reported HR-associated SNVs 12 covered on the Exome Chip explain 
1.14% of RR interval variance (P = 3.96 × 10-10) within the 1958 Birth Cohort study (Methods). The 
added contribution of the lead SNVs at our five unreported novel loci, combined with the 12 
previously reported SNVs, increases the variance explained to 1.28% overall (P = 9.17 × 10-11). 
 
Comparison of results between European and non-European populations 
To investigate our data from non-European samples (9,358 African Americans (AA), 1,411 Hispanic 
(HIS), and 754 Chinese-Americans (CH); Supplementary Table 4), we first extracted results for the 12 
of the 21 previously reported HR-associated SNVs covered on the Exome Chip 12. In contrast to 
previous results for Europeans, only two known HR-SNVs showed evidence of association (P < 0.05), 
at the GJA1 and MYH6 loci, in the AA population only. This is likely due to a lack of power from the 
smaller non-European sample sizes, considering the power was calculated to be only 48%, 11.7% and 
8.5% for AA, HIS and CH, respectively. Concordance in the direction of effects compared to 
Europeans was only significant for AA, with 92%, 64% and 50% concordance, corresponding to P-
values of 2.9×10-3, 0.16 and 0.23 from binomial tests for AA, HIS and CH, respectively. The lack of 
support of previous findings from the under-powered non-European data led us to restrict our 
primary discovery meta-analysis to Europeans only. 
We also performed a look-up of the nine validated SNV associations in the non-European 
samples. Due to the lack of power, and different allele frequencies compared to Europeans, none of 
the SNVs had results with P < 0.05 within any ancestry (Supplementary Figure 6), and there was little 
concordance in effect directions: 56% and P = 0.246 for AA; 33% and P = 0.164 for HIS and CH. 
  
Gene-based tests 
Gene-based testing was performed to identify genes which may have multiple rare variant 
associations. None of the gene-based test results were significant, after excluding the single most 
significant low-frequency variant from the tests (Supplementary Table 5).  
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Look-up of UK Biobank heart rate SNVs 
Since completion of our meta-analysis of Exome Chip genotypes, a genome-wide scan for HR has 
been completed in UK Biobank 17. This study published 46 new HR loci. Four of these novel loci were 
simultaneously discovered in our analyses (RNF207, SCN10A, 5p13.3, KDELR3: Table 1B). Among the 
42 remaining UK Biobank loci, only 5 of the lead SNVs were covered on the Exome Chip at r2 ≥ 0.8. 
Results from our exome RR European-ancestry meta-analyses show support for all five of these loci 
(P < 0.01; Bonferroni-adjusted significance for 5 tests; Supplementary Table 6). 
 
Heart rate loci and association with other traits 
To provide insights into possible shared aetiologies or mechanisms of disease, we assessed 
association of our five unreported novel HR SNVs (and their proxies, r2 ≥ 0.8) with other traits. 
Genome-wide significant phenotype-genotype associations were observed for three novel loci 
(Supplementary Table 7). The SNV at the DLRD3 locus was associated with age of menarche. The SNV 
at the JAZF1 locus was highly pleiotropic, as shown by associations with several autoimmune 
disorders (systemic lupus erythematosus, Crohn’s disease, and selective immunoglobulin A 
deficiency), height, type 2 diabetes, and JAZF1 transcript levels in adipose tissue. The SNV at the 
SEC31B locus was associated with plasma palmitoleic acid levels and differential exon expression of 
SEC31B. 
 
Functional annotation of novel heart rate SNVs and candidate genes 
Four of the five unreported novel HR SNVs or their proxies (r2 > 0.8) are non-synonymous SNVs in 
TESK2, DALRD3, C10orf71, and SEC31B (Table 1A). The non-synonymous SNV in SEC31B (rs2295774, 
c.1096T>G, p.Ser332Ala) is in a conserved region of the protein, and is predicted to be damaging 
using three different algorithms in ANNOVAR 19. We also investigated if the novel HR-associated 
SNVs or their proxies (r2 > 0.8) were associated with changes in expression levels of nearby genes 
(i.e., as expression quantitative trait loci, or eQTLs) in the GTEx dataset 20. We observed a significant 
eQTL association at one novel HR locus (Supplementary Table 8). Specifically, the HR increasing allele 
of the non-synonymous SNV at SEC31B was associated with increased levels of SEC31B in tibial 
nerves (P = 8.08 x 10-33), lung (P = 1.22 x 10-23 ), atrial appendage tissue (P = 4.56 x 10-11), and the left 
ventricle (P = 4.0 x 10-9), tissues which may be regarded as physiologically relevant for HR.  
We also observed HR loci to be significantly enriched for DNase I hypersensitive sites (DHSs; Figure 
3). We evaluated regions containing the five unreported novel HR loci and five independent 
secondary variants at previously reported HR loci,12 together with all 67 published HR-associated 
SNVs (21 loci reported from the original GWAS 12 plus 46 loci recently published from UK Biobank17).  
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Figure 3. Enrichment of HR–SNVs in DNase I hypersensitive sites of 299 tissue samples. 
 
The right panel shows the enrichment of the 
combined known and novel (all) HR-SNVs in 
DNase I hypersensitivity sites of 212 Roadmap 
Epigenome tissue samples (those with positive 
Z-scores). Enrichment is expressed as a Z-score 
compared to the distribution of 1000 matched 
background SNV sets. Significant enrichments 
are shown in red (Z-score ≥ 2.58, FDR <1.5%), 
enrichments below this threshold are shown in 
blue. The left panel shows the enrichment 
difference ( Zscore= Zscoreall-Zscoreknown) for 
those tissue samples in which we found 
significant enrichment using all SNPs and that 
further show a positive change using all SNVs 
compared to only known SNVs, with increased 
enrichment hence due to the novel loci 
identified. 
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Highest enrichment for DHSs in HR loci occurred within regions that are transcriptionally 
active in fetal heart tissue and fetal lung, as reported in the UK Biobank study. Moreover, for the first 
time we found significant enrichment for DHSs in human neuronal progenitor cells (derived from 
embryonic stem cells) and fetal muscle samples, with the inclusion of our novel loci. 
 
Pathway analyses 
We used Ingenuity pathway analyses to determine if there was any increased enrichment in HR 
associated pathways with the contribution of our five newly identified loci. We identified 16 
significantly enriched pathways at P < 1 × 10-4. Most of these pathways are related to the 
cardiovascular system and involve, for example, supraventricular arrhythmias, dilated 
cardiomyopathy, and heart rate (Supplementary Table 9).  
 
Coding variants at heart rate loci 
The Exome Chip provides a unique opportunity to search for coding variants within known HR loci. 
Whereas GWAS analyses typically identify intron or intergenic variants, Exome Chip analysis may 
identify HR-associated coding variants, which would point to candidate causal genes. We considered 
all 67 published HR loci (21 previously reported GWAS loci,12 plus 46 recently published loci from UK 
Biobank17) and extracted all SNVs in high LD with the lead variants (r2 ≥ 0.8), tagging the same 
association signal, restricted to variants covered on the Exome Chip. We further filtered variants to 
obtain SNVs that reached exome-wide significance for associations with RR interval in our primary 
discovery meta-analysis, to ensure that variants have a highly significant association with the trait. 
Coding SNVs were identified, using the CHARGE Exome Chip annotation file. 
We only observed two such coding variants in two reported loci: CCDC141 and KIAA1755. 
The published CCDC141 coding variant was previously annotated as being non-synonymous 12, and is 
predicted to be damaging in our annotation (rs17362588; p.Arg935Trp). The coding SNV at KIAA1755 
is the best proxy (r2~1) for the published non-synonymous SNV (rs6127471) covered on the Exome 
Chip (Supplementary Table 1). The original GWAS 12 had reported this signal as non-synonymous. 
Therefore, our Exome Chip analyses do not reveal any new evidence of likely causal coding variants 
at well-established HR loci.  
 
Regulatory variants at heart rate loci 
Our analyses of coding variants at all known HR loci indicated that the majority of HR-associated 
SNVs and the variants in high LD with them are non-coding. We thus investigated which variants 
could have a causal effect through regulatory chromatin interactions, such as promoter-enhancer 
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contacts. We considered all 67 published HR loci (21 previously reported GWAS loci 12, plus 46 
recently published loci from UK Biobank 17), and the five novel loci reported here. We found variants 
that potentially affect enhancer function using RegulomeDB 21 and found genes whose promoter 
regions form significant chromatin interaction with them from right ventricle Hi-C data 22. We found 
64 potential target genes in 49 HR loci (4 new loci, 18 loci from the GWAS study and 27 loci from the 
UK Biobank study; Supplementary Table 10). Including these long range interactors in the candidate 
causal genes list increased the significance of enrichment for many HR related terms, such as 
arrhythmia and cardiac fibrillation in our Ingenuity® Pathway Analysis (IPA®; Supplementary Table 
11). 
For newly identified loci, the TESK2 promoter had a long-range interaction with the SNVs 
with highest regulatory potential in the locus, underlining it as a candidate. LOC441204, a gene of 
unknown function was found to interact with the JAZF1 locus. At the SEC31B locus, there were 
interactions with two genes, SCD and SLF2. At the C10orf71 locus, MAPK8 showed the most 
significant interaction.  
In the 21 loci from the previously published GWAS 12, we identified significant chromatin 
contacts for the regulatory SNVs of 18 loci. We found CALCRL, TTN, HTR2B, PLD1 and CHRM2 as 
strongest interactors at the TFPI, CCDC141, B3GNT7, FNDC3B and CHRM2 loci, respectively, out of 
these only CALCRL is in LD (r2 > 0.8) with the lead SNV. The previous study 12 functionally tested 31 
candidate genes, they found 20 of them to have a HR phenotype in either Drosophila melanogaster 
or Danio rerio experiments. All five of the strongest interactor genes were amongst the 20 genes 
with a HR phenotype. 
Finally, we found 41 potential causal genes that have not been implicated by previous 
GWASs. A few of these genes have a cardiac function, including RAPGEF4 18 and PIM1 23, while some 
are involved in neuronal development and function e.g. PBX3, NRNX3. These candidates open up 
new avenues that may aid our understanding of heart rate biology.  
 
Discussion 
Our meta-analysis of Exome Chip genotypes yielded five unreported novel HR loci, and one 
unreported independent new secondary signal, which was a low-frequency non-synonymous SNV at 
the previously reported KIAA1755 locus. Our data strongly supported the association of SNVs at 11 
of the 12 previously reported GWAS loci that were covered on the Exome Chip. All lead SNVs at all 
validated novel loci are common (MAF ≥ 5%) and have similar effect sizes, which are smaller than the 
effect sizes for the majority of previously reported SNVs (Supplementary Figure 7). Our study did not 
yield any rare SNV associations with HR, indicating that much larger sample sizes will be required in 
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future studies to have sufficient power to detect effects of any rare variants and assess their 
contributions to HR heritability. 
 The same observation of the need of larger sample sizes applies to the analysis of HR loci 
identified within Europeans in other ancestries, where the lack of significance and concordance in 
the results from non-European populations is most likely due to a lack of power, as well as 
differences in the allele frequencies and LD patterns between Europeans and non-Europeans. As the 
non-European samples were much smaller, we did not perform a comprehensive comparison across 
populations or a robust trans-ethnic meta-analysis.  
Annotation of novel HR SNVs or their close proxies, eQTL analyses and long range chromatin 
interactions in heart tissue reveal new potential causal candidate HR genes (Supplementary Tables 
10 and 12). At the SEC31B locus there is a predicted damaging non-synonymous variant in SEC31B, 
and SNVs at this locus are also significantly associated with SEC31B expression levels. Although its 
precise function is unknown, the SEC31B gene encodes SEC31 homolog B, a COPII coat complex 
component. SEC31B has been proposed to function in vesicle budding, and cargo export from the 
endoplasmic reticulum 24. The gene is ubiquitously expressed at low levels, but there are higher 
levels of expression in the cerebellum. There are 13 transcripts, and thus several predicted SEC31B 
proteins. The major isoform is 129 kDa, but the HR-associated non-synonomous SNV maps to all 
SEC31B transcripts. There are no existing mouse models, and the predicted protein does not directly 
interact with other proteins or pathways currently recognized as being important to HR. Chromatin 
interactions in heart tissue indicate SCD and SLF2 as two other candidate genes for consideration at 
this locus. SCD encodies a stearoyl-CoA desaturase, which has a role in myocardial dysfunction 25 and 
SLF2 encodes the SMC5-SMC6 complex localization factor 2. TESK2, C10orf71 and DALRD3 can be 
considered as candidates for further analyses, based on the lead SNVs being non-synonymous 
variants in each gene. TESK2 encodes a serine/threonine protein kinase with an N-terminal protein 
kinase domain that is structurally similar to the kinase domains of testis-specific protein kinase-1 and 
the LIM motif-containing protein kinases (LIMKs). TESK2 is ubiquitously expressed, but its function is 
unknown 26. There is also support for TESK2 from the chromatin interaction analyses. C10orf71 
encodes an ORF of unknown function, that is highly expressed in heart and skeletal muscle. 
Chromatin interaction analyses indicate MAPK8 as a second candidate gene at the C10orf71 locus, 
MAPK8 is involved in formation of the heart as well as heart rate regulation 27,28. DALRD3 encodes a 
protein with a DALR anticodon binding domain similar to that of class Ia aminoacyl tRNA synthetases 
29. 
The conditional analysis results provided one new, unreported association at a previously 
reported HR locus, KIAA1755 (rs41282820; c.1528C>T or c.1528C>A; p. Arg510Ter, a loss of function 
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variant). KIAA1755 is predicted to encode an uncharacterized protein, and is only characterized at 
the transcriptional level. The transcript is highly expressed in the brain and nerves, and it is also 
expressed in the heart.  
Our analyses and the recently published UK Biobank analyses 17 discovered a second low-
frequency non-synonymous SNV at CCDC141 (rs10497529, c. 442C>T, P. Ala141Val). CCDC141 (also 
known as CAMDI) encodes the coiled-coil domain containing 141 protein and interacts with DISC1 
(disrupted in schizophrenia 1) and MYL2 (phosphorylatable myosin light chain). CCDC141 is highly 
expressed in heart muscle 30. Knockdown of CCDC141 in neurons leads to abnormal cortical neuronal 
migration, but there are otherwise limited functional studies of CCDC141 30. The CCDC141 locus 
includes TTN (titin), which encodes a major structural protein in striated muscle. TTN mutations are 
associated with a range of hereditary myopathies 31. Prior work 12 using RNA interference (RNAi) in 
Drosophila melanogaster have shown that knockdown of TTN leads to significant changes in resting 
HR and HR post tachypacing, supporting TTN is a causal candidate gene at this locus. The new data 
described here implicates CCDC141 as a second candidate gene at this locus for functional follow-up.  
Enrichment analysis of HR variants in DNase I hypersensitivity sites across nearly 300 tissue 
samples and cell lines indicated new candidate tissues, such as neuronal progenitors and fetal 
muscle as being functionally relevant. Our data suggest these tissues should be targeted for future 
functional studies. 
Our long range regulatory chromatin interaction analyses provided additional support for 
some of the candidate genes have been experimentally tested previously 12 and shown to have a HR 
related phenotype (CALCRL, TTN, HTR2B, PLD1 and CHRM2). By expanding the list of HR loci to 
include new and published, several new candidate genes are highlighted for functional studies in 
Supplementary Table 10. 
The Exome Chip contains non-synonymous, splicing, and stop-coding variants that are thought to 
alter protein expression and function. Our analyses discovered four novel coding variants, indicating 
potential candidate causal genes at these loci. Our two-stage study design permitted the robust 
validation of all our novel loci findings, with a large replication sample size from UK Biobank (N = 
134,251) to add together to our European discovery data (N = 104,452) for a large combined meta-
analysis. However, due to the Exome Chip covering mainly coding regions, we were not able to 
compare results with all previous GWAS findings. In conclusion, our results taken together with 
recent studies 12 indicate HR-associated SNVs are mostly common (MAF > 5%) and have relatively 
small effect sizes. The maximum effect sizes reported thus far are ~0.70 bpm per allele and MAF of 
1% for SNVs at CCDC141 (rs17362588) and GJA1 (rs1015451). An analysis of much larger sample 
sizes (1M and above) including rare and common SNVs, and samples across different ancestries may 
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provide further information on the contributions of both coding and non-coding variants, and the 
importance of rare coding variants in HR.  
 
Materials and Methods 
Study populations, phenotypes and exclusions 
Thirty cohorts contributed data to the discovery meta-analysis in individuals of European ancestry. 
Details of all participating cohorts are provided in Supplementary Table 13, including phenotype, 
cohort ancestry, study design, and key references. The UK Biobank study, which was only recently 
published since the completion of our meta-analysis 17, provided results for replication analyses. 
Details of this study are also included in Supplementary Table 13.  
All participating cohorts either measured RR intervals from the standard 12-lead electrocardiogram 
(ECG) or used HR measurements (in beats per minute) from peripheral pulse measurements 
(Supplementary Table 14), which were converted to the RR interval scale (in milliseconds) using the 
inverse relationship formula: RR (ms) = 60,000/HR (bpm). The discovery analysis was undertaken 
using the RR interval phenotype. The exclusion criteria included: extreme RR intervals (< 600 ms or > 
1500 ms), atrial fibrillation on the ECG, a history of myocardial infarction or heart failure, use of non-
dihydropyridine calcium-antagonists (Anatomic Therapeutic Chemical (ATC) code C08D), digoxin 
(ATC code C01AA5), second or third degree atrioventricular block, and a pacemaker signal on the 
ECG. Local ethics committees approved the contributing studies from the CHARGE consortium, and 
all individuals provided their consent in writing. The UK Biobank study has approval from the North 
West Multi-centre Research Ethics Committee (MREC)  and has Research Tissue Bank (RTB) approval. 
 
Study level genotyping and quality control 
All discovery cohorts were genotyped using a human Exome Chip array (exact details of the chip for 
each study are provided in Supplementary Table 15). Quality Control (QC) was done according to 
CHARGE Exome QC guidelines, including joint variant calling with zCall 32. At the study-level, the 
sample-level QC consisted of excluding samples of non-European ancestry (for European-ancestry 
cohorts), samples with call rates < 95%, samples with sex discordance, or related samples with an 
unexpected high identical by descent (IBD) estimate. It was recommended that principal 
components (PCs) be obtained using variants with MAF ≥ 1%. The variant QC consisted of exclusion 
of SNVs with call rate < 95%, with Hardy-Weinberg equilibrium values of P < 1 × 10−6, and of variants 
that were strongly associated with plate assignment.  
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Study-level statistical analysis 
Each cohort performed two SNV association analyses using an additive model implemented with the 
R package seqMeta 33. Analyses were stratified by ancestry. One SNV association analysis used an 
untransformed model with RR interval as the outcome, adjusted for age, sex, body-mass index (BMI) 
and cohort-specific adjustments. The other SNV association analysis was a model based on the rank-
based inverse-normal transformed residuals (RR-INVN), with residuals taken from a linear regression 
RR interval adjusted for age, sex and BMI covariates. The RR-INVN analysis was performed to check 
for potential sensitivity to deviations from normality within the analysis of rare variants. Additional 
cohort-specific covariate adjustments were also applied, which included for example principal 
components (PCs) or family structure. 
Central QC and meta-analyses 
We performed additional QC checks centrally. For each study we checked the sample size and the 
total number of SNVs (monomorphic and polymorphic) and assessed the beta distribution. Within 
each cohort’s results, all monomorphic SNVs were checked to have NA results. In order to detect 
potential strand-flip issues, the cohort coded effect allele frequencies (EAF) of each SNV were 
compared to the meta-analyzed EAF of a group of CHARGE cohorts (AGES, ARIC, CHS, FHS and WHI). 
Any discordant SNVs showing cohort-EAF ~ 0 in at least one study, but meta-EAF ~ 1, or vice versa, 
were excluded from the central meta-analysis. A set of approximately 11,000 SNVs that were known 
to have QC issues from central CHARGE QC were also excluded from the meta-analysis. Quantile-
Quantile (QQ) plots were produced to inspect each cohort. After all QC steps were completed 
235,677 SNVs remained. The results from all cohorts were then combined into a discovery meta-
analysis using the SeqMeta R package.  
 
Sensitivity analyses 
A sensitivity analysis was performed on the use of beta-blockers (ATC code C07) due to the 
recognized effects of beta-blockers on HR. All cohorts with data on beta-blocker use were re-
analyzed with exclusion of individuals using beta-blockers at the time of phenotype measurement. 
Results of this meta-analysis were compared with the results from the same subset of cohorts with 
beta-blocker users included. 
 
Selection of variants for replication 
All SNVs with P < 1 × 10-5 from the discovery meta-analysis in European individuals were considered 
for follow-up. As a QC step after meta-analysis, we excluded four SNVs with unrealistically high beta 
values, large standard errors, and results that were reported in less than four studies. We defined a 
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novel locus as a genomic region (i) with SNVs not in LD (r2 < 0.2) with any well-established HR-
associated SNVs from the previously reported GWAS 12 (Supplementary Table 1), and (ii) mapping to 
more than 500 kb from either side of a previously reported HR-associated SNV. At the time of our 
study, there were 21 loci reported from GWAS analyses with HR-associated SNVs 12. A potential 
secondary signal within a previously reported locus was defined as being within a 1 Mb region 
centred around the published SNV, but not in LD (r2 < 0.2) with the published SNV in that region. 
LocusZoom plots were produced for all selected SNVs. Only the lead SNV was carried forward, for 
each signal being followed up. Specifically, the most significantly associated SNV was selected for 
any SNVs in pairwise-LD (r2 > 0.2). LD was calculated within UK Biobank genetic data, in order to 
calculate pairwise-LD for all 21 known SNVs (not only those covered on the Exome Chip).  
 
Replication analyses 
We used data from UK Biobank for replication of the selected SNVs (at the time of analysis genetic 
data was available for 150,000 individuals). The UK Biobank data were analysed with untransformed 
HR as the phenotype, with no exclusions for medication use. In UK Biobank resting heart rate was 
assessed by two methods: first, pulse rate using an automated reading during blood pressure 
measurement, and second, pulse rate during arterial stiffness measurement using the pulse wave 
form obtained of the finger with an infra red sensor. When multiple heart rate measurements were 
available during the first visit for an individual, these measurements were averaged. In 99.7% of 
participants at least one single measurement was available. Individuals were excluded with extreme 
(> 4SD) values (N=818). Further details are provided 17. The results of our European exome discovery 
meta-analysis for RR were combined with the UK Biobank replication results for HR (N = 134,251), 
and a combined meta-analysis, using sample-size weighted fixed effects meta-analysis in METAL was 
performed 34. All alleles were aligned between the discovery and replication data, and the inverse 
relationship between RR-interval and HR was taken into account, i.e. so that a negative beta 
direction from our discovery data for a decreased effect on RR-interval was made equivalent to a 
positive beta 
A novel locus was declared if the lead SNV reached exome-wide significance in the combined 
meta-analysis of discovery and replication data (P < 2.12 × 10-7) and replicated with Bonferroni-
adjusted significance (P < 0.0042 for 12 tests) in the replication data alone. In addition, the directions 
of effect between the discovery and replication data were required to be concordant, taking into 
account the inverse relationship between RR from our discovery data and HR from the replication 
data. 
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Potential secondary SNVs at known regions were declared as validated if there was an 
exome-wide significant association in the combined meta-analysis. Variants that validated were 
subsequently tested for independence from previously reported HR variants in a conditional 
analysis. 
 
Conditional analysis 
In order to determine whether the validated secondary signals at previously reported loci were 
independent of the published SNV, conditional analysis was performed within Genome-wide 
Complex Traits Analysis (GCTA) software 35 applying the –cojo method (consisting of conditional and 
joint analysis with stepwise model selection). The input data was the exome-wide summary statistics 
from the full discovery meta-analysis of RR interval in Europeans. The 1958 Birth Cohort Study 
(1958BC; N = 5,815) dataset was used as the reference for genotype data, because it represents one 
of the largest discovery studies (See Supplementary Table 13). LD was calculated between pairwise 
SNVs, but any SNVs further than 10 Mb apart were assumed to not be in LD. All autosomal 
chromosomes were analyzed, with MAF restricted to ≥ 0.01%, to allow for low frequency secondary 
SNVs, whilst taking into account the statistical power achievable. To allow for secondary associations 
a P-value cut-off of 1 × 10-4 was used as the modelling selection threshold within the GCTA analysis. 
Results were then extracted for the nine previously reported regions, within which potential 
secondary signals had been validated from the combined meta-analysis. To be consistent with the 
look-up threshold for selecting SNVs to carry forward from discovery to replication, results were 
restricted to SNVs with a significance level of P < 1 × 10-5 from both the discovery meta-analysis and 
the joint association from GCTA. 
 
Gene-based testing 
Gene-based testing was conducted using the primary discovery data in Europeans. Analysis was 
performed using the SNV-set Kernel Association (SKAT) test within the seqMeta R Package. SKAT 
tests were performed according to two different MAF filters of 1% and of 5%, and three different 
levels of variant filtering, based on annotations within the CHARGE Exome SNP Info annotation file: 
(i) all variants, (ii) variants deemed predicted to be damaging and (iii) variants that were non-
synonymous or leading to abnormal splicing. For gene-based tests we adjusted for multiple testing 
using the Bonferroni correction, according to the number of genes tested. The gene-wide 
significance level was calculated as 1.98 x 10-6 for 25,241 tests (i.e. the number of genes on the 
Exome Chip). For any genes attaining significance, the gene-based tests were repeated with 
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exclusion of the most significantly associated lead variant, in order to confirm that the association 
was due to multiple rare variants. 
 
Non-European ancestry analyses 
Association results were also received for non-European samples. Analysis and QC were performed 
as described for the European data. A meta-analysis was performed centrally in seqMeta for AA 
ancestry, combining data from the five AA cohorts. Study-level results remained for HIS and CH 
ancestries (from only the MESA cohort), in order to consider the three non-European ancestries (AA, 
CH, and HIS) separately from stratified analyses. Due to the smaller sample sizes, power calculations 
were performed using the Genetic Power Calculator 36, based on the average percent trait variance 
explained per locus being 0.04%, according to the recently published results from 64 validated HR 
loci explaining ~2.5% of HR variance 17. To assess the level of heterogeneity by ancestry in non-
European data, we performed a look-up of SNVs at the 12 published HR loci covered on the Exome 
Chip, extracting results for these variants from each of the AA, CH and HIS results. We restricted our 
primary discovery analysis to Europeans only after finding a lack of significant validation and 
concordance between EUR and non-EUR data for previously reported HR variants. As a secondary 
analysis, we performed look-ups of all validated novel loci within the non-European data. The forest 
plots for all validated novel loci display non-European results, to serve as a comparison to results 
within Europeans. In addition to calculating the percentage of concordance of effect directions for 
each ancestry compared to Europeans, a Binomial sign test was also performed in R. This test was 
based on the number of SNVs with consistent effect directions, and it was done to determine 
whether the concordance was higher than expected by chance alone, using P < 0.05 to declare 
significant concordance. 
 
Variance explained 
The percentage variance explained for RR interval was calculated using data from all subjects in the 
1958BC study. The SNV genotypes were extracted from the 1958BC Exome Chip data and considered 
in two different sets: the 12 previously reported SNVs covered on the chip including proxies (r2 ≥ 0.8; 
see Supplementary Table 1); and the lead SNVs from the five unreported novel loci (see Table 1A). 
First, RR interval was regressed in a linear model against the sex and BMI covariates (not age, as all 
1958BC subjects are of same age). Then the trait residuals from this first model were used as the 
phenotype in a second linear regression model, with all SNVs in the given set analysed jointly as 
multiple predictors, and adjusted for the top ten PCs. The percentage trait variance explained by the 
set of SNPs was estimated from this second model, according to the adjusted R2 value. 
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Heart rate loci annotation 
For the purposes of annotation, all signals were expanded to include SNVs in LD. LD was calculated 
within the UK Biobank full genetic dataset using PLINK (v1.9). All variants with an r2 ≥ 0.8 within 500 
kb downstream or upstream of the SNVs of interest were identified. These variants were annotated 
using ANNOVAR (vJun2015) 19. ANNOVAR functionally annotates variants, provides their 
conservation score, identifies SNVs that may cause protein-coding changes and reports their 
damaging prediction scores. Various prediction scores are available in ANNOVAR, including SIFT, 
PolyPhen, and MutationTaster, among others.  
 
We investigated the unreported novel SNVs and their proxies (r2 ≥ 0.8) across 44 tissues available in 
the Genotype-Tissue Expression database (GTEx) dataset 20 for expression quantitative trait loci 
(eQTL). We reviewed the results for SNV-eQTL associations across all tissues, focusing on the heart, 
nerve, lung, muscle, adrenal, and brain tissues which may be relevant tissues for HR based on known 
physiology of heart rate and our results from the enrichment analysis. Genes reported as eQTLs are 
based on study specific significance thresholds (P values < 10-8) and r2 ≥ 0.8 between HR-SNV and 
top-eQTL SNV (the SNV most significantly associated with transcript). 
 
PhenoScanner 
PhenoScanner 37was used to identify variants that are associated with other traits. All proxy SNVs in 
high LD (r2 ≥ 0.8) with the lead SNVs at our five unreported novel loci were investigated in the 
PhenoScanner 1000 Genomes reference dataset. Results were filtered to those reaching a genome-
wide significance P-value ≤ 5 x 10-8. 
 
Potential candidate genes at new heart rate loci 
Candidate genes at each locus were compiled using LD information, ANNOVAR-derived-annotation, 
and eQTL lookup results. A literature review was conducted for potential candidate genes at each 
new HR locus. Sources of information included: published articles, GeneCards, Online Mendelian 
Inheritance in Man®, the Human Protein Atlas, STRING, and UniProt. We searched for information 
on the corresponding mouse models via the International Mouse Phenotyping Consortium (IMPC) 
and the Jackson Laboratory online catalog. URLs for each of the sources is provided in the URL 
section below. 
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Pathway analyses 
Pathway analyses were performed using QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN 
Redwood City) software. In order to distinguish the pathway enrichment contribution of novel loci 
from known HR loci, two sets of analyses were conducted. The first analysis captured the total 
known signal to date, investigating all 67 loci currently published, which include the 21 loci from the 
previously reported GWAS 12 and the 46 loci recently published from UK Biobank 17 since the 
completion of our meta-analysis. The second analysis included our five unreported novel loci in 
addition to all the previously reported loci. In each case, the analysis included all genes annotated 
from the lead SNVs and their proxies (r2 ≥ 0.8). Results were filtered for pathway enrichment of P-
values ≤ 10-4. We specifically report the pathways for which enrichment is increased with the 
inclusion of genes from our novel loci.  
 
Enrichment in DNaseI hypersensitive sites 
To identify the tissues in which HR associated SNVs are active, we used FORGE to look for 
enrichment of DNaseI hypersensitive sites (DHS) in 299 tissue samples from the Roadmap 
Epigenome Project 38.  FORGE calculates enrichment for overlap of HR variants with DHS by 
comparison with overlap of DHSs with 1000 matched background variant sets (matching distance to 
transcriptional start sites, GC content, and minor allele frequency).  
We performed two different enrichment analyses. First, we did a ‘known’ analysis using all 
67 currently published lead SNVs to date [21 previously reported from the original GWAS 12 and 46 
new loci from the recently published UK Biobank study 17].  Second, we did an ‘all’ analysis using the 
lead SNVs at our five unreported novel loci and the 5 independent secondary SNVs that we found at 
previously reported loci; together with the 67 known signals, denoted as the “all” analysis. We 
compared the enrichment results of the two analyses, in order to identify any new enrichment due 
to the inclusion of our novel loci. The enrichment is expressed as Z-score statistics. A Z-score of 2.58 
was used as a threshold for statistical significance, which corresponds to FDR<1.5%. We calculated 
the Z-scoreall-Z-scoreknown ( Z-score) for those tissue samples that were found statistically significant 
in the “all” analysis in order to assess the effect of the ten new, additional SNVs from our study. 
 
Regulatory potential of SNVs 
We selected the HR associated SNVs and proxies in LD (r2 ≥ 0.8; calculated using the UK Biobank full 
genetic dataset) that were identified in this study, and from the previous GWAS (16) and UK Biobank 
studies (17) for annotation. To identify the potential regulatory variants, we retrieve the functional 
confidence score for SNVs from the RegulomeDb database 21. RegulomeDb assigns a functional 
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confidence score to each SNV by overlapping them with functional genomic data mainly from 
ENCODE (e.g. DNase I hypersensitivity, DNase I footprinting, ChIP-seq), with eQTL data and with 
computational prediction (e.g. TF-binding sites and their disruption). We considered any SNP with at 
least one functional annotation to have regulatory potential (this corresponds to functional 
confidence scores: 1a-6). 
 
Long-range regulatory contacts 
Using significant long-range chromatin interactions as identified by Fit-Hi-C in right ventricle Hi-C 
data (40kb resolution) 22, we annotated the potential regulatory SNVs with potential target genes, 
whose promoter is in contact with the given SNV. Where the 40kb genomic region containing the 
SNV had more significant promoter interactions, we show the genes in order of most significant 
interaction to least significant. We took the genes with the most significant promoter interaction 
with the SNVs with regulatory potential per locus, and using IPA®, we assessed which pathways were 
affected, and specifically those that were enriched compared to using only genes in LD with HR-
SNVs. 
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Abstract 
Objective: Sudden cardiac death (SCD) is a major health burden and is primarily caused by ventricular 
arrhythmias. Currently, the most well-known marker for the risk of ventricular arrhythmias is 
QT/QTc prolongation. Animal studies indicate that QT variability might be a better indicator. Our 
objective was to give an overview of the literature on QT variability in humans.  
Methods: We performed a free-text search in PubMed and Embase, from inception through 
February 2013.  
Results: We identified nine QT variability markers in 109 studies reporting on QT variability markers, 
measured on the surface ECG. QT variability can be distinguished using two characteristics: heart-
rate normalisation and whether QT interval is measured on consecutive beats. Most study 
populations were small (median 48 subjects, range 1-805) and different methods, time intervals, and 
leads for measurement were used. QT variability markers were determinants for the risk of 
ventricular arrhythmias, (sudden) cardiac death and total mortality. Few studies compared the 
predictive value of QT variability with that of QT/QTc prolongation. A study comparing all different 
QT variability markers is lacking.  
Conclusions: QT variability markers are potential determinants of ventricular arrhythmias and 
cardiac mortality. However, it is unclear which marker and methodology is clinically most useful as 
well as reliable reference values. More studies on larger datasets are needed to find the most 
accurate marker for the prediction of arrhythmias and SCD to assess its value in addition to QT/QTc 
duration and its role in drug-induced arrhythmia and sudden death.  
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Introduction 
Sudden cardiac death (SCD) is a common lethal manifestation of heart disease.1,2 It is primarily 
caused by ventricular arrhythmias such as ventricular fibrillation (VF), ventricular tachycardia (VT), 
and torsade de pointes.3,4 Risk factors include drug and alcohol use, history of heart failure or cardiac 
ischemia, and certain syndromes with electrocardiogram (ECG) abnormalities, e.g. long QT (LQTS) 
and Brugada syndrome.5,6 Although specific groups with these risk factors have a high risk of SCD, 
50% of all SCDs due to coronary heart disease occur as a first event of this condition or in patients 
thought to be at low risk.7 Risk assessment has two main clinical applications: drug safety testing and 
risk stratification for SCD.  
  In clinical drug-safety studies, the applied method for predicting the arrhythmogenic 
potential is prolongation of the heart-rate corrected QT (QTc) interval on the ECG.8,9 However, 
studies have shown that some QTc prolonging drugs do not increase the incidence of ventricular 
arrhythmias,10,11 while some drugs that do carry an arrhythmogenic risk do not always show QTc 
prolongation.12 Through animal studies an increased QT interval variability has been proposed as a 
less equivocal method for the prediction of arrhythmogenic effects.13-23  
Another application of QT variability is risk stratification for ICD implantation. Berger et al. 
hypothesized that cardiac abnormalities lead to changes in ventricular repolarization.24 However, 
these changes will not necessarily lead to arrhythmias, but it will lower the repolarisation 
reserve.25,26 Repolarization reserve is the concept that the complexity of the repolarisation includes 
some redundancy.26 QT variability is thought to be a measure of decreased repolarization reserve 
and therefore of the risk for arrhythmias.25 
In high-risk patients, antiarrhythmic therapy is administered using implantable cardioverter-
defibrillators (ICD).27-29 Although ICD therapy reduces mortality due to SCD, it has a high cost-
effectiveness ratio,30-32 (inappropriate) shocks can lower quality of life33 and are related to adverse 
outcomes.34 Therefore improved risk stratification for ICD therapy is necessary.  
The objective of this review is to provide an overview of the literature regarding short-term QT 
variability.  
 
Methods 
A PubMed and Embase search from inception until 4 February 2013 was performed. Because no 
MeSH-terms exist for QT variability we used the following free-text keywords: QTVI, QTV index, QT 
variability index, QT variability, QT interval variability, short term variability, beat-to-beat variability, 
STV, BVR, temporal variability, QT, repolarization, monophasic action potential duration or MAPD. 
We excluded papers with the term “Quantitative Tissue Velocity Imaging”, a term not related to our 
topic but also abbreviated QTVI. We limited the search to papers in English. In Supplement 1 the 
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exact search strategy is outlined. We hand-searched citation lists of all studies for publications not 
captured by our electronic search. Results were stored in an EndNote X5 (version 5.0.1, Thomson 
Reuters, USA) database.  
Study selection was performed in two stages. Primary physiological or clinical studies measuring QT 
variability on the surface ECG were candidates for inclusion. First, publications were independently 
assessed on title and abstract by two reviewers (MNN, MEB). Second, the two reviewers 
independently assessed the full text manuscripts. When full text publications could not be retrieved 
online, we contacted the authors.  
  QT variability can be distinguished into short- and long-term. Currently, the most frequently 
studied QT variability markers have been measured on signal windows of 256 seconds24 or 30 
beats.23 Long-term variability has been measured over periods of up to 24 hours.35 We limited this 
review to short-term variability, and applied a maximum time window of 10 minutes or 600 beats. 
Disagreements between reviewers were resolved in consensus meetings. For each included 
publication all relevant information was extracted. This review was conducted according to the 
PRISMA guideline.36 
 
Results 
Search results 
We retrieved 297 unique publications from the electronic search and included 109 publications after 
full-text review. These studies included 58 case-control studies, 23 cross-sectional studies, 15 clinical 
trials, 12 cohort studies and one case report. The selection process and reasons for exclusion are 
shown in Figure 1. In Supplement 3, a full overview of all included studies is shown. We could not 
retrieve the full text of nine publications: one review,37 one conference paper,38 one comment,39 one 
clinical trial with nadolol and metoprolol,40 two studies of post-coronary artery bypass graft 
patients41,42 and case-control studies of patients with diabetes,43 non-alcoholic liver cirrhosis,44 and 
congestive heart failure.45  
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Figure 1. Overview of selection process 
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Table 1. Overview of markers and studies included 
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2 
123 
61.5±9.262* 
55-68 
* mean±SD. The sum of studies exceeds 109 because several papers cover more than one marker. 
QTvar: QT variance; QTm: mean QT interval; QTVN: QT variance normalised for mean QT interval; 
SDqt: standard deviation of QT intervals; MADqt: median absolute difference of QT intervals; STVqt: 
short-term variability of QT interval; RMSSDqt: root meand square of the successive QT interval 
differences; QTVI: QT variability index; HRvar: heart-rate variance; HRm: mean heart rate 
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General findings 
Nine QT variability markers were identified: QT variance (QTvar), QT variance normalised for mean 
QT interval (QTVN), standard deviation of the QT intervals (SDqt), median absolute difference of QT 
intervals (MADqt), short-term variability of the QT interval (STVqt), root mean square of the 
successive QT interval differences (RMSSDqt), QT variability index (QTVI) MADqtc/MADrr and QTRR 
(Table 1). QT variability measures can be grouped based on the combination of two characteristics. 
The first is whether or not the variability is derived from measurements on consecutive beats. When 
measured on consecutive beats, the differences in QT interval between the first and second beat, 
the second and third beat, and so on are the basis for the variability measure (consecutive QT 
variability). Alternatively, beat order is not taken into account and QT intervals of all beats in a 
certain time window are used to calculate variability (non-consecutive QT variability). This distinction 
may have important consequences for the result. Figure 2 shows two different hypothetical patterns 
of four QT intervals. In the case of non-consecutive QT variability measures, the variability in pattern 
1 and 2 is equal because the order is irrelevant. Consecutive QT variability measures will be larger in 
pattern 1 than in pattern 2. 
 The second characteristic to classify the different measures is whether QT variability is 
normalised for heart-rate (variability) (QTn). It is well-known that the QT interval duration is 
influenced by the duration of the RR interval, therefore in clinical practice it is common to apply a 
heart-rate correction method. Through the same mechanism, it could also be important whether or 
not QT variability is normalized for heart-rate (variability). However, heart-rate correction methods 
for QT interval have limitations, e.g. an overestimation of the QTc interval at higher heart rates when 
using Bazett’s formula. Similar problems could arise with QT variability. 
 Thus, four groups can be distinguished: non-consecutive QT variability, consecutive QT 
variability, non-consecutive QTn variability, and consecutive QTn variability. Table 1 gives an 
overview of the nine QT variability markers, classified into these four groups, with their formulas, 
the number of studies per marker and the number of participants. Table 1 and Figure 3 illustrate 
that the study populations are generally small with a median size of 48 subjects (range 1-805 
subjects). 
A variety of ECG leads and time windows are used to calculate the QT variability. The 
majority used either lead II or V5. Time windows ranged from 10 seconds to 10 minutes. In a small 
number of studies measurements were performed manually, in most studies semi-automatic 
methods were applied, usually template stretching according to Berger.24 In this method, a digitised 
ECG is displayed on a graphical interface. The operator defines the template QT interval by selecting 
the beginning of the QRS complex and the end of the T wave for one beat. The algorithm then 
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detects all R waves with automatic peak detection and subsequently determines the QT interval of 
all other beats by stretching or compressing each beat in time to best match the user-defined 
template.24 
We will first describe available physiological and clinical information for all QT variability 
markers. After that we will summarise information from publications comparing different QT 
variability markers. Finally, we will discuss publications comparing QT variability markers and QT(c) 
duration. 
 
Association between QT variability and physiological and clinical endpoints 
QT variability markers had a diurnal pattern being low at night and during sleep, increasing in the 
morning, peaking at noon.46-49 Variability was lower in children than in adults and further increased 
with age49-53 No conclusion could be drawn on gender differences.51-57 Variability was higher in 
standing position compared to supine.58-60 Passive head tilting,61-63 head-down bed rest (simulating a 
long-duration space flight),64 job strain and exercise showed inconsistent results, but most studies 
showed an increased QT variability during exercise.54,56,65-69 
An increased variability was found in patients with cardiac abnormalities,61-63,66,70-100 e.g. 
congenital LQTS,78,95,96,101,102 drug-induced LQTS77,98 and was associated with the occurrence of 
VF/VT.70-76 Ten cohort studies (n=132-687) on patients with cardiac diseases showed that an 
increased variability was associated with the occurrence of VF/VT, (cardiovascular) mortality and 
SCD.55,71,73,76,85,88,103-106 However, three case-control studies did not show an increased QT variability 
in patients with SCD.72,107,108 Case-control studies further showed that QT variability was increased in 
patients with cardiomyopathies,24,62,79,109-111 coronary artery disease,80,84,86,112,113 and 
hypertension.94,109,114 
When patients with structural heart disease received cardiac resynchronization therapy, QT 
variability did not change when electrical remodeling was reversed (reversal of electrical remodeling 
was defined as a decrease of the QRS duration with more than 10 ms.),71 QT variability was not 
increased in patients with postural tachycardia syndrome61 and in teenage patients who underwent 
an arterial switch operation in the neonatal period.115 Three studies showed that sympathetic 
activity of the heart elevated QT variability.61,114,116 Six studies showed an increased variability in 
patients who had a disturbed cardiac autonomous regulation.87,117-121 This indicates that neuronal 
regulation of cardiac function influences repolarization patterns and stability represented in QT 
variability. Several other studies report on QT variability in conditions that have a weak association 
with SCD. Most of these studies found a higher QT variability in cases.49,59,93,116-119,122-150 
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Figure 2. Effect of QT interval patterns on QT variability measures 
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variability 
Pattern 1 
 
Pattern 2
 
consecutieve QT variability: 
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SDqt 
√
1
n
∑(QTi − QTm)2
n
i=1
 
 
sqrt(1/4 ((450-420)2 + (400-420)2     
+ (450-420)2 + (380-420)2))  
 
35.59 
 
sqrt(1/4 ((450-420)2 + (450-420)2     
+ (380-420)2 + (380-420)2))   
 
35.59 
Two hypothetical ECG patterns consisting of four beats are shown. The duration of QT intervals are 
identical in pattern 1 and 2, but their order is different. In case of non-consecutive QT variability 
measures, e.g. the standard deviation, there is no difference between pattern 1 and 2 because the 
order of beats is irrelevant. Consecutive QT variability, e.g. short-term variability, will be larger in 
pattern 1 than in pattern 2. 
 
 
Chapter 2.1 
120 
 
Figure 3. The distribution of population sizes across studies 
 
 
 
In Table 2 the effect of drugs on QT variability is shown.53,63,68,77,89,110,116,127,128,135,151-158 Variability was 
decreased by β-blockers, but increased by sotalol, a drug that can cause ventricular arrhythmias. 
Drugs that stimulate the sympathetic nervous system as well as most QTc interval prolonging drugs 
increased QT variability. Amiodarone neither increases QT variability, nor does it increase the risk of 
ventricular arrhythmias, but it does prolong the QTc interval. This observation is of particular 
interest given the inconsistent relation between observed QTc prolongation and SCD risk by certain 
drugs. 
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Table 2. Effects of several drugs on non-consecutive QTn variability 
Drug Effect Drug Effect 
β-blocker  Antidepressants  
    Carvedilol[W63 ↓     Clonidine[W158 ↑ 
    Metoprolol[W63 ↓     Pemoline[W157 ↑ 
    Sotalol[W53,W 77,W110,W151 ↑/=     Venlafaxine[W135 ↑ 
Antiarrhythmics      Duloxetine[W135 ↑ 
    Digoxin[W151 ↑     Nortriptyline[W128 ↑ 
    Amiodarone[W110 =     Yohimbine[W158 ↑ 
    Ibutilide[W152 ↑     Fluoxetine[W157 = 
Atorvastatin[W154 =     Fluvoxamine[W116 = 
β-sympaticomimetics      Sertraline[W116 = 
    Dobutamine[W89 ↑     Citalopram[W116,W135 ↑/= 
    Epinephrine[W153 ↑     Paroxetine[W128,W135 ↑/= 
    Isoproterenol[W127 ↑ Magnesium sulfate[W151 ↓ 
Sevoflurane[W155 ↑ Sildenafil[W156 ↑ 
 
 
Comparison between QT variability marker groups 
As described earlier, QT variability markers can be divided into four groups based on whether or not 
the measurement is performed on consecutive beats and whether or not it is normalized for heart-
rate (variability). Because these marker groups are physiologically different, as mentioned in the 
general findings section, there could be differences in the association with the endpoints between 
marker groups. In 57 studies, the results for different QT variability markers are described, however 
no direct comparisons are made. Most studies (51) described non-consecutive QT and non-
consecutive QTn variability together. In Table 3 all possible combinations of simultaneous analyses 
are shown. There are no studies that studied all four QT variability marker groups. In the majority of 
studies comparing two or three markers, the markers showed similar results, i.e. they showed a 
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significantly higher QT variability in persons with a higher risk for arrhythmias and SCD. None of the 
studies compared sensitivity and specificity or predictive power of different QT variability markers. 
 
Comparison between QT variability and QTc interval 
Seventy of the 109 included publications reported on the QT/QTc interval alongside QT variability. In 
40 of these publications, the QT interval was corrected for heart-rate. Only two studies made a 
direct comparison. Hinterseer et al. compared the sensitivity and specificity of QTc interval and QT 
variability for diagnosing congenital LQTS among 40 patients and 40 controls, and found that 
sensitivity of QT variability was higher than for QTc interval (83% vs. 43%), but specificity was lower 
(68% vs. 97%).96 When tested in 20 patients with drug-induced LQTS, the predictive power of QT 
variability was superior to that of QTc prolongation (area under the receiver operating 
characteristics curve 0.89 vs. 0.57).98 Of the other 68 studies, 66 described an increased QT 
variability, while only 27 found an increased QT(c) interval. Unfortunately in these studies nothing 
was reported on the predictive power of QT variability compared to QTc prolongation. 
 
 
Table 3. Studies comparing different QT variability groups 
All possible combinations of comparison are shown in column 1 and 2. The third column shows in 
how many studies there is a difference in association of the markers with the outcome. The fourth 
column shows how many studies show no difference.  
 
 
 
 
 
 
 
 
 
1st marker 2nd marker Difference No difference Total 
Non-consecutive QT Consecutive QT 1 6 7 
Non-consecutive QT Non-consecutive QTn 19 32 51 
Non-consecutive QT Consecutive QTn - 2 2 
Consecutive QT Non-consecutive QTn 2 1 3 
Consecutive QT Consecutive QTn - 2 2 
Non-consecutive QTn Consecutive QTn - - 0 
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Discussion 
Key findings 
This is the first review that focuses on all QT variability markers. It shows that QT variability markers 
are potentially useful determinants of ventricular arrhythmias, (sudden) cardiac death and total 
mortality, both in the context of risk stratification and drug safety. Possibly, QT variability could be a 
useful addition to risk stratification for ventricular arrhythmias and SCD. However, many studies 
used small populations and a few studies did not show an association between QT variability 
markers and conditions assumed to enhance the risk of arrhythmias and SCD.71,77,99,108,115 Moreover, 
a wide variety of markers and methods is used while studies that compare the predictive value of 
markers directly are unavailable. 
 
Overview of results and further research 
We identified nine different markers of QT variability. Non-consecutive QTn was the most 
prominent, covered in 83% of the included studies. Most studies were case-control studies with 
small sample sizes. Reference values and differences between sex, age groups and ethnicities have 
not been established. 
The measurement methods lack uniformity. First, there is no consensus on which lead to 
use, although most studies use either lead II or V5. Two studies found significant differences in QTVI 
between the standard ECG leads.57,159 All studies used a single lead to determine the markers. It is 
plausible that some method of combining leads will give better results, but this has not been 
investigated to date. 
Second, there are different methods to measure the subsequent QT intervals. While a few studies 
measured manually, the majority used the semi-automatic algorithm as proposed by Berger et al.24 
Since beat-to beat changes in the QT interval are in the magnitude of a few millisecond, QT 
variability can considerably be affected by accuracy of measurement. For comparison of the results 
between studies, a standard method of measuring QT intervals should be chosen. A recent study by 
Baumert et al. showed that template matching algorithms, in particular a time shifting algorithm, 
performs better than conventional methods.160 Third, the time window in which QT variability is 
determined varies between studies. As indicated by Magri et al., variation in time window can give 
different results for the same marker.112 As of yet, no studies have been performed to assess the 
optimal time window. Fourth, the effect of heart-rate (variability) normalization on QT variability is 
unclear. One study specifically comparing QTVN with QTVI noted that an increase in QTVI could be 
due to a decrease in heart-rate variability or an increase in QT variability.88 The other studies we 
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found however, did not consistently report the heart-rate variability and QT variability component of 
QTVI. Therefore we could not elucidate this further. 
Studies that described different QT variability marker groups did not unequivocally show 
that one specific marker group performs better than the others. However, without direct 
comparison of the predictive value of these markers, we cannot, on the basis of the current 
literature, conclude that one marker or marker group is superior. In a paper by Oosterhoff et al. 
predictive value of consecutive and non-consecutive QT variability on intracardiac ECGs were 
compared. They hypothesized that consecutive QT variability accentuates sudden changes in QT 
interval, which are likely due to stochastic activity of ion channels and thus are arrhythmogenic. 
Conversely, non-consecutive QT variability should be more sensitive to slow changes in QT due to 
variation in autonomic tone or respiration, and reflects changes in the autonomic tone in the 
ventricles.161 In Figure 2, pattern one corresponds to the sudden i.e. high-frequency changes, and 
pattern two corresponds to the slow, low-frequency changes. As non-consecutive variability is the 
same in both patterns, it cannot be said to be more sensitive to slow changes. 
In two small studies direct comparison of the predictive and discriminative power showed that QT 
variability performs better than QTc prolongation. Although in other studies no direct comparisons 
of the predictive value was made, QT variability discriminated between cases with an increased risk 
for SCD and controls in more studies than QTc prolongation. Evidence for superiority of QT variability 
over QT duration is limited. However, it can be of high relevance, even if the predictive power in the 
general population is limited. It could lead to re-evaluating the place of the obliged assessment of QT 
duration prolonging effects in drug development. Also the withdrawal of several drugs could be 
disputed. 
 
Clinical relevance 
To date no study systematically investigated which marker and measuring method is optimal for risk 
prediction. For drug safety studies, study sample sizes were small and methodological heterogeneity 
was substantial. Therefore we cannot draw any firm conclusions. For risk stratification there is 
evidence that QT variability is a marker of cardiovascular mortality and SCD, including a number of 
cohort studies, indicating that QT variability might indeed be a useful risk indicator. However, further 
research is needed before this promising marker can be used in clinical practice. 
 
Limitations 
As our intention was to restrict ourselves to the literature on short-term QT variability we only 
included studies that measured over at most 10 minutes. Consequently, we excluded 20 publications 
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on long-term QT variability. The value of long-term variability is still unknown and remains a subject 
for further investigation. Furthermore, we only included studies performed in humans on surface 
ECGs since these studies have the highest clinical impact and are of interest for future epidemiologic 
research. Finally, due to substantial clinical heterogeneity we were not able to quantify our results 
through meta-analysis. This heterogeneity was caused by differences in signal processing, formulas 
used and clinical endpoints that were studied. 
 
Conclusion 
This review shows that QT variability might be a clinically useful determinant of ventricular 
arrhythmias and SCD. However, more comparative studies are needed to find the most accurate QT 
variability marker and the best method for measurement. We believe this overview of the current 
scientific status of QT variability markers aids clinicians and epidemiologist in future research on ECG 
derived markers for sudden cardiac death and arrhythmias. 
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Supplement 1. Exact search strategy 
Embase 
#1  qt OR repolarization 
#2  ‘monophasic action potential duration’ OR mapd 
#3  ‘short term variability’ OR ‘beat-to-beat variability’ OR stv OR bvr OR ‘temporal variability’  
#4   qtvi OR 'qtv index' OR 'qt variability index' OR 'qt variability' OR 'qt interval variability' NOT 
'quantitative tissue velocity imaging'  
#5  (#1 AND #3) OR (#2 AND #3) OR #4 
#6  #5 AND [english]/lim AND ([article]/lim OR [article in press]/lim) 
283 publications 
(((qt OR repolarization) AND (‘short term variability’ OR ‘beat-to-beat variability’ OR stv OR bvr OR 
‘temporal variability’)) OR ((‘monophasic action potential duration’ OR mapd) AND (‘short term 
variability’ OR ‘beat-to-beat variability’ OR stv OR bvr OR ‘temporal variability’)) OR (qtvi OR 'qtv 
index' OR 'qt variability index' OR 'qt variability' OR 'qt interval variability' NOT 'quantitative tissue 
velocity imaging')) AND [english]/lim AND ([article]/lim OR [article in press]/lim) 
Pubmed 
#1  qt OR repolarization OR repolarisation 
#2  “monophasic action potential duration” OR mapd 
#3  “short term variability” OR “beat-to-beat variability” OR stv OR bvr OR “temporal variability”  
#4  qtvi OR “qtv index” OR “qt variability index” OR “qt variability” OR “qt interval variability” NOT 
“quantitative tissue velocity imaging” 
#5  (#1 AND #3) OR (#2 AND #3) OR #4  Filters activated: Journal Article, English 
#6  (#1 AND #3) OR (#2 AND #3) OR #4  Filters activated: Review, English 
#7  #5 NOT #6 
268 publications 
 ((qt OR repolarization OR repolarisation) AND (“short term variability” OR “beat-to-beat variability” 
OR stv OR bvr OR “temporal variability”)) OR ((“monophasic action potential duration” OR mapd) 
AND (“short term variability” OR “beat-to-beat variability” OR stv OR bvr OR “temporal variability”)) 
OR qtvi OR “qtv index” OR “qt variability index” OR “qt variability” OR “qt interval variability” NOT 
“quantitative tissue velocity imaging” 
Filters activated: Journal Article [or review], English 
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Supplement 2. Overview of included studies 
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 QT variability markers 
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Alam 2009 11 11 Obese subjects  after surgery         
Arnol 2008 68 28 Renal transplant recipients         
Atiga 1998 105 81 SCD, heart disease         
Atiga 2000 62 36 Hypertrophic CM         
Bar 2007 50 25 Paranoid schizophrenia         
Bar 2007 51 18 Acute alcohol withdrawal         
Bar 2008 30 15 Paranoid schizophrenia         
Bar 2010 108 36 Relatives of schizophrenics         
Baumert 2008 12/5  Depression/panic disorder         
Baumert 2008 20  OSAS         
Baumert 2011 25 13 Postural tachycardia syndrome         
Baumert 2011 32 23 Essential hypertension         
Berger 1997 147 83 Dilated CM         
Berger 2003 30 22 Dilated CM         
Boettger 2010 23  Sport students         
Boettger 2010 131  Age, sex differences          
Bonnet 2005 15  Young adult subjects          
Carney 2003 36 18 Depression in MI patients         
Cheng 2009 21 13 Heart failure         
Collins 2005 36  Job strain in middle-aged men         
Couderc 2009 34 17 Drug-induced LQTS         
Couderc 2010 8 3/2 Drug-induced/congenital LQTS         
Desai 2004 34 17 Heart failure, effect of posture         
Dobson 2009 372  Diurnal changes, heart failure         
Dobson 2011 268 55 Mortality, heart failure         
Falkenberg 2013 23 8 Arterial switch operation         
Frljak 2003 47 27 Cardiac surgery         
Furakawa 2006 26 12 Β-blockers in MI patients         
Galeano 2003 86 69 VF/VT in organic heart disease         
Gao 2005 46 17 Chronic renal failure         
Haigney 2004 463 104 VF/VT in patients with ICD         
Haigney 2006 29  Effect of cocaine         
Haigney 2009 805 663 Sexe, VF/VT, ischemic CM, ICD         
Haigney 2009 70 47 Coronary artery disease, ICD         
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Hasan 2012 72  Healthy subjects         
Hinterseer 2008 40 20 Drug-induced LQTS         
Hinterseer 2009 64 40 Congenital LQTS         
Hinterseer 2010 120 60 Heart failure, ICD         
Hiromoto 2005 59  Previous anterior MI         
Huang 2012 23  Effect of air pollution         
Ince 2001 15  Heart failure, effect of MgSO4         
Jie 2010 33 16 Drug-induced LQTS         
Jindal 2009 50 24 1st episode psychosis         
Johansson 2004 153 67 Chronic renal failure         
Kanemori 2008 23 13 Brugada syndrome         
Koschke 2009 150 75 Major depression         
Koschke 2010 40 20 Anorexia nervosa         
Kudaiberdieva 2003 54 27 MI patients, VF/VT         
Kuriki 2011 50 25 Kawasaki disease         
Kusuki 2011 173  QT variability in healthy children         
La Fountaine 2010 114 83 Spinal cord injury         
La Fountaine 2011 6 3 Concussion in athletes         
Lengyel 2011 152 76 Professional soccer players         
Lewis 2006 17  Exercise         
Lewis 2008 8  Progressive bicycle exercise         
Lewis 2012 38  QT variability in the eldery         
Magri 2007 60 30 β-thalassemia major         
Magri 2012 50 20 MI, β-blocker therapy         
Magri 2012 63 43 Myotonic dystrophy type 1         
Mezilis 1998 10  Hypertrophic CM         
Mine 2008 11  Atrial pacing, propranolol, atropin         
Murabayashi 2002 68  Ischemic episodes during holter         
Myredal 2005 121 20 Renovascular hypertension         
Myredal 2008 93 61 Recovery after CABG         
Nishi 2011 9  Cardiac rehabilitation program         
Nussinovitch 2010 24 12 Familial dysautonomia         
Nussinovitch 2012 106 53 Familial Mediterranean fever         
Nussinovitch 2012 88 43 Anorexia nervosa         
Nussinovitch 2012 26 12 Familial Mediterranean fever         
Piccirillo 2001 143 91 Propranolol, sotalol, age          
Piccirillo 2002 82  Heart failure         
Piccirillo 2002 20 10 Heart failure         
Piccirillo 2002 83 44 Hypertension, HCM, ICD         
Piccirillo 2006 190 44 Heart failure         
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Piccirillo 2007 396 42 Heart failure         
Piccirillo 2008 32 22 CM         
Piccirillo 2008 32 22 CADASIL patients         
Pohl 2001 17 6 Panic disorder         
Pohl 2003 23  Effect of fluoxetine, pemoline         
Sachdev 2010 63 30 ICU patients         
Sacre 2012 31 16 Cardiac dysinnervation         
Sakowski 2011 20  Head-down bed rest         
Satomi 2005 19 14 Congenital LQTS         
Seethala 2011 10  Atrial pacing, dobutamine         
Segerson 2008 687 12/3 Patients 6-8 weeks post MI         
Singh 1997 49  Sleep, awakening         
Singh 1997 1  Cardiac arrest         
Solaimanzadeh 2008 28 14 Familial dysautonomia         
Spears 2012 21 11 SCD, epinephrine         
Sullivan 2004 16  Panic disorder         
Svernhage 1998 12 4 Torsades de Pointes         
Tereschenko 2009 298  VF/VT, ICD         
Tereschenko 2011 69 22 CRT-D, VF/VT         
Tereschenko 2012 714 533 Heart failure         
Vrtovec 2000* 55 25 Angina pectoris         
Vrtovec 2001 53 30 Hormone replacement therapy         
Vrtovec 2005 80 40 Heart failure, atorvastatin         
Vrtovec 2008 110 29 Heart failure         
Vrtovec 2009 142 55 Dilated cardiomyopathy         
Yeragani 2000 49  Posture, breathing, age         
Yeragani 2000 19  Posture, breathing         
Yeragani 2000 16  Panic disorder         
Yeragani 2000 30 16 Panic disorder         
Yeragani 2000 88 36 Panic disorder, depression         
Yeragani 2001 22 6 Overanxious disorder         
Yeragani 2002 54 22 Panic disorder         
Yeragani 2003 31 19 Panic disorder         
Yeragani 2005 49  Diurnal changes in QT variability         
Yeragani 2006 48 25 Anxiety, panic disorder         
  
 
 
143 
Chapter 2.2 
Validation of Automatic Measurement of QT 
Interval Variability 
 
Peter R. Rijnbeek1, Marten E. van den Berg1, Gerard van Herpen1, Henk J. Ritsema van Eck1, Jan A. 
Kors1 
 
1 Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The 
Netherlands 
Chapter 2.2 
144 
 
Abstract 
Background Increased variability of beat-to-beat QT-interval durations on the electrocardiogram 
(ECG) has been associated with increased risk for fatal and non-fatal cardiac events. However, 
techniques for the measurement of QT variability (QTV) have not been validated since a gold 
standard is not available. In this study, we propose a validation method and illustrate its use for the 
validation of two automatic QTV measurement techniques. 
 
Methods Our method generates artificial standard 12-lead ECGs based on the averaged P-QRS-T 
complexes from a variety of existing ECG signals, with simulated intrinsic (QT interval) and extrinsic 
(noise, baseline wander, signal length) variations. We quantified QTV by a commonly used measure, 
short-term QT variability (STV). Using 28,800 simulated ECGs, we assessed the performance of a 
conventional QTV measurement algorithm, resembling a manual QTV measurement approach, and a 
more advanced algorithm based on fiducial segment averaging (FSA). 
 
Results The results for the conventional algorithm show considerable median absolute differences 
between the simulated and estimated STV. For the highest noise level, median differences were 4-6 
ms in the absence of QTV. Increasing signal length generally yields more accurate STV estimates, but 
the difference in performance between 30 or 60 beats is small. The FSA algorithm proved to be very 
accurate, with most median absolute differences less than 0.5 ms, even for the highest levels of 
disturbance. 
 
Conclusion In conclusion, artificially constructed ECGs with a variety of disturbances allow validation 
of QTV measurement procedures. The FSA algorithm provides highly accurate STV estimates under 
varying signal conditions, and performs much better than traditional beat-by-beat analysis. The fully 
automatic operation of the FSA algorithm enables STV measurement in large sets of ECGs. 
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Introduction 
The duration of the QT interval in the electrocardiogram (ECG) may vary between individual beats, 
reflecting beat-to-beat changes in ventricular depolarization and repolarization1. A recent position 
paper about QT-interval variability (QTV) extensively reviewed the measurement, physiological basis, 
and clinical value of QTV.2 Increased QT-interval variability (QTV) has been associated with increased 
risk for arrhythmias and cardiovascular events in general.2,3 
The measurement of QTV is a challenging task because the QT-interval variations are usually subtle, 
in the order of milliseconds, and noise or baseline wander may further complicate the determination 
of the end of the T wave, which in itself is ill-defined. QT intervals have been measured manually, 
which is time-consuming and cumbersome. Alternatively, several (semi-)automatic techniques have 
been proposed2, but little is known about their measurement accuracy. Validation of manual or 
automatic measurement techniques, preferably under different operating conditions, is needed. 
However, validation is equivocal because no reference standard is available. 
This issue was in part addressed by Baumert et al.,4 who constructed artificial ECGs by concatenating 
a single, noise-free ECG beat, and then added various forms of simulated disturbances (noise, 
baseline wander, amplitude modulation). The simulated ECGs were then used for testing the 
performance of three QTV measurement algorithms. These authors did not simulate beat-to-beat 
QT-interval variations, and thus could only validate the performance of the algorithms in the 
absence of QTV. Moreover, all simulated ECGs were based on just one ECG beat from a single lead. 
Here we present a validation method that generates artificial standard 12-lead ECGs based on the 
averaged P-QRS-T complexes from a variety of existing ECG signals, with simulated intrinsic (QT 
interval) and extrinsic (noise, baseline wander, signal length) variations. Using the simulated ECGs, 
we assessed the performance of two fully-automatic QTV measurement algorithms, viz. a 
conventional QTV measurement algorithm, resembling a manual QTV measurement approach, and a 
more advanced algorithm based on the fiducial segment averaging technique.5 
 
Methods 
Our validation approach consists of the following steps. First, low-noise artificial ECGs of different 
durations are constructed from a collection of 12-lead ECGs, and initial QT intervals of the individual 
beats in each artificial ECG are set. Various amounts of intrinsic variability (QTV) and extrinsic 
variations (noise and baseline wander) are simulated and added to the artificial ECGs. Second, the 
artificial ECGs are processed by a QTV measurement program and the computed QTV is compared 
with the simulated QTV to assess program performance. These steps are discussed in more detail 
below. 
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Construction of artificial ECGs 
For a given standard 12-lead ECG, we constructed an artificial ECG by computing an averaged P-QRS-
T complex for each lead and concatenating this single complex at the same heart rate as in the 
original ECG. Since the complexes of the artificial ECG are per lead exactly identical, there is no QTV. 
To determine the averaged complex, we had recourse to the Modular ECG Analysis System (MEANS). 
This program for automatic ECG measurement and diagnosis has been evaluated extensively, both 
by its developers and by others.6-8 For each lead, MEANS performs baseline correction, removes 
mains interference, and determines an averaged complex from the dominant beats after having 
excluded ectopic beats. This results in a low-noise representative complex without baseline wander. 
MEANS determines global fiducial points in the averaged beats of all 12 leads, resulting in a common 
P onset, P end, QRS onset, QRS end, and T end over all leads. The fiducial points determined by 
MEANS are transferred to each beat in the artificial ECG, and serve as the reference points for 
subsequent evaluation of the QTV measurement algorithms. 
 
Simulation of intrinsic and extrinsic variations 
Assuming that QTV is mainly determined by ventricular repolarization, we simulated QT interval 
changes by stretching or compressing the ST-T wave of complexes, effectively shifting the end of the 
T wave. We did not change the onset of the QRS complex. The end of the T wave as determined by 
MEANS was taken as starting point. Simulated changes in the end of the T wave always consisted of 
an integer number of sample points (sampling interval 2 ms). A symmetric window of 90 sample 
points around T end was shifted in time foreward or backward without deformation, bringing about 
a compression or extension of the signal segments before and after the window (see Figure 1). The 
samples in the T wave before this window were shifted proportionally in time, interpolated, and 
resampled at the original sampling frequency (500 Hz). Similarly, the samples after the window till 
the start of the next P wave were shifted, interpolated, and resampled. For a given complex, the 
shift in T end was the same across all leads.  
We quantified QTV by a commonly used measure, short-term QT variability (STV), which is 
defined as the mean absolute difference between successive QT intervals 9: 
𝑆𝑇𝑉 =  ∑
|𝑄𝑇𝑖+1 − 𝑄𝑇𝑖|
𝑁√2
𝑁
𝑖=1
 
To simulate a particular STV value for a signal consisting of N+1 beats, we generated a sequence of N 
absolute QT-interval differences (i.e., |𝑄𝑇𝑖+1 − 𝑄𝑇𝑖|) by drawing from a uniform distribution 
centered around the required STV value, with a minimum of 0 and a maximum of twice the required 
STV. 
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Figure 1. Example of a simulated QT-interval change 
 
 
 
The black line indicates the original ECG signal with the vertical line denoting the end of the T wave 
as determined by the MEANS program. The grey line indicates the signal with a shifted end of the T 
wave. The horizontal bars below the signals mark symmetric windows of 180 ms around the end of 
the T wave in which the signal is not deformed. The signal segment from QRS end till the start of the 
window is extended, whereas the signal segment from the end of the window till the onset of the 
next P wave is compressed. 
 
Figure 2. Example of simulated extrinsic disturbances 
 
 
Top panel: artificial ECG signal constructed by concatenating the averaged P-QRS-T complex of the 
original ECG. Middle panel: artificial signal with added noise (SNR 20). Bottom panel: artificial signal 
with added residual baseline wander (standard deviation of slope 30 μV/s). 
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If the absolute difference between the STV of the sequence and the required value was greater than 
0.1 ms, the sequence was rejected and a new sequence was generated. This was repeated until the 
difference was  0.1 ms. The QT durations of the individual beats were then derived from the 
generated QT differences, taking for the first beat the original QT interval as determined by MEANS. 
To avoid an ever-increasing QT interval, each (absolute) difference was added to or subtracted from 
the preceding QT interval so that the cumulative sum of the (signed) differences was minimized. 
Two types of extrinsic variation were simulated, muscle noise and baseline wander (see Figure 2). To 
simulate muscle noise, we generated white noise. For each lead, this noise was added after scaling 
of the noise amplitude to a prespecified signal-to-noise ratio (SNR). Baseline wander was simulated 
by piecewise linear baseline shifts, where each piece started at the onset of a QRS complex and 
ended at the onset of the next QRS complex. The slope of each piece of baseline shift was randomly 
selected from a normal distribution with a prespecified standard deviation and zero mean. Since the 
simulated baseline wander might easily be removed by an automatic correction method, we chose 
to simulate small baseline shifts that were considered to constitute the residual baseline wander 
that remained after a (hypothetical) baseline correction algorithm was applied. Since small 
simulated pieces of baseline wander may add up to a large baseline shift if successive pieces have 
slopes with the same sign, we applied the following rule: if the simulated baseline amplitude at the 
end of a particular complex was positive, the slope of the next piece of baseline was taken negative, 
and vice versa, if the baseline amplitude was negative, the slope of the next piece was taken 
positive. 
 
QT variability measurement 
We assessed the performance of two fully automatic QTV measurement algorithms: a conventional 
method based on the processing and measurement of individual ECG beats, and fiducial segment 
averaging, which exploits the correlation between signal segments across beats. 
 
Conventional computerized measurement  
The MEANS program described above also has the option to measure each individual beat in a 
recording separately. We used this option to determine beat-to-beat QT interval estimates for the 
artificial ECGs. The baseline correction of MEANS was turned off to assess the effect of residual 
baseline wander on QTV measurement. The processing of individual beats by MEANS reflects a 
manual measurement process in which QT intervals are also measured separately. 
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Fiducial segment averaging 
Fiducial segment averaging (FSA) uses beat-to-beat coherence of relatively small segments within 
the P-QRS-T complex to improve the accuracy of fiducial point estimates. A semi-automatic version 
of the measurement process using FSA was first described by Ritsema van Eck.5 In this study, we 
have implemented a fully automatic version (Figure 3).  
 
 
Figure 3. Pseudocode of the FSA algorithm 
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First, MEANS determines the initial fiducial points (onset of QRS complex and end of T wave) 
and constructs a detection function consisting of the root-mean-square ECG signal.10 Second, the 
fiducial point in each individual beat is shifted until maximum correlation is achieved between a 120-
ms signal segment of the detection function around this fiducial point and the average of the 
segments around the fiducial points of all complexes. The amount of shifting is retained and 
constitutes the individual beat variation in the fiducial point estimate. Based on the new fiducial 
point estimates another round of shifting is carried out. This process is repeated until the 
correlations cannot be further improved. Finally, the QT interval for each beat is calculated taking 
into account the final shifts. 
To safeguard against signal segments with excessive noise or baseline wander, the FSA 
algorithm applies an additional test after each round of shifting. If the averaged absolute amplitudes 
of the difference between the ST-T wave of an individual beat and the averaged ST-T wave of the 
remaining beats is larger than a preset value, the beat is discarded and the iteration process is 
repeated for the remaining beats. It should be noted that a rejected beat may reduce the number of 
QT-interval differences in the STV computation by more than one because only differences between 
QT intervals of consecutive beats are taken into account. Since we did not intend to simulate 
excessive noise or baseline wander, the number of rejected beats was expected to be negligible.     
 
Validation experiments 
To validate the two measurement algorithms, we used the first 200 ECGs from the Common 
Standards for Electrocardiography (CSE) diagnostic ECG library.8 The CSE library consists of 1,220 
fully anonymized ECGs that have previously been used in various studies to assess and compare the 
performance of computerized ECG programs. The leads of these ECGs were recorded simultaneously 
at a sampling rate of 500 Hz during 10 seconds. The diagnostic classification of individual ECGs has 
not been released, but the database is known to contain 382 normal ECGs while the rest have 
various abnormalities.8 
Each of the 200 ECGs was processed by MEANS to construct averaged beats, which were 
used to generate artificial noise-free ECGs without QTV consisting of 10, 30, and 60 beats, as 
described above. For each of these ECGs, new ECGs with simulated STV values of 2, 4, 6, 8, and 10 
ms were generated. For each of the resulting ECGs, further ECGs were generated by adding different 
amounts of noise (SNR 40, 30, or 20), residual baseline wander (standard deviation of the 
distribution of slopes 10, 20, or 30 μV/s), or a combination (SNR 30 and 20 μV/s baseline wander), 
for a total of 28,800 ECGs. 
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Results 
Conventional computerized measurement 
Table 1 shows the median and 95th percentile (p95) of the absolute differences between the 
simulated STV and the STV estimated by the conventional, beat-by-beat measurement of MEANS. 
For disturbance-free ECGs, the median absolute differences are in the order of 15% of the simulated 
STV, while p95 values are about twice as high. For low and medium noise levels (SNR 40 or 30), 
similar results are observed for simulated STV values of 4 ms or larger. Interestingly, the median and 
p95 values of the absolute differences in the absence of STV are higher than those for a simulated 
STV of 2 ms. This may be explained by the fact that if the simulated STV is 0, any QT-interval 
mismeasurement will yield an estimated STV > 0, whereas if the simulated STV is larger than 0 and 
QT mismeasurements are made, the estimated STV can be lower or higher, or even the same, as the 
simulated STV. For the highest noise level (SNR 20), performance deteriorates greatly, with median 
differences of 4-6 ms in the absence of STV and p95 values varying between 10 and 20 ms. 
Measurements are much more robust for ECGs with residual baseline wander. The absolute 
differences are comparable to those of slightly noisy ECGs (SNR 40). The amount of residual baseline 
wander hardly affects the estimates. The combination of medium noise and residual baseline (SNR 
30 + slope 20 μV/s) shows similar performance as medium noise alone. An increase in number of 
beats generally results in more accurate STV estimates, but the difference in performance between 
30 or 60 beats is small in most cases. 
 
FSA measurement 
Table 2 shows the median and p95 of the absolute differences between simulated and estimated 
STV for the FSA algorithm. For ECGs without artifacts, FSA perfectly estimates the different 
simulated STV values, i.e., all differences between simulated and estimated STV are zero. For ECGs 
with low or medium noise, most of the differences are very small (p95 well below 1 ms). For higher 
noise levels (SNR 20), the median absolute differences are still very small (about 1 ms for STV = 0 and 
less than 0.5 ms for STV > 0), while p95 values are in the range of 1-2 ms. A similar pattern with very 
low differences is observed for various amounts of residual baseline wander. The combination of 
medium noise and baseline residual gives slightly worse results than those of either artifact 
separately, but almost all median values remain below 0.5 ms, and most p95 values below 1 ms. 
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Table 1. Median (95th percentile) of the absolute differences between simulated STV and STV as measured by the MEANS algorithm for different signal-
to-noise ratios (SNR), residual baseline wander, and number of beats. 
  Simulated STV (ms) 
Artifact No. of beats 0 2 4 6 8 10 
None 10 0.00 (0.00) 0.31 (0.79) 0.63 (1.34) 1.06 (2.12) 1.26 (2.99) 1.65 (3.50) 
 30 0.00 (0.00) 0.27 (0.49) 0.59 (1.02) 0.83 (1.43) 1.17 (2.23) 1.46 (2.57) 
 60 0.00 (0.00) 0.26 (0.40) 0.55 (0.84) 0.83 (1.34) 1.09 (1.78) 1.40 (2.30) 
SNR 40 10 1.02 (2.59) 0.31 (1.34) 0.67 (1.65) 1.02 (2.44) 1.34 (2.79) 1.69 (4.32) 
 30 1.15 (2.44) 0.22 (1.05) 0.44 (1.24) 0.80 (1.77) 1.18 (2.46) 1.39 (2.97) 
 60 1.20 (2.18) 0.18 (1.14) 0.42 (0.91) 0.71 (1.58) 1.05 (1.73) 1.31 (2.40) 
SNR 30 10 1.49 (3.22) 0.47 (2.12) 0.79 (2.44) 1.02 (3.02) 1.22 (3.42) 1.53 (3.77) 
 30 1.63 (3.91) 0.37 (2.45) 0.46 (1.27) 0.68 (1.91) 1.12 (2.35) 1.46 (3.16) 
 60 1.64 (4.25) 0.43 (2.25) 0.32 (1.73) 0.66 (1.47) 0.95 (2.04) 1.27 (2.56) 
SNR 20 10 4.48 (19.05) 2.36 (16.42) 1.81 (14.89) 1.57 (18.38) 1.89 (10.21) 2.12 (10.69) 
 30 5.73 (18.08) 3.71 (18.28) 2.07 (14.24) 1.54 (11.29) 1.22 (14.78) 1.45 (12.19) 
 60 5.82 (17.49) 3.74 (17.31) 2.40 (14.81) 1.53 (15.02) 1.10 (13.96) 1.13 (11.69) 
Baseline 10 μV/s 10 0.94 (2.63) 0.39 (1.26) 0.71 (1.49) 1.02 (2.24) 1.41 (2.99) 1.65 (3.77) 
 30 1.05 (2.24) 0.22 (1.13) 0.46 (1.21) 0.78 (1.71) 1.09 (2.01) 1.46 (3.06) 
 60 1.03 (2.08) 0.20 (0.89) 0.47 (1.03) 0.77 (1.53) 1.06 (2.04) 1.40 (2.40) 
Baseline 20 μV/s 10 1.02 (2.71) 0.39 (1.41) 0.79 (1.73) 1.02 (2.47) 1.37 (3.22) 1.57 (3.89) 
 30 1.02 (2.24) 0.24 (1.27) 0.44 (1.15) 0.84 (1.55) 1.11 (2.21) 1.51 (2.91) 
 60 1.07 (2.26) 0.22 (1.10) 0.46 (1.05) 0.74 (1.53) 1.08 (2.10) 1.32 (2.62) 
Baseline 30 μV/s 10 1.02 (2.44) 0.39 (1.61) 0.79 (1.96) 1.10 (2.40) 1.41 (3.10) 1.73 (4.01) 
 30 1.07 (2.46) 0.24 (1.68) 0.51 (1.29) 0.72 (1.84) 1.12 (2.45) 1.39 (2.84) 
 60 1.10 (2.54) 0.19 (1.14) 0.41 (0.96) 0.77 (1.50) 1.04 (2.16) 1.35 (2.84) 
SNR 30 + 10 1.49 (3.18) 0.47 (2.20) 0.71 (2.12) 1.02 (2.87) 1.57 (3.50) 1.73 (3.89) 
baseline 20 μV/s 30 1.65 (4.17) 0.43 (2.12) 0.45 (1.66) 0.73 (1.99) 1.04 (2.33) 1.38 (2.96) 
 60 1.75 (4.45) 0.36 (2.97) 0.32 (1.97) 0.71 (1.38) 0.97 (1.89) 1.33 (2.56) 
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Table 2. Median (95th percentile) of the absolute differences between the simulated STV and STV as measured by the FSA algorithm for different signal-
to-noise ratios (SNR), residual baseline wander, and number of beats. 
  Simulated STV (ms) 
Artifact No. of beats 0 2 4 6 8 10 
None 10 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
 30 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
 60 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
SNR 40 10 0.00 (0.31) 0.00 (0.24) 0.00 (0.16) 0.00 (0.31) 0.00 (0.31) 0.00 (0.31) 
 30 0.00 (0.24) 0.00 (0.10) 0.00 (0.10) 0.00 (0.10) 0.00 (0.10) 0.00 (0.15) 
 60 0.00 (0.18) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05) 
SNR 30 10 0.47 (1.34) 0.16 (0.79) 0.31 (0.71) 0.16 (0.63) 0.16 (0.94) 0.16 (0.79) 
 30 0.20 (0.93) 0.10 (0.39) 0.10 (0.39) 0.10 (0.39) 0.10 (0.39) 0.10 (0.29) 
 60 0.22 (0.79) 0.05 (0.31) 0.05 (0.24) 0.05 (0.24) 0.05 (0.22) 0.05 (0.29) 
SNR 20 10 1.26 (2.75) 0.31 (1.81) 0.47 (1.57) 0.47 (1.41) 0.47 (1.96) 0.47 (1.57) 
 30 0.88 (2.32) 0.24 (1.02) 0.20 (1.02) 0.20 (0.95) 0.20 (1.07) 0.22 (1.19) 
 60 0.77 (2.21) 0.19 (0.95) 0.14 (0.90) 0.14 (0.77) 0.17 (1.21) 0.16 (1.19) 
Baseline 10 μV/s 10 0.16 (0.94) 0.00 (0.47) 0.00 (0.63) 0.00 (0.63) 0.00 (0.63) 0.00 (0.47) 
 30 0.20 (1.02) 0.05 (0.34) 0.05 (0.29) 0.05 (0.29) 0.05 (0.34) 0.05 (0.29) 
 60 0.19 (0.90) 0.05 (0.34) 0.05 (0.22) 0.02 (0.24) 0.05 (0.26) 0.05 (0.24) 
Baseline 20 μV/s 10 0.63 (2.12) 0.16 (1.02) 0.16 (0.94) 0.16 (0.94) 0.16 (0.79) 0.16 (0.94) 
 30 0.68 (1.80) 0.15 (0.76) 0.10 (0.44) 0.10 (0.49) 0.10 (0.51) 0.10 (0.59) 
 60 0.67 (1.95) 0.12 (0.68) 0.10 (0.44) 0.10 (0.46) 0.10 (0.38) 0.07 (0.40) 
Baseline 30 μV/s 10 0.94 (2.91) 0.31 (1.49) 0.31 (1.49) 0.31 (1.41) 0.31 (1.26) 0.31 (1.41) 
 30 0.98 (2.37) 0.24 (1.24) 0.19 (0.95) 0.15 (0.88) 0.19 (0.68) 0.15 (0.78) 
 60 0.96 (2.34) 0.26 (1.09) 0.13 (0.85) 0.11 (0.79) 0.10 (0.54) 0.12 (0.50) 
SNR 30 + 10 0.79 (1.73) 0.31 (1.10) 0.31 (0.94) 0.31 (0.94) 0.31 (1.10) 0.31 (1.10) 
baseline 20 μV/s 30 0.59 (1.41) 0.19 (0.59) 0.15 (0.49) 0.10 (0.44) 0.15 (0.49) 0.15 (0.59) 
 60 0.50 (1.41) 0.10 (0.52) 0.10 (0.34) 0.07 (0.35) 0.10 (0.37) 0.10 (0.38) 
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The number of ECGs in which the FSA algorithm rejected beats for further analysis was very low: one 
ECG for the highest level of simulated noise (SNR 20), and two ECGs for the largest slope of residual 
baseline wander (30 μV/s). 
 
Discussion 
We have validated the performance of two QTV measurement tools under different operating 
conditions by constructing artificial ECGs with different amounts of simulated STV and disturbances. 
Our results indicate that the FSA algorithm produces highly accurate STV estimates. A traditional 
beat-by-beat measurement algorithm performed less well, especially for higher levels of noise or 
residual baseline wander. 
We are not the first to use simulated data as a means to validate the performance of QTV 
measurement algorithms 4,11. Baumert et al. 4 concatenated a noise-free beat of one ECG lead and 
added different forms of artifacts to validate several (semi-)automatic measurement techniques. The 
same data were also used in a later study, in which the authors evaluated an alternative 
measurement approach 11. Beat-to-beat QT-interval variations were not simulated, and thus the 
performance of the algorithms was only validated in the absence of QTV. Moreover, all simulated 
ECGs were constructed from just one ECG beat from a single lead. We used a set of 200 different 
artificial 12-lead ECGs, and also simulated different amounts of STV. Contrary to the previous 
studies, this allowed us to validate the performance of measurement algorithms for non-zero STV 
values, in a morphologically diverse set of ECGs. 
The same approach that we applied to validate automatic algorithms, could, in principle, also be 
used to validate a manual measurement procedure. We did not attempt to do this since the effort of 
measuring individual QT intervals in thousands of ECGs was considered prohibitive. However, the 
MEANS algorithm, like the manual method, also measures on a beat-by-beat basis. Our results 
clearly indicate that this beat-by-beat measurement is inferior to an approach that exploits the 
correlation between individual beats, as is done in FSA. In particular for larger noise levels, the errors 
in the MEANS estimates become unacceptably large. This suggests that STV estimates obtained with 
a beat-by-beat measurement procedure, automatic or manual, must be interpreted cautiously.  
Previous studies that used STV have measured QT intervals in 30 or 60 consecutive beats 9,12, but the 
effect of varying recording durations on the accuracy of STV estimates has not been investigated. 
Our results indicate that accuracy generally improves with increasing signal length. This effect is 
more pronounced for FSA than for MEANS, likely because FSA employs an averaged signal segment 
that will become less noisy with increasing signal length, whereas MEANS does not use averaging 
when measuring individual beats. We also found that FSA already performs very well for signal 
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durations of 10 s. This finding increases the practical utility of STV as the far majority of ECGs that 
are recorded in clinical practice or epidemiological studies are standard 10-s ECGs. The ability to 
process large sets of ECGs also allows to quantify circadian effects and establish normal values of 
QTV, as recommended in a recent QTV position paper 2. 
In this study we have focused on the validation of STV measurement. The same approach can be 
used to validate the measurement of other QTV parameters, such as the standard deviation of QT-
interval durations. QTV parameters that normalize for heart rate variability, like the QTV index 1, 
would require additional modeling of variations in RR-interval duration. The approach could also be 
applied to validate measurement algorithms of other types of variability, such as T-wave alternans, 
after appropriate modelling.  
Our study has several limitations. First, our simulation of QTV by shifting the tail of individual T 
waves, preserving their shape, is straightforward but may not fully reflect reality. Unfortunately, 
little is known about the underlying mechanisms that affect QTV and the shape of the T wave. Once 
such knowledge becomes available, a more elaborate simulation is imaginable. Second, for practical 
reasons we only tested the effect of a limited set of artifacts, i.e., noise and residual baseline 
wander, but simulation of other types of artifacts can be envisaged. For example, simulated 
respiratory modulation of T-wave amplitudes has previously been shown to affect QTV estimates 
based on single-lead measurement 4. Although we expect our algorithms to be less sensitive for 
respiratory movements because we combine information from all ECG leads, this may be 
investigated in future research. 
In conclusion, artificially constructed ECGs with a variety of disturbances allow validation of QTV 
measurement procedures. The FSA algorithm provides accurate STV estimates under varying signal 
conditions, and performs significantly better than traditional beat-by-beat analysis. The fully 
automatic operation of the FSA algorithm enables STV measurement in large sets of ECGs. 
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Abstract 
Aims QT variability is a promising electrocardiographic marker. It has been studied as a possible 
screening tool for patients with coronary artery disease and left ventricular hypertrophy, and it is a 
known risk factor for sudden cardiac death. Because comprehensive normal values for QT variability 
are lacking, we aim to establish these in standard 10-second electrocardiograms (ECGs) covering 
both sexes and all ages. 
Methods Ten-second, 12-lead ECGs were provided by five Dutch population studies (Pediatric 
Normal ECG Study, Leiden University Einthoven Science Project, Prevention of Renal and Vascular 
End-stage Disease Study, Utrecht Health Project, Rotterdam Study). ECGs were recorded digitally 
and processed by well-validated analysis software. We selected cardiologically healthy participants, 
46% being women. Ages ranged from 11 days to 91 years. After quality control, 13,882 ECGs were 
available. We assessed three markers: standard deviation of QT intervals (SDqt), short-term QT 
variability (STVqt), and QT variability index (QTVI). 
Results For SDqt and STVqt, the median and lower limit of normal remained stable with age. The 
upper limit of normal declined until around age 45, and increased strongly in the elderly. For QTVI, 
median and normal limits decreased until age 20, and steadily went up afterwards except for the 
lower limit of normal, which decreased after age 65. Generally, women had higher SDqt, STVqt, and 
QTVI than men, notably so after age 30. 
Conclusion We report the first comprehensive set of normal values for QT variability based on 10-
second ECGs. These normal values should be valuable for research and clinical practice. 
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Introduction 
QT variability is a measure of the spontaneous fluctuations in the duration of the QT interval on the 
electrocardiogram (ECG). These fluctuations are thought to be the result of local variations in cardiac 
repolarization, and to reflect cardiac electrical instability.1 For this reason, QT variability has been 
studied in relation to ventricular arrhythmias2 and sudden cardiac death (SCD).3 Moreover, QT 
variability was found to be an effective screening tool for coronary artery disease and left ventricular 
hypertrophy, which are important underlying causes of SCD.4 The effects of cardiac drugs on QT 
variability have also been studied: β-blockers decrease QT variability (except sotalol), while digoxin 
and β-sympathomimetic drugs increase QT variability.5 The most commonly used QT variability 
markers are the standard deviation of QT intervals (SDqt), short-term QT variability (STVqt), and the 
QT variability index (QTVI).1,5 
 QT variability has been measured on ECG signals as short as 10 seconds, and as long as 24 
hours.1,5 Because the standard 10-second ECG is cheap, non-burdening, and in ubiquitous use, it 
would be valuable to have comprehensive normal values for QT variability based on 10-second ECGs. 
A recent position paper on QT variability presented a meta-analysis of SDqt and QTVI of healthy 
participants from previous studies.1 However, this meta-analysis was of limited size (1,954 adults for 
QTVI, and 1,190 adults for SDqt) and did not stratify on age or sex. Also, differences between the 
individual studies in ECG processing and in duration of ECG recording were not addressed.1 The 
various studies referred to in this meta-analysis reported normal limits for QT variability, but these 
studies often did not use standard 10-second ECGs, but analyzed much longer ECG signals.6-10 
In the present study we provide comprehensive normal values for QT variability, applying 
the commonly used QT variability markers SDqt, STVqt, and QTVI to a large set of standard 10-
second, 12-lead ECGs of cardiologically healthy persons, covering both sexes and all ages.  
 
Methods 
Study population 
We combined data from five population studies conducted in the Netherlands. The 10-second, 12-
lead ECGs from these studies were digitally recorded and stored at sampling rates of at least 500 Hz, 
up to 1200 Hz in the pediatric group. All data were anonymized. The following studies were included: 
(1) Pediatric Normal ECG Study:11 The population of this study consists of 1,912 children, 
their ages ranging from 11 days to 16 years. The children were recruited in the year 2000 at three 
children’s health centers, three primary schools, and one secondary school in the city of Rotterdam. 
The children’s height and weight, measured before ECG recording, corresponded well with the Dutch 
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growth standard.11 ECGs were recorded with a portable PC-based acquisition system (Cardio Control, 
Delft, The Netherlands).  
(2) Leiden University Einthoven Science Project:12 The population of this study contains 787 
medical students of Leiden University. The ages of the participants ranged between 17 and 29 years, 
and all attested to be in good health. The ECGs were recorded from 2005 until 2007 with Megacart 
electrocardiographs (Siemens, Erlangen, Germany). 
(3) Prevention of Renal and Vascular End-stage Disease (PREVEND) Study:13 This study, which 
started 1997, aims to investigate the natural course of microalbuminuria and its relation to renal and 
cardiovascular disease in the general population. The PREVEND population consists of 8,592 
participants aged 28-75 years, from the city of Groningen. Medical records, including medication 
use, were available for all participants. ECGs were recorded with CardioPerfect equipment (Welch 
Allyn Cardio Control, USA). 
(4) Utrecht Health Project:14 This ongoing study started in 2000 in Leidsche Rijn, a newly 
developed residential area of Utrecht. All new inhabitants were invited by their general practitioner 
to participate. The population of this study consists of 6,542 participants. Written informed consent 
was obtained and an individual health profile was made by dedicated research nurses. Baseline 
assessment included physical examination, ECG, blood tests, and interview-assisted questionnaires. 
Pharmacy records were used to obtain medication use. ECGs were recorded with CardioPerfect 
equipment (Welch Allyn Cardio Control, USA). 
(5) Rotterdam Study:15 This study, which started in 1990, investigates determinants of a 
number of age-related disorders in an elderly population, prominently among them cardiovascular 
disease. The first two cohorts of the Rotterdam Study population consist of 10,994 inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years or older. Participants were visited at home for an 
interview and were subsequently examined at the research center. Detailed information was 
collected on health status, medical history, and medication use. ECGs were recorded with an ACTA 
electrocardiograph (Esaote, Florence, Italy). 
 From these five populations, totaling 28,827 participants, we selected a subgroup with no 
indication of cardiac disease. Reasons for exclusion were a history of myocardial infarction, heart 
failure, coronary bypass surgery, coronary angioplasty, or pacemaker implantation. Other exclusion 
criteria were hypertension and diabetes mellitus. Hypertension was defined as a systolic blood 
pressure ≥160 mmHg or a diastolic blood pressure ≥100 mmHg or use of antihypertensive 
medication, including use of beta-blockers. Diabetes mellitus was defined as a non-fasting serum 
glucose ≥11 mmol/l or use of glucose-lowering drugs. After applying these criteria, 15,248 
individuals remained available.  
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ECG quality control 
We removed ECGs with excessive noise, excessive baseline wander, ventricular arrhythmias, and 
second or third degree atrioventricular block. This resulted in 13,882 ECGs available for analysis. In 
11 ECGs all measured QT intervals were identical, producing a SDqt and STVqt of zero. In those 
cases, the log-transformation contained in the QTVI formula produced values of minus infinite. 
These values were set to the lowest non-infinite QTVI value of –3.60.  
 
QT-variability measurement  
All QT intervals on the ECGs were measured automatically by the Modular ECG Analysis 
System (MEANS) using fiducial segment averaging (FSA),16 a technique that exploits the correlation 
between signal segments from individual beats. First, MEANS determines the locations of the 
individual QRS complexes and initial fiducial points (i.e., the onset of the QRS complex and the end 
of T wave). Baseline wander is corrected using restricted splines, and a detection function consisting 
of the root-mean-square ECG signal is computed. Second, the fiducial point in each individual beat is 
shifted in an iterative procedure until maximum correlation is achieved between a small signal 
segment of the detection function around this fiducial point and the average of the segments around 
the fiducial points of the remaining complexes. The amount of shifting is retained and constitutes 
the individual beat variation in the fiducial point estimate. Finally, the QT interval for each beat is 
calculated taking into account the shifts of the initial QRS onset and T end. MEANS automatically 
detects ectopic beats, such as premature (supra)ventricular complexes, and excludes them from 
further processing. Also, the beats immediately before and after an ectopic beat are not used. To 
safeguard against signal segments with excessive noise or baseline wander, an additional test is 
applied after each FSA iteration. If the averaged absolute amplitudes of the difference between the 
ST-T wave of an individual beat and the averaged ST-T wave of the remaining beats is larger than a 
preset value, the beat is discarded and the iteration process is repeated for the remaining beats.  
We calculated the QT-variability markers SDqt, STVqt, and QTVI.5 SDqt is defined as the 
standard deviation of the QT intervals on a 10-second ECG. STVqt is defined as the average of the 
absolute differences between the QT intervals of subsequent beats: STVqt = ∑
|𝑄𝑇𝑖+1 −𝑄𝑇𝑖|
𝑛√2
𝑛
𝑖=1  , where 
n is the number of differences. QTVI normalizes the variance of the QT intervals (QTv) for mean QT 
(QTm) squared, and the variance of the heart rate (HRv), for mean heart rate (HRm) squared, and is 
defined as QTVI = 𝑙𝑜𝑔10 [(
𝑄𝑇𝑣
𝑄𝑇𝑚
2 ) (
𝐻𝑅𝑣
𝐻𝑅𝑚
2 )⁄ ]. 
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Estimation of normal values  
We used the Box-Cox t distribution in a semi-parametric model for location, scale, and shape to 
estimate centile curves.17 The Box-Cox t distribution allows for modeling of the distribution of the 
median, skewness, and kurtosis as functions of age. The lower limit of normal (LLN) was defined as 
the 2nd percentile and the upper limit of normal (ULN) was defined as the 98th percentile. The Box-
Cox t distribution was implemented with the lms function of the R-package gamlss, and the normal 
values for all age categories were estimated using the predict.gamlss function of the gamlss 
package. The normal values of a given age category were estimated for the central age in that 
category. For example, normal values for the category of 30-40 years are based on the estimated 
values for participants aged 35 years. 
This study was approved by the Medical Ethics Committee of the Erasmus University Medical 
Center. Since all data were anonymized and retrospectively collected, informed consent of the 
subjects was not required according to Dutch legislation. 
 
Results 
Table 1 shows the number of available ECGs grouped by sex and age category. Most age groups had 
more than 100 ECGs, only the age groups below six months or above 90 years contained fewer ECGs. 
Table 2 gives the age-dependent median, ULN, and LLN of SDqt, stratified by sex. Table 3 shows 
these statistics for STVqt and table 4 for QTVI. Additional percentile values for the three markers are 
given in Supplementary tables 1, 2, and 3. Figures 1, 2, and 3 show continuous age-dependent curves 
of the median and the normal limits of SDqt, STVqt and QTVI, respectively.  
The median and LLN of SDqt remain relatively constant over age, but the ULN changes 
considerably: it decreases from birth to approximately 45 years, after which age it starts to increase 
again, the rate of ascent being higher than that of descent. The age-dependent pattern of STVqt is 
similar to that of SDqt: the median and LLN are fairly constant, while the ULN decreases from birth 
to age 45, and increases strongly afterwards. The normal values of QTVI show a decrease until about 
20 years, after which they start to rise. 
There were some notable sex differences. For SDqt, boys have a higher ULN than girls until 
the age of 15, but after that age, women have a higher ULN than men. The sex differences in the 
median or LLN are minimal. For STVqt, the point at which women have a higher ULN than men lies at 
around 20 years, while the sex differences in the median and LLN are again minimal. QTVI follows a 
similar pattern (men higher values at younger ages, women have higher values later in life), but less 
pronounced than SDqt and STVqt. 
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Table 1. The study population stratified on sex and age groups 
Age group Boys/Men Girls/Women Total 
Younger than 1 month 9 8 17 
1 to 3 months† 26 22 48 
3 to 6 months 33 37 70 
6 to 12 months 69 53 122 
1 to 3 years 50 51 101 
3 to 5 years 60 61 121 
5 to 8 years 123 104 227 
8 to 12 years 115 163 278 
12 to 16 years 139 100 239 
16 to 20 years 155 384 539 
20 to 30 years 522 844 1,366 
30 to 40 years 1,942 1,402 3,344 
40 to 50 years 1,492 583 2,075 
50 to 60 years 1,270 934 2,204 
60 to 70 years 1,173 1,038 2,211 
70 to 80 years 329 427 756 
80 to 90 years 49 110 159 
90 years and older 1 4 5 
Total 7,557 6,325 13,882 
†The term “to” specifies the upper limit in the sense of “less than”. 
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Table 2. Normal values for SDqt in milliseconds per age group and sex 
 Median   (2nd Percentile, 98th Percentile) 
Age Category Boys/Men Girls/Women 
< 1 month 3.15 (1.13; 10.77) 3.13 (1.12; 8.70) 
1 to 3 months† 3.15 (1.13; 10.76) 3.13 (1.12; 8.70) 
3 to 6 months 3.15 (1.13; 10.74) 3.13 (1.13; 8.71) 
6 to 12 months 3.16 (1.13; 10.71) 3.13 (1.13; 8.73) 
1 to 3 years 3.16 (1.14; 10.62) 3.14 (1.13; 8.78) 
3 to 5 years 3.16 (1.15; 10.47) 3.15 (1.12; 8.87) 
5 to 8 years 3.16 (1.15; 10.28) 3.15 (1.11; 9.01) 
8 to 12 years 3.12 (1.14; 9.98) 3.13 (1.08; 9.25) 
12 to 16 years 3.02 (1.10; 9.55) 3.08 (1.01; 9.60) 
16 to 20 years 2.88 (1.05; 9.06) 2.99 (0.95; 9.85) 
20 to 30 years 2.63 (0.95; 8.32) 2.90 (0.96; 9.43) 
30 to 40 years 2.34 (0.83; 7.59) 2.79 (1.00; 8.94) 
40 to 50 years 2.14 (0.76; 7.19) 2.63 (0.97; 9.16) 
50 to 60 years 2.11 (0.73; 7.84) 2.54 (0.94; 10.22) 
60 to 70 years 2.24 (0.77; 8.95) 2.61 (0.98; 12.44) 
70 to 80 years 2.48 (0.90; 10.17) 2.81 (1.05; 16.25) 
80 to 90 years 2.78 (1.02; 12.47) 3.11 (1.16; 22.67) 
†The term “to” specifies the upper limit in the sense of “less than”. 
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Table 3. Normal  values for STVqt in milliseconds per age group and sex 
 Median   (2nd Percentile, 98th Percentile) 
Age Category Boys/Men Girls/Women 
< 1 month 2.22 (0.46; 7.57) 2.13 (0.61; 7.16) 
1 to 3 months† 2.22 (0.46; 7.58) 2.14 (0.61; 7.16) 
3 to 6 months 2.22 (0.46; 7.59) 2.14 (0.61; 7.17) 
6 to 12 months 2.23 (0.46; 7.61) 2.14 (0.61; 7.19) 
1 to 3 years 2.23 (0.47; 7.69) 2.15 (0.60; 7.23) 
3 to 5 years 2.25 (0.47; 7.79) 2.17 (0.60; 7.30) 
5 to 8 years 2.25 (0.48; 7.90) 2.17 (0.60; 7.36) 
8 to 12 years 2.23 (0.48; 7.97) 2.16 (0.58; 7.38) 
12 to 16 years 2.15 (0.47; 7.84) 2.12 (0.55; 7.28) 
16 to 20 years 2.03 (0.45; 7.51) 2.06 (0.53; 7.11) 
20 to 30 years 1.82 (0.43; 6.85) 2.01 (0.50; 7.04) 
30 to 40 years 1.58 (0.39; 6.07) 1.98 (0.49; 7.18) 
40 to 50 years 1.42 (0.36; 5.56) 1.87 (0.47; 7.33) 
50 to 60 years 1.42 (0.35; 5.92) 1.83 (0.46; 8.05) 
60 to 70 years 1.58 (0.38; 7.02) 1.92 (0.49; 9.51) 
70 to 80 years 1.83 (0.43; 8.51) 2.13 (0.56; 11.55) 
80 to 90 years 2.13 (0.51; 10.45) 2.44 (0.67; 14.27) 
†The term “to” specifies the upper limit in the sense of “less than”. 
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Table 4. Normal values for QTVI per age group and sex 
 Median   (2nd Percentile , 98th Percentile) 
Age Category Boys/Men Girls/Women 
 1 month -1.48 (-2.36; 0.17) -1.48 (-2.42; -0.13) 
1 to 3 months* -1.48 (-2.36; 0.16) -1.48 (-2.42; -0.14) 
3 to 6 months -1.49 (-2.37; 0.15) -1.49 (-2.43; -0.14) 
6 to 12 months -1.50 (-2.38; 0.13) -1.50 (-2.44; -0.15) 
1 to 3 years -1.52 (-2.40; 0.08) -1.53 (-2.47; -0.19) 
3 to 5 years -1.57 (-2.44; 0.01) -1.58 (-2.51; -0.24) 
5 to 8 years -1.62 (-2.49; -0.08) -1.63 (-2.57; -0.29) 
8 to 12 years -1.67 (-2.55; -0.17) -1.69 (-2.64; -0.35) 
12 to 16 years -1.72 (-2.62; -0.24) -1.74 (-2.71; -0.38) 
16 to 20 years -1.74 (-2.67; -0.28) -1.76 (-2.75; -0.39) 
20 to 30 years -1.75 (-2.73; -0.26) -1.73 (-2.75; -0.35) 
30 to 40 years -1.67 (-2.77; -0.16) -1.58 (-2.67; -0.16) 
40 to 50 years -1.55 (-2.71; -0.08) -1.39 (-2.55; 0.08) 
50 to 60 years -1.36 (-2.61; 0.12) -1.18 (-2.41; 0.38) 
60 to 70 years -1.14 (-2.53; 0.39) -0.96 (-2.29; 0.69) 
70 to 80 years -0.93 (-2.46; 0.69) -0.78 (-2.23; 0.97) 
80 to 90 years -0.68 (-2.41; 1.05) -0.63 (-2.23; 1.25) 
†The term “to” specifies the upper limit in the sense of “less than”.  
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Figure 1. Median, 2nd and 98th percentiles for SDqt for all ages in men and women 
 
Abbreviation: SDqt: Standard deviation of QT intervals 
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Figure 2. Median, 2nd and 98th percentiles for STVqt for all ages in men and women 
 
Abbreviation: STVqt: Short-term variability of the QT interval 
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Figure 3. Median, 2nd and 98th percentiles for QTVI for all ages in men and women 
 
Abbreviations: QTVI: QT variability index 
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Discussion 
This is the first paper to report comprehensive normal values of QT variability based on 10-second, 
standard 12-lead ECGs. We report the median, LLN, and ULN of SDqt, STVqt and QTVI across all ages 
and stratified on sex. 
 A recent paper by Baumert et al. presents a meta-analysis of normal values from 45 studies 
involving 1,954 adults with QTVI measurements and from 23 studies involving 1,190 adults with SDqt 
measurements.1 Without taking age or ECG-recording duration into account, this meta-analysis 
found for men a mean QTVI of –1.6 and a mean SDqt of 3.3 milliseconds. Some of the larger 
component studies of this meta-analysis did not use standard 10-second ECGs, but analyzed much 
longer ECG signals. In children, there is a study by Kusuki et al. that reported normal values of 
children without organic heart disease aged 0 to 7 years, using ECG recordings containing 120 beats.9 
This paper concluded that QTVI decreased from birth to age 7, which is in accordance with our 
findings. Unfortunately this study did not report percentiles. A study by Yeragani et al. using 10-
minute recordings found no significant difference in QTVI between 15 children aged 6-14 years and 
34 normal adults aged 20-55 years.6 Assuming the 10-minute recordings have the same age-
dependent pattern as 10-second recordings, this may be explained by the children being on the 
descending limb of the QTVI curve, while the adults are at the same height on the ascending limb. 
There are three studies that track normal values for QTVI over a longer age range, between 20 and 
90 years.7,8,10 These studies, with 40,10 131,8 and 1437 healthy participants respectively, showed that 
QTVI increases over this age range, which is similar to our findings. These three studies used 10-
minute, 15-minute and 30-minute recordings, respectively. SDqt was analyzed by Kraus et al., 
showing that SDqt is higher in women and that SDqt increases with age;18 both findings are 
consistent with the results of this study. Kraus et al. used 24-hour Holter recordings, and calculated 
hourly mean values for SDqt. To the extent comparisons are possible, the current findings are in 
general agreement with these previous studies that used longer recordings. The age and sex 
dependent normal values of QT variability reported here may serve to establish cut-off values for 
various clinical and pharmacological applications. For example, a drug associated with risk of 
ventricular arrhythmias might be withheld if the QT variability is above a certain limit. 
 Our study has a number of strengths. With 13,882 ECGs it is by far the largest study 
reporting normal values for QT variability. We include both men and women, and have a wide age 
coverage, from 11 days to 90 years. Although the ECGs in this study were retrieved from five 
different population studies, they were all analyzed consistently and automatically with the well-
validated MEANS program and FSA technique.16 This approach eliminates intra-observer bias, and 
uses all 12 ECG leads, which limits dependency of QT variability on the T-wave amplitude. 
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 Our study also has some limitations. First, we had a relatively low number of ECGs in the 
extremes of the age distribution. For this reason, the normal limits of the groups younger than six 
months and older than ninety years should be used with caution. Second, the use of 10-second 
recordings prohibits measurement of QT variability over longer time intervals and detection of, e.g., 
respiratory modulation and diurnal changes. However, respiratory modulation was studied by Emori 
et al., and this study concluded that respiratory modulation does not affect QT variability in healthy 
participants.19 As for diurnal changes, a study by Yeragani et al. has shown that QT variability differs 
between the waking and sleeping hours, but it has also shown that QT variability is fairly constant 
within the waking or sleeping period.20 Therefore, if all ECGs are recorded in awake participants, this 
should not materially affect the results. Finally, 10-second ECGs may sometimes contain only a few 
QT intervals for QT-variability calculation, and may render QT-variability estimates less reliable than 
those from longer recordings.  
 In conclusion, normal limits have been established for SDqt, STVqt, and QTVI derived from 
10-second ECGs, using a consistent and automatic methodology for all ages and both sexes. We 
found strong age effects for SDqt and STVqt, as the ULN increases in the elderly. Using these normal 
values, both researchers and clinicians have a tool to decide upon cut-off values of QT variability, 
which improves the applicability of 10-second QT variability in practice. 
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Supplementary Table 1. Percentiles of SDqt in milliseconds by age category of men and women 
†The term “to” specifies the upper limit in the sense of “less than” 
 
 
 
 
 
 
 
 
 
Percentiles for Men 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 1.13 1.37 1.64 2.21 3.15 4.58 6.57 8.24 10.77 
1 to 3 months† 1.13 1.37 1.64 2.22 3.15 4.58 6.56 8.23 10.76 
3 to 6 months 1.13 1.37 1.64 2.22 3.15 4.58 6.56 8.22 10.74 
6 to 12 months 1.13 1.38 1.64 2.22 3.16 4.58 6.55 8.21 10.71 
1 to 3 years 1.14 1.38 1.65 2.23 3.16 4.58 6.52 8.16 10.62 
3 to 5 years 1.15 1.39 1.66 2.24 3.16 4.56 6.48 8.07 10.47 
5 to 8 years 1.15 1.40 1.66 2.24 3.16 4.54 6.40 7.96 10.28 
8 to 12 years 1.14 1.39 1.65 2.22 3.12 4.46 6.26 7.75 9.98 
12 to 16 years 1.10 1.35 1.61 2.16 3.02 4.30 6.01 7.42 9.55 
16 to 20 years 1.05 1.29 1.54 2.07 2.88 4.08 5.69 7.03 9.06 
20 to 30 years 0.95 1.17 1.41 1.89 2.63 3.70 5.15 6.38 8.32 
30 to 40 years 0.83 1.05 1.26 1.70 2.34 3.25 4.53 5.68 7.59 
40 to 50 years 0.76 0.97 1.17 1.57 2.14 2.96 4.13 5.24 7.19 
50 to 60 years 0.73 0.93 1.14 1.54 2.11 2.94 4.19 5.44 7.84 
60 to 70 years 0.77 0.98 1.19 1.61 2.24 3.18 4.63 6.10 8.95 
70 to 80 years 0.90 1.10 1.32 1.77 2.48 3.60 5.32 7.02 10.17 
80 to 90 years 1.02 1.23 1.46 1.96 2.78 4.14 6.30 8.46 12.47 
  
Percentiles for Women 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 1.12 1.38 1.66 2.24 3.13 4.37 5.91 7.08 8.70 
1 to 3 months 1.12 1.38 1.66 2.24 3.13 4.37 5.91 7.08 8.70 
3 to 6 months 1.13 1.38 1.66 2.24 3.13 4.37 5.91 7.09 8.71 
6 to 12 months 1.13 1.38 1.66 2.24 3.13 4.38 5.92 7.10 8.73 
1 to 3 years 1.13 1.39 1.66 2.25 3.14 4.39 5.94 7.13 8.78 
3 to 5 years 1.12 1.39 1.66 2.25 3.15 4.41 5.98 7.19 8.87 
5 to 8 years 1.11 1.38 1.66 2.25 3.15 4.42 6.01 7.26 9.01 
8 to 12 years 1.08 1.35 1.64 2.23 3.13 4.41 6.04 7.35 9.25 
12 to 16 years 1.01 1.29 1.58 2.18 3.08 4.35 6.04 7.45 9.60 
16 to 20 years 0.95 1.23 1.52 2.11 2.99 4.26 5.98 7.47 9.85 
20 to 30 years 0.96 1.22 1.49 2.05 2.90 4.13 5.79 7.22 9.43 
30 to 40 years 1.00 1.22 1.46 1.98 2.79 3.99 5.61 6.95 8.94 
40 to 50 years 0.97 1.17 1.38 1.86 2.63 3.81 5.49 6.93 9.16 
50 to 60 years 0.94 1.13 1.33 1.78 2.54 3.77 5.63 7.34 10.22 
60 to 70 years 0.98 1.16 1.36 1.82 2.61 3.96 6.17 8.38 12.44 
70 to 80 years 1.05 1.24 1.45 1.94 2.81 4.36 7.10 10.10 16.25 
80 to 90 years 1.16 1.36 1.59 2.13 3.11 4.96 8.49 12.73 22.67 
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Supplementary Table2.  Percentiles of STVqt in milliseconds by age category of men and women 
†The term “to” specifies the upper limit in the sense of “less than” 
 
 
 
 
 
 
 
 
Percentiles for Men 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 0.46 0.67 0.91 1.43 2.22 3.34 4.78 5.92 7.57 
1 to 3 months† 0.46 0.67 0.91 1.43 2.22 3.34 4.78 5.93 7.58 
3 to 6 months 0.46 0.67 0.91 1.43 2.22 3.35 4.79 5.93 7.59 
6 to 12 months 0.46 0.68 0.92 1.43 2.23 3.35 4.80 5.95 7.61 
1 to 3 years 0.47 0.68 0.92 1.44 2.23 3.37 4.82 5.99 7.69 
3 to 5 years 0.47 0.69 0.93 1.45 2.25 3.39 4.86 6.05 7.79 
5 to 8 years 0.48 0.69 0.93 1.45 2.25 3.40 4.89 6.11 7.90 
8 to 12 years 0.48 0.69 0.93 1.44 2.23 3.37 4.87 6.11 7.97 
12 to 16 years 0.47 0.67 0.90 1.39 2.15 3.25 4.73 5.96 7.84 
16 to 20 years 0.45 0.65 0.86 1.32 2.03 3.07 4.48 5.68 7.51 
20 to 30 years 0.43 0.60 0.79 1.19 1.82 2.74 4.01 5.11 6.85 
30 to 40 years 0.39 0.55 0.71 1.06 1.58 2.36 3.45 4.44 6.07 
40 to 50 years 0.36 0.51 0.66 0.96 1.42 2.09 3.07 3.98 5.56 
50 to 60 years 0.35 0.50 0.65 0.96 1.42 2.11 3.12 4.11 5.92 
60 to 70 years 0.38 0.54 0.71 1.05 1.58 2.38 3.59 4.79 7.02 
70 to 80 years 0.43 0.61 0.80 1.20 1.83 2.81 4.33 5.81 8.51 
80 to 90 years 0.51 0.70 0.91 1.38 2.13 3.36 5.26 7.11 10.45 
  
Percentiles for Women 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month 0.61 0.79 0.99 1.44 2.13 3.16 4.50 5.59 7.16 
1 to 3 months 0.61 0.79 0.99 1.44 2.14 3.16 4.50 5.59 7.16 
3 to 6 months 0.61 0.79 0.99 1.44 2.14 3.16 4.51 5.60 7.17 
6 to 12 months 0.61 0.79 1.00 1.44 2.14 3.17 4.52 5.61 7.19 
1 to 3 years 0.60 0.79 1.00 1.45 2.15 3.18 4.54 5.64 7.23 
3 to 5 years 0.60 0.79 1.00 1.45 2.17 3.21 4.58 5.69 7.30 
5 to 8 years 0.60 0.79 1.00 1.45 2.17 3.23 4.61 5.73 7.36 
8 to 12 years 0.58 0.77 0.98 1.44 2.16 3.22 4.60 5.73 7.38 
12 to 16 years 0.55 0.74 0.95 1.41 2.12 3.16 4.53 5.64 7.28 
16 to 20 years 0.53 0.71 0.92 1.36 2.06 3.07 4.41 5.51 7.11 
20 to 30 years 0.50 0.68 0.89 1.32 2.01 3.02 4.35 5.44 7.04 
30 to 40 years 0.49 0.67 0.86 1.29 1.98 3.00 4.36 5.50 7.18 
40 to 50 years 0.47 0.63 0.82 1.22 1.87 2.87 4.26 5.46 7.33 
50 to 60 years 0.46 0.62 0.80 1.19 1.83 2.85 4.35 5.73 8.05 
60 to 70 years 0.49 0.66 0.85 1.26 1.92 3.01 4.72 6.41 9.51 
70 to 80 years 0.56 0.75 0.95 1.39 2.13 3.34 5.35 7.44 11.55 
80 to 90 years 0.67 0.88 1.11 1.61 2.44 3.86 6.27 8.88 14.27 
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Supplementary Table3. Percentiles of QTVI by age category of men and women 
†The term “to” specifies the upper limit in the sense of “less than” 
 
Percentiles for Men 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month -2.36 -2.22 -2.08 -1.82 -1.48 -1.05 -0.59 -0.26 0.17 
1 to 3 months† -2.36 -2.22 -2.09 -1.83 -1.48 -1.06 -0.59 -0.26 0.16 
3 to 6 months -2.37 -2.23 -2.09 -1.83 -1.49 -1.06 -0.60 -0.27 0.15 
6 to 12 months -2.38 -2.24 -2.10 -1.84 -1.50 -1.07 -0.61 -0.28 0.13 
1 to 3 years -2.40 -2.26 -2.13 -1.87 -1.52 -1.11 -0.65 -0.33 0.08 
3 to 5 years -2.44 -2.30 -2.17 -1.91 -1.57 -1.15 -0.71 -0.39 0.01 
5 to 8 years -2.49 -2.35 -2.21 -1.95 -1.62 -1.21 -0.77 -0.46 -0.08 
8 to 12 years -2.55 -2.41 -2.27 -2.01 -1.67 -1.27 -0.84 -0.55 -0.17 
12 to 16 years -2.62 -2.47 -2.32 -2.06 -1.72 -1.32 -0.90 -0.61 -0.24 
16 to 20 years -2.67 -2.51 -2.36 -2.09 -1.74 -1.35 -0.93 -0.64 -0.28 
20 to 30 years -2.73 -2.56 -2.39 -2.10 -1.75 -1.34 -0.92 -0.63 -0.26 
30 to 40 years -2.77 -2.56 -2.37 -2.05 -1.67 -1.26 -0.84 -0.54 -0.16 
40 to 50 years -2.71 -2.48 -2.27 -1.93 -1.55 -1.14 -0.72 -0.44 -0.08 
50 to 60 years -2.61 -2.35 -2.13 -1.76 -1.36 -0.93 -0.51 -0.23 0.12 
60 to 70 years -2.53 -2.24 -1.99 -1.59 -1.14 -0.69 -0.25 0.04 0.39 
70 to 80 years -2.46 -2.14 -1.86 -1.41 -0.93 -0.43 0.03 0.33 0.69 
80 to 90 years -2.41 -2.04 -1.72 -1.22 -0.68 -0.15 0.35 0.67 1.05 
  
Percentiles for Women 
Age 2nd 5th 10th 25th 50th 75th 90th 95th 98th 
< 1 month -2.42 -2.25 -2.09 -1.82 -1.48 -1.10 -0.72 -0.46 -0.13 
1 to 3 months -2.42 -2.25 -2.10 -1.82 -1.48 -1.11 -0.72 -0.46 -0.14 
3 to 6 months -2.43 -2.26 -2.10 -1.83 -1.49 -1.11 -0.73 -0.47 -0.14 
6 to 12 months -2.44 -2.27 -2.11 -1.84 -1.50 -1.12 -0.74 -0.48 -0.15 
1 to 3 years -2.47 -2.30 -2.14 -1.87 -1.53 -1.16 -0.77 -0.51 -0.19 
3 to 5 years -2.51 -2.34 -2.19 -1.91 -1.58 -1.21 -0.82 -0.56 -0.24 
5 to 8 years -2.57 -2.40 -2.24 -1.96 -1.63 -1.26 -0.88 -0.62 -0.29 
8 to 12 years -2.64 -2.46 -2.30 -2.02 -1.69 -1.32 -0.94 -0.68 -0.35 
12 to 16 years -2.71 -2.52 -2.36 -2.07 -1.74 -1.37 -0.99 -0.72 -0.38 
16 to 20 years -2.75 -2.56 -2.39 -2.10 -1.76 -1.39 -1.00 -0.74 -0.39 
20 to 30 years -2.75 -2.56 -2.38 -2.08 -1.73 -1.34 -0.95 -0.68 -0.35 
30 to 40 years -2.67 -2.47 -2.28 -1.96 -1.58 -1.17 -0.76 -0.49 -0.16 
40 to 50 years -2.55 -2.34 -2.14 -1.80 -1.39 -0.95 -0.52 -0.25 0.08 
50 to 60 years -2.41 -2.19 -1.98 -1.61 -1.18 -0.71 -0.25 0.04 0.38 
60 to 70 years -2.29 -2.04 -1.82 -1.42 -0.96 -0.46 0.02 0.32 0.69 
70 to 80 years -2.23 -1.96 -1.71 -1.28 -0.78 -0.26 0.25 0.58 0.97 
80 to 90 years -2.23 -1.92 -1.64 -1.17 -0.63 -0.07 0.48 0.83 1.25 
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Abstract 
Aims Increased QT variability (QTV), the variation of QT-interval durations on the electrocardiogram 
(ECG), has been proposed as a risk factor for cardiac morbidity and mortality in general, and for 
ventricular arrhythmias and sudden cardiac death (SCD) in particular. However, QTV has not yet 
been assessed as a risk factor in the general population. We therefore aimed to assess QTV as a risk 
factor for total mortality, coronary heart disease (CHD) mortality, and SCD in a population-based 
cohort. 
 
Methods and Results The Rotterdam Study is a cohort of middle-aged and elderly people. We 
included 9,024 participants, with 22,610 ECGs in total. 3,847 participants died after a median follow-
up of 10.5 years. Total mortality, CHD mortality, SCD, and witnessed SCD were the endpoints in Cox’ 
regressions. The standard deviation of the QT intervals (SDqt), short-term variability (STVqt), root-
mean-square of successive QT-interval differences (RMSSDqt), and QT variability index (QTVI) were 
measured automatically from 10-second ECGs. QTVI and QTVI2 were significant risk factors for total 
mortality (hazard ratios (HRs) 1.06 and 1.01, respectively). SDqt, STVqt, and RMSSDqt were 
significant risk factors for total mortality (HRs 1.12, 1.12, and 1.11, respectively), CHD mortality (HRs 
1.22, 1.23, and 1.21), and in women, for witnessed SCD (HRs 1.44, 1.63, and 1.50). 
 
Conclusions The association of QTV markers with total mortality and CHD mortality was confirmed in 
a population-based cohort. An association with witnessed SCD was established only in women. 
Future research may elucidate the underlying sex-specific pathophysiology of these findings. 
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Introduction  
Despite improvements in prevention and treatment, cardiovascular diseases still impose a major 
burden of morbidity and mortality in Western Europe.1 About half of the deaths associated with 
heart disease are sudden cardiac deaths (SCDs).2 SCD has a multifactorial etiology: various 
underlying pathologies may cause electric instability, which in turn can lead to ventricular 
arrhythmias and ensuing SCD.3 The underlying pathologies have different prevalences in men and 
women, but coronary heart disease (CHD) and dilated cardiomyopathy are most common in both.4 
Still, SCD can occur in a structurally normal heart and can also be drug-induced.4 As SCD is often the 
first expression of heart disease, prediction of SCD in the general population remains a challenging 
problem.5 
 The heart-rate corrected QT (QTc) interval is the best known electrocardiographic (ECG) 
marker of ventricular arrhythmias and SCD.5 Yet, QTc prolongation has limited predictive value for 
SCD.6 QT variability (QTV), the beat-to-beat variation of QT-interval duration, has been advocated as 
a more specific risk factor for ventricular arrhythmias.7 It is hypothesized that regional heterogeneity 
of cardiac repolarization leads to beat-to-beat changes in the QT interval,7 and thus, QTV is thought 
to be a marker of electric instability.3 QTV has come forward as a promising marker of SCD: an 
increase of a few milliseconds in QTV was predictive of ventricular arrhythmias in animal models of 
cardiac pathology,8 QTV had a higher sensitivity and specificity for drug-induced arrhythmias than 
QTc prolongation in a case-control study in humans,6 and QTV was associated with total mortality,9 
cardiovascular mortality,9 and SCD10 in cohort studies. These cohort studies, however, were small (at 
most 805 participants) and exclusively contained heart-failure patients or patients that had had a 
myocardial infarction (MI), while improvement of SCD prediction is most needed in the general 
population.5 Several QTV markers have been proposed, but the predictive value of a comprehensive 
set of QTV markers has not yet been assessed and compared.11 Finally, studies have not specifically 
addressed older adults, in whom the incidence of cardiovascular disease and SCD is highest.1 
Therefore, we aimed to establish the association of four different QTV markers with total mortality, 
CHD mortality, and SCD in a community-dwelling population of older adults. 
 
Methods 
Setting 
Our study is part of the prospective population-based Rotterdam Study. The design and rationale of 
the Rotterdam Study have been described in more detail elsewhere.12 In short, from 1990 to 1993, 
all inhabitants aged 55 years and older from the Ommoord district in Rotterdam, the Netherlands, 
were invited to participate in the initial cohort, and 7,983 individuals agreed to participate (response 
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rate 78%). In 2000, the cohort was extended by inviting all inhabitants from the same district who 
had turned 55 or who had moved into the district after the start of the initial cohort. For this 
extension, 3,011 individuals agreed to participate (response rate 67%). Of the 10,994 participants we 
included 8,990 in our study. Figure 1 shows a flowchart of the selection of the study population. 
Follow-up examinations were conducted every four to five years. The Rotterdam Study has been 
approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, 
Welfare and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO 
(Population Studies Act: Rotterdam Study)”. We included only participants who provided written 
informed consent to participate in the study, including access to information from their general 
practitioner for follow-up monitoring. 
 
Electrocardiography 
Standard 12-lead ECGs were recorded at rest with an ACTA Gnosis electrocardiograph (Esaote 
Biomedica, Florence, Italy) at a sampling frequency of 500 Hz and stored digitally. ECGs were 
processed by the Modular ECG Analysis System (MEANS), which has been validated and applied 
extensively.13 We excluded ECGs with atrial fibrillation, atrial flutter, pacemaker rhythm, or left 
bundle branch block. We calculated the short-term variability of QT intervals (STVqt), the root mean 
square of successive QT-interval differences (RMSSDqt), the standard deviation of QT intervals 
(SDqt), and the QT variability index (QTVI).11 Supplementary Table 1 shows their formulas. 
To determine QTV, QT intervals were measured automatically using the fiducial segment 
averaging (FSA) technique.14 Briefly, MEANS determines the locations of the individual QRS 
complexes in the ECG and their initial fiducial points (global onset of QRS complex and end of T wave 
across all leads), and computes a detection function consisting of the root-mean-square ECG signal. 
MEANS automatically detects and excludes ectopic beats from further processing together with the 
beats immediately before and after the ectopic beat. Second, the fiducial point of each individual 
beat is shifted in an iterative procedure until maximum correlation is achieved between a small 
signal segment of the detection function around this fiducial point (the “fiducial segment”) and the 
average of the fiducial segments of the remaining complexes. The amount of shifting is retained and 
constitutes the individual beat variation in the fiducial point estimate. Finally, the QT interval for 
each beat is calculated while taking into account the shifts of the initial QRS onset and T end. To 
safeguard against signal segments with excessive noise or baseline wander, an additional test is 
applied after each FSA iteration. If the averaged absolute amplitudes of the difference between the 
ST-T wave of an individual beat and the averaged ST-T wave of the remaining beats is larger than a 
preset value, the beat is discarded and the iteration process is repeated for the remaining beats. 
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The following ECG-derived markers were analyzed as covariables: heart rate, heart-rate 
variability (HRV), average QT interval, and Sokolow-Lyon index. HRV was expressed as the standard 
deviation of normal-to-normal RR intervals (SDNN).15 Based on an earlier study that showed a 
quadratic relationship between SDNN and both total and cardiovascular mortality,16 SDNN squared 
was also added to the model. The Sokolow-Lyon index was taken as the sum of the voltages of the S 
in lead V1 and the R in lead V5 or V6, whichever was larger. 
 
Covariables 
We analyzed age, sex, smoking, body-mass index (BMI), hypertension, history of CHD, history of 
diabetes mellitus, and history of heart failure. All covariables were determined at the date of each 
ECG recording. Based on a home interview, participants were classified into never, former, and 
current smokers. BMI was defined as weight in kilograms divided by height squared in meters. Blood 
pressure was measured twice in the sitting position on the right upper arm. The average of two 
measurements was used. Hypertension was defined as a systolic blood pressure ≥140 mmHg, or a 
diastolic blood pressure ≥90mmHg, or the use of blood-pressure-lowering medication with the 
indication hypertension. CHD was defined as a history of a MI or a percutaneous or surgical coronary 
revascularization procedure.17 The diagnosis of heart failure was established in accordance with the 
guidelines of the European Society of Cardiology18 and was based on typical signs or symptoms of 
heart failure confirmed by objective evidence of cardiac dysfunction.17 Diabetes mellitus was defined 
as a fasting serum glucose level ≥7.0 mmol/L or a non-fasting serum glucose level ≥11.1 mmol/L, or 
use of glucose-lowering medication, or a previous diagnosis of diabetes mellitus. 
 
Outcome definitions 
Total mortality was death due to any cause. The definition of CHD mortality in the Rotterdam Study 
has been described previously.17 In short, all available information for each candidate case of fatal 
CHD was reviewed by research physicians to ascertain the cardiac cause of death. CHD mortality as 
used in this study includes mortality due to definite fatal MI, definite fatal CHD and possible fatal 
CHD.17 
SCD was defined in accordance with the Myerburg definition, which is endorsed by the 
European society of Cardiology,19 as “a natural death due to cardiac causes, heralded by abrupt loss 
of consciousness within one hour from onset of acute symptoms. Pre-existing heart disease may 
have been known to be present, but the time and mode of death are unexpected.” Cases of 
unwitnessed death were labeled as SCD if the person had been seen in a stable medical condition 24 
hours preceding death and if there was no evidence of a non-cardiac cause of death. In addition, in 
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case of sparse information, cases were labelled as SCD when the attending physician recorded death 
as sudden or unexpected.1 Identification and validation of SCD cases was based on a two-step 
process. Initially, when a participant died, research assistants gathered the relevant portions from 
the medical records. A study physician then coded the death according to the International 
Classification of Disease, 10th revision (ICD-10). A medical specialist pertinent to the field validated 
the study physician’s coding. The decision of the medical specialist was decisive. In the second step, 
the medical files of participants whose deaths were coded according to the following ICD-10 codes 
were assessed: I05-I09 (Chronic rheumatic heart diseases), I20-I25 (Ischemic heart diseases), I30-I52 
(Other forms of heart disease), I60-I69 (Cerebrovascular diseases), and R96-R99 (Ill-defined and 
unknown causes of mortality). Classification as SCD was done independently by two research 
physicians and subsequently by an experienced cardiologist. For the outcome "witnessed SCD", we 
subtracted SCD cases that were unwitnessed, or for which it was unclear if death was witnessed. 
Follow-up was complete for 96% of all mortality events until January 1st, 2011. 
 
Statistics 
All variables were used as time-dependent variables in a Cox' proportional hazard model, updated at 
each center visit. ECG variables were updated when a new ECG had been made. QTV variables that 
were not normally distributed were log-transformed before analysis. We plotted the Schoenfeld 
residuals to assess the proportional hazards assumption. In case of missing values, last observations 
were carried forward if a previous center visit was available. Remaining missing values were imputed 
using 10-times multiple imputation. 
For every QTV marker we reported both crude hazard ratios (HRs) and HRs adjusted for the 
covariables age, sex, QT interval, heart rate, and the additional confounders smoking, body-mass 
index (BMI), hypertension, history of CHD, history of diabetes mellitus, and history of heart failure. 
The additional confounders were only included if they changed the beta estimate of the QTV marker 
by more than 10%. For CHD mortality, history of CHD was excluded because it is highly associated 
with the event. For analyses with QTVI we did not consider HRV because this variable is part of the 
QTVI formula. If a quadratic term for a QTV marker was significant, this was added to all analyses. In 
case of a significant interaction between age or sex and the QTV marker, results were presented 
stratified by age group or sex. The correlation between QTV markers was assessed on baseline ECGs 
with the Pearson correlation coefficient. 
For all analyses, we used R (R Foundation for Statistical Computing, Vienna, Austria), specifically the 
packages survival, rms and Hmisc. Results were presented as HRs for each QTV marker with 95% 
confidence intervals (95%CIs). Two-sided p-values <0.05 were considered significant. 
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Figure 1. Flowchart of the generation of the study population. 
 
Abbreviations: ECG: electrocardiogram; LBBB: Left bundle branch block; AF: atrial fibrillation; RS: 
Rotterdam Study cohort; QTV: QT variability; n: number 
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Results 
Baseline characteristics of the study population are shown in Table 1. In short, 58.3% were women, 
and the mean age at baseline was 68 years. Median follow-up duration was 10.5 years. During 
follow-up, 3,847 persons died, of whom 774 due to CHD and 401 due to SCD. There was 
considerable overlap of SCD and CHD: 366 SCD cases were also classified as CHD (91%). Of the 401 
SCD cases, 215 cases were witnessed SCD. No covariable had more than 5% missing values. 
 Table 2 presents the association of all QTV markers with all four outcomes. SDqt, RMSSDqt, 
and STVqt were not normally distributed, and therefore log-transformed. ln(SDqt), ln(STVqt), and 
ln(RMSSDqt) were significantly associated with total mortality. QTVI had a significant quadratic term 
for total mortality. All four markers were significantly associated with total mortality. ln(SDqt), 
ln(STVqt), and ln(RMSSDqt) were significantly associated with CHD mortality. None of the QTV 
markers were significantly associated with SCD. These were all multivariable-adjusted results. We 
stratified the analyses for witnessed SCD on sex because the interaction term of ln(STVqt) and 
ln(RMSSDqt) with sex was significant. Table 3 shows that ln(STVqt) and ln(RMSSDqt) were 
significantly associated with a higher risk of witnessed SCD in women, but not in men. 
The Pearson correlation coefficients of STVqt, SDqt, RMSSDqt ranged between 0.82 and 
0.97, showing a high correlation, but each of these had a weaker correlation with QTVI, as the 
Pearson Correlation Coefficients of STVqt, SDqt and RMSSDqt with QTVI ranged between 0.46 and 
0.48. 
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Table 1. Baseline characteristics 
 
Abbreviations: BMI: body-mass index; ECG: electrocardiogram; IQR: interquartile range; QTVI: QT 
variability index; RMSSDqt: Root mean square of successive differences in QT intervals; SD: standard 
deviation; SDNN: Standard deviation of normal-to-normal RR intervals; SDqt: Standard deviation of 
QT intervals; STVqt: Short-term QT variability. 
 
 
 
 
 
 
 
Participants, N 9,024 
Women, N (%) 5,265 (58.3%) 
Number of ECGs, N 22,610 
Follow-up time in years, median (IQR) 10.5 (7.7-17.3) 
Age in years, mean (SD) 68.0 (8.7) 
BMI in kg/m2, mean (SD) 26.6 (3.9) 
Smoking Never, N (%) 2,968 (33.8%) 
               Former, N (%) 3,825 (43.5%) 
               Current, N (%) 1,993 (22.7%) 
Hypertension, N (%) 5,256 (59.1%) 
Coronary heart disease, N (%) 653 (7.5%) 
Diabetes mellitus, N (%) 949 (10.9%) 
Heart failure, N (%) 190 (2.1%) 
Heart rate in beats per minute, mean (SD) 70.1 (11.8) 
QT interval in milliseconds, mean (SD) 402 (30) 
QTc interval (Bazett) in milliseconds, mean (SD) 431 (25) 
ln(SDNN), mean (SD) 2.9 (0.8) 
Sokolow-Lyon index, mean (SD) 2,304 (748) 
ln(SDqt), mean (SD) 1.5 (0.6) 
QTVI, mean (SD) -0.9 (1.0) 
ln(STVqt), mean (SD) 1.3 (0.6) 
ln(RMSSDqt), mean (SD) 1.7 (0.6) 
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Discussion 
We analyzed the association of QTV as measured on 10-second ECGs with four endpoints in a large 
population of older adults. With adjustment for relevant covariables, an elevated QTV was 
significantly associated with an increased risk of total mortality and CHD mortality. There was also an 
association of QTV with witnessed SCD, but only in women. 
We found that QTV markers were associated with total mortality in a community-dwelling 
older population, confirming previous studies11 conducted in cohorts of patients with cardiac 
diseases. The associations of QTV markers with CHD mortality were significant, with higher point 
estimates than those of total mortality, confirming a study that found an association of QTV markers 
with cardiovascular death and SCD in a cohort of heart failure patients.9 
The association of QTV with SCD was not significant, even though this association was 
reported in cardiac patients in previous cohort studies.10 Nevertheless, in women we found such an 
association for witnessed SCD, and with a higher point estimate of the HR than that for total 
mortality or CHD mortality. We venture the following explanation for the observed difference 
between witnessed and unwitnessed SCD: because information of symptoms and of the timeframe 
previous to death is lacking, unwitnessed deaths due to a non-arrhythmic (non-cardiac) cause could 
more readily be classified as SCD than witnessed deaths.19 Thus, the unwitnessed cases dilute the 
pool of deaths of pure arrhythmic origin and weaken the association between QTV and SCD. The 
difference between men and women may be explained by different underlying pathologies.4 
According to our study, QTV is not significantly associated with CHD mortality, implying that QTV is 
not or weakly associated with SCD when caused by underlying CHD. A study of cardiac arrest 
survivors found that in men, 80% of the cardiac arrests are related to CHD, while in women only 45% 
of the cardiac arrests are related to CHD.4 Therefore, it is possible that most cases of witnessed SCD 
in men are due to CHD and thus only weakly associated with QTV. However, a study in patients with 
ischemic cardiomyopathy found that QTV is a risk factor for ventricular arrhythmias in men only.20 
The opposite results of that study might be explained by the widely different participant selection. 
Our study indicates that further research on the difference in SCD risk prediction between men and 
women is warranted. 
Two observations can be made with regard to the different types of QTV markers. First, 
consecutively measured QTV (e.g. RMSSDqt) and non-consecutively measured QTV (e.g. SDqt) were 
highly correlated and showed similar results in the analyses, even though some studies have 
previously found a difference between SDqt and RMSSDqt.21 The absence of this difference in our 
study might derive from the use of 10-second ECGs. Second, both a decreased and an increased 
QTVI was associated with a higher risk of total mortality (the significant term QTVI2), while for the 
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other three QTV markers, only an increase was associated with a higher risk. As QTVI is defined by a 
formula with QTV in the numerator and HRV in the denominator (Table 1), the association between 
QTVI and total mortality can be mediated through both QTV and HRV. As both a low and a high HRV 
have been associated with an increased risk for total mortality,16 a low QTVI may be associated with 
total mortality by way of a high HRV or a low QTV and vice versa. A separate assessment of HRV and 
QTV would yield more specific information than a combined marker. 
Our study has several strengths. First, it is part of a population-based study of community-
dwelling middle-aged and elderly participants. Clinical and ECG data were available for many 
relevant cardiovascular risk factors and for multiple center visits, with <5% missing values. 
Successive ECGs were available for many participants. Second, all QTV markers were automatically 
calculated by MEANS in combination with FSA, which enhanced precision and prevented bias in ECG 
assessment, whereas most previous studies used semi-automatic or manual methods.11 There are, 
however, also some limitations. First, the QTV markers are based on 10-second routine ECGs, 
whereas most other studies of QTV used longer ECG recordings.11 However, one study reported 
good agreement between STVqt estimates from 10-second ECGs and 3-minute ECGs (Pearson 
correlation coefficient 0.81). 22 Second, even though we adjusted for the most relevant clinical risk 
factors, we cannot rule out residual confounding. Third, we did not have information on the 
underlying causes of SCD (e.g., by autopsy), and the arrhythmia before death was unknown. 
However, incidence rates of SCD in our study are comparable to those of other studies, indicating 
sufficient validation quality.1,3 Fourth, there are conflicting studies about the confounding effect of 
respiration on QTV23,24 , but we had no data on respiration. Fifth, we could not adjust the sex-
stratified model for witnessed SCD due to the small number of events. The inclusion of too many 
covariables would lead to overfitting. Additionally, multiple testing might be an issue due to the 
multiple QTV markers and the multiple outcomes. However, the effect of multiple testing is likely to 
be limited, as the QTV markers are highly correlated, and the HR estimates of the QTV markers are 
highly similar, with the exception of QTVI. 
In conclusion, we found an association of QTV markers with total mortality and CHD 
mortality, and a stronger association with witnessed SCD, but only in women. Further study of the 
underlying pathophysiology of QTV and its gender-specific components is necessary. 
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Supplementary table 1. QT-interval variability measures 
Variable Based on 
consecutive 
differences 
Heart-rate 
Normalization 
 
Formula 
SDqt  No No  
√
1
𝑛 − 1
∑(𝑄𝑇𝑖 − 𝑄𝑇𝑚)2
𝑛
𝑖=1
 
QTVI  No Yes 
𝑙𝑜𝑔10 [
(
𝑄𝑇𝑣
𝑄𝑇𝑚
2 )
(
𝐻𝑅𝑣
𝐻𝑅𝑚
2 )
] 
 
STVqt  Yes No 
∑
|𝑄𝑇𝑖+1 − 𝑄𝑇𝑖|
𝑛√2
𝑛
𝑖=1
 
 
RMSSDqt  Yes No 
√
1
𝑛
∑(𝑄𝑇𝑖+1 − 𝑄𝑇𝑖)2
𝑛
𝑖=1
 
Abbreviations: HRm: mean heart rate; HRv: variance of heart rate; n: number of beats used for 
calculation; QTi: QT interval of beat i; QTm: mean QT interval; QTv: variance of QT interval; QTVI: QT 
variability index; RMSSDqt: root mean square of successive differences in QT intervals; SDqt: 
standard deviation of QT intervals; STVqt: short-term QT variability. 
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Supplementary figure 1. Log relative hazards of SDqt for witnessed SCD in women 
 
Log relative hazards were estimated with 3-knot restricted cubic splines. The solid line represents 
the estimate, the dotted lines represent the limits of the 95% confidence interval. Abbreviations: 
SCD: sudden cardiac death, SDqt: standard deviation of QT intervals 
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Supplementary figure 2. Log relative hazards of STVqt for witnessed SCD in women 
 
Log relative hazards were estimated with 3-knot restricted cubic splines. The solid line represents 
the estimate, the dotted lines represent the limits of the 95% confidence interval. Abbreviations: 
SCD: sudden cardiac death, STVqt: short-term variablity of QT intervals 
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Supplementary figure 3. Log relative hazards of RMSSDqt for witnessed SCD in women 
 
Log relative hazards were estimated with 3-knot restricted cubic splines. The solid line represents 
the estimate, the dotted lines represent the limits of the 95% confidence interval. Abbreviations: 
SCD: sudden cardiac death, RMSSDqt: root mean square of successive differences between QT 
intervals. 
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Abstract 
Background Various electrocardiographic (ECG) markers have been proposed as risk factors for 
sudden cardiac death (SCD). Because these markers were usually studied individually, we aimed to 
evaluate the additional value of a comprehensive set of ECG markers for predicting SCD. 
 
Methods and Results We used data from the Rotterdam Study, a cohort of community-dwelling 
participants. SCD within ten years was the endpoint in a proportional subdistribution hazards model. 
We assessed a model combining ECG markers and clinical risk factors over a basic model with only 
clinical risk factors. Variables for these models were chosen by backwards selection. When creating 
the combined model, the variables of the basic model were fixed. There were 13 candidate clinical 
risk factors and 24 candidate ECG markers. The discrimination of the basic and the combined model 
was evaluated with a bootstrapped Harrell’s C-statistic. The study cohort consisted of 5,558 
participants, of whom 149 died of SCD. The basic model consisted of age, sex, total/HDL cholesterol 
ratio, smoking, diabetes mellitus, and use of agents acting on the renin-angiotensin system. The 
combined model additionally contains heart rate, Sokolow-Lyon index, spatial J amplitude, T 
amplitude in lead aVR, right bundle branch block, and heart-rate corrected SDNN. The Model with 
the additional ECG variables had a significantly higher C-statistic than the basic model. 
 
Conclusion This study suggests that the prediction of SCD in the general population can be improved 
by combining clinical risk factors with ECG markers, as adding the ECG markers significantly 
improved the discrimination of the model. 
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Introduction 
Sudden cardiac death (SCD) is a major health burden. Incidence rates in the general population 
range from 50 to 100 cases per 100,000 person-years in developed countries.1 The underlying causes 
of SCD include coronary heart disease (CHD),2 cardiomyopathies,3 and ion-channelopathies.4 SCD is 
often the first presentation of heart disease, which makes the occurrence of SCD difficult to predict 
in the general population.5 
 The opportunities for SCD risk prediction in the general population have been described by 
Wellens et al.6 In their paper, it was recommended that integrated risk models be investigated by 
combining parameters that characterize the underlying causes of SCD. As a matter of course, 
electrocardiographic (ECG) markers can be useful for this, as they represent different aspects of 
cardiac function and pathology. Many ECG markers have been associated with increased risk for 
cardiac mortality or SCD in population-based studies. Examples are the heart-rate corrected QT 
(QTc) interval,7 the Sokolow-Lyon index, and T axes.8 However, these population-based studies have 
analyzed only one ECG marker or a limited number of combinations of markers.6 The most 
comprehensive study evaluated five basic ECG risk factors (atrial fibrillation, Cornell voltage, 
corrected QT interval, QRS duration, and heart rate) for an SCD prediction model.9 
In this study, we evaluated a large number of ECG markers, in order to discover which 
markers are associated with SCD, independently of clinical risk factors. By creating a combination of 
ECG markers, we aimed to assess the true additional worth of the ECG in addition to clinical risk 
factors. 
 
Methods 
Setting and study population 
This study was performed as part of the Rotterdam Study, a prospective population-based cohort 
study. Details regarding design, objectives, and methods of the Rotterdam Study have been 
described previously.10 In short, the Rotterdam Study started in 1990 with an initial cohort of 7,983 
persons (response rate 78%) aged 55 years or older living in the Ommoord district of the city of 
Rotterdam in the Netherlands. In 2000, the cohort was extended with 3,011 participants (response 
rate 67%) who had become 55 years of age or who moved into the study district. Follow-up 
examinations were conducted approximately every four to five years. These examinations consisted 
of a home interview and an extensive set of tests at a research center located in the study district. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and 
by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO” (Population Study Act: Rotterdam Study). We included only 
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participants who provided written informed consent to participate in the study and who provided 
written informed consent to obtain information from their treating physicians. By linking the general 
practitioners’ and municipality records to the study database, participants were continuously 
monitored for major morbidity and mortality during follow-up. Other exclusion criteria were a 
missing ECG, an unreadable ECG (e.g., due to excessive noise), or an ECG showing a pacemaker 
rhythm or atrial fibrillation. 
 
Clinical risk factors 
Candidate clinical risk factors were age, sex, body-mass index (BMI), total cholesterol/high-density 
lipoprotein cholesterol (TC/HDL) ratio, smoking, systolic blood pressure, diastolic blood pressure, 
prevalent heart failure, and prevalent diabetes mellitus. We additionally considered use of four 
groups of cardiovascular drugs as candidate covariables: diuretics (Anatomical Therapeutic Chemical 
(ATC) code C03), beta-blocking agents (ATC C07), agents acting on the renin-angiotensin system (ATC 
C09), and lipid-lowering drugs (ATC C10). TC and HDL levels were acquired by an automated 
enzymatic procedure (Boehringer Mannheim System). Smoking status was assessed during a home 
interview, and participants were classified into never, past, and current smoker categories. Systolic 
blood pressure and diastolic blood pressure were measured in sitting position at the right upper 
arm. For each visit, the average of two consecutive blood pressure measurements was used. Heart 
failure diagnosis was established in accordance with the guidelines of the European Society of 
Cardiology11 and included typical signs or symptoms of heart failure confirmed by objective evidence 
of cardiac dysfunction.12 Diabetes mellitus was defined as a fasting serum glucose level ≥ 7.0 
mmol/L, a non-fasting serum glucose level ≥11.1 mmol/L, or use of blood-glucose lowering 
medication. Prevalent CHD was defined as a previous myocardial infarction or a coronary 
revascularization procedure.12 More than 99% of the participants had their drug prescriptions filled 
at one of the seven fully computerized regional pharmacies, which use one common computer 
network. Dispensing data was available on a day-to-day basis, and included the ATC code. 
Participants were considered exposed to a drug group if there was overlap of a dispensing episode of 
this drug group and a window of 90 days before the date of ECG recording. 
ECG markers 
A standard 12-lead resting ECG was recorded with an ACTA electrocardiograph (ESAOTE, Florence, 
Italy) at a sampling frequency of 500 Hz and stored digitally. All ECG and VCG measurements were 
obtained with the Modular ECG Analysis System (MEANS).13 The MEANS program uses template-
matching techniques to determine common wave onsets and offsets for all 12 leads together on one 
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representative averaged beat. The X, Y, and Z leads of the VCG were synthesized from the 12-lead 
ECGs in good approximation.14 
Supplementary Table 1 in gives an overview of the 24 candidate ECG and VCG markers with 
their formulas and definitions. These ECG and VCG markers were selected because they have been 
associated in previous studies with cardiac death or SCD. Fridericia’s formula was used to calculate 
the QTc interval since this formula is more accurate than Bazett’s formula in correcting the QT 
interval for heart rate.15 Heart-rate variability (HRV) markers standard deviation of normal-to-normal 
RR-intervals (SDNN) and root-mean-square of successive RR-interval differences (RMSSD) were 
corrected for heart rate with an exponential formula, denoted with SDNNc and RMSSDc.16 The 
measurement of QT variability markers is given in the supplementary methods. 
 
Sudden cardiac death 
SCD was defined in accordance with the Myerburg definition, endorsed by the European Society of 
Cardiology17 as “a natural death due to cardiac causes, heralded by abrupt loss of consciousness 
within one hour from onset of acute symptoms; pre-existing heart disease may have been known to 
be present, but the time and mode of death are unexpected”. We included cases of unwitnessed 
death if the person was seen in a stable medical condition in the twenty-four hours preceding death 
and if there was no evidence of a non-cardiac cause of death. In the case of sparse information, 
cases were labelled as SCD when treating physicians labelled their deaths as sudden or unexpected.1 
Identification and validation of SCD cases was based on medical files, which were reviewed 
independently by two research physicians and subsequently by an experienced cardiologist. 
 
Statistics 
The primary outcome was SCD within ten years. Total mortality was defined as death from any cause 
within ten years. Follow-up was calculated from date of the ECG recording until date of death, end of 
study period, after ten years follow-up, or loss to follow-up (n = 223, 4%). All visits occurred between 
1997 and 2001, corresponding with the third visit of the initial cohort (which originally started in 
1990) and the first visit of the additional cohort. 
We evaluated the risk factors and ECG markers for SCD in proportional subdistribution 
hazards models according to Fine and Gray.18 The variable selection procedure was as follows: all 
candidate variables were included in the model and the variable with the highest p-value was 
determined. If this p-value was larger than 0.2,19 the variable was removed and a new model was 
built. This elimination procedure was repeated until all p-values were below 0.2. Two models were 
created. First, a basic model was built from 13 candidate clinical risk factors. Second, the risk factors 
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selected in the basic model were kept fixed, and 24 candidate ECG and VCG variables were added as 
input for the elimination procedure. In a separate analysis, we bootstrapped Harrell’s C-statistic 100 
times for both the basic model and the combined model in order to obtain confidence intervals. In 
order to assess the influence of prevalent CHD, one of the most important underlying causes of 
SCD,20 we performed a sensitivity analysis including prevalent CHD at baseline as a candidate 
covariable for the basic model and the combined model. 
We used multiple imputation, specific methods are given in the supplementary methods. 
 
 
Figure 1. Flowchart of included and excluded participants of the Rotterdam Study 
Abbreviations: ECG: electrocardiogram; N: number of ECGs 
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Results 
Study population 
Figure 1 shows the flowchart of the study population, consisting of 5,558 participants. Baseline 
characteristics are shown in Table 1. In short, the mean age was 69.2 years with a standard deviation 
of 8.0 years, and 43.1% of the participants were men. During median follow-up of 10 years, 1,395 
participants died, of whom 149 due to SCD. 
 
Variable selection  
The selected variables associated with increased risk of SCD are shown in Table 2. The basic model 
consisted of six clinical risk factors: age, sex, TC/HDL ratio, smoking, diabetes mellitus, and use of 
agents acting on the renin-angiotensin system (ATC 09). The combined model contained seven 
additional ECG markers: heart rate, Sokolow-Lyon index, spatial J amplitude, T amplitude in lead 
aVR, (T aVR) right bundle branch block (RBBB), and SDNNc. 
 
Characteristics of the basic model and the combined model 
Table 2 shows the variables selected for the basic model and the combined model, with 
subdistribution hazard ratios (SHRs) and 95% confidence intervals (CIs). Based on 100 bootstraps, 
the C-statistic of the basic model was 0.75, while the C-statistic of the combined model was 0.78. 
The bootstrapped difference in C-statistic between these models was statistically significant: 0.03, 
95%CI 0.02-0.06. 
 
Sensitivity analyses 
Additional inclusion of prevalent CHD as a candidate covariable resulted in the same basic model 
(with the addition of prevalent CHD). The combined model with CHD additionally included heart 
rate, Sokolow-Lyon index, T aVR, right RBBB and SDNNc. Spatial J amplitude was not selected, but - 
otherwise - the combined model with CHD was comparable to the model from the main analysis. 
The bootstrapped C-statistic was 0.75 for the basic model with prevalent CHD, and 0.79 for the 
combined model with prevalent CHD. The bootstrapped difference between these models was 0.03, 
95%CI 0.02-0.06. 
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Table 1. Baseline characteristics of the study population 
Total study population 5557 
Women, N(%) 
3,162 (56.9%) 
Death within ten years, N(%) 
1397 (25.1%) 
SCD within ten years, N(%) 
149 (2.7%) 
Follow-up (years), Median (1st ; 3rd quartile) 
10.0 (9.0; 10.0) 
age (years), Mean ± SD 
69.2 ± 7.9 
Body mass index (kg/m2) , Mean ± SD 
27.0 ± 3.9 
TC/HDL ratio, Mean ± SD 
4.5 ± 1.3 
Systolic blood pressure (mmHg) , Mean ± SD 
144 ± 21 
Diastolic blood pressure (mmHg) , Mean ± SD 
77 ± 11 
Smoking     never, N(%) 
1,765 (32%) 
                    past, N(%) 
2,702 (48.9%) 
                    current, N(%) 
1,053 (19.1%) 
Use of diuretics (C03†), N(%) 
604 (10.9%) 
Use of beta-blocking agents (C07†), N(%) 
890 (16.0%) 
Use of renin-angiotensin agents (C09†), N(%) 
634 (11.4%) 
Use of lipid-lowering drugs (C10†), N(%) 
662 (11.9%) 
Coronary heart disease, N(%) 
449 (8.2%) 
Heart failure, N(%) 
137 (2.5%) 
Diabetes mellitus, N(%) 
628 (11.7%) 
Heart rate (bpm), Mean ± SD 
69 ± 11 
QTc interval (ms), Mean ± SD 
423 ± 21 
QRS duration in (ms), Mean ± SD 99 ± 17 
JT interval in (ms), Mean ± SD 
308 ± 28 
Cornell index (μV), Mean ± SD 
1,456 ± 578 
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12-lead sum (μV), Mean ± SD 
14,228 ± 3,113 
Sokolow-Lyon index (μV), Mean ± SD 
2,254 ± 695 
QRS-T angle (°), Median (1st ; 3rd quartile) 
58 (40; 82) 
Frontal T-axis deviation (°), Median (1st ; 3rd quartile) 
12 (6; 21) 
Horizontal T-axis deviation (°), Median (1st ; 3rd quartile) 
15 (7; 27) 
Spatial J amplitude (μV), Median (1st ; 3rd quartile) 
39 (26; 55) 
Max. spatial T amplitude (μV), Median (1st ; 3rd quartile) 
354 (267; 449) 
T-loop width (°), Median (1st ; 3rd quartile) 
23 (15; 35) 
T amplitude in aVR (μV), Mean ± SD 
-193 ± 96 
STVqt, Median (1st ; 3rd quartile) 
1.98 (1.26; 3.34) 
QTVI, Mean ± SD 
-0.94 ± 0.84 
SDNNc, Median (1st ; 3rd quartile) 
18.7 (12.3; 29.5) 
RMSSDc, Median (1st ; 3rd quartile) 
20.5 (14.2; 31.4) 
ST depression, N(%)  
374 (6.7%) 
T wave inversion, N(%) 
381 (6.9%) 
Early repolarization, N(%) 
16 (0.3%) 
Right bundle branch block, N(%) 
155 (2.8%) 
Left bundle branch block, N(%) 
92 (1.7%) 
One or more PVCs on the ECG, N(%) 
325 (5.8%) 
Abbreviations: bpm: beats per minute; mmHg: millimeter of mercury; ms: millisecond; μV: microvolt; 
N : number of participants; PVCs: premature ventricular contractions; Q: quartile; QTc: heart-rate 
corrected QT interval; QTVI: QT variability index; RMSSDc: heart-rate corrected root mean square of 
successive RR interval differences. SD: standard deviation; SCD: sudden cardiac death; SDNNc: heart-
rate corrected standard deviation of normal-to-normal RR intervals; STVqt: short-term variability of 
the QT interval; TC/HDL ratio: total cholesterol / high-density lipoprotein cholesterol ratio. 
†According to the Anatomical Therapeutic Chemical (ATC) codes. 
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Table 2. Subdistribution hazard ratios for SCD with 95% confidence intervals 
Variable (units) basic model SHR (95%CI) combined model SHR (95%CI) 
Age (years) 1.08 (1.06-1.10)¶ 1.06 (1.04-1.09)¶ 
Male sex 2.00 (1.37-2.94)¶ 1.71 (1.17-2.51)‡ 
TC/HDL ratio 
1.10 (0.98-1.23) 1.10 (0.98-1.23) 
Smoking:  never 1 (reference) 1 (reference) 
                  past 1.13 (0.76-1.69) 1.16 (0.78-1.74) 
                  current 2.08 (1.26-3.44)§ 1.99 (1.19-3.32)‡ 
Diabetes mellitus 
2.02 (1.38-2.97)¶ 1.88 (1.28-2.77)§ 
Use of RAS blockers (ATC C09) 
1.61 (1.06-2.45)† 1.27 (0.81-1.98) 
Heart rate (10bpm)  1.14 (0.99-1.32) 
Sokolow-Lyon index (100μV)  1.02 (1.00-1.05) 
Spatial J Amplitude (10μV)  1.03 (0.98-1.09) 
T aVR (10μV)  1.03 (1.01-1.05)‡ 
Right bundle branch block  2.92 (1.52-5.61)‡ 
SDNNc (10 milliseconds)  1.06 (1.02-1.10)§ 
Subdistribution hazard ratios were calculated according to Fine and Gray. Abbreviations: ATC: 
Anatomical Therapeutic Chemical code; bpm: beats per minute; CI: confidence interval; HR: hazard 
ratio; μV: millivolt; PVCs: premature ventricular complexes; RAS blockers: renin-angiotensin system 
blockers; SCD: sudden cardiac death; SHR: subdistribution hazard ratio; TC/HDL ratio: total 
cholesterol/high-density lipoprotein cholesterol ratio. 
†p-value <0.05; ‡p < 0.01; §p< 0.005; ¶p <0.001 
 
 
Discussion 
In the present study, we considered a large number of ECG markers previously associated with 
cardiac mortality or SCD. We created a basic model containing age, sex, total/HDL cholesterol ratio, 
smoking, diabetes mellitus, and use of agents acting on the renin-angiotensin system and a 
combined model with the additional ECG markers heart rate, Sokolow-Lyon index, spatial J 
amplitude, T amplitude in lead aVR, right bundle branch block, and heart-rate corrected SDNN. The 
Model with the additional ECG markers had a significantly higher bootstrapped C-statistic than the 
basic model. The majority of previous studies analyzed ECG markers individually, although a number 
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of previous studies have assessed risk models with a limited number (<6) of ECG or VCG markers 
combined, while adjusting for clinical risk factors.8,9,21,22 
Some ECG parameters that were selected or eliminated merit additional explanation. First, a 
previous publication from the Rotterdam Study analyzed the association of uncorrected HRV with 
cardiac mortality,23 and reported that both high and low HRV were associated with increased cardiac 
mortality risk. In this analysis, we found that only an increase in SDNNc was associated with SCD. It is 
possible that the previously reported U-shaped association of HRV with SCD was caused by residual 
confounding by heart rate, which has a strong inverse association with HRV.24 Second, a previous 
study reported that isolated RBBB is a risk factor for cardiovascular morbidity and mortality.25 The 
selection of RBBB in our study in the combined model confirmed this finding. Third, early 
repolarization has been shown to be a promising risk factor, 26 but was not selected for the 
prediction model, and in only 26% of the bootstraps. This is probably due to the fact that early 
repolarization was much rarer in the current cohort of elderly persons than in a cohort of younger 
people.27 Fourth, the QTc interval is a known risk factor for SCD in the Rotterdam Study and other 
study populations,7,26 and is important in drug-safety research,28 but was eliminated during variable 
selection. It is possible that the predictive value of QTc prolongation for SCD was limited in this study 
because the most common underlying cause of SCD in the general population is CHD,20 whereas QTc 
prolongation is associated with drug-induced arrhythmias like torsade de pointes, which are 
relatively uncommon in the general population.5 Fifth, ace-inhibitors were selected for the basic 
model, while ace-inhibitors have been associated with a reduction in SCD.29 We think that the 
association of ace-inhibitors with SCD is probably based on confounding by indication. Sixth, QTVI 
and STVqt, markers of QT variability,30 were not selected for the final model, although found to be 
promising in the literature. A previous study showed that QT variability is a risk factor only in 
women, and it is possible that using both men and women in this cohort lead to the elimination of 
QTVI and STVqt.31 
The sensitivity analysis showed results similar to the main analysis. Additionally including 
prevalent CHD in the list of candidate variables resulted in a model with the same variables as the 
main analysis, except for the inclusion of prevalent CHD and the elimination of spatial J amplitude. 
The C statistic of the combined model with CHD was 0.79, versus 0.78 without CHD. More 
importantly, the ECG markers significantly improved the models’ performance in both the main 
analysis and the sensitivity analysis. 
This study has a number of strengths. The Rotterdam Study is a cohort of community-
dwelling elderly representative of the general older population.12 ECG markers were based on 
standard 12-lead ECGs, which are commonly used in clinical practice. Inter- and intra-observer 
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variability was reduced by calculating all ECG markers systematically and automatically with MEANS, 
a program that has been evaluated extensively.32 We are the first to use competing risk analysis for a 
combination of ECG markers and clinical risk factors. The SHRs from the competing risk model take 
into account that most people die of other causes than SCD.18 
 A limitation of this study was the low number of SCD cases. Therefore, we could not create a 
prediction model for SCD for men and women separately. Furthermore, both witnessed and 
unwitnessed SCD cases were included in the definition of SCD and the information on symptoms 
prior to death and the timing of death was incomplete in unwitnessed cases. This could have 
increased the risk of including deaths due to other causes,17 resulting in a more heterogeneous SCD 
phenotype. However, since it is likely that this heterogeneity would underestimate the observed 
effects of the included parameters, its contribution would be minor / small it is consequently 
conservative. Another limitation of this study is that a family history of SCD is often considered to 
represent a risk factor for SCD,33,34 but information on such data was unavailable to us. Finally, our 
prediction model is based on an elderly population. As the risk factors for SCD and the underlying 
causes of SCD are probably age-dependent, this prediction model is probably not valid for a younger 
population. This is illustrated by the fact that early repolarization was rare in this population, while it 
has been shown to be an important risk factor in a younger population.27 We were not able to do 
external validation and calibration of our model. 
In conclusion, we report here that a combination of seven ECG markers improves the 
discrimination of a model with basic cardiovascular risk factors. Our findings strongly suggest that 
future research on novel ECG markers should focus on the additional value of combinations of ECG 
markers, rather than studying ECG markers individually. 
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Supplementary Methods 
QT variability 
QT variability was assessed with two variables: short-term variability of the QT interval (STVqt) and 
the QT variability index (QTVI).1 In order to measure STVqt and QTVI, all QT intervals on an ECG were 
measured automatically using fiducial segment averaging (FSA):2 First, MEANS determines the 
locations of the individual QRS complexes on the ECG and initial fiducial points (onset of QRS 
complex and end of T wave), and computes a detection function consisting of the root-mean-square 
ECG signal. Second, the fiducial point in each individual beat is shifted in an iterative procedure until 
maximum correlation is achieved between a small signal segment of the detection function around 
this fiducial point and the average of the segments around the fiducial points of the remaining 
complexes. The amount of shifting is retained and constitutes the individual beat variation in the 
fiducial point estimate. Finally, the QT interval for each beat is calculated taking into account the 
shifts of the initial QRS onset and T end. MEANS automatically detects ectopic beats, and excludes 
them from further processing. To safeguard against signal segments with excessive noise or baseline 
wander, an additional test is applied after each FSA iteration. If the averaged absolute amplitudes of 
the difference between the ST-T wave of an individual beat and the averaged ST-T wave of the 
remaining beats is larger than a preset value, the beat is discarded and the iteration process is 
repeated for the remaining beats. QT intervals of premature ventricular complexes and of beats 
immediately before and after these beats were not used. 
 
Imputation 
Before imputation, we set values more extreme than the 1st or 99th percentile of the continuous 
variables to the value of the 1st or 99th percentile. Missing values were imputed with ten-times 
multiple imputation. If reported in de literature, non-linearity was assessed by adding a quadratic 
term to an age-and sex adjusted model. If this term was significant, it was added in all models. 
SDNNc and RMSSDc had 12% missing values, the other covariables had less than 10% missing values. 
The proportional hazards assumption was assessed by evaluating the Schoenfeld residuals over 
follow-up time. We used R (R Foundation for Statistical Computing, Vienna, Austria) for all analyses. 
References for supplementary methods 
1. Niemeijer MN, van den Berg ME, Eijgelsheim M, van Herpen G, Stricker BH, Kors JA, Rijnbeek 
PR. Short-term QT variability markers for the prediction of ventricular arrhythmias and 
sudden cardiac death: a systematic review. Heart. Dec 2014;100:1831-1836. 
2. Ritsema van Eck HJ. Fiducial segment averaging to improve cardiac time interval estimates. J 
Electrocardiol. 2002;35 Suppl:89-93. 
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Supplementary Table 1. Candidate electrocardiographic variables 
Name Definition Unit Reference for association with cardiac mortality or 
sudden cardiac death 
QTc interval1 
 
Heart rate-corrected QT interval. Fridericia's 
correction formula was used: 𝑄𝑇𝑐 =
𝑄𝑇(𝑚𝑖𝑙𝑙𝑖𝑠𝑒𝑐𝑜𝑛𝑑𝑠)
√𝑅𝑅(𝑠𝑒𝑐𝑜𝑛𝑑𝑠)
3  
milliseconds Straus SM, Kors JA, De Bruin ML, van der Hooft CS, 
Hofman A, Heeringa J, Deckers JW, Kingma JH, 
Sturkenboom MC, Stricker BH, Witteman JC. 
Prolonged QTc interval and risk of sudden cardiac 
death in a population of older adults. J Am Coll Cardiol 
Jan 17 2006;47:362-367. 
 
Heart rate2 60,000/RR interval in milliseconds beats per minute Chang HY, Yin WH, Lo LW, et al. The utilization of 
twelve-lead electrocardiography for predicting sudden 
cardiac death after heart transplantation. Int J Cardiol 
2013;168:2665-2672. 
 
QRS duration3 Interval from start to end of QRS complex milliseconds Aro AL, Huikuri HV. Electrocardiographic predictors of 
sudden cardiac death from a large Finnish general 
population cohort. J Electrocardiol 2013;46:434-438. 
 
JT interval2 Interval from J point (end of QRS complex) to end of T 
wave 
milliseconds Chang HY, Yin WH, Lo LW, et al. The utilization of 
twelve-lead electrocardiography for predicting sudden 
cardiac death after heart transplantation. Int J Cardiol 
2013;168:2665-2672. 
Sokolow-Lyon index3 S in V1 + R in V5 or V6 (whichever is larger)  microvolts Aro AL, Huikuri HV. Electrocardiographic predictors of 
sudden cardiac death from a large Finnish general 
population cohort. J Electrocardiol 2013;46:434-438. 
 
12-lead sum4 Sum of top-top deflections in all 12 ECG leads microvolts Ostman-Smith I, Wisten A, Nylander E, Bratt EL, 
Granelli A, Oulhaj A, Ljungstrom E. 
Electrocardiographic amplitudes: a new risk factor for 
sudden death in hypertrophic cardiomyopathy. Eur 
Heart J Feb 2010;31:439-449. 
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Cornell index5 S in V3 + R in aVL microvolts Schroder K, Wegscheider K, Wenger NK, Vettorazzi E, 
Schroder R. Resting electrocardiogram predicts 
mortality in postmenopausal women with coronary 
heart disease or with risk factors for coronary heart 
disease. Eur J Prev Cardiol Jun 29 2012;21:749-757. 
 
Spatial QRS-T angle6, 7 Spatial angle between the QRS axis and the T axis  degrees Kardys I, Kors JA, van der Meer IM, Hofman A, van der 
Kuip DA, Witteman JC. Spatial QRS-T angle predicts 
cardiac death in a general population. Eur Heart J Jul 
2003;24:1357-1364. 
 
Frontal T-axis deviation8, 9 Absolute difference between 45 degrees and the T-
wave axis in the frontal plane  
degrees Kors JA, de Bruyne MC, Hoes AW, van Herpen G, 
Hofman A, van Bemmel JH, Grobbee DE. T axis as an 
indicator of risk of cardiac events in elderly people. 
Lancet Aug 22 1998;352:601-605. 
Horizontal T-axis 
deviation8, 9 
Absolute difference between 45 degrees and the T-
wave axis in the horizontal plane 
degrees Kors JA, de Bruyne MC, Hoes AW, van Herpen G, 
Hofman A, van Bemmel JH, Grobbee DE. T axis as an 
indicator of risk of cardiac events in elderly people. 
Lancet Aug 22 1998;352:601-605. 
Spatial J amplitude9 Spatial amplitude at the J point microvolts Kors JA, Rijnbeek P, Van Herpen G, Keulers PP, Hofman 
A, Witteman JC. Spatial repolarization parameters for 
predicting cardiac death in the elderly. J Electrocardiol 
2004;37 Suppl:198-200. 
 
Max. spatial T amplitude9 Maximum spatial amplitude of the T wave microvolts Kors JA, Rijnbeek P, Van Herpen G, Keulers PP, Hofman 
A, Witteman JC. Spatial repolarization parameters for 
predicting cardiac death in the elderly. J Electrocardiol 
2004;37 Suppl:198-200. 
 
T-loop width9 Spatial angle between the axes of the first and the 
second part of the T loop 
degrees Kors JA, Rijnbeek P, Van Herpen G, Keulers PP, Hofman 
A, Witteman JC. Spatial repolarization parameters for 
predicting cardiac death in the elderly. J Electrocardiol 
2004;37 Suppl:198-200. 
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T amplitude in aVR10 Amplitude of the T wave in lead aVR microvolts Rautaharju PM, Zhang ZM, Warren J, Gregg RE, Haisty 
WK, Kucharska-Newton AM, Rosamond WD, Soliman 
EZ. Electrocardiographic predictors of coronary heart 
disease and sudden cardiac deaths in men and women 
free from cardiovascular disease in the Atherosclerosis 
Risk in communities study. J Am Heart Assoc 2013;2. 
 
Short-term QT variability 
(STVqt)11 
∑
|𝑄𝑇𝑖+1 − 𝑄𝑇𝑖|
𝑛2
𝑛
𝑖=1
 
milliseconds Niemeijer MN, van den Berg ME, Eijgelsheim M, van 
Herpen G, Stricker BH, Kors JA, Rijnbeek PR. Short-
term QT variability markers for the prediction of 
ventricular arrhythmias and sudden cardiac death: a 
systematic review. Heart Dec 2014;100:1831-1836. 
 
QT variability index 
(QTVI)11 
log10 [
(QTv/QTm
2 )
(HRv/HRm
2 )
] 
- Niemeijer MN, van den Berg ME, Eijgelsheim M, van 
Herpen G, Stricker BH, Kors JA, Rijnbeek PR. Short-
term QT variability markers for the prediction of 
ventricular arrhythmias and sudden cardiac death: a 
systematic review. Heart Dec 2014;100:1831-1836. 
 
SDNNc12 Standard deviation of normal-to-normal RR intervals, 
adjusted for heart rate 
milliseconds de Bruyne MC, Kors JA, Hoes AW, Klootwijk P, Dekker 
JM, Hofman A, van Bemmel JH, Grobbee DE. Both 
decreased and increased heart rate variability on the 
standard 10-second electrocardiogram predict cardiac 
mortality in the elderly: the Rotterdam Study. Am J 
Epidemiol Dec 15 1999;150:1282-1288. 
 
RMSSDc12 Root of the mean squared differences between 
consecutive RR intervals, adjusted for heart rate 
milliseconds de Bruyne MC, Kors JA, Hoes AW, Klootwijk P, Dekker 
JM, Hofman A, van Bemmel JH, Grobbee DE. Both 
decreased and increased heart rate variability on the 
standard 10-second electrocardiogram predict cardiac 
mortality in the elderly: the Rotterdam Study. Am J 
Epidemiol Dec 15 1999;150:1282-1288. 
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ST depression13 Minnesota code 4.1 or 4.2* - Laukkanen JA, Makikallio TH, Rauramaa R, Kurl S. 
Asymptomatic ST-segment depression during exercise 
testing and the risk of sudden cardiac death in middle-
aged men: a population-based follow-up study. Eur 
Heart J Mar 2009;30:558-565. 
T-wave inversion15 Minnesota code 5.1 or 5.2* - Laukkanen JA, Di Angelantonio E, Khan H, Kurl S, 
Ronkainen K, Rautaharju P. T-wave inversion, QRS 
duration, and QRS/T angle as electrocardiographic 
predictors of the risk for sudden cardiac death. Am J 
Cardiol Apr 1 2014;113:1178-1183. 
 
Early repolarization3 J amplitude > 100 microvolts in at least 1 of the 
lateral (II, III, aVF) or inferior (I, aVL, V4-V6) leads  
- Aro AL, Huikuri HV. Electrocardiographic predictors of 
sudden cardiac death from a large Finnish general 
population cohort. J Electrocardiol 2013;46:434-438. 
RBBB3 Right bundle branch block  - Aro AL, Huikuri HV. Electrocardiographic predictors of 
sudden cardiac death from a large Finnish general 
population cohort. J Electrocardiol 2013;46:434-438. 
 
LBBB3 Left bundle branch block - Aro AL, Huikuri HV. Electrocardiographic predictors of 
sudden cardiac death from a large Finnish general 
population cohort. J Electrocardiol 2013;46:434-438. 
 
PVCs16 Presence of one or more premature ventricular 
complexes  
- Cheriyath P, He F, Peters I, Li X, Alagona P, Jr., Wu C, 
Pu M, Cascio WE, Liao D. Relation of atrial and/or 
ventricular premature complexes on a two-minute 
rhythm strip to the risk of sudden cardiac death (the 
Atherosclerosis Risk in Communities [ARIC] study). Am 
J Cardiol Jan 15 2011;107:151-155. 
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Abstract 
Background QT variability reflects beat-to-beat changes of QT-interval duration on the 
electrocardiogram (ECG). QT variability is proposed as a risk factor for mortality in patients with 
heart failure (HF), but no study has assessed QT variability as a risk factor for HF itself. We aimed to 
study QT variability as a risk factor for HF. 
 
Methods We included 8,091 participants of the Rotterdam Study, a community-dwelling cohort of 
middle-aged and elderly persons, from whom 17,281 standard ECGs were recorded. We analyzed 
the short-term variability of the QT interval (STVqt) and the QT variability index (QTVI). Hazard ratios 
(HRs) and 95% confidence intervals (CIs) of the association between QT variability and HF were 
estimated with time-dependent Cox’ proportional-hazard models. Adjustment included ECG markers 
and known clinical risk factors for HF. We assessed non-linearity with restricted cubic splines and 
tested for an interaction with sex. 
 
Results A total of 787 participants developed HF. In a multivariable-adjusted model, a one standard 
deviation increase of STVqt was significantly associated with a higher risk of HF (HR 1.19, 95%CI 1.11-
1.26). QTVI was not significantly associated with HF in a multivariable-adjusted model. Tests for non-
linearity were not significant, and there was no interaction with sex. 
Conclusion: STVqt from standard 10-second ECGs was associated with an increased risk of HF. STVqt 
might be indicative of the myocardial remodeling and electrical instability. QTVI was not associated 
with HF, possibly because it is a marker containing both QT variability and heart rate variability. 
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Introduction 
Heart failure (HF) is a common and disabling disease. In developed countries, between 6 and 10% of 
people older than 65 suffer from HF, and 60-70% of patients die within five years after diagnosis.1,2 
Early diagnosis of these risk factors is important, as prevention can delay the onset of HF and 
mortality due to HF.3 The electrocardiogram (ECG) is currently a diagnostic tool for patients 
suspected of having HF,4 capable of detecting several underlying causes of HF.4 One of the main 
pathophysiological processes in the development of HF is ventricular remodeling.5 There is currently 
no established ECG marker for ventricular remodeling, but variability of QT-interval duration has 
been suggested as a marker for this process.6 
It is hypothesized that QT variability is a marker of increased repolarization instability in 
cardiomyopathies and of cardiac tissue remodeling.7 Previous studies have shown that for HF 
patients or people with mild to moderate left ventricular dysfunction, an increased QT variability is a 
risk factor for all-cause mortality,8,9 cardiovascular mortality8,10, ventricular fibrillation, ventricular 
tachycardia6,11, and sudden cardiac death.9,12 Two case-control studies found that QT variability was 
significantly higher in patients with heart failure than in healthy controls,10,13 while one case-control 
study reported that QT variability was only significantly increased in HF during ventricular pacing.14 
However, all those studies were relatively small (the smallest had 29, the largest 714 participants, of 
which 533 HF cases), all used a cross-sectional design and no study to date has assessed whether QT 
variability is prospectively associated with HF in the general population. 
Therefore, we analyzed the association of two commonly-used QT variability markers with 
HF in a prospective population-based cohort. We used the short-term variability of QT intervals 
(STVqt) and the QT variability index (QTVI).15 
 
Methods 
Research setting 
This study is based on the prospective population-based Rotterdam Study. The design and rationale 
of the Rotterdam Study have been described in more detail elsewhere.16,17 In short, from 1990 to 
1993, all inhabitants aged 55 years and older from the Ommoord district in Rotterdam, the 
Netherlands, were invited to participate in the initial cohort. A total of 7,983 individuals agreed to 
participate (response rate 78%). In 2000, the cohort was extended by including all inhabitants from 
the same district who had become 55 years or had moved into the district after the start of the 
initial cohort. In total, 3,011 individuals agreed to participate (response rate 67%). The cohort was 
additionally extended in 2006 by inviting inhabitants of the same district aged 45 years and older. In 
total, 3,932 individuals agreed to participate (response rate 65%). Follow-up examinations were 
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conducted every four to five years, with a current maximum of five center visits per participant. The 
Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the 
Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO” (Population Studies Act: Rotterdam Study).  
 
Study population and selection of ECGs 
We included all participants who provided informed consent for follow-up monitoring, and with at 
least one ECG available. We excluded ECGs on which we detected atrial fibrillation, atrial flutter, 
pacemaker rhythm, left bundle branch block, right bundle branch block and third degree 
atrioventricular block, because these interfere with accurate measurement of QT variability. We also 
excluded ECGs with excessive noise, excessive baseline wandering, or with premature ventricular or 
supraventricular complexes. 
 
Electrocardiography 
Standard 10-second, 12-lead ECGs were recorded at rest with an ACTA Gnosis electrocardiograph 
(Esaote Biomedica, Florance, Italy) at a sampling frequency of 500 Hz and stored digitally. ECGs were 
processed by the Modular ECG Analysis System (MEANS) program, which has been described 
previously and has been validated and applied extensively.18-22 QT intervals were measured 
automatically using fiducial segment averaging (FSA).23 This algorithm is explained more extensively 
in the supplementary methods. Briefly, MEANS determines the initial fiducial points (onset of QRS 
complex and end of T wave) and a detection function consisting of the root-mean-square ECG 
signal,24 is computed. Second, the fiducial point in each beat is shifted until maximum correlation is 
achieved between a small segment of the detection function around this fiducial point and the 
average around the fiducial points of the other complexes. The amount of shifting is retained and 
the QT interval for each beat is calculated taking into account the shifts of the initial QRS onset and T 
end. 
 
QT variability markers 
We assessed two commonly used QT variability markers: the short-term variability of QT intervals 
(STVqt)25 and the QT variability index (QTVI).7 The formulas of these markers are shown in Table 1. 
There are two differences between STVqt and QTVI. First, STVqt is a marker of beat-to-beat 
differences, while QTVI is based on the variance of QT. Second, QTVI is normalized for average QT, 
heart rate, and heart-rate variably, while STVqt is not. On ten ECGs all QT intervals had equal 
duration, which would result in an infinite value of QTVI. QTVI for these ECGs was therefore set to 
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the lowest QTVI value that was observed in the other ECGs (QTVI = -3.33). Because of the skewed 
distribution of STVqt, we log-transformed this variable in all analyses. In order to deal with those 
cases in which STVqt was zero, we added 1 to STVqt before transformation, ln(STVqt + 1). 
 
Potential covariables 
The following ECG variables were considered as covariable: heart rate, (average) QT interval, and 
Sokolow-Lyon index. For STVqt we additionally considered heart-rate variability and heart-rate 
variability squared, because of a previous study that showed that both a high and low heart-rate 
variability is a risk factor for total mortality and cardiovascular mortality.26,27 Heart-rate variability 
was expressed as the standard deviation of normal-to-normal RR intervals (SDNN). Heart rate 
variability was not included in the models for QTVI, because heart-rate variability is already included 
in the denominator of QTVI. 
We considered the following non-ECG covariables, which reflect common HF risk factors: 
age, sex, smoking status, body-mass index (BMI), systolic blood pressure, diastolic blood pressure, 
history of coronary heart disease, and history of diabetes mellitus.28 The covariables for each 
participant were determined at the date of the ECG recording. Smoking status was assessed during a 
home interview: participants were classified as never, former, or current smokers. Weight and 
height were measured at the study center. Blood pressure was measured twice in a sitting position 
at the right upper arm. The average of the two measurements was used. A history of coronary heart 
disease was defined as myocardial infarction or a percutaneous or surgical coronary 
revascularization procedure.29 Diabetes mellitus was defined as a fasting serum glucose level greater 
than or equal to 7.0 mmol/L or, if fasting glucose was not available, a non-fasting serum glucose 
level greater than or equal to 11.1 mmol/L, use of glucose-lowering medication, or a previous 
diagnosis of diabetes mellitus.30 
 
Outcome definition 
Methods on event adjudication of incident HF for the Rotterdam Study have been described 
previously.2,29 Adjudication of HF cases is described extensively in the supplementary methods. 
Briefly, we used automated linkage with files from general practitioners to allow for continuous 
monitoring, and the diagnosis of HF was based on criteria from the European Society of Cardiology.4 
Follow-up for heart failure ended at the first occurrence of heart failure, death, or end of the study 
period. 
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Table 1. Formulas of QT interval variability markers 
Variable Full name Formula 
QTVI  QT variability index   
log10 [
(QTv/QTm
2 )
(HRv/HRm2 )
] 
 
STVqt  Short-term QT variability 
∑
|QTi+1 − QTi|
n√2
n
i=1
 
 
Abbreviations: HRm: mean heart rate; HRvar: variance of heart rate; n: number of beats used for 
calculation; QTi: QT interval of beat i; QTm: mean QT interval; QTvar: variance of QT interval 
 
 
Statistical analyses 
The association of QT variability with HF was assessed using Cox’ proportional hazards models. All 
determinants were used as time-dependent covariables. The proportional hazards assumption was 
tested by assessing the slope of the time-dependent beta, and this was not significant. 
In the main analyses, we used STVqt and QTVI as continuous variables. We calculated a 
crude hazard ratio, and then two models with multivariable adjustment. In Model 1 we adjusted for 
age, sex, and study cohort. In Model 2, additional covariables were added if they changed the beta 
estimate of either STVqt or QTVI by more than 10%. We considered the possibility of a non-linear 
association by adding a quadratic term (STVqt2 or QTVI2). We additionally used QTVI and STVqt 
divided into quartiles to illustrate the association of QT variability with HF. The quartile limits are 
specified in Supplementary Table 1. Missing values were imputed using 10-times multiple 
imputation. All covariables had less than 6% missing values. 
The analysis were performed with R Statistical Software version 3.0.1 (Foundation for 
Statistical Computing, Vienna, Austria).31 The time-dependent Cox' proportional hazard regressions 
were done with the R package survival.32 Non-linearity was assessed with the R package rms.33 For 
multiple imputation and subsequent pooling we used the function aregImpute and fit.mult.impute 
from the Hmisc package.34 Results were shown as hazard ratios (HRs) for each QT-variability marker 
with 95% confidence intervals (CIs). Two-sided p-values less than 0.05 were considered statistically 
significant. 
QT Variability and Incident Heart Failure 
223 
Figure 1. Flowchart of in-and exclusion criteria resulting in the study population 
 
*Major abnormalities include atrial fibrillation, atrial flutter, third degree atrioventricular block, left 
bundle branch block and right bundle branch block.  
Abbreviations: ECG: Electrocardiogram; HF: heart failure; AF: atrial fibrillation; PVC: premature 
ventricular complex; PSVC: premature supraventricular complex.  
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Results 
Population characteristics  
The flowchart of the population selection is shown in Figure 1. There were 8,091 participants with 
17,281 ECGs available after applying the inclusion and exclusion criteria. Baseline characteristics of 
the study population are shown in Table 2. The study population had 59% women, and the mean age 
was 67.7 years. The median follow-up duration was 8.8 years. During follow-up, 787 participants 
were diagnosed with HF.  
 
QT variability and HF 
Table 3 shows that STVqt as a continuous variable was a significant risk factor for HF in the crude 
model, in Model 1 with adjustment for age, sex and Rotterdam study cohort, and in Model 2 with 
additional adjustment for other ECG parameters, coronary heart disease, systolic blood pressure and 
diabetes mellitus. The risk of HF increased per standard deviation of ln(STVqt + 1) with a HR of 1.19 
(95%CI 1.11 - 1.26), p-value = 1.07 x 10-7. In the categorical analysis, which was also fully adjusted, 
higher quartiles of STVqt had higher risk estimates for HF, but only the fourth quartile carried a 
significantly increased risk, with a HR of 1.52 (1.23 – 1.88), p-value = 1.01 x 10-4. Figure 2 illustrates 
the analysis with quartiles, Supplementary Table 1 shows the HRs and 95% CIs. 
QTVI as a continuous variable was a significant risk factor in the crude model and in Model 1, 
but was not significantly associated with HF in the fully adjusted model. In the categorical analysis, 
none of the quartiles carried a significantly increased risk of HF, shown in Figure 2. Quadratic terms 
of STVqt and QTVI were not significant, and there was no significant interaction of STVqt or QTVI 
with sex. 
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Table 2. Baseline characteristics of the study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BMI: body-mass index; bpm: beats per minute; ECG: electrocardiogram; IQR: 
interquartile range; ms: milliseconds; N: number of participants; QTc: heart-rate corrected QT 
interval (using Bazett’s formula); QTVI: QT variability index; SD: standard deviation; SDNN: standard 
deviation of normal-to-normal RR intervals; STVqt: short-term QT variability. 
 
 
 
 
Participants, N 8,091 
Women, N (%) 4,798 (59%) 
Follow-up time in years, median (IQR) 8.7 (6.0; 15.1) 
Age in years, mean (SD) 67.8 (8.3) 
BMI in kg/m2, mean (SD) 26.7 (3.9) 
Smoking  
    Never, N (%) 2,668 (34%) 
    Former, N (%) 3,472 (44%) 
    Current, N (%) 1,780 (22%) 
Hypertension, N (%) 4,818 (60%) 
Systolic blood pressure, mean (SD) 140.3 (21.7) 
Diastolic blood pressure, mean (SD) 75.7 (11.5) 
Coronary heart disease, N (%) 506 (6%) 
Diabetes mellitus, N (%) 795 (10%) 
Number of available ECGs, N 17,281 
Participants with one/two/three/four ECGs, N 2,724/2,761/1,389/1,217 
Participants with one/two/three/four ECGs, % 34%/34%/17%/15% 
Heart rate in bpm, mean (SD) 69.7 (11.6) 
QT interval in ms, mean (SD) 401 (29) 
QTc interval in ms, mean (SD) 429 (23) 
Sokolow-Lyon index in mV, mean (SD) 2,325 (723) 
SDNN, median (IQR) 15.5 (9.8; 25.3) 
STVqt, median (IQR) 2.0 (1.3; 3.3) 
QTVI, median (IQR) -0.9 (-1.4; -0.3) 
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Figure 2. Estimates and 95% confidence intervals for of STVqt and QTVI in quartiles for risk of heart 
failure 
  
The blue dot represents the estimate, the whiskers represent the upper and lower limit of the 95% 
confidence interval. The estimates are adjusted for age, sex, cohort, heart rate, heart-rate variability 
(only for STVqt), Sokolow-Lyon index, QT interval, coronary heart disease and diabetes mellitus. 
Abbreviations: STVqt: short-term variability of QT intervals; QTVI: QT variability index. 
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Table 3. Association between QT variability and incident heart failure 
 Crude Model 1 Model 2 
ln(STVqt + 1) per SD 1.34 (1.27 - 1.42) 1.21 (1.14 - 1.29) 1.19 (1.11 - 1.26) 
QTVI per SD* 1.23 (1.15 - 1.32) 1.10 (1.03 - 1.18) 1.07 (1.00 - 1.14) 
All results are shown as Hazard ratios (95% Confidence intervals). Model 1 is adjusted for age, sex 
and cohort. Model 2 is adjusted for age, sex, cohort, heart rate, heart-rate variability, Sokolow-Lyon 
index, QT interval, coronary heart disease and diabetes mellitus. *Not adjusted for heart-rate 
variability. Abbreviations: QTVI: QT variability index; SD: standard deviation; STVqt: short-term 
variability of QT intervals. Bold indicates p-value below 0.05 
 
 
Discussion 
We report that a higher STVqt is associated with an increased risk of HF, but QTVI is not associated 
with HF after adjustment for other ECG parameters and well-known HF risk factors. 
Our study is the first study to analyze the association of QT variability with HF in a large 
population-based setting. Previous studies focused on QT variability as a risk factor for mortality or 
sudden death within groups of patients with HF or mild-to-moderate left ventricular systolic 
dysfunction.6,8-12 Three previous case-control studies compared HF patients with healthy controls. 
The first study looked into the standard deviation of QT intervals (SDqt),14 a marker similar to STVqt, 
and found a significant difference between 20 HF patients and 9 healthy controls, but only during 
ventricular pacing (80 and 100 beats per minute). During pacing, SDqt was approximately 5 
milliseconds (ms) in the healthy control group, but 11 ms in the HF group. In the second study, the 
average QTVI was lower (-0.16) in a group of healthy controls (n = 146) than in a group of patients 
with chronic heart failure (-1.40, n = 44), a statistically significant difference.13 The third study found 
that QTVI as measured in 3-minute recordings was significantly higher in patients with HF compared 
with in healthy controls: -1.56, 95% CI -2.61 to -0.42 versus -2.23, 95% CI -3.39 to -1.05.10 The results 
of these three papers are in line with our study. The estimates of risk of HF were higher in the third 
and fourth quartile of STVqt and QTVI, and STVqt was a significant risk factor for HF, even after 
adjustment for clinical covariables. The results for QTVI were significant without adjustment for 
clinical covariables, confirming the three aforementioned case-control studies, which also did not 
adjust or matched their results.10,13,14 
Based on the differences in the formulas of STVqt and QTVI, a number of explanations are 
possible for the fact that we found significant results for STVqt, but not for QTVI. First, STVqt 
measures beat-to-beat changes and takes the order of the beats into account while QTVI uses the 
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variance of QT intervals, which is not affected by beat order. A second possible explanation is that 
QTVI is a composite marker: the numerator of the QTVI formula contains QT variability, while the 
denominator contains heart-rate variability. This means that QTVI is increased in two situations: 
when QT variability is high, and/or when heart-rate variability is low.10 A previous study in the 
Rotterdam Study population found that both high and low heart-rate variability are associated with 
cardiac mortality.26 Participants with a high heart-rate variability and consequently a high risk of 
heart disease could, as a result of the QTVI formula, have a high risk of HF with a low QTVI. This 
would dilute the effect of those participants who have a higher risk of HF and an increased QTVI due 
to a higher QT variability. This effect does not exist for STVqt, because we adjusted for heart-rate 
variability by using heart-rate variability in the model. 
HF is usually caused by abnormalities in cardiac structure and function resulting from 
myocardial infarction, hypertension, or cardiomyopathies.1,4 QT variability has previously been 
associated with both hypertrophic35,36 and dilated7,13,37 cardiomyopathies. As this study shows that 
STVqt is a risk factor for heart failure, future studies could focus on the interplay between STVqt, 
markers of cardiac pathology, and risk of HF. 
This study has a number of strengths. First, it is a population-based study of community-
dwelling middle-aged and elderly persons and data was collected prospectively. The diagnosis of HF 
was based on criteria from the European Society of Cardiology.4 QT variability was calculated 
automatically, thereby preventing observer bias in ECG assessment. There are also some limitations 
that need to be considered. First, most previous studies used longer ECG recordings than the 
standard 10-second ECGs.15 While this could be a limitation, a previous study reported that QTVI as 
measured on 10-second ECGs compared to QTVI measured on 3-minute ECGs had a high correlation, 
with a Pearson correlation coefficient of 0.81. Furthermore, our results do show that QT variability 
measured on 10-second ECGs is associated with HF. Second, data on echocardiographic parameters 
at the time of HF diagnosis were not systematically collected, therefore we could not discern 
between HF with reduced ejection fraction or HF with preserved ejection fraction.38 Third, we did 
not assess the effect of atrial fibrillation on the relation between QT variability and HF, as individuals 
with atrial fibrillation at the time of ECG measurement were excluded. 
 In conclusion, we show an association of STVqt, but not of QTVI, with a higher risk of HF in 
the general middle-aged and elderly population. Our results show that STVqt measured on 10-
second ECGs is a promising marker for HF. 
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Supplementary Methods 
Fiducial segment averaging (FSA) 
The main goal of FSA is to measure the QT interval of each beat separately, while still using the 
information from the other beats, in order to reduce the effect of noise and to increase accuracy. 
FSA works as follows: first, MEANS determines the locations of the individual QRS complexes on the 
ECG and initial fiducial points (onset of QRS complex and end of T wave) and a detection function 
consisting of the root-mean-square ECG signal,1 is computed. Second, the fiducial point in each 
individual beat is shifted in an iterative procedure until maximum correlation is achieved between a 
small signal segment of the detection function around this fiducial point and the average of the 
segments around the fiducial points of the remaining complexes. The amount of shifting is retained 
and constitutes the individual beat variation in the fiducial point estimate. Finally, the QT interval for 
each beat is calculated taking into account the shifts of the initial QRS onset and T end. To safeguard 
against signal segments with excessive noise or baseline wander, an additional test is applied after 
each FSA iteration. If the averaged absolute amplitudes of the difference between the ST-T wave of 
an individual beat and the averaged ST-T wave of the remaining beats is larger than a preset value, 
the beat is discarded and the iteration process is repeated for the remaining beats. 
 
Adjudication of HF cases 
Automated linkage with files from general practitioners allowed for continuous monitoring of 
participants of the Rotterdam Study for the occurrence of HF during follow-up. The date of incident 
HF was defined as the day of the first occurrence of symptoms suggestive of HF, obtained from the 
medical records, or if information on onset of symptoms was missing, the day of receipt of a first 
prescription for a loop diuretic or an ACE-inhibitor in someone with confirmed HF, whichever came 
first. The diagnosis of HF was classified as definite, probable, possible, or unlikely.2,3 For our analyses, 
we used only definite and probable cases. Definite HF was defined as the presence of at least one of 
the typical signs or symptoms of HF, such as breathlessness at rest, breathlessness during exertion, 
ankle edema, and pulmonary crepitations combined with confirmation by objective evidence of 
cardiac dysfunction by chest X-ray or echocardiography. This definition is in accordance with the 
criteria of the European Society of Cardiology.4 To be classed as definite HF, the diagnosis of a 
medical specialist was necessary. HF was classified as probable when at least two typical symptoms 
suggestive of HF was present, and at least 1 of the following criteria: a history of cardiovascular 
disease (e.g. myocardial infarction or hypertension), response to treatment for HF, or objective 
evidence of cardiac dysfunction, while symptoms could not be attributed to another underlying 
disease, such as chronic obstructive pulmonary disease.  
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Supplementary Table 1. QT variability in quartiles and its association with heart failure 
STVqt Quartile limits HR (95%CI) 
1st quartile 1  ≤ 1.27 1.00 (ref) 
2nd quartile > 1.27 and ≤ 1.98 1.04 (0.83 – 1.31) 
3rd quartile > 1.98 and ≤ 3.21 1.13 (0.91 – 1.41) 
4th quartile > 3.21 1.52 (1.23 – 1.88) 
QTVI Quartile limits HR (95%CI) 
1st quartile 1 (ref) ≤  -1.39 1.00 (ref) 
2nd quartile > -1.39 and ≤ -0.89 0.93 (0.75 – 1.16) 
3rd quartile > -0.89 and ≤ -0.37 1.01 (0.82 – 1.24) 
4th quartile > -0.37 1.16 (0.95 – 1.42) 
The estimates and confidence intervals were adjusted for age, sex, cohort, heart rate, heart-rate 
variability (only for STVqt), Sokolow-Lyon index, QT interval, coronary heart disease and diabetes 
mellitus. Abbreviations: CI: confidence interval; HR: hazard ratio; STVqt: short-term variability of QT 
interval; QTVI: QT variability index 
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Abstract 
Background Short-term variability of QT intervals (STVqt) is a promising electrocardiographic marker 
for ventricular arrhythmias and sudden cardiac death (SCD). Both hypothyroidism and 
hyperthyroidism have been linked to ventricular arrhythmias; while higher thyroid function is 
associated with SCD. Our objective was to study the association between thyroid function and STVqt. 
 
Methods and Results The association of thyroid function and STVqt was analyzed in a cross-sectional 
study using linear regression models. Thyroid function was expressed by thyroid-stimulating 
hormone (TSH) and free thyroxine (FT4), and by thyroid status (i.e. hypothyroidism, subclinical 
hypothyroidism, euthyroidism, subclinical hyperthyroidism, and hyperthyroidism). Nonlinearity was 
tested by adding polynomial terms of FT4. Analyses were stratified on age and sex. In sensitivity 
analyses we excluded users of thyroid medication, participants with anti-TPO antibodies above 
35kU/mL and non-euthyroid participants.  
The setting was the Rotterdam Study, a cohort of community-dwelling participants. The study 
population comprised 8,708 participants, 56.9% were women. The mean age was 64.5 years. FT4 
had a significant quadratic association with STVqt; both low and high levels of FT4 associated with a 
higher STVqt. The association was significantly stronger in men than in women (p interaction FT4 
0.014; FT42 0.006). After excluding users of thyroid medication, TSH was significantly associated with 
a higher STVqt. STVqt was not significantly different across thyroid categories (p-trend 0.41). 
 
Conclusions Both high and low levels of FT4 are associated with a higher STVqt, which is stronger in 
men. Further studies can elucidate if the association of FT4 and SCD is mediated via STVqt. 
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Introduction 
The short-term variability of QT intervals (STVqt) is a marker of QT variability.1 QT variability reflects 
the beat-to-beat changes in QT interval duration on the electrocardiogram (ECG).1-3 It has been 
hypothesized that a high QT variability is indicative of repolarization instability. For example, QT 
variability has been investigated in studies that focused on cardiomyopathies or drug use as the 
substrate leading to repolarization instability.2,4 Moreover, an increase in QT variability has been 
associated with an increased risk of ventricular arrhythmias 5 and sudden cardiac death (SCD).6 
Thyroid hormones (triiodothyronine (T3) and its precursor, thyroxine (T4)), could also affect 
repolarization stability. Thyroid hormones can influence repolarization indirectly via the heart rate,7 
or directly via potassium, sodium and calcium channels,8 or by changing the expression of Ca2+ 
ATPase and its inhibitor Phospholamban in the sarcoplasmic reticulum.9 The possible effect of 
thyroid hormones on repolarization instability is reflected by the fact that higher thyroid hormone 
levels are associated with an increased risk of atrial fibrillation, even in euthyroid subjects,10 and that 
high free thyroxine (FT4), even within the normal range, is associated with SCD.
3 On the other side of 
the thyroid spectrum, lack of thyroid hormone (i.e. hypothyroidism) is related to bradycardia and 
prolongation of the QT interval. 11 Case reports have suggested that both hyperthyroidism12-14 and 
hypothyroidism11,15-17 are associated with ventricular arrhythmias, albeit probably through different 
mechanisms. 
Although both high thyroid function3 and high QT variability6 have been associated with SCD, 
the association of thyroid function with QT variability, and the marker STVqt, has not yet been 
studied. Analysis of this association would elucidate the relation of thyroid function with 
repolarization instability, and could provide pathophysiological insights into why higher FT4 levels are 
associated with an increased risk of SCD. We therefore assessed the association of thyroid function 
with STVqt as measured on standard ECGs in a community dwelling middle-aged and elderly cohort. 
 
Methods 
Research Setting 
The study is embedded in the prospective population-based Rotterdam Study. Design and rationale 
of the Rotterdam Study have been described in more detail elsewhere.18,19 In short, 10,215 
inhabitants aged 55 years and older from the well-defined Ommoord district in the city of Rotterdam 
were invited from 1990 to 1993 to participate in the initial cohort. Of the invitees, 7,983 persons 
agreed to participate (response rate 78%). In 2000, the cohort was extended by inviting 4,472 
inhabitants of the same district who had turned 55 or who had moved into the district after the start 
of the initial cohort. In total, 3,011 individuals agreed to participate (response rate 67%). A second 
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extension of the cohort was created in 2006 by inviting 6,057 persons living in the Ommoord district 
aged 45 years or over, of whom 3,932 subjects were included in the study (response rate 65%). Thus, 
by the end of 2008, 14,926 persons were included in the Rotterdam Study. Follow-up examinations 
were conducted every four to five years. This study used thyroid measurements from the third 
examination of the first cohort and the first examination of the second and third cohorts, 11,740 
participants in total. Thyroid measurements taken in the first visit of the first cohort were not used 
because these were measured with a different assay. No thyroid measurements were taken during 
the second visit of the first cohort. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. We only included 
participants who provided written informed consent to participate in the study, to give access to 
information from their attending physicians and for follow-up monitoring. 
 
Assessment of Thyroid Function 
Thyroid function assessment included measurement of thyroid-stimulating hormone (TSH), FT4, and 
thyroid peroxidase antibodies (TPOAb) in serum samples stored at -80°C (electrochemiluminescence 
immunoassay for thyroxine, thyrotropine and thyroid peroxidase antibodies, “ECLIA”, Roche, Basel, 
Switzerland). The cut-off values of the normal range of TSH were set to 0.4-4.0 mIU/L, while the 
reference range for FT4 was 11-25 pmol/L, in accordance with previous studies and in line with Dutch 
national guidelines.3,10,20 TPOAb levels greater than 35 kU/mL were regarded as positive, as 
recommended by the assay manufacturer. Euthyroidism was defined as a TSH value within the 
reference range. Hypothyroidism was defined by TSH > 4.0 and FT4 <11, whilst subclinical 
hypothyroidism was defined as TSH > 4.0 and FT4 within the reference range. Hyperthyroidism was 
defined by TSH < 0.4 and FT4 > 25, while subclinical hyperthyroidism was defined as TSH < 0.4 and 
FT4 within the reference range. 
 
Electrocardiography 
ECGs were recorded during the same center visit as the thyroid function measurements. Standard 
12-lead 10-second ECGs were recorded during rest with an ACTA Gnosis electrocardiograph (Esaote 
Biomedica, Florence, Italy). We used a sampling frequency of 500 Hz and the ECGs were stored 
digitally. ECGs were processed by the Modular ECG Analysis System (MEANS), which has been 
described previously and has been validated and applied extensively.21,22 Exclusion criteria for ECGs 
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were atrial fibrillation, atrial flutter, or pacemaker rhythm. We used short-term variability of QT 
intervals (STVqt)1 as marker for QT variability. STVqt is defined as 
STVqt =  ∑
|QTi+1 − QTi|
n√2
n
i=1
 
where QTi is the QT interval of beat i, and n is the total number of beats in the ECG recording. 
QT intervals were measured automatically using fiducial segment averaging (FSA).23 First, 
MEANS determines the locations of the individual QRS complexes on the ECG and initial fiducial 
points (onset of QRS complex and end of T wave) and a detection function consisting of the root-
mean-square ECG signal,24 is computed. Second, the fiducial point in each individual beat is shifted in 
an iterative procedure until maximum correlation is achieved between a small signal segment of the 
detection function around this fiducial point and the average of the segments around the fiducial 
points of the remaining complexes. The amount of shifting is retained and constitutes the individual 
beat variation in the fiducial point estimate. Finally, the QT interval for each beat is calculated taking 
into account the shifts of the initial QRS onset and T end. MEANS automatically detects ectopic 
beats, and excludes them from further processing. To safeguard against signal segments with 
excessive noise or baseline wander, an additional test is applied after each FSA iteration. If the 
averaged absolute amplitudes of the difference between the ST-T wave of an individual beat and the 
averaged ST-T wave of the remaining beats is larger than a preset value, the beat is discarded and 
the iteration process is repeated for the remaining beats. 
 
Covariables 
The following covariables were derived from the ECG: heart rate, heart-rate variability, (average) QT 
interval, and Sokolow-Lyon index. Heart-rate variability was expressed as the standard deviation of 
normal-to-normal RR intervals (SDNN, in milliseconds)25 and log-transformed in the analyses to 
approximate a normal distribution. The Sokolow-Lyon index was defined as the sum of the voltages 
(in millivolt) of the S wave in lead V1 and the R wave in lead V5 or V6, whichever was larger. The 
following clinical covariables were used: age, sex, smoking, BMI, hypertension, coronary heart 
disease (CHD), and diabetes mellitus. Smoking was based on a home interview. Participants were 
classified into never, former, and current smokers. BMI was defined as weight/height2, with weight 
in kg and height in meters. Blood pressure was measured twice in the sitting position on the right 
upper arm. The average of two measurements was used. Hypertension was defined as a systolic 
blood pressure ≥140 mmHg, or a diastolic blood pressure ≥90 mmHg, or the use of blood-pressure-
lowering medication with the indication hypertension. CHD was defined as a history of a myocardial 
infarction (MI) or a surgical or percutaneous coronary revascularization procedure.26 Diabetes 
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mellitus was defined as a fasting serum glucose level ≥7.0 mmol/L or a non-fasting serum glucose 
level ≥11.1 mmol/L (if fasting serum glucose was not present), or use of glucose-lowering 
medication, or a previous diagnosis of diabetes mellitus. 
 
Statistics 
STVqt and TSH were log-transformed to normalize their distributions for all continuous analyses. 
Zero values for STVqt (n = 14) were set to one fourth of the lowest nonzero value to allow log-
transformation. We implemented linear regression models to study the association of FT4 with 
STVqt, using the Wald-test for confidence intervals (CIs) and p-values. The possibility of a nonlinear 
association between log-transformed TSH or FT4 and STVqt was tested by successively adding 
polynomial terms of FT4: FT4 
2, FT4 
3 and FT4 
4. The value of adding these terms was assessed with the 
likelihood ratio test. 
All participants with a TSH measurement and an STVqt measurement were included in the 
main analysis (six missing values for FT4 were imputed). Three sensitivity analyses were performed. 
First, to assess the possible influence of drug use, we excluded all users of thyroid function altering 
preparations (Anatomical Therapeutic Chemical (ATC) code H03A), anti-thyroid preparations (ATC 
H03B), iodine therapy (ATC H03C), corticosteroids for systemic use (ATC H02A and H02B), or 
amiodarone. Second, we limited the analyses to euthyroid participants (as defined above). Third, to 
rule out a potential effect of auto-immunity on STVqt, we excluded participants with TPOAb >35 
kU/l. Furthermore, we performed pre-specified analyses stratified by sex and stratified by age (older 
or younger than 65 years). For all analyses, we created a basic model adjusted for age and sex and a 
multivariable model with adjustment for age, sex, cohort, averaged QT interval, heart rate, and log-
transformed heart-rate variability, BMI, hypertension, smoking status, serum total cholesterol, 
prevalent diabetes mellitus, and prevalent CHD. If the association of STVqt with FT4 or with TSH was 
significant, we plotted the estimated regression line with 95% confidence intervals of FT4 or TSH 
versus values of STVqt. The association of thyroid function with STVqt was additionally assessed 
using thyroid status, a categorical variable with the categories hypothyroid, subclinical hypothyroid, 
euthyroid, subclinical hyperthyroid and hyperthyroid. This categorical variable was analyzed in a 
linear regression model, using the same covariables and sensitivity analyses as in the analyses with 
TSH and FT4. 
After selecting those participants with both a TSH measurement and an ECG, remaining 
missing values in the other covariables were imputed with five-times imputation. There were no 
variables with more than 5% missing values. For all analyses we used SPSS (IBM SPSS Statistics for 
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Windows, version 21.0. Armonk, NY). The regression line and 95% confidence intervals were 
calculated in R. 
 
 
Figure 1. Flowchart of the study population 
 
Abbreviations: RS, Rotterdam Study; RS I-3, Third visit of the first cohort; RS II-1, First visit of the 
second cohort; RS III-1, First visit of the third cohort; ECG, electrocardiogram; TSH, Thyroid-
stimulating hormone; AF, Atrial fibrillation 
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Results 
Population Characteristics 
Figure 1 shows the flowchart of the study population. There were 8,987 participants with a TSH 
measurement and an ECG. We excluded 279 participants because their ECG showed a pacemaker 
signal (n = 8), atrial fibrillation (n = 138), atrial flutter (n = 13), or because their ECG had no usable 
consecutive QT intervals (n = 120). Of the remaining 8,708 participants, 4,955 were women (56.9%) 
and the average age was 64.5 years, with a standard deviation of 9.7 years. Further characteristics of 
the study population are shown in Table 1. 
 
Association of TSH and FT4 with STVqt 
Table 2 shows the association of TSH and FT4 with STVqt in the multivariable models. Both FT4  and 
FT4
2 were significantly associated with STVqt, indicating a U-shaped relationship of FT4 with STVqt. 
TSH was not significantly associated with STVqt, except in the sensitivity analysis excluding users of 
thyroid-affecting medication. Otherwise, the sensitivity analyses did not reveal relevant changes in 
the association between thyroid function and STVqt. Results of the basic model were very similar to 
the multivariate model, e.g. main analysis FT4 -0.086 (95%CI-0.124; -0.047), FT4
2 0.003 (95%CI 0.001; 
0.004) and thus not shown for all analyses. 
Table 3 shows the analyses stratified on age and sex. There was a significant interaction of 
sex with FT4 and FT4
2 (p-values 0.014 and 0.006, respectively). The association of FT4 with STVqt was 
significantly stronger in men than in women FT4 : -0.143 (95% CI -0.202; -0.085) in men versus -0.048 
(95% CI -0.096; 0.001) in women, FT4
2 : 0.004 (95% CI 0.003; 0.006) in men versus 0.001, 95% CI 0; 
0.001 in women. In the stratification on age, there was no significant interaction with FT4 or FT4
2 
when comparing those younger than 65 with those older than 65. 
Figure 2 shows the regression lines of FT4 and back-transformed STVqt, based on the model 
including all men. The figure shows that STVqt is higher with an increased or a decreased FT4. Figure 
3 shows the same plot but then for all women, revealing a weaker U-shaped association between FT4 
and STVqt. Supplementary Figure 1 and 2 show the same regression lines for men and women with 
euthyroid status, showing a similar pattern. 
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Table 1. Baseline characteristics of included participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BMI, body-mass index; CHD, coronary heart disease; FT4, thyroxine; IQR, interquartile 
range; QTc, heart-rate corrected QT interval; SD, standard deviation; SDNN, standard deviation of 
normal-to-normal RR intervals; STVqt, short-term variability of the QT interval; TPOAb, thyroid 
peroxidase antibodies; TSH, thyroid-stimulating hormone 
 
 
 
 
Characteristic Result 
Participants, N 8,708 
Women, N (%) 4,955 (56.9%) 
Age (years), mean (SD) 64.5 (9.7) 
Diabetes mellitus 1,604 (18.4%) 
Smoking, N (%)           never                          2,704 (31.1%) 
                                    former 4,247 (48.8) 
                                    current 1,711 (19.6%) 
Hypertension, N (%) 5,306 (60.9%) 
Prevalent CHD, N (%) 575 (6.6%) 
BMI (kg/m2), mean (SD) 27.3 (4.2) 
Total cholesterol (mmol/L), mean (SD) 5.7 (1.0) 
TSH (mU/l), median (IQR) 1.9 (1.3; 2.8) 
FT4 (pmol/l), mean (SD) 15.7 (2.3) 
TPOAb > 35 (kU/mL), N (%) 1,147 (13.2%) 
Hypothyroidism, N (%) 67 (0.8%) 
Subclinical hypothyroidism, N (%) 815 (9.4%) 
Euthyroidism, N (%) 7,591 (87.2%) 
Subclinical hyperthyroidism, N (%) 215 (2.5%) 
Hyperthyroidism, N (%) 20 (0.2%) 
Heart rate (bpm), mean (SD) 68.9 (10.9) 
QT interval (ms) / QTc bazett, mean (SD) 405 (30) / 431 (24) 
SDNN (ms), median (IQR) 16.4 (10.4; 27.0) 
STVqt (ms), median (IQR) 1.8 (1.2; 3.0) 
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Table 2. Association of thyroid function with log-transformed STVqt 
Population Determinant Beta (95% CI) 
All participants log-transformed TSH 0.016 (-0.004; 0.036) 
n = 8,708 FT4
 -0.079 (-0.117; -0.041) 
    FT4
2 0.002 (0.001; 0.003) 
No thyroid  log-transformed TSH 0.023 (0.001; 0.045) 
medication FT4
 -0.088 (-0.138; -0.039) 
n = 8,181     FT4
2 0.003 (0.001; 0.004) 
Euthyroid status log-transformed TSH 0.013 (-0.023; 0.048) 
n = 7,591 FT4
 -0.168 (-0.244; -0.092) 
    FT4
2 0.005 (0.003; 0.007) 
TPOAb ≤ 35 log-transformed TSH 0.009 (-0.014; 0.033) 
n = 7,552 FT4
 -0.076 (-0.122; -0.031) 
    FT4
2 0.002 (0.001; 0.004) 
Notes: TSH and FT4 were assessed in separate linear regression models. Estimates were adjusted for 
cohort, age, sex, QT interval, heart rate and heart-rate variability, BMI, hypertension, serum total 
cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. No thyroid 
medication excludes users of thyroid function altering preparations (Anatomical Therapeutic 
Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B) , iodine therapy (ATC H03C), 
corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. Bold indicates P-value 
below 0.05. 
Abbreviations: FT4, Thyroxine; STVqt, short-term variability of the QT interval; TPOAb, thyroid 
peroxidase antibodies; TSH, thyroid-stimulating hormone.  
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Table 3. Association of thyroid function with log-transformed STVqt stratified on age and sex 
 
Notes: TSH and FT4 were assessed in separate linear regression models. Estimates were adjusted for 
cohort, age, sex, QT interval, heart rate and heart-rate variability, BMI, hypertension, serum total 
cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. Bold indicates 
P-value below 0.05 
Abbreviations: FT4, thyroxine; STVqt, short-term variability of the QT interval; TSH, thyroid-
stimulating hormone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Men; n = 3,753 Women; n = 4,955 
 Beta (95% CI) Beta (95% CI) 
log-transformed TSH -0.001 (-0.036; 0.034) 0.021 (-0.004; 0.046) 
(log-transformed TSH)2  0.022 (0.007; 0.038)  
FT4
 -0.136 (-0.195; -0.078) -0.044 (-0.094; 0.006) 
   FT4
2 0.004 (0.002; 0.006) 0.001 (0.000; 0.003) 
 Age ≤ 65; n = 5,018 
Beta (95% CI) 
Age > 65; n =  3,690 
Beta (95% CI) 
log-transformed TSH 0.004 (-0.023; 0.030) 0.028 (-0.003; 0.058) 
FT4 -0.036 (-0.099; 0.026) -0.102 (-1.53; -0.052) 
   FT4
2 0.001 (-0.001; 0.003) 0.003 (0.001; 0.004) 
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Figure 2. Estimated regression line of STVqt by FT4 status with 95% confidence intervals in men 
 
STVqt was used as a log-transformed variable in the analysis and back-transformed for presentation. 
The prediction was based on all included men (n = 3,753). The analysis was adjusted for cohort, age, 
sex, QT interval, heart rate, heart-rate variability, BMI, hypertension, serum total cholesterol, 
prevalent diabetes, prevalent coronary heart disease and smoking status. The continuous line 
indicates the estimate, the dotted lines indicate the limits of the 95% confidence interval. 
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Figure 3. Estimated regression line of STVqt by FT4 status with 95% confidence intervals in women 
 
STVqt was used as a log-transformed variable in the analysis and back-transformed for presentation. 
The prediction was based on all included women (n = 4,955). The analysis was adjusted for cohort, 
age, sex, QT interval, heart rate, heart-rate variability, BMI, hypertension, serum total cholesterol, 
prevalent diabetes, prevalent coronary heart disease and smoking status. The continuous line 
indicates the estimate, the dotted lines indicate the limits of the 95% confidence interval. 
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Categorical Analysis of the Association between Thyroid Status and STVqt 
The categorical analyses are shown in Supplementary Tables 1 and 2. Supplementary Table 1 first 
shows the main analysis, where subclinical hyperthyroid participants had the lowest beta for STVqt. 
However, differences with the other categories were not statistically significant, and the p-for trend 
was 0.41. In the sensitivity analysis excluding subjects that used thyroid function altering drugs, the 
hyperthyroid participants had the lowest beta for STVqt (Supplementary Table 1). When excluding 
participants with TPOAbs > 35, the hypothyroid participants had the lowest beta for STVqt. It should 
be noted that there were very low numbers (n = 8 and n = 10, respectively) in those categories. 
Supplementary Table 2 shows the categorical analysis stratified on sex. In the stratified analysis, no 
results were significant, except that hyperthyroid women had a significantly higher STVqt than 
euthyroid women. 
 
Discussion 
Our study shows that there is a U-shaped association between FT4 and STVqt. This association is 
significantly stronger in men than in women. TSH was only significantly associated with STVqt when 
excluding users of thyroid-affecting drugs. The analysis of overt thyroid dysfunction with STVqt 
showed no significant results, probably due to small numbers in several categories. 
 This is the first study that analyzes the association between thyroid function and QT 
variability.4 Studies of heart-rate variability (HRV) found that HRV was decreased in both subclinical 
hyperthyroidism27 and overt hypothyroidism,28 suggesting a U-shaped association of thyroid function 
with heart-rate variability. Our study demonstrates a similar relationship of FT4 with STVqt. We did 
not find a significant association of TSH with STVqt in the main analysis. Similarly, in previous studies 
in the elderly, FT4, but not TSH, was associated with SCD 
3 or atrial fibrillation10. This might be due to 
changes in the set point of the hypothalamic-pituitary-thyroid axis, with an altered TSH secretion in 
reaction to negative feedback of thyroid hormone due to ageing.20 The fact that the association of 
TSH with STVqt is significant when excluding thyroid-affecting drugs could indicate a different 
association between TSH and STVqt in users of thyroid-affecting drugs, which interferes with the 
association in the main analysis. 
QT variability is thought to be increased when channels of the inward rectifying current (Ikr) 
in cardiac myocytes are blocked. Blockade of Ikr delays repolarization and increases the QT interval. 
1 
Ikr potassium channels can be blocked by the use of certain drugs,
4 or in congenital long-QT 
syndromes,29 which are also associated with an increase in QT variability. It has been shown in 
animal models that an increase in FT3 leads to a quick decrease in the Ikr current, prolonging 
repolarization.30 it is possible that the Ikr potassium channels are the pathway by which higher levels 
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of thyroid hormone lead to an increase in STVqt. The association of thyroid function and STVqt may 
also be indirect: case reports suggest that both hyperthyroidism31 and hypothyroidism32 can lead to 
dilated cardiomyopathy, and it is known that STVqt and other QT variability markers are increased in 
dilated cardiomyopathy.2,33 However, we could not address dilated cardiomyopathy in our study, as 
we did not have data of this diagnosis, and future studies should address this issue. Other possible 
pathways, e.g. common genetic factors, have also not yet been investigated.  
Previous studies have reported that an increased QT variability is associated with ventricular 
arrhythmias5,34 and sudden cardiac death.35-38 Our study indicates that both lower and higher levels 
of FT4 lead to an increase in STVqt, which suggests that both hyperthyroidism and hypothyroidism 
could lead to ventricular arrhythmias. This is supported by a number of case reports of ventricular 
arrhythmias and sudden cardiac death in both hyperthyroidism12-14 and hypothyroidism.11,15-17 In a 
previous study we reported an association of higher FT4 with an increased risk of SCD.
3 Also, there 
seemed to be a stronger positive association of FT4 with SCD in men than in women, but this was not 
statistically significant. This suggests that STVqt could be involved in underlying mechanisms of the 
association between FT4 and SCD. In our previous study of thyroid function and SCD,
3 there was no 
association between a low FT4 and SCD, and it is possible that when a low FT4 leads to a higher 
STVqt, other morbidity and mortality than SCD occurs. Also, the previously mentioned association of 
FT3 and the Ikr potassium channels
30 cannot explain why hypothyroidism is associated with an 
increased STVqt. Thus, further studies are needed to elucidate the role of STVqt in mortality 
associated with thyroid disease. 
We found that the (U-shaped) association of FT4  with STVqt was stronger in men than in 
women, with significant interaction terms between sex and FT4, FT4
2. A previous study in the 
Rotterdam Study population reported that an increased FT4 was associated with a higher risk of 
(average) QTc prolongation, but only in men.39 Moreover, animal studies in dogs have shown that 
testosterone increases expression of potassium channels in cardiac myocytes and the QT interval on 
the ECG.40 These studies suggest that repolarization of the heart affected both by testosterone and 
by thyroid hormone, perhaps leading to interaction between the effects of the two hormones. 
Our study has a number of strengths and limitations. Strengths of our study include the use 
of a large population-based cohort of community-dwelling middle-aged and elderly participants. 
Furthermore, ECGs and thyroid measurements were performed prospectively without knowledge of 
the study question, and the ECGs were processed automatically, which reduced observer bias. 
A limitation of our study is that most previous studies used longer ECG recordings (usually 3 
to 5 minutes) than the standard 10-second ECGs used in this study,4 and the relationship between 
STVqt measured on short ECGs and STVqt measured on longer ECGs has not yet been studied. 
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However, despite this limitation, we were able to find a significant association between FT4 and 
STVqt. Additionally, the results that are obtained in this middle-aged and elderly population might 
not be representative of younger populations. We could not evaluate temporal relationships 
between FT4 and STVqt due to the cross-sectional design of our study. 
In conclusion, we found that FT4 has a U-shaped association with STVqt, as measured on 10-
second ECGs. Since STVqt is a marker of repolarization instability, our study suggests that both high 
FT4 and low FT4 levels lead to repolarization instability. Further studies should elucidate the role of 
STVqt in mortality associated with thyroid disease, and possible sex differences in the relationship 
between thyroid function, STVqt and sudden cardiac death. 
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Supplementary table 1. Effect of thyroid status on log-transformed STVqt 
 All participants No thyroid medication TPOAb ≤35 
Thyroid status n β (95% CI) n β (95% CI) n β (95% CI) 
Hypothyroid 67 0.08 (-0.09; 0.27)  59 0.13 (-0.06 - 0.33) 10 -0.02 (-0.48; 0.45) 
Sub. Hypothyroid 815 0.05 (0.00; 0.10) 712 0.06 (0.00; 0.12) 502 0.08 (0.01; 0.15) 
Euthyroid  7,591 Reference 7,238 Reference 6,844 Reference 
Sub. Hyperthyroid 215 -0.02 (-0.13; 0.08) 164 0.00; (-0.11; 0.12) 179 0.00 (-0.11; 0.11) 
Hyperthyroid 20 0.06 (-0.27; 0.39) 8 -0.05 (-0.56; 0.47) 17 0.11 (-0.25; 0.47) 
Notes: β Estimates were adjusted for cohort, age, sex, QT interval, heart rate and heart-rate 
variability, BMI, hypertension, serum total cholesterol, prevalent diabetes,  prevalent coronary heart 
disease and smoking status. No thyroid medication excludes users of thyroid preparations 
(Anatomical Therapeutic Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B) , iodine 
therapy (ATC H03C), corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. 
Abbreviations: STVqt, short-term variability of the QT interval; Sub, Subclinical; BMI, Body-mass 
index 
 
 
Supplementary table 2. Effect of thyroid status on log-transformed STVqt stratified on sex 
 Men Women 
Thyroid status n β (95% CI) n β (95% CI) 
Hypothyroid 17 0.21 (-0.13; 0.55) 50 0.04 (0.01; 0.13) 
Sub. Hypothyroid 240 0.03 (-0.06; 0.13) 575 0.05 (-0.17; 0.27) 
Euthyroid  3,427 Reference 4,164 Reference 
Sub. Hyperthyroid 66 0.10 (-0.08; 0.27) 149 -0.08 (-0.20; 0.05) 
Hyperthyroid 3 0.41 (-0.40; 1.21) 17 0.00 (-0.37; 0.38) 
Notes: β Estimates were adjusted for cohort, age, sex, QT interval, heart rate and heart-rate 
variability, BMI, hypertension, serum total cholesterol, prevalent diabetes, prevalent coronary heart 
disease and smoking status. No thyroid medication excludes users of thyroid preparations 
(Anatomical Therapeutic Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B) , iodine 
therapy (ATC H03C), corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. 
Abbreviations: STVqt, short-term variability of the QT interval; Sub, Subclinical 
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Supplementary figure 1. Estimated regression line with 95% confidence intervals of STVqt by FT4 
status in euthyroid men 
 
Notes: STVqt was used as a log-transformed variable in the analysis and back-transformed for 
presentation. The prediction was based on men with euthyroid status (n = 3,427). The analysis was 
adjusted for cohort, age, sex, QT interval, heart rate, heart-rate variability, BMI, hypertension, serum 
total cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. The 
continuous line indicates the estimate, the dotted lines indicate the limits of the 95% confidence 
interval. 
Abbreviations: STVqt, short-term variability of the QT interval; BMI, Body-mass index 
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Supplementary figure 2. Estimated regression line of STVqt by FT4 status with 95% confidence 
intervals in euthyroid women
 
Notes: STVqt was used as a log-transformed variable in the analysis and back-transformed for 
presentation. The prediction was based on women with euthyroid status (n = 4,164). The analysis 
was adjusted for cohort, age, sex, QT interval, heart rate, heart-rate variability, BMI, hypertension, 
serum total cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. 
The continuous line indicates the estimate, the dotted lines indicate the limits of the 95% confidence 
interval. 
Abbreviations: STVqt, short-term variability of the QT interval; BMI, Body-mass index 
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Abstract 
Background Both chronic obstructive pulmonary disease (COPD) and sudden cardiac death (SCD) are 
major health burdens. A number of studies have addressed their interrelationship, but currently no 
systematic review has been published. Our objective is to give an overview of the literature of the 
association between COPD and SCD. 
 
Methods A search on PubMed with both MeSH headings and free-text key words was performed. 
We selected all original articles of studies in humans that assessed COPD on the on hand and SCD, 
electrocardiographic markers for SCD, ventricular arrhythmias or asystole on the other. 
 
Results The electronic search yielded 251 papers, from which 27 full publications were selected after 
careful evaluation of the full-text papers. In these studies, COPD was associated with a prolonged 
and with a shortened QT interval. In patients with a myocardial infarction (MI), COPD was associated 
with an increased risk of ventricular arrhythmias and decreased survival. COPD was a risk factor for 
SCD both in cardiovascular patient groups and in community based studies, independent from 
cardiovascular risk profile. Studies of the potential impact of respiratory treatment on the 
occurrence of SCD showed conflicting results. 
 
Conclusion Cumulating evidence associates COPD with an increased risk of SCD. Asystole and 
pulseless electric activity could be more common than VT/VF in deaths associated with COPD. 
Underlying mechanisms explaining this association require further investigation. 
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Introduction 
Cardiovascular disease is the leading cause of death and imposes a large global burden of morbidity 
and mortality.1-4 About half of all cardiovascular deaths are sudden cardiac deaths (SCDs). SCDs occur 
suddenly and unexpectedly, often as a first sign of cardiac disease.5,6 SCD remains a major cause of 
death, even though the incidence seems to be decreasing in Western Europe.2,7 The majority of SCDs 
is thought to result from ventricular arrhythmias.8 However, in recent years the proportion of SCDs 
resulting from pulseless electrical activity (PEA) and asystole is increasing,9 possibly due to advances 
in treatment of coronary heart disease (CHD) and increased use of implantable cardioverter-
defibrillators (ICDs).10 SCD can be the result of various of underlying causes, such as CHD,11 
cardiomyopathies12 or use of QT-prolonging drugs.13 However, many possible etiological pathways 
have not yet been established.6 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally.4 
Progressive airflow limitation is the hallmark of COPD. Progressive airflow limitation is associated 
with a local chronic inflammatory response in the airways and lungs,14 but in a subgroup of patients 
with COPD biomarkers of systemic inflammation (e.g. fibrinogen, C-reactive protein) are also 
increased.15-17 COPD and cardiovascular disease are notably linked. For example, ECG abnormalities 
such as bundle branch blocks and axis deviations are common in COPD patients.18 COPD patients 
also have a higher rate of cardiovascular morbidity and mortality than the general population.19 
Moreover, half of the deaths of COPD patients is attributable to cardiovascular disease.19 The 
association of COPD with cardiovascular disease in general suggests that there could also be an 
association between COPD and SCD. Indeed, COPD can cause respiratory arrest, which can lead to 
PEA and asystole, and ultimately SCD. Accurate prediction of SCD in the general population is still a 
challenge because most cases of SCD occur in people with seemingly low cardiovascular risk.6 Thus, 
risk assessment of SCD might be improved by studying the link between COPD and SCD. Studying the 
association of COPD with SCD includes assessing possible common risk factors (e.g. ageing or 
smoking) and the effect of respiratory drugs on SCD risk. To date, there has not yet been a 
systematic review of the literature that has studied the association of COPD with SCD. The objective 
of this paper is to provide an overview of the published literature on this association. 
 
Methods 
We searched PubMed from inception until December 10, 2015 using a combination of MeSH terms 
and free-text keywords. For COPD we used the MeSH term "Pulmonary Disease, Chronic Obstructive 
". The free-text keywords were all terms derived from COPD and pulmonary emphysema, including 
the terms “obstructive pulmonary disease” and “COPD”. For SCD we used the MeSH terms "Death, 
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Sudden, Cardiac", "Heart Arrest”, "Tachycardia, Ventricular", "Ventricular Fibrillation", "Ventricular 
Flutter", and "torsades de pointes". Free-text keywords for SCD were all derived from these MeSH 
terms. In order to retrieve unindexed papers we searched without additional filters for the 
publication dates after 2014. After that, we filtered our search results on papers written in English 
and on human participants aged older than 18 years. The online supplement contains the complete 
search strategy, including all MeSH terms and free-text keywords. Citation lists of the publications 
found by the electronic search were hand-searched for additional relevant publications. 
Papers were deemed relevant for this review if they contained original research, included 
COPD patients or lung function measurements and the outcome SCD, ventricular arrhythmias, or 
electrocardiographic (ECG) markers for SCD. We extracted relevant papers from the list of the initial 
search in a two-step process. In the first step, two reviewers (MvdB, LL) independently screened the 
abstracts of the list of papers. Disagreements in abstract selection were resolved with consensus 
meetings. In the second step, the full-text articles were retrieved and all relevant information was 
extracted and tabulated. Based on this, a final selection was made. 
 
Results 
General findings 
The electronic search on PubMed yielded 251 publications. A further 5 publications were found by 
hand- searching citation lists. After screening the abstracts, we included 27 publications for 
reviewing. The selection process and its results are shown in more detail in Figure 1. The selected 
papers included 26 observational studies (10 cohort studies, 9 cross-sectional studies and 7 case-
control studies) and 1 randomized controlled clinical trial (RCT). A list with summaries of all included 
papers is provided in supplementary Table 1. 
The results section consists of two parts. Part one addresses the association of COPD with 
SCD, ventricular arrhythmias and ECG markers for SCD. First, we review COPD and 
electrocardiographic markers associated with SCD. Then, we review publications addressing COPD, 
ventricular arrhythmias, and cardiac arrest; and provide an overview of studies addressing COPD and 
SCD in patient cohorts and community-based studies. In part two, we discuss potential sex 
differences in the association between COPD and SCD. Finally, we focus on possible mechanisms 
underlying the association of SCD and COPD, including smoking, hypertension, respiratory drugs and 
the role of COPD exacerbations. 
 
 
 
Chronic Obstructive Pulmonary Disease and Sudden Cardiac Death 
265 
Figure 1. An overview of the electronic search and selection process 
 
Abbreviations: COPD: chronic obstructive pulmonary disease, SCD: sudden cardiac death, VT/VF: 
ventricular tachycardia/ventricular fibrillation. 
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Part one: association of COPD with SCD, ventricular arrhythmias and ECG markers for SCD. 
COPD and electrocardiographic markers of SCD 
The heart-rate corrected QT (QTc) interval is a known risk factor for SCD,20 and it was the most 
commonly used ECG marker in the studies we found. In the study by Zulli et al,21 QTc prolongation 
was associated with an increased mortality risk in a cohort of 246 COPD patients.21 The association 
of COPD with the QTc interval was addressed in fours studies, with mixed results: Tukek et al. (total 
n = 73)22 and Sievi et al.(n = 164)23 found that QTc was significantly higher in COPD cases compared 
to controls,22,23 but the study by Lahousse et al,24 which compared 1615 COPD patients with all other 
participants (n = 11,856) at baseline, and Zupanic et al.(n = 62)25 did not find a significant difference. 
However, Lahousse et al. only compared the median QTc of COPD patients to participants without 
COPD at baseline24 and the study by Zupanic et al. was possibly underpowered.25 A fifth study by 
Yildiz et al,26 measured the maximum QT interval without heart-rate correction on 24-hour Holter 
recordings. This study found that the uncorrected maximum 24-hour QT interval was significantly 
higher in COPD patients.26 
An abnormally short QT interval (≤ 300 milliseconds) has also been associated with SCD.27 A 
large cross-sectional population-based study found that although QT shortening was rare (incidence 
of 2.7 per 100,000 persons), it was significantly associated with COPD with an odds ratio(OR) of 2.4 
(95% confidence interval (CI) 1.3 - 3.5).28 This study included 6,547,785 ECGs of which 660,534 were 
recorded in COPD patients.28 
In addition to the QTc interval, heart-rate variability has also been associated SCD.29 Heart-
rate variability was assessed next to the QTc interval by Tukek et al,22 Yildiz et al,26 and Zupanic et 
al.25 These studies found that heart-rate variability was significantly decreased in COPD patients.20, 21, 
23 A reduced heart-rate variability is indicative of an increased sympathetic tone and a reduced vagal 
tone, which might be pathways from COPD to an increased SCD risk.30 
QT dispersion (QTD) is the difference between the longest and shortest QT interval in any 
lead for a given set of ECG leads.31 QTD has been challenged on the ground that it is only a derivative 
attribute of T-loop morphology and not indicative of repolarization instability, and therefore an 
unsound marker for the prediction of ventricular arrhythmias.31,32 Nevertheless, four studies 
addressed this marker:21-23,26 In the study by Sievi et al,23 QTD was not significantly increased in COPD 
patients compared with controls matched for age, cardiovascular risk and medication use, but it was 
increased in COPD patients in Tukek et al.22 and Yildiz et al.22,26 Finally, the cohort study of Zulli et 
al,21 an increased QTD was associated with higher mortality risk.21 
COPD, ventricular arrhythmias and cardiac arrest 
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Between 30% and 70% of SCD cases result from ventricular tachycardia and ventricular fibrillation 
(VT/VF).9,10 For this reason, the association of COPD with ventricular arrhythmias can be relevant for 
the association of COPD with SCD. Two studies addressed the underlying rhythm of COPD patients 
with a cardiac or a respiratory arrest. Frist, a study33 in 70 patients with chronic airway obstruction 
admitted for acute respiratory failure noted that 15 patients (21.4%) developed cardiac arrest (which 
included VF and asystole), and 4 patients (5.7%) developed VT.33 In a cross-sectional study (n = 
5,415)34 of people who were resuscitated for out-of-hospital cardiac arrests (OHCAs), 20% of OHCAs 
were judged to be caused by COPD based on case history. The initial rhythm of resuscitation differed 
between the causes of the OCHAs: For the OHCAs with a cardiac cause, the initial rhythm was VT/VF 
in 48% of the cases, and PEA or asystole in 50% of the cases. For the OHCAs caused by COPD, the 
initial rhythm at was VT/VF in 8% of the cases, and PEA or asystole in 88% of the cases.34 These 
studies indicate that the occurrence of VT/VF in COPD patients is relatively low and PEA might be 
more frequently associated with SCD in COPD.33,34 Furthermore, there was no significant increase of 
sustained VTs on a 24-hour ECG in stable COPD patients after adjustment for cardiovascular risk 
factors.35 In patients with a non-ST-segment elevation myocardial infarction (non-STEMI), the 
association of COPD with VT/VF seems to be stronger: In 26,416 patients with a non-STEMI, a history 
of COPD was associated with a significantly increased risk of VT (HR 1.9, 95% CI 1.1 - 3.1) and VF (HR 
2.5, 95% CI 1.6 - 4.1).36 In addition to this, one study found that after an OHCA with VT/VF, 30-day 
survival was significantly lower in COPD patients.37 
 
COPD and SCD in cohorts of patient populations 
Almost all studies defined SCD first as a witnessed unexpected death within one hour of onset of 
abrupt change in symptoms and second as an unwitnessed death within 24 hour of the last 
observation as medically stable. Supplementary Table 1 shows the definitions of SCD for all included 
studies. 
A study in 5,992 COPD patients reported that 7.7% of all deaths were SCDs,38 while a study 
of non-traumatic prehospital SCDs (defined as death within one hour post-ER arrival, n = 905) found 
that COPD was relatively common in those SCD cases (11% had COPD).39 However, neither study had 
a control group (non-COPD patients and non-SCD deaths, respectively). 
Studies in patient groups with cardiac diseases found that COPD as comorbidity is a risk 
factor for SCD. These clinic-based cohorts included patients who survived percutaneous coronary 
interventions (PCIs, n = 6,846)40 and coronary artery bypass graft (CABG, n = 2,910)40 and patients 
with atrial fibrillation (AF, n = 334) who underwent atrioventricular-node ablation.41 However, COPD 
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was not a significant risk factor for SCD in a study in elderly patients (n = 3,726, mean age 81 years) 
who underwent transcatheter aortic valve replacement (TAVR).42 
Patients with an ICD are a special patient group for the study of ventricular arrhythmias and 
SCD. COPD was a risk factor for appropriate ICD shocks, which indicate the occurrence of ventricular 
arrhythmias in a cohort study of patients with an ICD (n = 628).43 A second cohort study (n = 202) 
found that COPD was also associated with ICD shocks, but this study did not differentiate 
appropriate from inappropriate ICD shocks (due to non-ventricular arrhythmias).44 
 
COPD and SCD in community-based studies 
Three community-based studies investigated the association of SCD or SCA with COPD. First, SCA risk 
was increased in COPD patients (OR 1.4, 95% CI 1.2 - 1.6), in a case-control study that compared SCA 
patients with VT/VF (n = 1,310) to controls matched for age, sex and index date (n = 5,793). This 
study adjusted for cardiovascular risk factors, which were estimated by the use of cardiovascular 
drugs.45 Second, COPD was a risk factor for SCD in a population-based cohort of middle-aged and 
elderly participants (HR 1.4, 95% CI 1.0 - 1.5). This study additionally created competing risk models, 
which showed that COPD is a risk factor for SCD beyond the generalized increased risk of death in 
COPD patients.24 Third, a higher frequency of respiratory diseases (international classification of 
diseases 10 - group J which includes COPD) was observed in SCA patients. However, this was 
statistically not significant (p=0.184). In this study, a large cross-sectional study of emergency 
medical service interventions, the medical records on comorbid conditions of patients with out-of-
hospital sudden cardiac arrest (SCA, n = 245) were examined retrospectively and compared with 
patients that underwent interventions for other reasons (n = 26,398).46 The fact that the higher 
frequency of respiratory diseases was not significant could be explained by the lack of specific COPD 
phenotyping or by the underdiagnosis of COPD in the medical records of emergency operations.  
 
Part two: sex differences and mechanisms of the association of SCD and COPD 
Sex differences in the association of COPD with SCD 
Three studies analyzed sex differences as possible effect modifiers of the association between COPD 
and VT/VF or SCD. First, men were more prone to VT than women in a cross-sectional study of 
ambulatory ECGs of 69 COPD patients.47 In contrast, there was no sex difference in the risk of SCA 
between participants with COPD or asthma and participants without COPD or asthma in a study of 
SCA cases (n = 1,568) 48 Third, SCD occurred more frequently in men with COPD in the population-
based study of Lahousse et al. with 13,471 community-dwelling participants.24 However, this study 
found that frequent COPD exacerbations carried a slightly higher risk for women (HR 3.5, 95%CI 1.8 - 
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6.8) than for men (HR 3.1, 95%CI 1.7 - 5.5).24 Since the risk increased further when restricted to post-
menopausal women, a role of stress-induced cardiomyopathy during COPD exacerbations was 
suggested.24 
 
Smoking  
The association of COPD with SCD was adjusted for smoking in two cohort studies. The first cohort 
study (total n = 7,441) found that low FEV1 and FVC were associated with SCD both in smokers and 
non-smokers,15 and the study by Lahousse et al. reported that the association between COPD and 
SCD was independent of smoking behavior.24 Moreover, smoking was not a significant predictor for 
ICD shocks in a study in a cohort of patients with ICDs.44 These studies suggest that the association of 
COPD and SCD is independent of smoking. 
 
Hypertension and timing of SCA/SCD 
Two studies assessed factors associated with both COPD and cardiac endpoints (myocardial 
infarction (MI) or OHCA). First, hypertension: acute MI patients admitted to the ICU with 
hypertension more often had COPD than normotensive MI patients, but they presented less often 
with VF.49 Second, the time of incidence: nighttime admissions for OHCAs more often had COPD as 
comorbidity, and lower 1-year survival.49 Furthermore, in the study by Lahousse et al,24 SCDs in 
COPD patients occurred more often at night than SCDs in non-COPD patients (53% vs. 36%).24 The 
increased number of ventricular ectopic episodes during sleep could be the result of reduced 
ventilation and a blunted response to hypercapnia.50,51 
 
Respiratory drugs 
The study by Warnier et al.45 reported that use of inhaled short-acting beta-agonists (SABAs) and use 
of inhaled muscarinic antagonists (the study did not specify if these were long-acting or short-acting 
anticholinergics) were associated with sudden cardiac arrest (SCA) due to VT/VF. The OR for SABAs 
was 3.9 (95% CI 1.7 - 8.8) and for anticholinergics 2.7 (95% CI 1.5 - 4.8), after adjustment for 
concomitant cardiovascular disease. Use of inhaled corticosteroids was not associated with SCA in 
this study.45 However, increased drug use during exacerbations or increased drug use due to more 
severe COPD might be plausible confounders for the increased risk of SCA in users of SABAs and 
anticholinergics.52 In contrast, two studies found no effect of respiratory drugs on the risk of SCD in 
COPD. First, use of the long-acting anticholinergic tiotropium did not increase the risk of VT/VF in a 
meta-analysis combining thirty clinical trials and including 19,545 COPD patients.53 However, 
because there were only five fatal VT/VF cases this meta-analysis was underpowered for this 
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endpoint.53 Clinical trials of COPD patients possibly have a low incidence of VT/VF due to the 
selection of relatively stable patients without significant cardiovascular comorbidities.54 Second, use 
of sympathomimetic respiratory drugs did not significantly interact with COPD on the risk of SCD in 
the study by Lahousse et al, but this study did not take duration of drug use or dosage into 
account.24 
 
COPD exacerbations 
In the study by Lahousse et al,24 long-term COPD patients with frequent exacerbations had a higher 
risk of SCD (HR 3.2, 95% CI 2.1 – 5.0) than long-term COPD patients without frequent exacerbations 
(HR 1.52, 95% CI 1.1 – 2.2). Exacerbations only increased the risk of SCD in those participants with 
elevated systemic inflammation at cohort entry, indicating that the association of COPD 
exacerbations with SCD is at least partially mediated by systemic inflammation. Thus, severity and 
duration of COPD are of importance for the risk of SCD.24 
 
Discussion 
The majority of the studies supports the hypothesis that COPD is associated with SCD. COPD was a 
risk factor for SCD independent of cardiovascular risk profile, both in cohorts of cardiovascular 
patients and in community based studies. Evidence for the association of COPD with VT/VF is much 
weaker, and the evidence for the potential impact of respiratory treatment on the onset of SCD is 
inconclusive. COPD was also associated with reduced heart-rate variability, while the studies for QTc 
prolongation were inconclusive. 
 There are several theoretical explanations for an association between COPD and SCD, which 
are illustrated in Figure 2. We will review each of these mechanisms and note what has been 
studied, and identify gaps needing further research. First, COPD might cause pathophysiological 
changes which directly increase the risk of SCD. Examples of previously studied pathological changes 
in COPD are changes in cardiac repolarization, represented by QT or QTc interval abnormalities,22-
26,28 and increased sympathetic tone or reduced vagal tone indicated by a reduced heart-rate 
variability.22,25,26 Other studies have also found that COPD is associated with baroreceptor sensitivity 
abnormalities55, heart-rate variability abnormalities,56 and a direct increase in muscle sympathetic 
nerve activity.57 Further research might focus on the interaction of COPD and autonomic neuropathy 
for the risk of SCD. The evidence for the association of COPD with QTc interval prolongation was 
inconclusive, and QT interval variability, a promising ECG marker of ventricular arrhythmias and 
SCD,58 has not yet been studied in COPD. Therefore, QT variability might be an avenue for future 
research. Besides ECG markers, the effect of systemic inflammation in COPD on the risk of SCD has 
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been assessed.24 However, there are also a number of pathophysiological changes associated with 
COPD that have not yet been studied in relation to SCD risk, including hypoxia and hypoxemia,14 
cardiac ischemia,8,19 heart failure,59 and possibly pulmonary hyperinflation and pulmonary 
hypertension.24 
Second, there may be common risk factors acting as confounders. The association of COPD 
with SCD was independent of smoking, which was addressed in two studies.15,24 The role of common 
genetic risk factors need to be elucidated, since these studies will provide more insights into 
common pathogenic pathways that lead to increased SCD risk in COPD (e.g. systemic inflammation 
or tissue remodeling). No study to date has assessed common genetic risk factors between COPD 
and SCD. 
Third, use of respiratory drugs could be associated with SCD. The studies included in this 
review give contradictory results and no study assessed the dose-response relationship of 
respiratory drugs and SCD.24,45,53 The TIOSPIR60 and SUMMIT61 randomized controlled trials were not 
included in our review because they have not (or not yet) reported on the endpoint SCD. Because 
the association of respiratory drugs with SCD risk is probably dose-dependent, future studies should 
address the dose-effect. In addition to inhaled COPD drugs, none of the included studies have 
addressed the oral macrolide antibiotics, which are often prescribed for COPD exacerbations. These 
antibiotics are known QT-prolonging drugs, and suspected of increasing the risk of ventricular 
arrhythmias and SCD.20,62 
Fourth, the diagnosis of COPD could change the prescription pattern of cardiovascular drugs. 
On the one hand, contra-indications for drugs like beta-blockers might lead to inadequate 
cardiovascular prevention, which might increase the risk of SCD. On the other hand, the medical 
attention which is sought for COPD may also lead to improved cardiovascular prognosis by active 
prevention of cardiovascular risks (such as smoking and hypertension). Warnier et al.45 studied the 
prevalence of use of cardiovascular drugs in SCD cases and controls, but did not assess the 
interaction with COPD. Therefore, a time-dependent and dose-dependent assessment of individual 
cardiovascular drugs in COPD patients and non-COPD patients, and the associated SCD risk, is 
needed. 
Fifth, the association of COPD with SCD could be caused by misclassification of acute 
respiratory deaths as sudden cardiac deaths especially when non-witnessed. However, the ratio of 
witnessed to non-witnessed SCD was not different for participants with COPD compared to 
participants without COPD in the largest study of the association between COPD and SCD.24 
Lastly, the occurrence of a higher rate of exacerbations has also been reported to increase 
the risk of SCD in COPD patients.24 Among explanatory mechanisms recently reviewed,52 this 
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association can be caused by a direct increase in systemic inflammation associated with frequent 
exacerbations,63 or indirectly by use (and abuse) of SABAs and LABAs. Excessive use of SABAs and 
LABAs may lead to hypomagnesemia,64 which has also been associated with an increased risk of 
SCD.65 
A strength of the studies addressing SCD is the uniform definition of SCD as a witnessed 
unexpected death within one hour of onset of abrupt change in symptoms or an unwitnessed death 
within 24 hour of the last observation as medically stable. However, none of the studies with the 
endpoint SCD reported the preceding cardiac arrhythmia. Therefore, we were unable to distinguish 
between SCD caused by VT/VF and SCDs resulting from PEA and asystole. One study indicates that 
PEA and asystole are more common than VT/VF in COPD patients with cardiac arrest.34 As these 
different direct causes of SCD are possibly the results of different pathologies and associated with 
different risk factors, this is a limitation of the studies included in this review. 
In conclusion, accumulating evidence associates COPD with an increased risk of SCD. 
Asystole and PEA could be more common than VT/VF in COPD-associated deaths. Underlying 
mechanisms explaining this association require further investigation. Promising avenues of further 
research include studies of QT variability and hypoxia, genetic studies and pharmaco-epidemiological 
studies. 
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Figure 2: Possible mechanisms of the association between COPD and SCD 
 
 
 
Note: Besides potential misclassification, COPD exacerbations are known to amplify both 
cardiovascular pathophysiology and the use of respiratory drugs. 
Abbreviations: COPD: chronic obstructive pulmonary disease, SCD: sudden cardiac death 
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Supplementary table 1. Overview of all included studies 
 
First author year  
 
Study type 
 
Population Cases Controls Exposure or 
Determinants 
Endpoint 
 
follow-
up time 
Conclusion 
Abrignani
1
 
2005 
 
Case-control 
 
Consecutive patients 
with AMI admitted to 
the ICU (n=4,994) 
Hypertensive patients 
with first infarction 
(n=915) 
Age: 68.8±11.4 years 
Gender- and Age- 
matched 
normotensives 
(n=915) 
COPD 
VF 
From hospital 
records 
  Cases more often 
COPD (13.1 
vs.7.5%, p<0.001), 
less VF (2.2 vs. 
3.7%, p = 0.036) 
Al Khatib
2
 
2002 
Cross-
sectional 
 
Pooled datasets from 4 
trials of patients with 
non–ST-segment 
elevation MI (n=26,416) 
  History of COPD In-hospital VT or VF 
(n=552) 
 COPD OR for VT 
 2.5 (1.6–4.1)  
COPD OR for VF  
1.9 (1.1–3.1) 
Blom
3
 
2013 
Cohort 
 
Patients with non-
traumatic OHCA with 
ECG-documented VT/VF 
(n=1,172) 
Patients with OPD 
(n=178) OPD: at least 
2 prescriptions of any 
meds  with ATC R03 
in the year before 
OHCA. 
Non-OPD patients 
(n=993) 
 I.  30-day survival 
II. Survival to 
hospital discharge 
30 days I. OR 0.7 (0.5-0.97) 
II. OR 0.6 (0.4-0.9) 
For OPD 
Celli
4
 
2010 
 
Clinical trial 
 
COPD Patients: at least 
40 years of age, ≥10 
pack-years, airflow 
limitation FEV1 ≤70% of 
FVC 
Users of  tiotropium 
(n=10,846) 
Placebo users  
(n=8,699) 
 VT/VF:  IR users: 
0.24 
IR placebo: 0.16 
Cardiac arrest: IR 
users: 0.26 IR 
placebo 0.16 
4 years Users of tiotropium  
VT/VF: 
RR 0.67 (0.38-1.19) 
Cardiac arrest: 
RR 0.68 (0.39-1.16) 
Chugh
5
  
2009 
Cross-
sectional 
 
SCA: a sudden 
unexpected pulseless 
condition <1h of 
symptom onset or <24h 
of having been seen alive 
and 
symptom-free. (n=1,568) 
Men with adult SCA 
(n=805) 
Women with adult 
SCA (n=453) 
History of COPD or 
asthma 
  No sex-related 
difference COPD / 
asthma in SCA 
(P=0.10) 
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Dougherty
6
 
2009 
 
Cohort 
  
SCA survivors or those 
with 
malignant ventricular 
arrhythmias who 
received an ICD for the 
first time 
No ICD shock within 
12 months (n = 151) 
ICD shock within 12 
months (n = 51) 
COPD collected 
from self-report 
and/or from 
medical records 
review at the time 
of study entry 
 12 
months 
COPD, congestive 
HF  or VT at ICD 
implant were  
significant 
predictors of an 
ICD shock in the 
first year  
Engdahl
7
 
2003 
 
Cross-
sectional   
All patients suffering 
from OHCA with 
resuscitation in 
Goteborg in years 1981-
2000. 
Cardiac arrests from a 
non-cardiac aetiology 
(n=1,360) of which 
20% by COPD (n=275) 
Cardiac arrests 
from a cardiac 
aetiology (n=4,055) 
 Initial rhythm 
VT/VF:  
Cases: 8%  
COPD cases: 8% 
Controls: 48%  
 Lower occurrence 
of ventricular 
fibrillation in cases 
(p<0.001). 
Hudson
8
 
1973 
 
Cross-
sectional   
Patients with chronic 
airway obstruction 
(n=70) from 147 
consecutive admissions 
for acute respiratory 
failure. 
   Cardiac arrest 
(n=15) 
VF (n=4) 
  
Iribarren
9
 
2014 
Cross-
sectional  
12-lead ECGs recorded in 
1.7 million participants 
(n = 6,547,785) 
  ECGs in patients 
with COPD 
ascertained by 
combining 
inpatient and 
outpatient 
diagnostic and 
procedure codes 
(n = 660,534) 
Confirmed ECGs 
with QTcreg 
(corrected by 
regression) ≤300, 
n=45 
(from1,086 
machine-read short 
QTs) 
 COPD: 
OR of short QT  
2.4 (1.3–4.5) 
Short QT known 
risk factor of SCD 
Karlsson
10
 
2014 
Cross-
sectional   
 
The nationwide Danish 
Cardiac Arrest Registry 
(2001-2010);  OHCA 
patients (n=18,929) 
  Daytime  
(07.00–14.59h) 
Evening 
(15.00–22.59h) 
Nighttime 
(23.00–06.59h) 
COPD discharge 
diagnosis codes up 
to 10 years before 
OHCA 
(Danish National 
Registry) 
 For OHCA during 
nighttime 
significantly higher 
percentage COPD 
(p<0.001) 
Konecny
11
 
2014 
 
Case-control  
 
Consecutive adults who 
underwent clinically 
indicated pulmonary 
function testing and 24h 
Holter (n=7,441) 
Patients with COPD 
based in electronical 
medical records 
(n=3,121) 
Patients without 
COPD based in 
electronical medical 
records 
(n=4,320) 
 Sustained VT 
 
 COPD patients ↑ 
sustained VT 
(p=0.012), 
multivariate model 
ns. 
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Kurl
12
 
2015 
 
Cohort  Participants with lung 
function test at baseline. 
(n=1,250) 
  FEV1 
FVC 
FEV1 to FVC-ratio 
in quintiles 
SCD: Death <1h of 
onset of abrupt 
change in symptoms 
or <24h 
of last observed 
medically stable, 
without non-cardiac 
cause. (n = 95) 
Mean  
20 years 
Range 
0.3-25.7 
Low FEV1 risk 
factor for SCD 
Low FVC risk factor 
for SCD 
FEV1/FVC ratio n.s. 
Lahousse
13
 
2015 
 
Cohort  Participants aged  ≥45 
(n=13,471) living in 
Ommoord area of 
Rotterdam 
  COPD diagnosis 
(FEV1/FVC < 70% 
from medical 
records, n=1,615) 
 
SCD: Death <1h of 
onset of abrupt 
change in symptoms 
or <24h 
of last observed 
medically stable, 
without non-cardiac 
cause. (n=551) 
Median 
8.8 
years 
IQR 
10 years 
COPD ↑ risk of 
SCD HR, 1.34 (1.06-
1.70) 
Frequent 
exacerbations ↑↑ 
risk of SCD 
McGarvey
14
 
2012 
Cohort Study participants 
with a clinical diagnosis 
of COPD  (n=5,992) 
   Unexpected deaths 
in stable patients 
<1h. 
(SCD, 4.4%) or >1h 
and  <24h of last 
observed medically 
stable (sudden 
death, 3.4%) 
4 years SD occurs relatively 
commonly in COPD 
patients:7.7% of 
fatal cases in 
patients. 
Seems 
independent of 
disease severity 
Naksuk
15
 
2013 
Cohort  Consecutive patients 
who underwent ICD 
implantation. (n=628) 
  COPD diagnosis 
(FEV1/FVC < 70%) 
from medical 
records 
(n=1615) 
Death (n=152) 
Appropriate ICD 
shock 
(n=138) 
Median 
4.1 
years 
IQR 
2.2-5.7 
COPD ↑ risk Death 
(p=0.02) and 
appropriate ICD 
shock.(p<0.001) 
Nishiyama
16
 
2010 
 
Cohort  Consecutive patients 
who 
survived first elective PCI 
(n=6,846) and CABG 
(n=2,910) (total n=9,756) 
  COPD SCD: Death <1h of 
onset of abrupt 
change in symptoms 
or <24h 
of last observed 
medically stable, 
without HF, MI, 
other. (n=140) 
Mean 
3.5 
years 
SD 
1.3 
years  
 
COPD HR 2.04 
(1.48-2.70, p< 
0.001) for SCD 
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Ozcan
17
 
2002 
Cohort  Consecutive patients 
with AF who underwent 
AV node ablation. 
(n=334) 
Participants without 
SCD (n=327) 
SCD: death <1h of 
onset of symptoms 
or <1h from last 
seen to when the 
body was found. 
(n=9) 
COPD from 
medical records 
 Mean 
36 
months  
SD 26 
months 
COPD for SCD 
RR 14.23 (1.69-
119.71, p=0.01) 
Shih
18
 
1988 
 
Cross-
sectional  
 
Ambulatory 24-hour 
ECGs from stable COPD 
patients (n=69) 
  
   VT (n=22)  Men and patients 
with edema are 
more prone to 
repetitive 
ventricular 
arrhythmia. 
Sievi
19
 
2014 
Case-control  
 
 COPD patients 
objectively 
confirmed according 
to GOLD-guidelines 
(n=91) 
Controls matched 
for age, CV risk and 
meds (n=32), and 
healthy subjects 
(n=41) 
QTc interval from 
the ECG  
QT dispersion 
>60ms 
  QTc was 
significantly longer 
in cases vs. 
matched controls 
and healthy 
subjects 
QT dispersion was 
not significantly 
different in cases 
vs. matched 
controls. 
Tukek
20
 
2003 
Case-control  
 
 COPD patients (n=41) Healthy controls 
(n=32) 
SDNN, SDANN , 
QTc, QTc 
dispersion from 
24h  ECG 
recordings 
  SDNN, SDANN ↓ in 
cases 
Max. QTc and QT 
dispersion↑ in 
cases 
Uchmanowicz
21
 
2015 
 
Cross-
sectional 
 
Emergency medical 
service interventions 
(n=26,219) 
Emergency medical 
service interventions 
with  ICD-10 code I46 
(OHSCA, n=245) 
Emergency  medical 
service 
interventions 
without ICD-10 
code I46 (n=26,398)  
ICD-10 group J 
(COPD & bronchial 
asthma) 
  Chi-square group J 
and OHSCA p-value 
0.184 
 
Urena
22
 
2015 
Cohort  Patients who underwent  
transcatheter aortic 
valve replacement  
(n=3,726) 
  COPD SCD: death within 
1h of symptom 
onset if witnessed 
or within the 
previous 24h if 
unwitnessed. (n=57) 
Mean 
22  
months 
SD 18 
months 
COPD ns. HR 
1.34(0.77–2.35, 
p-value 0.305) for 
SCD 
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.
Wang
23
 
2007 
Cross-
sectional  
 
NPSD due to heart 
disease or rapid organ 
deterioration outside 
hospital or <1h post-ER 
arrival ( n = 605) 
  COPD (11%)   COPD common in 
NPSD 
Warnier
24
 
2013 
Case-control   SCA patients with 
VT/VF age > 40 years 
(n=1,310) 
Controls matched 
by age, sex and 
index date 
(n=5,793) 
OPD users of β-
blockers, Short-
acting β-agonists 
(SABA), and 
anticholinergics 
(ACs) 
  SCA risk 40%↑ in 
OPD. SCA risk ↑↑ 
in OPD patients 
with high CV risk-
profile, users of 
SABA, and AC 
Yildiz
25
 
2002 
Case-control   COPD patients (n=30) Age- and sex 
matched controls 
(n=31) 
24h ambulatory 
ECG:  SDNN, 
SDANN, QT 
interval, QT 
dispersion 
  In cases SDNN, 
SDANN↓, QTmax,  
QTmin , QT 
dispersion↑  
All p < 0.05 
Zulli
26
 
2006 
 
Cohort  COPD patients without 
significant comorbidities, 
and mild to moderate 
functional impairment 
(n=246) 
  QTcmax > 440 ms 
QTc max 
(continuous 
variable) 
QT dispersion, QTc 
dispersion 
IC < 80% predicted 
PaO2 < 60 mmHg 
Death (n = 81) Mean 
59.7 
range 
5-114 
months 
QTcmax, QT 
dispersion, IC and 
Pa02 associated 
with mortality (NB: 
paper uses RR 
instead of HR for 
Cox’ model.) 
Zupanic
27
 
2014 
I. Case-
control II. 
Pseudo-
randomized 
control study  
 I. Patients with COPD 
(n=31) 
II. COPD patients who 
underwent a 4-week 
rehabilitation 
program  
(n=18) 
I. Healthy controls 
(n=31) 
II.  COPD patients 
who did not 
undergo 4-week 
rehabilitation 
program(n=13) 
I. 20-min ECGs 
SDNN, RMSSD, 
QTc  
II. 20-min ECGs 
SDNN, RMSSD, 
QTc  
 
 II.  
4 weeks  
I. SDNN, 
RMSSD↓in cases. 
QTc ns. 
II. SDNN ↑ after 
program. 
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Abbreviations of supplementary table 1 
AMI: acute myocardial infarction, AF: atrial fibrillation, ATC code: anatomical therapeutic chemical 
code, AV-node: atrioventricular node, CABG: coronary artery bypass graft, COPD: chronic obstructive 
pulmonary disease, CV: cardiovascular, ECG: electrocardiogram, ER: emergency room, FEV1: forced 
expiratory volume in one second, FVC: forced vital capacity, GOLD: global initiative for chronic 
obstructive lung disease,  h: hour, IC: inspiratory capacity, ICD: implantable cardioverter-defibrillator, 
ICD-10: international classification of diseases and related health problems 10th revision, ICU: 
intensive care unit, IQR: interquartile range, IR: incidence ratio, NPSD: non-traumatic prehospital 
sudden death, ns: not significant, OHCA: out-of-hospital cardiac arrest, OHSCA: out-of-hospital 
sudden cardiac arrest, OPD: obstructive pulmonary disease, OR: odds ratio, PaO2: partial oxygen 
pressure in arterial blood, PCI: percutaneous coronary intervention, QTc: heart-rate corrected QT 
interval, RMSSD: root mean square of successive RR-interval differences, RR: risk ratio, SCA: sudden 
cardiac arrest, SCD: sudden cardiac death, SD: standard deviation, SDANN: standard deviation of the 
average of the normal-to-normal RR intervals over 5 minutes, SDNN: standard deviation of normal-
to-normal RR intervals, VF: ventricular fibrillation, VT: ventricular tachycardia
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Abstract 
Background The association between thyroid function and cardiovascular disease is well-
established, but no study to date has assessed whether it is a risk factor for sudden cardiac death 
(SCD). Therefore we studied the association of thyroid function with SCD in a prospective 
population-based cohort.  
 
Methods Participants from the Rotterdam Study ≥45 years with thyroid-stimulating hormone (TSH) 
or free thyroxine (FT4) measurements and clinical follow-up were eligible. We assessed the 
association of TSH and FT4 with the risk of SCD using an age- and sex-adjusted Cox-proportional 
hazards model, in all participants and also after restricting to euthyroid subjects (defined by TSH 0.4-
4.0 mIU/L). Additional adjustment included cardiovascular risk factors, notably hypertension, serum 
cholesterol and smoking. We stratified by age and sex and performed sensitivity analyses by 
excluding subjects with abnormal FT4 values (0.85-1.95 ng/dL) and including only witnessed SCDs as 
outcome. Absolute risks were calculated in a competing risk model by taking death by other causes 
into account.  
 
Results We included 10,318 participants with 261 incident SCDs (median follow-up of 9.1 years). 
Higher levels of FT4 were associated with an increased SCD risk, even in the normal range of thyroid 
function (hazard ratio 2.28 per 1ng/dL FT4, 95% Confidence Interval, 1.31-3.97). Stratification by age 
or sex and sensitivity analyses did not change the risk estimates substantially. The absolute 10-year 
risk of SCD increased in euthyroid participants from 1% to 4% with increasing FT4 levels. 
 
Conclusions Higher FT4 levels are associated with an increased risk of SCD, even in euthyroid 
subjects.  
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Introduction 
Thyroid hormone is critical for the development and function of nearly all organs and tissues, with 
the cardiovascular system being one of the major targets. Thyroid hormone is known to increase 
heart rate, increase cardiac contractility, alter systolic and diastolic function and decrease 
systematic vascular resistance 1. Thyroid dysfunction, even in the subclinical range, is associated 
with an increased incidence of cardiovascular risk factors and disease 2-4. Both overt and subclinical 
hypothyroidism are associated with hypertension, dyslipidemia and coronary heart disease (CHD)4,5, 
whereas excess of thyroid hormone, subclinical and overt hyperthyroidism, increases the risk of 
atrial fibrillation (AF), CHD and heart failure (HF) 2,6. However, little is known about the association 
between thyroid (dys)function and the risk of sudden cardiac death (SCD).  
SCD is defined as unexpected natural death from a cardiac cause within a short time period, 
generally <1 hour from the onset of symptoms, in a person without any prior condition that would 
appear fatal 7. SCD accounts for over 50% of cardiovascular deaths and 15% to 20% of total mortality 
8. As much as 75 percent of SCDs have been attributed to CHD (known or unknown) and the risk 
factors for CHD and SCD are therefore very similar and include older age, male sex, hypertension, 
HF, smoking and dyslipidemia 7,9,10. Additional risk factors include non-ischemic cardiac disease (e.g. 
congenital heart disease) and non-cardiac disorders (e.g. drug-induced) 10. However, the 
predictability of SCD in the general population remains poor, as almost half of the SCD cases are the 
first presentation of cardiac disease 11. It is therefore of crucial importance to identify additional risk 
factors other than well-established cardiovascular risk factors. We hypothesized that thyroid 
function is associated with an increased risk of SCD and set to determine this association and 
possible subgroups at risk in a population-based cohort study. 
 
Methods 
Setting 
All analyses were performed in the Rotterdam Study (RS), a prospective population-based cohort 
study that investigates determinants and occurrence of cardiovascular, neurological, 
ophthalmologic, psychiatric, and endocrine diseases in the middle-aged and elderly population. The 
aims and design of the Rotterdam study have been described in detail elsewhere 12. We included 
participants from three independent cohorts within the Rotterdam Study. The RS Cohort 1 (RSI) 
includes participants aged 55 years and older and baseline data were collected during 1990-1993. RS 
Cohort II (RSII) includes participants aged 55 years and older and baseline data were collected from 
2000-2001. For the RS Cohort 3 (RSIII), all residents of Ommoord aged 45 years and over who had 
not been invited before, were asked to participate and baseline data were collected from 2006 to 
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2008. The Medical Ethics Committee of the Erasmus University approved the study protocols and by 
the Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All included participants 
provided a written informed consent in accordance with the Declaration of Helsinki to participate in 
the study and to obtain information from their family physicians. 
 
Study Population  
Participants were eligible for inclusion if they had thyroid-stimulating hormone (TSH) or free 
thyroxine (FT4) measurements made at baseline visit of the study cohorts RSI (RSI-1), RSII (RSII-1) 
and RSIII (RSIII-1). Since a number of participants from RSI did not have thyroid measurements at the 
first visit, they were included in the analyses using data from their third visit 3 (RSI-3) and were 
follow-up since the date of their laboratory measurement. A total of 10,318 participants from the 
three cohorts were included in our analyses. All study participants were followed up from the day of 
baseline laboratory testing to date of SCD, to death from other causes, or to December 12th, 2010, 
whichever came first. 
 
Assessment of thyroid function 
For RSI-1, serum TSH (TSH Lumitest; Henning, Berlin, Germany) and F T4 levels (FT4; Vitros, ECI 
Immunodiagnostic System; Ortho-Clinical Diagnostics, Amersham, UK) were determined in a random 
subset of the baseline serum samples (n=1855). For RSI-3, RSII-1 and RSIII-1, thyroid function 
assessment was also performed in baseline serum samples for TSH and FT4 (The 
electrochemiluminescence immunoassay for thyroxine and thyrotropine, “ECLIA”, Roche). The two 
tests’ TSH reference ranges did not differ substantially and had a good Spearman correlation co-
efficient (0.96 for TSH, p < 0.0001and 0.81 for FT4, p < 0.0001). We determined the cut-off values for 
normal range TSH as 0.4-4.0 mIU/L according to national guidelines and our previous studies.13 The 
reference range for FT4 was 0.85-1.95 ng/dL (=11-25 pmol/L) 14. Euthyroidism was defined as a TSH 
value within the reference range. Hypothyroidism was defined by TSH mIU/L > 4.0 and FT4 <0.85 
ng/dL whilst with subclinical hypothyroidism FT4 was still within the reference range. 
Hyperthyroidism was defined by TSH mIU/L < 0.4 and FT4 > 1.95 ng/dL whilst with subclinical 
hyperthyroidism FT4 was still within the reference range. 
 
Sudden cardiac death definition and case ascertainment 
Information on SCD was obtained from medical records and death certificates. Deaths were 
considered from study entry through December 12th 2010. SCD was defined in accordance with the 
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Myerburg definition15, which is endorsed by the European Society of Cardiology16, as “a natural 
death due to cardiac causes, heralded by abrupt loss of consciousness within one hour from onset of 
acute symptoms. Pre-existing heart disease may have been known to be present, but the time and 
mode of death are unexpected. We included cases of unwitnessed death if the person was seen in a 
stable medical condition 24 hours preceding death and if there was no evidence of a non-cardiac 
cause of death. We considered both witnessed and unwitnessed SCD cases for the main outcome, 
and conducted a sensitivity analysis excluding participants with unwitnessed SCD. In addition, in 
case of sparse information, cases were labelled as SCD when treating physicians labelled death as 
sudden or unexpected 17. Case validation and definition of SCD has been described earlier in 
previous publications from the Rotterdam Study 17,18. In short, SCD cases were adjudicated by two 
independent reviewers. SCD cases were coded as “possible” if there was insufficient information in 
the medical file regarding the period prior to and until death to code an SCD as “certain”. We 
conducted a sensitivity analysis excluding SCD cases coded as possible. If there was disagreement, 
this was resolved by consensus meetings. All cases were ultimately reviewed by a senior 
cardiologist.  
 
Baseline and other measurements 
Blood pressure was measured twice using a random-zero sphygmomanometer and averaged. 
Hypertension was defined as having a systolic blood pressure > 140 mmHg or a diastolic blood 
pressure > 90 mmHg or using antihypertensives at baseline (diuretics, anti-adrenergic agents, β 
blockers, calcium channel blockers and RAAS inhibitors). Smoking was categorized in current or non-
current smokers. QT-interval was measured on a resting ECG. Heart-rate variability was 
automatically determined by MEANS. We assessed the standard deviation of the normal-to-normal 
RR intervals (SDNN)19: a time-domain HRV marker, based on all the RR intervals on the 10-second 
ECGs. For the analyses with heart-rate variability, we removed ECGs with excessive noise, excessive 
baseline wander, premature ventricular beats, and premature supraventricular beats. Outliers of 
heart-rate variability values were visually checked and discarded if related to poor signal quality. 
Pulse rate was measured twice with a pulse oximeter and averaged. Serum total cholesterol was 
measured using standard laboratory techniques. Diabetes was defined by an impaired fasting 
glucose ≥ 7 mmol/L, non-fasting glucose use ≥ 11.1 mmol/L or use of glucose lowering medication. 
Body-mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. 
Ascertainment of AF in the Rotterdam Study has been described in detail previously 20. In short, it 
was ascertained using three methods 1) ECG’s at baseline and during follow-up, ascertained by a 
cardiologist, 2) medical information obtained from the General Practitioners, after ascertainment of 
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ECG and 3) national registry of hospital discharge diagnosis. Cases of incident HF were obtained by 
continuous monitoring of participants during follow-up through automated linkage with files from 
general practitioners 12,21. All available data on HF, such as hospital discharge letters and notes from 
general practitioners, were copied from the medical records. HF was adjudicated in accordance with 
in accordance with the guidelines of the European Society of Cardiology 22 and included typical signs 
and symptoms of heart failure confirmed by objective evidence of cardiac dysfunction.  
 
Statistical analysis 
We assessed the association of TSH or FT4 at baseline, in separate models, with the risk of SCD both 
in the full and the euthyroid range of thyroid function (defined by TSH 0.4-4.0 mIU/L), using Cox-
proportional hazards model. We also evaluated the risk of SCD according to thyroid state with 
euthyroidism as reference. All primary analyses were sex and age-adjusted. Multivariable models 
additionally adjusted for cohort, pulse rate, hypertension, serum cholesterol, diabetes mellitus, BMI, 
smoking and QT-interval, after applying multiple imputation for missing data of these covariates 
(missingness < 3% for all covariates). Variables in the multivariable models represent the most 
common confounding or mediating factors of the association between thyroid function and SCD. 
Absolute 10 year risk-probabilities were estimated, given the covariates used in the primary Cox-
proportional hazards model, according to the Fine and Gray model 23. This model takes the 
competing risks of death due to all other (non-SCD) causes into account. We also derived the 
subdistribution HRs (SHR) for included variables from this model.  
Pre-defined stratification by sex, age categories and cohort were performed. The cut-off of the age 
categories was 65 years, which is close to the median age of our population. Sensitivity analyses 
included 1) restricting to the analyses euthyroid individuals with witnessed SCDs as outcome 2) 
excluding possible SCD events 3) restricting the analyses to euthyroid subjects with normal FT4 
values and excluding individuals using thyroid medication defined as hormone replacement therapy 
or anti-thyroid drugs (e.g. Methimazole), 4) additionally censoring participants at thyroid medication 
use during follow-up 5) excluding abnormal FT4 values and thyroid function altering medication 
(defined as thyroid medication, amiodarone or corticosteroids) and 6) additionally excluding 
participants with CHD and HF at baseline 7) adjusting the analyses additionally for HRV. We explored 
the possible role of incident AF or HF in the association between thyroid function and SCD by 
censoring the analyses at time of AF or HF. Follow-up data on HF incidence was available in 6893 
participants. Furthermore, we calculated the hazard ratios for total mortality, total cardiovascular 
mortality as well as non-SCD cardiovascular mortality for comparison. The proportional hazards 
assumption was assessed with plots and test of Schoenfeld residuals. The proportional hazards 
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assumption was met for all analyses. We also performed a goodness-of-fit test for the Fine and Gray 
model for the absolute risk estimation, using the Zou Laird Fine test, and this revealed no linear, 
quadratic or log time varying effects of ft4 in the full or euthyroid range (p > 0.35 for all analyses). 
Non-linearity was tested using fractional polynomials and adding quadratic terms to the model. The 
best fit was determined to be linear. TSH was log transformed for all continuous analyses to 
approximate normality while FT4 levels were normally distributed. Fractional polynomials were 
performed using STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP). Schoenfeld plot, Schoenfeld test and competing risk calculations were performed in R 
(survival and cmprsk packages R-project, Institute for Statistics and Mathematics, R Core Team 
(2013), Vienna, Austria, version 3.0.2). All other statistical analyses were performed using SPSS 
version 21 (SPSS IBM, New York, U.S.A). Results of this study are reported according to the STROBE 
statement guidelines 24. 
 
Results 
Baseline characteristics 
We included 10,318 participants with a maximum follow-up of 21.2 years and a median of 9.2 years 
(interquartile range 3.8-11.1). A total of 261 SCD events occurred during follow-up (incidence rate = 
3.1 per 1000 person-years) and completeness of follow-up was 97.9% 25. When restricting to 
euthyroid subjects, there were 231 cases. Of the total number of participants, 10,314 had TSH 
measurements and 10,225 had FT4 measurements. Baseline characteristics are shown in Table 1.  
 
Thyroid function and SCD 
Higher levels of FT4 were associated with an increased risk of SCD with a hazard ratio (HR) of 1.87 
per 1 ng/dL increase of FT4 (95% Confidence Interval [CI], 1.09-2.86) (Table 2). The log relative 
hazard between FT4 and SCD as well as the distribution of FT4 in the population are plotted in 
Figure 1. When restricting to euthyroid subjects, there was an increased risk of SCD events with a HR 
of 2.26 (95% CI , 1.30-3.94). In line with an increased risk for higher FT4 levels, higher TSH levels 
were associated with a concomitant decreased risk but failed to reach statistical significance (HR 
0.92, 95% CI, 0.80-1.04, per one unit increase of natural log transformed TSH). The highest 
compared to the lowest tertile of FT4 had a higher risk of SCD in the full range (HR 1.35, 95% CI, 
1.01-1.83, p for trend 0.022) (Table 3). Sensitivity analyses did not alter risk estimates substantially 
(Table 4). When restricting to euthyroid subjects with normal FT4 values, the absolute 10 year risks 
increased from 1% to almost 4% with increasing FT4 values (Figure 2).  
There seemed to be a differential risk of SCD in different age groups (Supplemental Table 1). 
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However, the number of cases in the younger age category (≤ 65 years) was small and the p for 
interaction (p >0.30) insignificant. Stratification analyses for age, sex and cohort did not show 
differential risks (p for interaction for all analyses > 0.40) (Supplemental Table 1). Participants with 
subclinical or overt hypo- or hyperthyroidism did not have a higher risk of SCD compared to 
euthyroid participants (Supplemental Table 2), but the number of events per category was small. 
Censoring the analyses at time of incident AF or HF did not alter risk estimates meaningfully 
(Supplemental Table 3 and 4), neither did censoring the analyses for both AF and HF (data not 
shown). The SHRs obtained from the competing risk model were slightly more attenuated for all 
variables compared to the HRs obtained from the conventional Cox-proportional hazard model, but 
remained qualitatively similar for the FT4 analyses (Supplemental Table 5). As compared to the SCD 
analyses the risk estimates were slightly higher for non-SCD cardiovascular mortality and slightly 
lower for total mortality (Supplemental Table 6). 
 
 
Table 1. Baseline characteristics of included participants 
Variable Mean (SD)* 
Number of individuals in the study 10,318 
Age, in years 64.7 (9.5) 
Age range, years 46-106 
Women N (%)  5886 (57.0) 
Diabetes mellitus N ( %) 1042 (10.1) 
BMI  27.2 (4.2) 
Cholesterol 5.89 (1.40) 
Smoking current N (%)  2372 (23.0) 
Hypertension N (%) 6142 (59.5) 
Pulse rate 71 (11) 
Median TSH (IQR) mIU/L 1.85 (1.23-2.72) 
FT4 ng/dL 1.23 (0.20) 
Thyroid hormone replacement therapy use N (%) 298 (2.9) 
*unless specified otherwise 
Abbreviations: BMI Body-Mass Index, IQR interquartile range, FT4 free thyroxine, SCD Sudden 
Cardiac Death, SD standard deviation, TSH Thyroid-Stimulating Hormone, N number, TSH is missing 
in 4 participants, FT4 is missing in 93 participants 
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Table 2. Association between thyroid function and the risk of SCD 
Thyroid 
Function 
Measurements 
SCD Events 
Total 
Participants 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
Full range of 
measurement 
     
TSH mIU/L 261 10,314 0.91 (0.80-1.04) 0.91 (0.80-1.03) 0.92 (0.80-1.04) 
FT4 ng/dL 249 10,225 1.87 (1.18-2.96) 1.76 (1.10-2.86) 1.77 (1.09-2.86) 
      
Euthyroid 
participants* 
     
TSH mIU/L 231 8953 0.81 (0.63-1.04) 0.80 (0.62-1.03) 0.80 (0.62-1.04) 
FT4 ng/dL 222 8881 2.54 (1.48-4.40) 2.24 (1.31-4.40) 2.26 (1.30-3.94) 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes, body-mass index and smoking. Model 3: adjusted for sex, age, cohort, pulse 
rate, hypertension, cholesterol, diabetes, body-mass index, smoking and QT-interval. *Euthyroidism is 
defined by TSH 0.4-4.0 mIU/L.  
TSH was log transformed for the continuous analyses, results for TSH are per one unit increase of the 
natural logarithm of TSH and results for FT4 per 1 ng/dL. 
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac death, 
TSH thyroid-stimulating hormone. 
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Table 3. Associations of tertiles of TSH and FT4 with SCD 
 
 
SCD 
Events 
Total 
Participants 
HR (95% CI) 
Model 1 
HR (95% CI)  
Model 2 
HR (95% CI)  
Model 3 
Full range      
 TSH tertiles      
 0.01-1.43 113 3436 REFERENCE REFERENCE REFERENCE 
 1.44-2.36 81 3442 0.88 (0.66-1.17) 0.87 (0.65-1.15) 0.86 (0.65-1.15) 
 2.37-80.64 67 3436 0.78 (0.57-1.05) 0.79 (0.58-1.07) 0.78 (0.58-1.06) 
 P for trend   0.17 0.18 0.18 
       
 FT4 tertiles      
 0.12-1.14 72 3420 REFERENCE REFERENCE REFERENCE 
 1.14-1.29 71 3404 1.03 (0.74-1.43) 1.03 (0.74-1.44) 1.03 (0.74-1.44) 
 1.29-4.73 106 3401 1.39 (1.03-1.87) 1.35 (1.01-1.83) 1.35 (1.01-1.83) 
 P for trend   0.008 0.026 0.022 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking. Model 3: adjusted for sex, age, cohort, 
pulse rate, hypertension, cholesterol, diabetes, body-mass index, smoking and QT-interval. 
*Euthyroidism is defined by TSH 0.4-4.0 mIU/L. FT4 is in ng/dL. 
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac death, 
TSH thyroid-stimulating hormone.  
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Table 4: Sensitivity analyses for association between thyroid function and risk of SCD in euthyroid 
subjects* 
Sensitivity analysis SCD Events Total participants 
HR (95% CI)  
Model 1 
HR (95% CI) 
Model 2 
Restricting to witnessed SCD’s    
TSH mIU/L 133 8953 0.74 (0.53-1.04) 0.74 (0.53-1.03) 
FT4 ng/dL 126 8881 3.36 (1.69-6.66) 3.39 (1.68-6.81) 
     
Excluding possible SCD’s     
TSH mIU/L 195 8953 0.85 (0.65-1.21) 0.84 (0.64-1.11) 
FT4 ng/dL 186 8881 2.20 (1.17-4.15) 2.02 (1.07-3.82) 
 
Excluding abnormal FT4 values† & thyroid medication at baseline ‡  
TSH mIU/L 216 8642 0.83 (0.64-1.08) 0.83 (0.64-1.08) 
FT4 ng/dL 216 8642 3.00 (1.44-6.18) 2.79 (1.34-5.71) 
     
Excluding abnormal FT4 values† & thyroid medication at baseline and censoring participants with 
thyroid medication use at during follow-up‡ 
TSH mIU/L 216 8642 0.83 (0.64-1.08) 0.83 (0.64-1.08) 
FT4 ng/dL 216 8642 2.99 (1.45-6.17) 2.80 (1.34-5.82) 
 
Excluding abnormal FT4 values† and thyroid function altering medication at baseline§ 
TSH mIU/L 206 8519 0.81 (0.62-1.06) 0.81 (0.62-1.06) 
FT4 ng/dL 206 8519 2.42 (1.14-5.16) 2.25 (1.05-4.82) 
     
Excluding abnormal FT4 values†, thyroid function altering medication§ & prevalent HF and CHD 
TSH mIU/L 145 7746 0.80 (0.58-1.09) 0.80 (0.58-1.10) 
FT4 ng/dL 145 7746 2.48 (1.00-6.11) 2.22 (0.95-5.52) 
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Additionally adjusting for HRV 
TSH mIU/L 135 7146 0.91 (0.65-1.28) 0.91 (0.65-1.28) 
FT4 ng/dL 133 7131 3.38 (1.41-8.14) 3.04 (1.27-7.03) 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking.* Euthyroidism is defined by TSH 0.4-
4.0 mIU/L. †Normal range of FT4 0.85-1.95 ng/dL. ‡Thyroid medication is defined as use of thyroid 
hormone replacement therapy or any anti-thyroid drug. §Thyroid function altering medication is 
defined as use of thyroid medication, amiodarone or corticosteroids. 
TSH was log transformed for the continuous analyses, results are per one unit increase of the 
natural logarithm of TSH. Results for FT4 are per 1 unit increase. 
Abbreviations: CHD coronary heart disease, CI confidence interval, FT4 free thyroxine, HF heart 
failure, HR hazard ratio, HRV heart rate variability, SCD sudden cardiac death, TSH thyroid-
stimulating hormone.  
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Figure 1. Log relative hazard plotted against absolute FT4 ng/dL values with historgram of FT4 
distribution in the population 
 
Estimates for the relative hazard were derived using 3 restricted cubic splines with a p for non-
linearity = 0.49 
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Figure 2. Absolute 10-years risks of SCD by FT4 values 
 
Absolute 10-years risks of SCD were calculated taking competing risk of death by other causes into 
account, and are plotted against FT4 values in all participants in the two upper figures and in 
euthyroid participants in the lower two. The normal range of FT4 is highlighted in the two right 
figures. 
FT4 free thyroxine, SCD Sudden Cardiac Death. 
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Discussion 
In the current study, higher FT4 levels were associated with an increased relative and absolute risk of 
SCD, even in the normal range of thyroid function. The relative risk estimates were similar in the 
analyses with only witnessed SCDs as outcome or when excluding prevalent cases of cardiac diseases 
and those using thyroid-function altering medication.  
 This is the first study addressing the association between thyroid function and SCD in the 
general population. Two earlier studies that evaluated the relation between thyroid function and 
SCD were conducted in specific patient populations (HF patients and diabetic hemodialysis patients). 
These studies did not investigate the association of FT4 with SCD and had conflicting results 26,27. The 
SCD-HeFT study, conducted in HF patients, found no difference in SCD risk between TSH categories 
27. The 4D study, investigating 1000 diabetic hemodialysis patients, reported a higher risk of SCD in 
subjects with subclinical hyperthyroidism 26. In the current study, additional adjustment for diabetes 
mellitus at baseline and exclusion of participants with prevalent HF did not alter risk estimates 
substantially. In addition, stratification by age and sex showed no differential risk. This suggests that 
the association of higher FT4 levels with an increased risk of SCD is not driven by a certain subgroup.  
 Thyroid hormone is an important overall regulator of the cardiovascular system 1. The 
pathways through which thyroid hormone can interfere with the cardiovascular system are both 
direct as well as indirect (e.g. cardiovascular risk factors). Thyroid hormone directly influences the 
adrenergic system where it has a stimulatory effect on beta-adrenergic signaling leading to positive 
chronotopic, dromotropic and inotropic effects 28. This hyperdynamic state, which causes many of 
the symptoms in hyperthyroid patients, could be one of the mechanisms explaining the relation 
between thyroid hormone and SCD. Furthermore, thyroid hormones have been shown to lead to QT-
interval prolongation 29,30, which in turn is related to cardiovascular disease in general 31 and SCD in 
particular 18. Another pathway could be through various cardiovascular risk factors related to thyroid 
dysfunction, and thus leading to ischemic heart disease, in turn a large contributor in SCD. 
Subclinical thyroid dysfunction has also been related to CHD and HF In large collaborative individual 
participant efforts2-4. In the current study we did not find evidence for either hypotheses as including 
pulse rate, reflecting a chronotropic effect of adrenergic system stimulation, and various 
cardiovascular risk factors, including QT-interval duration and HRV, did not change risk estimates in 
the multivariable analyses. The exact mechanism for the association between thyroid hormone and 
SCD therefore still needs to be determined. Alternative pathways could be via the effects of thyroid 
hormone on the activity and availability of several cation transporters such as cardiac Na-K-ATPase 
32,33 or via the transcription and translation of several cardiac genes (e.g. α- and β-myosin heavy 
chain genes) 34. 
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 We find an effect of FT4 on the risk of SCD, while the association with TSH is less evident. 
These findings seem to be in line with previous literature investigating the risk of thyroid function on 
several clinical endpoints 14,35-37. Thyroid hormone levels are regulated by the hypothalamus-
pituitary-thyroid axis, which has a unique set point for each individual 38. There is a wide variety of 
factors that can modulate this set point, including illness and ageing. A change in set point over time 
might be an explanation why the association with FT4 is stronger than for TSH. We do not have 
repeated measures of thyroid function and can therefore not investigate if changes in TSH over time 
could explain the apparent discrepant findings between FT4 and TSH.  
We find roughly similar estimates for SCD, (non-SCD) CVD mortality, and total mortality. Similar 
associations for these outcomes are not surprising, since the association between thyroid 
dysfunction and CVD mortality (mainly consisting of CHD mortality) has been described in several 
previous studies and is well established 4,39. Guidelines recommend treatment of subclinical thyroid 
disease from a certain TSH value cut-off mainly based on CHD outcomes from large collaborative 
studies. Cardiovascular diseases are the leading cause of burden of disease and mortality in elderly 
worldwide40. In high-income country, cancer mortality is the second leading cause. Although the 
underlying mechanisms are probably different to CVD mortality, the association of high thyroid 
dysfunction and cancer has been previously described and could therefore also contribute to the 
association found with total mortality. The associations of thyroid function with CVD mortality and 
of thyroid function and SCD seem to both be independent of cardiovascular risk factors. However, 
bigger sample size and more detailed data are needed to determine whether these association share 
the same or have distinct pathways.  
SCD develops within a short timeframe and there is limited time to start intervention and 
cardiopulmonary resuscitation. Therefore, identification of modifiable risk factors is crucial in the 
setting of identification of certain populations or subgroups at risk, as well as screening and 
prevention. In the current study we were not able to demonstrate differential risks by age and sex, 
but the association between thyroid function and SCD was more pronounced within the normal 
range of thyroid function. This can likely be explained by the fact that participants with a thyroid 
function outside the reference range have a higher probability of being treated, which will alter their 
risk. In contrast, people with FT4 levels in the normal range have no indication for treatment and are 
usually stable with very little intra-individual variation, reflecting the individual set point. When we 
exclude those using levothyroxine or anti-thyroid drugs at baseline or during follow-up, risk 
estimates only slightly shift towards the risk in euthyroid participants. However in our study, no 
conclusions on the benefits or risks of thyroid medication can be drawn. Ideally, this should be 
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investigated in a randomized controlled trial.  
 
Strengths and limitations 
Major strengths of our study are the number of participants and covariates included in the analyses. 
All data were collected irrespective of the current hypothesis. Furthermore, we were able to 
phenotype SCD in detail and make a distinction between witnessed and unwitnessed types. The 
setting of a population-based cohort and the long follow-up allowed for estimation of long-term 
absolute risks. Limitations include possible residual confounding and the availability of one baseline 
measurement of thyroid function, not allowing for assessment of temporal changes of TSH and FT4. 
Furthermore, there were a limited number of participants with FT4 values outside the reference 
range (190 participants). The vast majority of participants in the study were of Caucasian descent 
and therefore our results might not be generalizable to other populations.  
 
Conclusions 
In summary, we describe an increased risk of SCD with increasing FT4 levels, even when restricting to 
euthyroid participants. 
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Clinical Perspective 
1) What is new? 
Thyroid dysfunction, even in the subclinical range, is a known risk factor for coronary heart disease, 
but the association with SCD is unknown. In this study, we evaluated the association of thyroid 
function measurements and SCD in over 10,000 participants of a population-based study. In 
participants with a normal thyroid function (i.e. euthyroid participants), we show that higher free 
thyroxine levels are associated with a 2.5-fold increased risk of SCD, independent of cardiovascular 
risk factors. The absolute risk to die from SCD in the upcoming 10 years increased from 1% to 4% 
with higher free thyroxine levels. 
 
2) What are the clinical implications? 
The predictability of sudden cardiac death (SCD) in the general population is poor and almost half of 
the SCD cases are the first presentation of cardiac disease. Therefore, identification of additional risk 
factors for SCD is important. Free thyroxine could be an additive marker in risk prediction and 
screening in the general population. Further research is needed to assess the possible additional 
benefit of the use of FT4 levels in risk stratification for prevention of SCD.  
  
Thyroid Function and Sudden Cardiac Death 
305 
References 
1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. Feb 15 
2001;344(7):501-509. 
2. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary 
heart disease and mortality. Arch Intern Med. May 28 2012;172(10):799-809. 
3. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart 
failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 
Aug 28 2012;126(9):1040-1049. 
4. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of 
coronary heart disease and mortality. JAMA. Sep 22 2010;304(12):1365-1374. 
5. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab. 
Feb 2012;97(2):326-333. 
6. Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. EUR. J. 
ENDOCRINOL. Nov 2012;167(5):609-618. 
7. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 
1998. Circulation. Oct 30 2001;104(18):2158-2163. 
8. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. Jan 31 
2012;125(4):620-637. 
9. Zaman S, Kovoor P. Sudden cardiac death early after myocardial infarction: pathogenesis, 
risk stratification, and primary prevention. Circulation. Jun 10 2014;129(23):2426-2435. 
10. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. Nov 24 1998;98(21):2334-2351. 
11. Wellens HJ, Schwartz PJ, Lindemans FW, et al. Risk stratification for sudden cardiac death: 
current status and challenges for the future. Eur Heart J. Jul 1 2014;35(25):1642-1651. 
12. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and 
design update. Eur J Epidemiol. Nov 2013;28(11):889-926. 
13. Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and 
risk of atrial fibrillation: the Rotterdam study. Arch Intern Med. Nov 10 2008;168(20):2219-
2224. 
14. Chaker L, Buitendijk GH, Dehghan A, et al. Thyroid function and age-related macular 
degeneration: a prospective population-based cohort study - the Rotterdam Study. BMC 
Med. 2015;13:94. 
15. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden 
cardiac death and profiles of risk. Am J Cardiol. Sep 11 1997;80(5B):10F-19F. 
Chapter 3.2 
306 
16. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the 
European Society of Cardiology. Eur Heart J. Aug 2001;22(16):1374-1450. 
17. Niemeijer MN, van den Berg ME, Leening MJ, et al. Declining incidence of sudden cardiac 
death from 1990-2010 in a general middle-aged and elderly population: The Rotterdam 
Study. Heart Rhythm. Jan 2015;12(1):123-129. 
18. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac 
death in a population of older adults. J Am Coll Cardiol. Jan 17 2006;47(2):362-367. 
19. Malik M. Time-Domain Measurement of Heart Rate Variability. Cardiac Electrophysiology 
Review. 1997:3:329–334. 
20. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial 
fibrillation: the Rotterdam study. Eur Heart J. Apr 2006;27(8):949-953. 
21. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: 
prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. 
Eur Heart J. Sep 2004;25(18):1614-1619. 
22. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic 
heart failure: executive summary (update 2005): The Task Force for the Diagnosis and 
Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. Jun 
2005;26(11):1115-1140. 
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. 
Journal of the American Statistical Association. Jun 1999;94(446):496-509. 
24. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. 
Ann Intern Med. Oct 16 2007;147(8):573-577. 
25. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 
Apr 13 2002;359(9314):1309-1310. 
26. Drechsler C, Schneider A, Gutjahr-Lengsfeld L, et al. Thyroid function, cardiovascular events, 
and mortality in diabetic hemodialysis patients. Am J Kidney Dis. Jun 2014;63(6):988-996. 
27. Mitchell JE, Hellkamp AS, Mark DB, et al. Thyroid function in heart failure and impact on 
mortality. JACC Heart Fail. Feb 2013;1(1):48-55. 
28. Silva JE, Bianco SD. Thyroid-adrenergic interactions: physiological and clinical implications. 
Thyroid. Feb 2008;18(2):157-165. 
29. Owecki M, Michalak A, Nikisch E, Sowinski J. Prolonged ventricular repolarization measured 
by corrected QT interval (QTc) in subclinical hyperthyroidism. Horm Metab Res. Jan 
2006;38(1):44-47. 
Thyroid Function and Sudden Cardiac Death 
307 
30. van Noord C, van der Deure WM, Sturkenboom MC, et al. High free thyroxine levels are 
associated with QTc prolongation in males. J Endocrinol. Jul 2008;198(1):253-260. 
31. Nielsen JB, Graff C, Rasmussen PV, et al. Risk prediction of cardiovascular death based on the 
QTc interval: evaluating age and gender differences in a large primary care population. Eur 
Heart J. May 21 2014;35(20):1335-1344. 
32. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. May 
1993;87(5):1435-1441. 
33. Shao Y, Ojamaa K, Klein I, Ismail-Beigi F. Thyroid hormone stimulates Na, K-ATPase gene 
expression in the hemodynamically unloaded heterotopically transplanted rat heart. 
Thyroid. Sep 2000;10(9):753-759. 
34. Klein I, Danzi S. Thyroid disease and the heart. Circulation. Oct 9 2007;116(15):1725-1735. 
35. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal changes 
in thyroid function in the oldest old and survival: the cardiovascular health study all-stars 
study. J Clin Endocrinol Metab. Nov 2012;97(11):3944-3950. 
36. Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine 
concentration and atrial fibrillation. Arch Intern Med. May 14 2007;167(9):928-934. 
37. Chaker L, Heeringa J, Dehghan A, et al. Normal Thyroid Function and the Risk of Atrial 
Fibrillation: the Rotterdam Study. J Clin Endocrinol Metab. Oct 2015;100(10):3718-3724. 
38. Meier CA, Maisey MN, Lowry A, Muller J, Smith MA. Interindividual differences in the 
pituitary-thyroid axis influence the interpretation of thyroid function tests. Clin Endocrinol 
(Oxf). Jul 1993;39(1):101-107. 
39. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk 
for coronary heart disease and mortality. Ann Intern Med. Jun 3 2008;148(11):832-845. 
40. Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for 
health policy and practice. Lancet. Feb 7 2015;385(9967):549-562. 
 
 
 
 
 
 
 
 
  
Chapter 3.2 
308 
Supplemental table 1. Stratified associations for thyroid function and SCD  
Stratification 
variables 
Thyroid Function 
Measurement 
SCD events 
/participants 
HR (95% CI),  
Model 1 
HR (95% CI), 
 Model 2 
Age categories TSH mIU/L    
≤ 65 years  68/5871 1.08 (0.79-1.48) 1.09 (0.93-1.28) 
> 65 years  193/4443 0.88 (0.77-1.01) 0.87 (0.77-1.00) 
 P for interaction  0.31 0.31 
     
 FT4 ng/dL    
≤ 65 years  66/5855 0.80 (0.23-2.86) 0.75 (0.21-2.69) 
> 65 years  183/4370 2.28 (1.37-3.74) 2.09 (1.26-3.49) 
 P for interaction  0.74 0.60 
     
Sex TSH mIU/L    
Men   139 / 4432 0.92 (0.75-1.13) 0.91 (0.74-1.13) 
Women  122 / 5882 0.91 (0.78-1.07) 0.91 (0.78-1.08) 
 P for interaction  0.93 0.93 
     
 FT4 ng/dL    
Men  132/4397 2.48 (1.05-5.84) 2.30 (0.96-5.46) 
Women  117/5828 1.64 (0.90-2.96) 1.50 (0.81-2.82) 
 P for interaction  0.43 0.42 
     
Cohort TSH mIU/L    
I  210/4453 0.94 (0.81-1.08) 0.92 (0.80-1.07) 
II  42/2477 0.89 (0.64-1.23) 0.93 (0.79-1.09) 
III  9/3451 0.69 (0.37-1.26) 0.74 (0.54-1.01) 
 P for interaction  0.51 0.58 
     
 FT4 ng/dL    
I  198/4335 1.84 (1.13-3.00) 1.83 (1.08-3.10) 
II  42/2466 2.30 (0.49-10.93) 2.43 (0.70-8.47) 
III  9/3424 2.71 (0.08-97.26) 3.02 (0.53-17.06) 
 P for interaction  0.87 0.72 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking. TSH was log transformed for the 
continuous analyses, results are per one unit increase of the natural logarithm of TSH. Results for 
FT4 are per 1 ng/dL increase. Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard 
ratio, SCD sudden cardiac death, TSH thyroid-stimulating hormone. 
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Supplemental table 2: Thyroid function and SCD risk 
Thyroid Function Measurement SCD events Participants HR (95% CI),  
Model 1 
HR (95% CI),  
Model 2 
     
Hypothyroidism 4 80 1.59 (0.59-4.29) 1.53 (0.57-4.16) 
Subclinical hypothyroidism 14 945 0.64 (0.37-1.10) 0.65 (0.38-1.12) 
Euthyroidism 231 9006 REFERENCE REFERENCE 
Subclinical hyperthyroidism 11 312 1.02 (0.56-1.88) 1.05 (0.57-1.93) 
Hyperthyroidism 1 32 1.40 (0.20-10.00) 1.18 (0.16-8.48) 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking. 
Abbreviations: CI confidence interval, HR hazard ratio, SCD sudden cardiac death 
 
 
Supplemental Table 3: Association between thyroid function and the risk of SCD when censoring for 
incident atrial fibrillation 
Thyroid function 
measurements 
SCD 
Events 
Total 
participants 
HR (95% CI), 
Model 1 
HR (95% CI), 
Model 2 
HR (95% CI),  
Model 3 
Full range of 
measurement 
     
TSH mIU/L 238 10,314 0.94 (0.82-1.08) 0.94 (0.82-1.08) 0.93 (0.81-1.07) 
FT4 ng/dL 228 10,225 1.91 (1.17-3.11) 1.85 (1.11-3.09) 1.85 (1.10-3.09) 
      
Euthyroid participants*      
TSH mIU/L 211 8953 0.87 (0.67-1.14) 0.87 (0.66-1.13) 0.86 (0.66-1.13) 
FT4 ng/dL 203 8881 2.91 (1.56-5.44) 2.61 (1.40-4.88) 2.60 (1.39-4.87) 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking. Model 3: adjusted for sex, age, cohort, pulse 
rate, hypertension, cholesterol, diabetes, body-mass index, smoking and QT-interval. *Euthyroidism is 
defined by TSH 0.4-4.0 mIU/L.  
TSH was log transformed for the continuous analyses, results are per one unit increase of the natural 
logarithm of TSH. Results for FT4 are per 1 ng/dL increase. 
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac death, TSH 
thyroid-stimulating hormone. 
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Supplemental Table 4: Sensitivity analysis of the association between thyroid function and the risk of SCD in those 
with follow-up data on incident heart failure available 
Thyroid function measurements 
SCD 
Events 
Total 
participants 
HR (95% CI), 
Model 1 
HR (95% CI), 
Model 2 
HR (95% CI),  
Model 3 
      
All participants with incident heart failure data  
Full range of measurement      
TSH mIU/L 252 6892 0.92 (0.81-1.05) 0.92 (0.81-1.05) 0.92 (0.80-1.05) 
FT4 ng/dL 240 6801 1.87 (1.17-2.98) 1.77 (1.09-2.87) 1.77 (1.08-2.88) 
      
Euthyroid participants*      
TSH mIU/L 222 5898 0.83 (0.64-1.07) 0.83 (0.64-1.07) 0.83 (0.64-1.07) 
FT4 ng/dL 213 5827 2.57 (1.49-4.54) 2.29 (1.31-4.01) 2.29 (1.31-4.02) 
      
Censoring at time of incident heart failure 
Full range of measurement      
TSH mIU/L 210 6892 0.93 (0.81-1.07) 0.93 (0.80-1.07) 0.93 (0.80-1.07) 
FT4 ng/dL 202 6801 1.80 (1.07-3.02) 1.69 (0.98-2.91) 1.69 (0.98-2.91) 
      
Euthyroid participants*      
TSH mIU/L 183 5898 0.81 (0.61-1.07) 0.81 (0.61-1.07) 0.81 (0.61-1.07) 
FT4 ng/dL 177 5827 2.48 (1.34-4.59) 2.23 (1.20-4.15) 2.23 (1.19-4.16) 
Model 1: adjusted for sex and age. Model 2: adjusted for sex, age, cohort, pulse rate, hypertension, cholesterol, 
diabetes mellitus, body-mass index and smoking. Model 3: adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index, smoking and QT-interval. *Euthyroidism is defined by TSH 0.4-4.0 
mIU/L. TSH was log transformed for the continuous analyses, results are per one unit increase of the natural 
logarithm of TSH. Results for FT4 are per 1 unit increase. 
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac death, TSH thyroid-
stimulating hormone. 
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Supplemental Table 5: Methodological sensitivity analysis for the association of thyroid function, 
age and sex with the risk of SCD 
Model variables 
SCD 
Events 
Total 
participants 
HR (95% CI), 
Model 1 
SHR (95% CI), 
Model 1 
Full range of measurement of thyroid function 
FT4 ng/dL 249 10,225 1.87 (1.18-2.96) 1.65 (1.02-2.69) 
Age per year 249 10,225 1.09 (1.08-1.09) 1.05 (1.03-1.06) 
Sex (female vs male) 249 10,225 0.51 (0.46, 0.57) 0.60 (0.47,0.77) 
     
Euthyroid participants*     
FT4 ng/dL 222 8881 2.54 (1.48-4.40) 2.10 (1.20-3.68) 
Age per year 222 8881 1.09 (1.08-1.10) 1.05 (0.03-1.07) 
Sex (female vs male) 222 8881 0.51 (0.46, 0.57) 0.59 (0.45-0.77) 
Model 1: including, FT4, age and sex. *Euthyroidism is defined by TSH 0.4-4.0 mIU/L. Results for FT4 
are per 1 ng/dL. HR are obtained from a Cox-proportional Hazards Model, SHR are obtained from 
the estimates of a competing risk model taking death by other causes into account.  
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac 
death, SHR subdistribution hazard ratio, TSH thyroid-stimulating hormone. 
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Supplemental Table 6: Comparison analysis for the association of thyroid function, 
with the risk of SCD, CVD mortality non-SCD CVD mortality and total mortality 
 
HR (95% CI), 
CVD deaths 
HR (95% CI), 
CVD non-SCDs 
HR (95% CI), 
Total mortality 
Full range of measurement of thyroid function  
FT4 ng/dL 1.88 (1.69-2.08) 1.93 (1.71-2.18) 1.67 (1.57-1.78) 
    
Euthyroid participants*   
FT4 ng/dL 2.47 (2.19-2.79) 2.58 (2.24-2.97) 2.08 (1.92-2.25) 
These analyses are adjusted for sex, age, cohort, pulse rate, hypertension, 
cholesterol, diabetes, body-mass index, smoking and QT-interval. *Euthyroidism is 
defined by TSH 0.4-4.0 mIU/L. Results for FT4 are per 1 ng/dL. From the total of 
10.381 participants, 611 had a non-SCD CVD death and 872 total CVD deaths. There 
were 2541 deaths in total.  
Abbreviations: CVD cardiovascular disease, CI confidence interval, FT4 free 
thyroxine, HR hazard ratio, SCD sudden cardiac death,  
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Overview 
The overarching goal of this thesis was to contribute to the knowledge of electrocardiographic (ECG) 
markers for the risk assessment of sudden cardiac death (SCD). ECG markers are commonly used for 
research and in the clinic, but their capability to predict SCD is still less than perfect.1 To improve the 
situation, new ECG markers have been (and are being) devised, e.g. QT variability, but these have to 
be studied intensively before they can be put to practical use by clinicians. Necessary studies include 
analyses of the associations of a marker with cardiac morbidity and mortality, and studies of a 
marker’s dependence on and correlation with other markers, most importantly heart rate. Studies of 
normal limits of a marker can be used to set optimal cut-off values for risk stratification. 
 
Definition of SCD 
One of the hurdles in the study of SCD is its definition. The most commonly used definition stipulates 
that SCD is a natural unexpected death due to cardiac causes that occurs within one hour of the 
onset of acute symptoms.2 This definition has obvious limitations: the interval of one hour is 
arbitrary and not grounded in any study linking the time frame to underlying pathology. Also, it does 
not go into the various causes and is not concerned with a differentiation between arrhythmias 
directly leading to SCD, like ventricular tachycardia and ventricular fibrillation (VT/VF), pulseless 
electric activity (PEA), and asystole.3 In most studies the culprit rhythm of the vast majority of SCD 
cases is unknown, so it is evident that the definition of SCD is based on practicality rather than on 
pathology and physiology. A practical adaptation to the definition of SCD is the inclusion by many 
studies of unwitnessed cases.4 In the definition for the unwitnessed cases, death has occurred in a 
person observed to be in a stable medical condition for at least 24 hours before discovery, and in 
whom a non-cardiac cause has not been found. Again, the time frame is grounded in common sense 
and educated opinion, but has no evidential support. It could be argued that there is more 
misclassification of unwitnessed cases due to the inherent lack of information about symptoms 
before death. However, whether a case of sudden death is witnessed or not is essentially a matter of 
chance, and by excluding all unwitnessed cases the incidence of SCD is probably underestimated. 
Future studies could significantly improve upon this by recording the rhythm before death: large-
scale unobtrusive ECG monitoring in high-risk groups could yield the necessary empirical data. This 
material could also be used to empirically ground the time frame used in the definition of SCD. 
 
Validation of SCD 
SCD cases can be ascertained either by retrieving and scrutinizing medical records immediately after 
death, or by using death certificates. Unfortunately, death certificates often lack information 
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concerning the circumstances of death, and it was discovered that the use of death certificates leads 
to an overestimation of the SCD incidence.4 More importantly, SCD cases ascertained by death 
certificates correlated poorly with physician diagnoses.4 Most papers referred in this thesis used 
data from the Rotterdam study using a two-step prospective method of SCD ascertainment and 
validation. This process is described in detail in Figure 1. The initial ICD10 [International statistical 
classification of diseases and related health problems, 10th revision] coding was performed by a 
study physician and validated by a medical specialist pertinent to the field. For validation of SCD, the 
medical files of deaths associated with relevant ICD10 codes were selected for a second review by 
two physicians working independently. The relevant ICD10 codes were mainly cardiac causes of 
death, but also included deaths due to strokes. We checked the strokes to make sure that none of 
them were misclassified cardiac deaths. Suspected SCD cases were reviewed and discussed in 
consensus meetings with an experienced cardiologist. Using this methodology, we found an 
incidence of SCD in the Rotterdam Study that was comparable to the incidence found in other 
studies (42 per 1000 person-years).5 
Although the use of witnessed SCD cases only is too restrictive, suppletion with unwitnessed 
cases is likely to introduce misclassification due to the relative dearth of information about the 
circumstances at death. For that reason, it is advisable to use only the witnessed SCDs in sensitivity 
analyses. 
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Figure 1: Flowchart of ascertainment of SCD cases 
 
 
Abbreviations: SCD: Sudden cardiac death, ICD10: International statistical classification of diseases 
and related health problems, 10th revision 
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Re-evaluating the heart-rate correction of established ECG markers 
Bazett’s formula for heart-rate correction of the QT interval overestimates the QTc at higher heart 
rates,6,7 It is nevertheless still the most used QT correction formula in practice. Chapter 1.3 highlights 
one of the problems that can occur when using a biased heart-rate correction: when we studied the 
effects of tricyclic antidepressants on the QT interval, we found that QTc Bazett was spuriously 
increased due to the concomitant increase in heart rate caused by these drugs. When we used QTc 
according to Fridericia, no such increase appeared. Heart-rate variability (HRV) is another ECG 
marker known to have a strong association with heart rate.8,9 One study showed this association to 
be exponential, which would imply that the usual adjustment for heart rate by adding heart rate as a 
covariable in a linear regression model (as, for example, done by De Bruyne et al. in the Rotterdam 
study population10) is misleading. When we determined normal values for HRV for all ages, we at 
first noticed a very low value in infancy. This is counterintuitive because low HRV is usually 
associated with increased cardiovascular risk.11-13 Thereupon we estimated the exponential 
correction parameter separately for predetermined age groups, and then computed an inverse-
variance-weighted average. After correction for heart rate in this manner, HRV proved to 
continuously decrease from birth to old age, as was expected. One might ask whether the results of 
previous work on HRV in the Rotterdam study and in other population-based studies would not 
come out differently when repeated with the new heart-rate corrected markers. Future work could 
focus on the interplay of age, heart rate, and HRV with cardiovascular morbidity and mortality. Our 
observations show that even established markers like QT and HRV need critical revision. 
 
QT variability: a promising new marker for SCD 
The main marker studied in this thesis is QT variability. QT variability is a measure of the beat-to-
beat changes in the duration of the QT interval. This temporal variability is thought to be a measure 
of instability in the repolarisation of the cardiac ventricles, and therewith of the risk of arrhythmias 
leading, in the worst case, to SCD.14 A number of encouraging animal studies indicated (I) that an 
increased QT variability had a higher sensitivity and specificity for the prediction of torsade de 
pointes [a specific ventricular arrhythmia] than QT interval prolongation,15 and (II) that QT variability 
was consistently increased in animals treated with drugs of a known arrhythmogenic potential.16 The 
first step in our study of QT variability was to review all relevant investigations in humans (chapter 
2.1). We found 109 publications that covered QT variability. The majority of these studies found 
associations between QT variability and cardiac morbidity, cardiac mortality and SCD. Also, a higher 
QT variability was found to accompany the use of potentially arrhythmogenic QT prolonging drugs. It 
should be noted that the median sample size of the 109 studies in humans was 48 participants, and 
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that the largest study consisted of a mere 805 participants. Moreover, most studies were conducted 
in specific patient populations and no study was carried out in a community-dwelling population. 
Therefore, although QT variability is a promising feature, there is still room for improvement with 
studies in population-based cohorts using a consistent methodology for all ECGs. 
 
Fiducial segment averaging 
The sample sizes reported in chapter 2.1 were small because the researchers probably did not have 
a fast automatic method to measure all QT intervals on an ECG recording. The most commonly-used 
method was first proposed by Berger et al.14 This method was based on template matching, and had 
to be primed by human interaction for each ECG. To be able to study QT variability in larger 
numbers, we employed an automated fiducial segment averaging (FSA) algorithm as shown in 
chapter 2.2. FSA uses the coherence of subsequent beats in small segments around so-called fiducial 
points in the ECG signal, in our case the beginning of the Q wave and the end of the T wave, in order 
to determine the location of these points more accurately with less sensitivity to noise. Our FSA 
algorithm is an automated version of the semi-automatic measurement process devised by Ritsema 
van Eck.17 
 
Consecutive vs. non-consecutive QT variability 
Using the FSA algorithm, we were able to determine all nine different formulas for QT variability 
found in our literature review quickly and easily on a large number of standard 10-second ECGs. For 
reasons of practicality we focused on the most commonly used makers and did not analyse all nine, 
noting that several markers were statistically equivalent in theory (like SDqt = √QTvar) or highly 
correlated in practice. However, one fundamental difference between QT variability formulas was of 
special interest: on the one hand formulas based on the beat-to-beat variability (called consecutive 
QT variability, e.g. STVqt) and on the other hand formulas based on variability compared to the 
mean (non-consecutive QT variability, e.g. SDqt). It is not apparent which of these formulas result in 
markers that better reveal repolarisation instability and are better predictors of ventricular 
arrhythmias. One study proposed that only consecutive QT variability would be arrhythmogenic and 
that non-consecutive QT variability would be the result of low-frequency changes caused by 
respiration and fluctuations of autonomic tone.18 
At variance with this idea, we found in chapter 2.4 that SDqt and STVqt are strongly correlated 
(Pearson correlation coefficient of 0.96), and that the results of SDqt and STVqt are similar in almost 
all analyses performed in this thesis. 
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 A possible explanation of the high correlation between SDqt and STVqt in our measurements 
lies in the use of 10-second ECGs. For longer ECG signals, low-frequency variability would increase 
SDqt but not STVqt. This is illustrated in figure 2, where we simulated 1000 subsequent QT intervals 
with and without (exaggerated) long-term low-frequency changes. Introducing low-frequency 
changes did not materially increase either SDqt or STVqt when calculated over the first 30 beats, but 
when calculated over all 1000 beats, SDqt almost doubled while STVqt stayed the same. Incidentally, 
Feeny et al.19 found a high concordance (Lin’s rho 0.79) of STVqt based on a three-minute recording 
and STVqt based on a 10-second recording, which is in line with this simulation. These results show 
that STVqt does not increase in response to low-freqency changes, no matter the recording length 
and that SDqt only increases in response to low-freqency changes when the ECG recording is long 
enough to show them. 
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Figure 2. Comparing consecutive and non-consecutive QT variability on long and short simulations.
 
 
Top left figure: simulated QT intervals based on a normal distribution with mean 400 and standard 
deviation of 2. Top right figure: the same simulated QT intervals from the top figure but with added 
low-frequency changes with amplitude of 5 milliseconds and a period of 1000 beats. Bottom figure: 
simulated values of SDqt and STVqt for the different scenarios. 
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QT variability: normal limits and association with SCD 
As recommended in chapter 2.1, we conducted population-based studies of QT variability. An 
important but often overlooked aspect of any marker resides in its normal limits. Usually, a new 
biomarker is only evaluated by its distribution in a population (and log-transformed if necessary to 
create a normal distribution). But ideally, we think, the study of normal limits should be performed 
in population-based cohorts, covering all ages and both sexes with sufficient numbers in each 
category, using the same methodology for all participants. This was what we attempted for HRV in 
chapter 1.1 and for QT variability in chapter 2.3. Previous studies of normal values often 
retrospectively collected and meta-analyzed data from a large number of previous studies. Nunan et 
al.20 did this for heart rate variability and Baumert et al.21 for QT variability. Unfortunately, these 
meta-analyses too often yield limited information - despite the large collective sample size - and 
suffer from methodological variation between the component studies. The normal values in these 
meta-analyses are often derived from healthy controls from case-control studies, who tend to be too 
young and fit to be representative of the general normal population. In any case, these retrospective 
normal-limit studies do not report continuous change of the studied marker with age. The main 
additional worth of our normal-value studies of QT variability and HRV lies in showing the changes 
over all life stages for both sexes. Future research of new markers could incorporate more large-
scale normal value studies, and address other fundamental factors of influence on ECG markers like 
ethnicity. 
 
Creating a prediction model for SCD 
In chapter 2.4 we analyzed the association of QT variability with SCD in the general population, and 
found that QT variability was a significant risk factor for witnessed SCD, but only in women. In 
addition we adjusted for the ECG variables heart-rate, HRV and QT interval, but we did not address 
how QT variability performs compared to other ECG variables. As Wellens et al.1 show, there is a 
long list of ECG variables that have been found to have prognostic value, but no study has really 
compared and combined them. We therefore set out in chapter 2.5 to find the additional value of 
ECG markers to a prediction model for SCD based on clinical risk factors. A prediction model ideally 
specifies which variables are important and which must be left out. This signifies that one must 
choose the right candidate ECG markers before creating a model at all.22 A previous study that 
created a prediction model for SCD considered six candidate ECG markers, viz. atrial fibrillation, 
Cornell voltage, QTc interval, QRS interval, heart rate and left bundle branch block, of which only the 
QTc interval was selected. This paper did not assess the value of the ECG in addition to other risk 
factors.23 However, in our opinion six candidate ECG markers is not nearly enough: a large number of 
General Discussion 
324 
ECG markers have been described in the literature (for example, Kors et al. cover 18 repolarization 
markers derived from the ECG in one paper alone!24) and one marker can be expressed in multiple 
ways, e.g. the QT interval has many derivative markers, each with a different heart-rate correction.6 
Hence, we started our modeling with 24 candidate ECG markers that had been significantly 
associated with cardiac death or SCD in previous studies. Starting with 24 candidate markers we 
found that a model with six ECG markers (heart rate, Sokolow-Lyon index, spatial J amplitude, 
amplitude of the T wave in lead aVR, right bundle branch block, and SDNN adjusted for heart rate) 
and six clinical risk factors (age, sex, total cholesterol/HDL cholesterol ratio, smoking, diabetes 
mellitus and use of renin-angiotensin system blockers) performed better in the prediction of SCD 
than a model with clinical risk factors alone. This shows that the ECG has its own contribution to 
make in SCD risk prediction. We were hampered however, by the small number of SCD cases (n = 
149) and the lack of a validation cohort. Some variables were unexpectedly eliminated. To our 
surprise, QT variability, the main topic of chapter 2.4, and the QTc interval, a commonly used and 
well-studied predictor of SCD,25 were not selected in the SCD prediction model of chapter 2.5. This 
suggests that both QTc and QT variability are weak predictors of SCD. A possible explanation lies in 
the heterogeneous nature of SCD. As Albert et al. show in survivors of cardiac arrest, there are a 
number of different causes of SCD in the general population,26 and we surmise that QTc and QT 
variability are associated with only one or a small subset of these causes. For the marker QTc the 
specific cause would be ventricular arrhythmias like torsade de pointes, associated with use of QTc 
prolonging drugs27 or congenital long-QT syndromes.28 Thus, these conditions are only responsible 
for a small number of cases of SCD in the general population, although QTc is an important predictor 
in users of QTc prolonging drugs and in people with congenital long QT-syndromes.29 We conjecture 
that an increased QT variability is associated with a high risk of SCD mainly in patients with cardiac 
hypertrophy and associated heart failure. To test this hypothesis in the general population, we 
analyzed the association of QT variability with heart failure, the result of which was that QT 
variability has a stronger association with heart failure than with SCD, the estimate of the 
multivariate adjusted hazard ratio of STVqt being 1.06 for SCD and 1.36 for heart failure. Although 
the association of QT variability with witnessed SCD was only significant in women, the association 
of QT variability with heart failure came out similar in both sexes. 
The investigation of the different underlying causes and their determinants is a challenge for 
the future of SCD prevention. The inherently capricious nature of SCD makes it difficult to 
investigate, but some advancements have been made with the help of molecular autopsies.30 A 
molecular autopsy is the analysis of genes encoding for cardiac ion channels in suddenly deceased 
persons with no other discernable cause found during regular autopsy.31 This can also be done by 
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proxy by analyzing the genes of first- or second degree relatives of the patient.32 Another 
opportunity would be unobtrusive ECG monitoring of at-risk groups. Current clinical use of QT 
variability is limited, but based on the previously mentioned clinical studies and the normal limits of 
QT variability determined in chapter 2.3, clinicians could use QT variability as an additional measure 
of SCD risk stratification in the general population. Future studies could address the specific 
pathways leading to SCD. Examples are studies of the association of drugs with QT variability and risk 
of SCD and studies of SCD risk among heart failure patients or among patients with cardiac 
hypertrophy. 
Future aims in SCD research should be the combination of SCD cohorts in order to gain a 
larger combined sample size and testing of the model in other databases and other populations. 
Ideally the ascertainment of SCD cases should be done by identical criteria. In the field of genetic 
studies, this has already been accomplished: in the CHARGE consortium, a large genome-wide 
association study of genetic determinants of SCD, data from 10 cohorts were combined, creating a 
sample size of 4,496 SCD cases and over 25,0000 controls (manuscript in preparation in the CHARGE 
consortium). A similar set-up for the study of novel ECG markers would vastly improve the study of 
ECG markers and SCD. It would also allow for the creation of a general prediction model for SCD with 
more power. 
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Coronary heart disease is the number one cause of death globally.1 Half of all cases of coronary heart 
disease occur suddenly and unexpectedly, and half of those cases occur in people without a previous 
history of cardiac disease. This is why prediction of sudden cardiac death (SCD) in the general 
population is of great importance. The electrocardiogram (ECG) is already used as a tool to predict 
SCD,2 but it has not yet reached its full potential. The prediction of SCD could be improved by further 
study of ECG markers. This is the aim of this thesis: to explore and expand the use of the ECG in the 
prediction of SCD, in particular with respect to QT variability and heart-rate variability. 
In the first section, we began with a closer examination of ECG markers already commonly 
used in clinical practice. The first ECG marker that we explored was heart-rate variability. Low heart-
rate variability is a known risk factor for cardiac disease and SCD.3,4 We explored two issues with this 
marker. The first issue is the lack of comprehensive age- and sex dependent normal limits. We 
addressed this by determining age-dependent and sex-specific normal values for heart-rate 
variability in chapter 1.1. In this study, we applied a novel exponential heart-rate correction formula 
to remove the effect of heart rate on heart-rate variability. In chapter 1.2, we addressed an issue 
with heart-rate variability in psychiatry. It is known that patients with anxiety and depression have 
an increased risk of acute myocardial infarction,5,6 but it is unknown if the treatment with 
antidepressants might be partially responsible for this. Because heart-rate variability is associated 
with cardiovascular disease, 3,4 it is of interest to know what the interrelation is between depression, 
antidepressants and heart-rate variability. There are two opposing papers in the literature. One of 
these reported that depression lowers heart-rate variability 7 and the other one that antidepressants 
lowers heart-rate variability.8,9 The main limitations of both studies were the cross-sectional study 
designs and the lack of reporting on dose-response relationships. Our study in chapter 1.2 was 
longitudinal and did assess dose-response relationships. We found that tricyclic antidepressants 
(TCAs) lower heart-rate variability, independently from heart-rate and depressive symptoms, while 
the evidence for selective serotonin reuptake inhibitors (SSRIs) was weaker, although there was a 
dose-response relationship of the SSRI paroxetine with a lower heart-rate variability. The next 
commonly used ECG marker that was examined more closely was the QT interval. A prolonged QT 
interval is a well-known risk factor for SCD.10 Many formulas have been proposed to correct the QT 
interval for its dependency on heart rate. Two commonly used formulas were proposed by Bazett11 
and Fridericia,12 already in the 1920s. The importance of heart-rate correction is notable in those 
cases where heart rate can be a confounder, in our case when testing drugs that influence the heart 
rate. Inaccurate correction for heart rate might underestimate or overestimate the heart-rate 
corrected QT interval (QTc), and thus give false-positive results. This is illustrated in chapter 1.3: 
TCAs are known to increase the heart rate,13 and also are suspected of increasing the QTc,14 
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potentially increasing the risk of SCD. However, we found that the increased QTc associated with use 
of TCAs was based on overestimation of the QTc when using Bazett’s formula. When we used 
Fridericia’s formula, there was no QTc prolongation. We concluded that it is preferable to use that 
formula in future studies. 
The second section of this thesis focused on the ECG marker QT variability. QT variability 
denotes the variability of QT-interval durations of individual beats on the ECG. It is thought to be 
indicative of repolarization instability, and thus to be predictive of ventricular arrhythmias and SCD.15 
In chapter 2.1 we show a review of all relevant papers that had previously studied QT variability. The 
review revealed that short-term QT variability had already been studied in over 100 papers, using 
nine different formulas for QT variability. However, we also noted a number of shortcomings in 
these papers: the studies were conducted either in selected healthy volunteers or in specific patient 
populations - not in the general population, where prediction of SCD is needed most. A second 
concern was the limited population size of these studies. It is possible that the population sizes were 
limited by the lack of an accurate and automatic method to measure all QT intervals on an ECG. To 
address this problem, we introduced in chapter 2.2 an automatic implementation of the fiducial 
segment averaging (FSA) algorithm devised by Ritsema van Eck.16 The FSA algorithm is a relatively 
novel approach to accurately and automatically measure individual QT intervals on the ECG. What 
we did in chapter 2.2 was to propose a new method of validation of QT interval measurements. We 
simulated QT interval variability together with noise, baseline wander and signal-length variations in 
a signal based on the averaged P-QRS-T complexes of existing ECG recordings. In this set we 
compared the performance of a conventional QT variability measurement algorithm with that of 
FSA, and showed that FSA is more accurate than the conventional method. 
 We explored QT variability further in the next chapters. In chapter 2.3, we reported 
comprehensive age-and sex dependent normal limits of QT variability as measured on the 10-second 
ECG. We were the first to do this on such a large (>14,000 ECGs) dataset of 10-second ECGs.17 In 
chapter 2.4 we studied the association of four QT-variability markers (QTVI, SDqt, STVqt, and 
RMSSDqt) with total mortality, coronary heart disease (CHD) mortality, SCD, and witnessed SCD. We 
found that these markers were associated with total mortality, CHD mortality, and with witnessed 
SCD, but the latter only in women and not in men. We noted that SDqt, STVqt, and RMSSDqt were 
highly correlated, which we thought is due to the shortness of the ECG signal. QTVI had a weaker 
correlation with the other three QT-variability markers due to its correction for QT interval, heart 
rate, and heart-rate variability. QTVI performed worse (i.e., had a weaker and non-significant 
association with clinical endpoints) than the three uncorrected markers. In chapter 2.5, we 
addressed a limitation of many studies of ECG markers pointed out by Wellens et al,18 namely that 
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markers are often studied in isolation, adjusted for only a limited set of other ECG markers or clinical 
risk factors. Therefore, we created a prediction model for SCD to assess the additional value of 24 
ECG markers over a model based on only clinical risk factors. After a backwards stepwise elimination 
procedure, six clinical risk factors were selected: age, sex, total/HDL cholesterol ratio, smoking, 
diabetes mellitus, and use of agents acting on the renin-angiotensin system. A second backwards 
elimination procedure with the 24 ECG markers as input and keeping the six clinical risk factors fixed, 
resulted in a combined model with six clinical risk factors and six additional ECG markers. The 
selected ECG markers in question were heart rate, Sokolow-Lyon index, spatial J amplitude, T 
amplitude in lead aVR, right bundle branch block, and heart-are corrected SDNN. We found that 
these ECG markers significantly improved the discrimination of the model for predicting SCD. We 
also noted the limitations of creating a prediction model with limited data. In the future, this might 
be addressed by combining cohorts that study SCD on an international scale. In the last two chapters 
of the second section, we explored how QT variability might be related to other diseases that are 
hypothesized to be intermediate causes of SCD. In chapter 2.6 we reported that QT variability is 
associated with heart failure and that this association is stronger than the association of QT 
variability with SCD or witnessed SCD. We speculated that this might be caused by the multifactorial 
nature of the causes of SCD. It could be argued that only a fraction of the underlying causes of SCD is 
characterized by an increased QT variability. In chapter 2.7, we analyzed whether thyroid function 
influences QT variability. Previous studies have shown that both a high and a low thyroid function 
are associated with an increased risk of ventricular arrhythmias and that a high thyroid function is a 
risk factor for SCD. In this chapter, we report that both a high and a low free thyroxine (FT4) is 
associated with an increase in STVqt, an association which was stronger in men than in women. 
 In the final section we investigated the association of two medical conditions with SCD. In 
chapter 3.1, we showed in a review of the literature that chronic obstructive pulmonary disease 
(COPD) is a risk factor for SCD. This chapter could prompt future research in the interplay between 
COPD, SCD, and ECG markers. In chapter 3.2, we explored the association between thyroid function 
and SCD. This chapter can be linked to chapter 2.7, where we studied the influence of thyroid 
function on QT variability, and to chapter 2.4, where we studied the association of QT variability and 
SCD. Taken together, these chapters show that an increased thyroid function can lead to an 
increased QT variability and an increased risk of SCD. Thus, one of the ways in which QT variability is 
associated with SCD is via the pathway of thyroid function. 
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Wereldwijd zijn coronaire hartziekten de nummer één doodsoorzaak.1 De helft van alle coronaire 
hartziekten treden plotseling en onverwachts op, en de helft van de plotse gevallen treden op bij 
mensen die geen voorgeschiedenis van hartziekten hebben. Daarom is het van groot belang is om 
plotse hartdood te kunnen voorspellen in de algemene bevolking. Het elektrocardiogram (ECG) 
wordt reeds gebruikt als instrument om plotse hartdood te voorspellen,2 maar er is meer uit het ECG 
te halen dan nu gedaan wordt. Door de verschillende maten gebaseerd op het ECG nader te 
bestuderen, zou het voorspellen van plotse hartdood verbeterd kunnen worden. Hier ligt het doel 
van dit proefschrift: het verkennen en verbreden van het gebruik van het ECG bij het voorspellen van 
plotse hartdood, en meer specifiek met de ECG maten QT variabiliteit en hartslagvariabiliteit. 
In het eerste deel vingen we aan met een nadere inspectie van ECG maten die al algemeen 
gebruikt worden in de klinische praktijk. De eerste ECG maat die we verkenden was 
hartslagvariabiliteit. Een lage hartslagvariabiliteit is een risicofactor voor hartziekten en plotse 
hartdood.3,4 Twee aspecten van deze maat hebben we nader bekeken. Het eerste aspect is het feit 
dat er geen uitgebreide leeftijds- en geslachtsafhankelijke normale grenzen bekend zijn van 
hartslagvariabiliteit. Dit hebben we aangepakt door de leeftijds- en geslachtsafhankelijke normale 
grenzen te bepalen in hoofdstuk 1.1. In deze studie pasten we een nieuwe exponentiële 
hartslagcorrectieformule toe om het effect van hartslag op hartslagvariabiliteit te verwijderen. In 
hoofdstuk 1.2 verkenden we een tweede aspect van hartslagvariabiliteit. Het is namelijk bekend dat 
patiënten met angststoornissen en depressie een verhoogde kans op een myocardinfarct hebben,5,6 
maar het is niet bekend of dit mede veroorzaakt wordt door de behandeling met antidepressiva. 
Omdat hartslagvariabiliteit gerelateerd is aan hart- en vaatziekten,3,4 is het interessant te zien wat de 
samenhang is tussen depressie, antidepressivagebruik en hartslagvariabiliteit. Er zijn twee 
tegengestelde publicaties hierover in de vakliteratuur. De eerste publicatie liet zien dat depressie 
hartslagvariabiliteit verlaagt,7 en de andere publicatie dat antidepressiva verantwoordelijk zijn voor 
de verlaging van hartslagvariabiliteit.8,9 De voornaamste beperkingen van deze beide studies zijn hun 
cross-sectionele opzet en het ontbreken van informatie over dosis-respons effecten. Onze studie in 
hoofdstuk 1.2 had een longitudinale opzet en gaf wel informatie over dosis-respons effecten. Wij 
lieten zien dat tricyclische antidepressiva (TCA’s) hartslagvariabiliteit verlaagden, onafhankelijk van 
hartslagfrequentie en symptomen van depressie. Het bewijs voor serotonine heropnameremmers 
(SSRI’s) was zwakker, maar er was wel een significant dosis-responseffect voor een lagere 
hartslagvariabiliteit bij hogere SSRI doses. De volgende veelgebruikte ECG maat die we nader 
onderzochten was het QT interval. Een verlengd QT interval is een bekend risicofactor plotse 
hartdood.10 Het QT interval is afhankelijk van de hartslagfrequentie, en een groot aantal formules is 
voorgesteld om het QT interval voor de hartslagfrequentie te corrigeren. In de jaren ’20 van de 
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vorige eeuw zijn de twee meest gebruikte formules bedacht door Bazett11 en Fridericia.12 Het belang 
van correctie voor hartslagfrequentie komt naar voren in die gevallen waar hartslagfrequentie een 
confounder kan zijn, in ons geval bij het testen van medicijnen die de hartslag beïnvloeden. 
Onnauwkeurige correctie voor hartslagfrequentie kan leiden tot een onder- of overschatting van het 
voor hartslagfrequentie gecorrigeerde QT interval (QTc), wat weer kan leiden tot vals positieve 
resultaten. Hoofdstuk 1.3 is een illustratie hiervan: het is bekend dat TCA’s de hartslagfrequentie 
verhogen,13 maar ze worden ook ervan verdacht de QTc te verlengen,14 en dus in potentie het risico 
op plotse hartdood te verhogen. Desalniettemin vonden we dat de toename van het QTc 
gerelateerd aan het gebruik van TCA’s gebaseerd was op een overschatting van het QTc bij het 
gebruik van de formule van Bazett. Toen we Fridericia’s formule gebruikten, konden we geen QTc 
verlening vaststellen. Wij concludeerden dat het de voorkeur heeft om Fridericia’s formule te 
gebruiken. 
Het tweede deel van dit proefschrift is gericht op de ECG maat QT variabiliteit. QT 
variabiliteit geeft de variabiliteit van alle QT intervallen in een bepaalde tijdsspanne weer. Men 
denkt dat een verhoogde QT variabiliteit een indicatie is van instabiliteit van de repolarisatie, en dat 
het daarom voorspellend kan zijn voor ventriculaire aritmieën en plotse hartdood.15 In hoofdstuk 2.1 
laten we een overzicht en beoordeling zien van alle relevante vakliteratuur gericht op het 
bestuderen van QT variabiliteit. Deze review onthulde dat QT variabiliteit op ECG signalen van korte 
duur al onderzocht is in meer dan 100 publicaties, gebruikmakend van meer dan negen verschillende 
formules. Een aantal beperkingen van deze publicaties viel op: de studies waren uitgevoerd in een 
selectie van gezonde vrijwilligers of in specifieke patiëntgroepen, maar niet in de algehele bevolking, 
waar het voorspellen van plotse hartdood het meest van nut kan zijn. Een tweede probleem was de 
beperkte omvang van de studiepopulaties. Het is mogelijk dat de omvang van de studies beperkt 
was door het ontbreken van een nauwkeurige automatische methode om alle QT intervallen op een 
ECG te meten. Om dit probleem te verhelpen introduceerden wij in hoofdstuk 2.2 een automatische 
implementatie van het fiducial segment averaging (FSA) algoritme bedacht door Ritsema van Eck.16 
Het FSA algoritme is een relatief nieuwe benadering om QT intervallen op een ECG automatisch en 
accuraat te meten. Wij stelden ook in hoofdstuk 2.2 een nieuwe methode voor om metingen van QT 
intervallen te valideren. We simuleerden eerst QT variabiliteit samen met ruis, grondlijndwalen en 
variaties in signaallengte op een signaal gebaseerd op gemiddelde P-QRS-T complexen van 
bestaande ECG opnames. In deze dataset vergeleken we de prestaties van FSA met de conventionele 
methode om QT variabiliteit te meten, en toonden aan dat FSA veel nauwkeuriger is dan de 
conventionele methode. 
Nederlandse Samenvatting 
338 
 In de volgende hoofdstukken gingen we verder met het onderzoeken van QT variabiliteit. In 
hoofdstuk 2.3 rapporteerden we uitgebreide leeftijds- en geslachtsafhankelijke normale grenzen van 
QT variabiliteit zoals gemeten op standaard ECG’s van 10 seconden. Wij waren de eerste om dit te 
doen op zo’n grote schaal (±14,000 ECG’s).17 In hoofdstuk 2.4 bestudeerden we de relatie tussen vier 
maten van QT variabiliteit (QTVI, SDqt, STVqt, and RMSSDqt) met algehele mortaliteit, mortaliteit 
door coronair lijden (ook wel coronary heart disease mortality - CHD mortaliteit genoemd), plotse 
hartdood en geobserveerde plotse hartdood. We ontdekten dat deze maten geassocieerd waren 
met algehele mortaliteit, CHD mortaliteit en met geobserveerde plotse hartdood, maar in het laatste 
geval alleen bij vrouwen, en niet bij mannen. Het viel op dat SDqt, STVqt, en RMSSDqt onderling 
sterk gecorreleerd waren, wat mogelijk komt door de korte duur van het ECG signaal. QTVI was 
minder sterk gecorreleerd met de andere QT variabiliteitsmaten vanwege de correctie voor het 
gemiddelde QT interval, de gemiddelde hartfrequentie, en de hartslagvariabiliteit. QTVI had een 
zwakkere en statistisch niet significante associatie met de klinische eindpunten vergeleken met de 
drie ongecorrigeerde maten. In hoofdstuk 2.5 gaven we aandacht aan een zwak punt van veel 
voorgaande studies, opgemerkt door Wellens et al,18 namelijk dat ECG maten vaak apart bestudeerd 
worden, slechts geadjusteerd voor een beperkt aantal andere ECG maten of klinische risicofactoren. 
Wij hebben een predictiemodel gemaakt voor plotse hartdood om de aanvullende waarde van 24 
ECG maten te beoordelen boven een model gebaseerd op slechts klinische risicofactoren. Na 
stapsgewijze eliminatie werden zes klinische risicofactoren geselecteerd: leeftijd, geslacht, 
totaal/HDL cholesterol ratio, roken, diabetes mellitus en gebruik van medicatie die ingrijpen op het 
renine-angiotensine systeem. Een tweede stapsgewijze eliminatie, met behoud van de eerder 
geselecteerde zes risicofactor maar met de 24 ECG maten als extra input, resulteerde in een 
gecombineerd model met zes klinische risicofactoren en zes aanvullende ECG maten. De 
geselecteerde ECG maten in kwestie waren hartslagfrequentie, Sokolow-Lyon index, ruimtelijke J 
amplitude, T amplitude in afleiding aVR, rechter bundeltakblok en SDNN gecorrigeerd voor 
hartslagfrequentie. We ontdekten dat deze ECG maten samen de discriminatie van het model 
significant verbeterden, maar plaatsten ook enkele kanttekeningen bij het maken van een 
voorspellend model met beperkte data. Dit kan in de toekomst opgelost worden door op 
internationaal niveau cohortstudies naar plotse hartdood te combineren. 
In de laatste twee hoofdstukken van het tweede deel onderzochten we of QT variabiliteit 
gerelateerd is aan andere ziektes die mogelijk een directe oorzaak voor plotse hartdood kunnen zijn. 
In hoofdstuk 2.6 meldden we dat QT variabiliteit geassocieerd is met hartfalen, en ook dat deze 
associatie sterker is met hartfalen dan met plotse hartdood (al dan niet geobserveerd). We 
speculeerden dat dit veroorzaakt wordt door de multifactoriële aard van plotse hartdood. Het is 
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immers mogelijk dat slechts een deel van de onderliggende oorzaken van plotse hartdood 
gekarakteriseerd worden door een toegenomen QT variabiliteit. We analyseerden in hoofdstuk 2.7 
of de schildklierfunctie geassocieerd is met een verhoging van de QT variabiliteit. Voorgaande 
studies hebben aangetoond dat zowel een hoge als een lage schildklierfunctie geassocieerd zijn met 
een verhoogd risico op ventriculaire arithmieën en ook dat een verhoogde schildklierfunctie 
geassocieerd is met plotse hartdood. In dit hoofdstuk stellen wij dat zowel een hoog als een laag vrij 
thyroxine (FT4) gerelateerd is aan een verhoogde STVqt. Deze associatie was sterker in mannen dan 
in vrouwen.  
 In het laatste deel van het proefschrift onderzochten we de associatie van twee 
aandoeningen met plotse hartdood. In hoofdstuk 3.1 laten we een overzicht en beoordeling zien van 
de literatuur over chronisch obstructieve longziekten (COPD) als risicofactor voor plotse hartdood. 
Dit hoofdstuk is mogelijk een aanleiding voor verder onderzoek naar het samenspel van COPD, 
plotse hartdood en ECG maten. In hoofdstuk 3.2 verkenden we de associatie tussen 
schildklierfunctie en plotse hartdood. Dit hoofdstuk kan gerelateerd worden zowel aan hoofdstuk 
2.7, waar we de invloed van de schildklier op QT variabiliteit onderzochten als aan hoofdstuk 2.4, 
waar de associatie van QT variabiliteit en plotse hartdood analyseerden. Deze hoofdstukken samen 
laten zien dat een toegenomen schildklierfunctie kan leiden tot een verhoogde QT variabiliteit en 
een verhoogd risico op plotse hartdood. Dit leidt tot de conclusie dat de schildklierfunctie één van 
de manieren zou kunnen zijn waarop QT variabiliteit geassocieerd is met plotse hartdood.  
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